sentances,predictions
"Thymectomy of B6 mice at 5 weeks of age led to premature alterations in T-cell homeostasis and ANA production, by 15 weeks of age, similar to that in old mice.","[{'Thymectomy': 'O'}, {'of': 'O'}, {'B6': 'O'}, {'mice': 'O'}, {'at': 'O'}, {'5': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'age': 'O'}, {'led': 'O'}, {'to': 'O'}, {'premature': 'O'}, {'alterations': 'O'}, {'in': 'O'}, {'T-cell': 'O'}, {'homeostasis': 'O'}, {'and': 'O'}, {'ANA': 'I-Entity'}, {'production,': 'O'}, {'by': 'O'}, {'15': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'age,': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'that': 'O'}, {'in': 'O'}, {'old': 'O'}, {'mice.': 'O'}]"
The IVCM showed a significant increase in basal epithelium cells density and subbasal nerve plexus density and number and a decrease in Langerhans cells density (p < 0.05).,"[{'The': 'O'}, {'IVCM': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'basal': 'O'}, {'epithelium': 'O'}, {'cells': 'O'}, {'density': 'O'}, {'and': 'O'}, {'subbasal': 'O'}, {'nerve': 'O'}, {'plexus': 'O'}, {'density': 'O'}, {'and': 'O'}, {'number': 'O'}, {'and': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'Langerhans': 'O'}, {'cells': 'O'}, {'density': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"In contrast, the frequency of physician-confirmed diagnoses of thyroid, liver, and kidney disease and lymphoma was low and only primary biliary cirrhosis was associated with primary SS case status.","[{'In': 'O'}, {'contrast,': 'O'}, {'the': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'physician-confirmed': 'O'}, {'diagnoses': 'O'}, {'of': 'O'}, {'thyroid,': 'B-Entity'}, {'liver,': 'I-Entity'}, {'and': 'I-Entity'}, {'kidney': 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'lymphoma': 'I-Entity'}, {'was': 'O'}, {'low': 'O'}, {'and': 'O'}, {'only': 'O'}, {'primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cirrhosis': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'case': 'O'}, {'status.': 'O'}]"
"MATERIAL AND A prospective, monocentric, uncontrolled study was conducted between January 2012¬¨¬®‚Äö√Ñ‚Ä†and March 2015¬¨¬®‚Äö√Ñ‚Ä†on 110¬¨¬®‚Äö√Ñ‚Ä†eyes of 55¬¨¬®‚Äö√Ñ‚Ä†patients with severe dry eye on first line therapy or previously treated with Restasis(¬¨¬®‚àö√ú) who required the introduction of Ikervis(¬¨¬®‚àö√ú).","[{'MATERIAL': 'O'}, {'AND': 'O'}, {'A': 'O'}, {'prospective,': 'O'}, {'monocentric,': 'O'}, {'uncontrolled': 'O'}, {'study': 'O'}, {'was': 'O'}, {'conducted': 'O'}, {'between': 'O'}, {'January': 'O'}, {'2012¬¨¬®‚Äö√Ñ‚Ä†and': 'O'}, {'March': 'O'}, {'2015¬¨¬®‚Äö√Ñ‚Ä†on': 'O'}, {'110¬¨¬®‚Äö√Ñ‚Ä†eyes': 'O'}]"
"Our observations demonstrated that p63 nuclear labeling in pSS MECs is preserved whereas ‚âà√≠¬¨¬±-SMA cytoplasmic staining is strongly and significantly reduced when compared with healthy SGs; the digital images analysis quantification of the expression of labeled ‚âà√≠¬¨¬±-SMA and p63 protein in the healthy and pSS MECs salivary tissues, led to results suggesting a loss of mechanical support for acini and ducts in pSS, correlated, probably, with the reduction of salivary flow that features one important aspect of pSS disease.Section of Human Anatomy and Histology, University of Bari ""Aldo Moro"", piazza Giulio Cesare 1, 70124, Bari, Italy.","[{'Our': 'O'}, {'observations': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'p63': 'O'}, {'nuclear': 'O'}, {'labeling': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'MECs': 'O'}, {'is': 'O'}, {'preserved': 'O'}, {'whereas': 'O'}, {'‚âà√≠¬¨¬±-SMA': 'O'}, {'cytoplasmic': 'O'}, {'staining': 'O'}, {'is': 'O'}, {'strongly': 'O'}, {'and': 'O'}, {'significantly': 'O'}, {'reduced': 'O'}, {'when': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'healthy': 'O'}, {'SGs;': 'O'}, {'the': 'O'}, {'digital': 'O'}, {'images': 'O'}, {'analysis': 'O'}, {'quantification': 'O'}, {'of': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'labeled': 'O'}]"
"Therefore, we report herein one patient with childhood SLE (C-SLE) and Sjogrens syndrome overlap that presented encapsulated Cryptococcus yeast cells in lung tissue.","[{'Therefore,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'herein': 'O'}, {'one': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'childhood': 'O'}, {'SLE': 'I-Entity'}, {'(C-SLE)': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'overlap': 'O'}, {'that': 'O'}, {'presented': 'O'}, {'encapsulated': 'O'}, {'Cryptococcus': 'B-Entity'}, {'yeast': 'I-Entity'}, {'cells': 'O'}, {'in': 'O'}, {'lung': 'O'}, {'tissue.': 'O'}]"
"Ultrasound of major salivary glands is a useful tool for diagnosis, prognostic evaluation, and response to treatment in SS.","[{'Ultrasound': 'O'}, {'of': 'O'}, {'major': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'is': 'O'}, {'a': 'O'}, {'useful': 'O'}, {'tool': 'O'}, {'for': 'O'}, {'diagnosis,': 'O'}, {'prognostic': 'O'}, {'evaluation,': 'O'}, {'and': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'SS.': 'I-Entity'}]"
"Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created.","[{'Twenty-five': 'O'}, {'recommendations': 'O'}, {'for': 'O'}, {'determining': 'O'}, {'ANA': 'O'}, {'(1-13),': 'O'}, {'anti-double': 'O'}, {'stranded': 'I-Entity'}, {'DNA': 'I-Entity'}, {'antibodies': 'O'}, {'(14-18),': 'O'}, {'specific': 'O'}, {'antibodies': 'O'}, {'(19-23)': 'O'}, {'and': 'O'}, {'validation': 'O'}, {'of': 'O'}, {'methods': 'O'}, {'(24-25)': 'O'}, {'were': 'O'}, {'created.': 'O'}]"
"The characteristics of this case were acute onset (within a few days), severe clinical presentation (continued confinement to bed and malnutrition) and non-responsiveness to all treatments (intravenous immunoglobulins, corticosteroids, plasmapheresis, rituximab).","[{'The': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'this': 'O'}, {'case': 'O'}, {'were': 'O'}, {'acute': 'O'}, {'onset': 'O'}, {'(within': 'O'}, {'a': 'O'}, {'few': 'O'}, {'days),': 'O'}, {'severe': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'(continued': 'O'}, {'confinement': 'O'}, {'to': 'O'}, {'bed': 'O'}, {'and': 'O'}, {'malnutrition)': 'I-Entity'}, {'and': 'O'}, {'non-responsiveness': 'O'}, {'to': 'O'}, {'all': 'O'}, {'treatments': 'O'}, {'(intravenous': 'O'}, {'immunoglobulins,': 'O'}, {'corticosteroids,': 'O'}, {'plasmapheresis,': 'O'}]"
"Baseline and post cessation of treatment (baseline and 3 months) evaluations included, subjective symptom scoring, fluorescein and lissamine green staining, Schirmer's test, tear break-up time (BUT) and tear fluid BAFF assessments.","[{'Baseline': 'O'}, {'and': 'O'}, {'post': 'O'}, {'cessation': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'(baseline': 'O'}, {'and': 'O'}, {'3': 'O'}, {'months)': 'O'}, {'evaluations': 'O'}, {'included,': 'O'}, {'subjective': 'O'}, {'symptom': 'O'}, {'scoring,': 'O'}, {'fluorescein': 'B-Entity'}, {'and': 'I-Entity'}, {'lissamine': 'I-Entity'}, {'green': 'I-Entity'}, {'staining,': 'O'}, {""Schirmer's"": 'O'}, {'test,': 'O'}, {'tear': 'O'}, {'break-up': 'O'}, {'time': 'O'}, {'(BUT)': 'O'}, {'and': 'O'}, {'tear': 'O'}, {'fluid': 'O'}, {'BAFF': 'O'}, {'assessments.': 'O'}]"
"It uncommonly involves the kidneys in various forms, including tubulointerstitial nephritis, renal tubular acidosis, Fanconi syndrome, and rarely glomerulonephritis.","[{'It': 'O'}, {'uncommonly': 'O'}, {'involves': 'O'}, {'the': 'O'}, {'kidneys': 'O'}, {'in': 'O'}, {'various': 'O'}, {'forms,': 'O'}, {'including': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis,': 'I-Entity'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis,': 'I-Entity'}, {'Fanconi': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'rarely': 'O'}, {'glomerulonephritis.': 'I-Entity'}]"
"A subgroup of patients in pITP patients with some obvious autoimmune features (defined as AIF-ITP) such as positive ANA but failing to meet the diagnosis criteria now used for a specific kind of connective tissue diseases were also different with other pITP patients in some immunological features, indicating the difference in the pathogenesis mechanism of those autoimmune featured ITP patients.ITP patients were heterogeneous in clinical characteristics.","[{'A': 'O'}, {'subgroup': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'pITP': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'some': 'O'}, {'obvious': 'O'}, {'autoimmune': 'O'}, {'features': 'O'}, {'(defined': 'O'}, {'as': 'O'}, {'AIF-ITP)': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'positive': 'O'}, {'ANA': 'O'}, {'but': 'O'}, {'failing': 'O'}, {'to': 'O'}, {'meet': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'criteria': 'O'}, {'now': 'O'}, {'used': 'O'}, {'for': 'O'}, {'a': 'O'}, {'specific': 'O'}, {'kind': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'were': 'O'}, {'also': 'O'}, {'different': 'O'}, {'with': 'O'}, {'other': 'O'}, {'pITP': 'I-Entity'}, {'patients': 'O'}, {'in': 'O'}, {'some': 'O'}, {'immunological': 'O'}]"
These results indicated proximal tubular dysfunction.,"[{'These': 'O'}, {'results': 'O'}, {'indicated': 'O'}, {'proximal': 'O'}, {'tubular': 'B-Entity'}, {'dysfunction.': 'I-Entity'}]"
"Six such cases were identified, representing 12% of all sIBM cases.","[{'Six': 'O'}, {'such': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'identified,': 'O'}, {'representing': 'O'}, {'12%': 'O'}, {'of': 'O'}, {'all': 'O'}, {'sIBM': 'I-Entity'}, {'cases.': 'O'}]"
"A high prevalence of MG of undetermined significance (MGUS) has been noted in a series of patients with immune disorders, suggesting a possible association with MG. Further studies should focus on determining how MG relates to various clinical information and laboratory parameters, such as disease duration, disease activity and higher sedimentation rate.","[{'A': 'O'}, {'high': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'MG': 'I-Entity'}, {'of': 'O'}, {'undetermined': 'O'}, {'significance': 'O'}, {'(MGUS)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'noted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'series': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'immune': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'suggesting': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'association': 'O'}, {'with': 'O'}, {'MG.': 'I-Entity'}, {'Further': 'O'}, {'studies': 'O'}, {'should': 'O'}, {'focus': 'O'}, {'on': 'O'}, {'determining': 'O'}, {'how': 'O'}, {'MG': 'I-Entity'}, {'relates': 'O'}, {'to': 'O'}, {'various': 'O'}, {'clinical': 'O'}, {'information': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'parameters,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'disease': 'O'}, {'duration,': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'higher': 'O'}, {'sedimentation': 'O'}, {'rate.': 'O'}]"
"Research is needed to test the effect of psycho-educational therapies on key patient-reported outcomes, particularly pain, depression, and fatigue, in pSS.Jan 7.phenotypes and regulatory mechanisms.","[{'Research': 'O'}, {'is': 'O'}, {'needed': 'O'}, {'to': 'O'}, {'test': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'psycho-educational': 'O'}, {'therapies': 'O'}, {'on': 'O'}, {'key': 'O'}, {'patient-reported': 'O'}, {'outcomes,': 'O'}, {'particularly': 'O'}, {'pain,': 'I-Entity'}, {'depression,': 'I-Entity'}, {'and': 'O'}, {'fatigue,': 'I-Entity'}, {'in': 'O'}, {'pSS.Jan': 'O'}, {'7.phenotypes': 'O'}, {'and': 'O'}, {'regulatory': 'O'}, {'mechanisms.': 'O'}]"
"There is endothelial dysfunction in patients with primary Sjogren syndrome, although they had comparable carotid intima-media thickness with the healthy control group.Turkey.","[{'There': 'O'}, {'is': 'O'}, {'endothelial': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'although': 'O'}, {'they': 'O'}, {'had': 'O'}, {'comparable': 'O'}, {'carotid': 'O'}, {'intima-media': 'O'}, {'thickness': 'O'}, {'with': 'O'}, {'the': 'O'}, {'healthy': 'O'}, {'control': 'O'}, {'group.Turkey.': 'O'}]"
Dry mouth is not a trivial symptom for Sjogrens Syndrome sufferers; it has considerable impact on their day-to-day lives.,"[{'Dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'is': 'O'}, {'not': 'O'}, {'a': 'O'}, {'trivial': 'O'}, {'symptom': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'sufferers;': 'O'}, {'it': 'O'}, {'has': 'O'}, {'considerable': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'their': 'O'}, {'day-to-day': 'O'}, {'lives.': 'O'}]"
Double-labeling confocal fluorescence microscopy using H(+)-ATPase and pendrin antibodies demonstrated a decreased expression of these proteins in the patient's renal collecting duct compared to normal controls.,"[{'Double-labeling': 'O'}, {'confocal': 'O'}, {'fluorescence': 'O'}, {'microscopy': 'O'}, {'using': 'O'}, {'H(+)-ATPase': 'I-Entity'}, {'and': 'O'}, {'pendrin': 'O'}, {'antibodies': 'O'}, {'demonstrated': 'O'}, {'a': 'O'}, {'decreased': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'these': 'O'}, {'proteins': 'O'}, {'in': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'renal': 'O'}, {'collecting': 'O'}, {'duct': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'normal': 'O'}, {'controls.': 'O'}]"
Primary Sjogrens syndrome (pSS) is a systemic autoimmune disorder characterized by focal lymphocytic infiltration of the exocrine glands causing dry eyes and dry mouth.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'focal': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'causing': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"In this cross-sectional study, we evaluated the role of immunological factors and proviral load, in sicca syndrome associated with HTLV-1 in patients without myelopathy.","[{'In': 'O'}, {'this': 'O'}, {'cross-sectional': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'immunological': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'proviral': 'O'}, {'load,': 'O'}, {'in': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'HTLV-1': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'myelopathy.': 'I-Entity'}]"
"Correlation between EMP and EPC levels and parameters of disease activity and damage, clinical features and markers of immunological dysfunction was performed.","[{'Correlation': 'O'}, {'between': 'O'}, {'EMP': 'O'}, {'and': 'O'}, {'EPC': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'parameters': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'damage,': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'and': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'immunological': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'was': 'O'}, {'performed.': 'O'}]"
"She was diagnosed with Sjogrens syndrome based on the dry eyes, dry mouth, positive anti-nuclear antibody test, anti-Ro (SS-A) antibody, salivary gland biopsy, and salivary scintigraphy.","[{'She': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'positive': 'O'}, {'anti-nuclear': 'O'}, {'antibody': 'O'}, {'test,': 'O'}, {'anti-Ro': 'O'}, {'(SS-A)': 'O'}, {'antibody,': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy,': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'scintigraphy.': 'O'}]"
"Before and after a 2-month period of treatment with liposomal agents for oral, nasal, and ocular complaints (LipoSaliva¬¨¬®‚àö√ú, LipoNasal¬¨¬®‚àö√ú, and Tears Again¬¨¬®‚àö√ú,) AECG criteria and subjective symptoms were evaluated using visual analogue scales.","[{'Before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'a': 'O'}, {'2-month': 'O'}, {'period': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'liposomal': 'O'}, {'agents': 'O'}, {'for': 'O'}, {'oral,': 'B-Entity'}, {'nasal,': 'I-Entity'}, {'and': 'I-Entity'}, {'ocular': 'I-Entity'}, {'complaints': 'I-Entity'}, {'(LipoSaliva¬¨¬®‚àö√ú,': 'O'}, {'LipoNasal¬¨¬®‚àö√ú,': 'O'}, {'and': 'O'}, {'Tears': 'O'}, {'Again¬¨¬®‚àö√ú,)': 'O'}]"
"Hypothyroidism developed at a much younger mean age (24.3 years), suggesting that SLE might be a predisposing factor for the development of Hashimoto's thyroiditis.","[{'Hypothyroidism': 'I-Entity'}, {'developed': 'O'}, {'at': 'O'}, {'a': 'O'}, {'much': 'O'}, {'younger': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'(24.3': 'O'}, {'years),': 'O'}, {'suggesting': 'O'}, {'that': 'O'}, {'SLE': 'I-Entity'}, {'might': 'O'}, {'be': 'O'}, {'a': 'O'}, {'predisposing': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {""Hashimoto's"": 'B-Entity'}, {'thyroiditis.': 'I-Entity'}]"
"MR spectroscopy revealed a reduction of NAA levels or NAA/Cr ratio decrease in subcortical frontal and basal ganglia white matter, while ultrasonography showed an impairment of microvasculature response.","[{'MR': 'O'}, {'spectroscopy': 'O'}, {'revealed': 'O'}, {'a': 'O'}, {'reduction': 'O'}, {'of': 'O'}, {'NAA': 'I-Entity'}, {'levels': 'O'}, {'or': 'O'}, {'NAA/Cr': 'I-Entity'}, {'ratio': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'subcortical': 'O'}, {'frontal': 'O'}, {'and': 'O'}, {'basal': 'O'}, {'ganglia': 'O'}, {'white': 'O'}, {'matter,': 'O'}, {'while': 'O'}, {'ultrasonography': 'O'}, {'showed': 'O'}, {'an': 'O'}, {'impairment': 'B-Entity'}, {'of': 'I-Entity'}, {'microvasculature': 'I-Entity'}, {'response.': 'O'}]"
"Our aim was to investigate the prevalence of pulmonary involvement in pSS patients and to classify patients according to the pulmonary domain of the EULAR Sjogrens Syndrome Disease Activity Index (ESSDAI).This retrospective cohort study included consecutive pSS patients, fulfilling American-European Consensus Group/American College of Rheumatology classification criteria, who visited the Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, in 2015.","[{'Our': 'O'}, {'aim': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'to': 'O'}, {'classify': 'O'}, {'patients': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'pulmonary': 'O'}, {'domain': 'O'}, {'of': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI).This': 'O'}, {'retrospective': 'O'}, {'cohort': 'O'}, {'study': 'O'}, {'included': 'O'}, {'consecutive': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'fulfilling': 'O'}, {'American-European': 'O'}]"
This report describes the clinical manifestations of 35 patients sent to a University Immunology clinic with a diagnosis of fatigue and exercise intolerance who were identified to have low carnitine palmitoyl transferase activity on muscle biopsies.,"[{'This': 'O'}, {'report': 'O'}, {'describes': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'35': 'O'}, {'patients': 'O'}, {'sent': 'O'}, {'to': 'O'}, {'a': 'O'}, {'University': 'O'}, {'Immunology': 'O'}, {'clinic': 'O'}, {'with': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'exercise': 'B-Entity'}, {'intolerance': 'I-Entity'}, {'who': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'to': 'O'}, {'have': 'O'}, {'low': 'O'}, {'carnitine': 'I-Entity'}, {'palmitoyl': 'O'}, {'transferase': 'O'}, {'activity': 'O'}, {'on': 'O'}, {'muscle': 'O'}, {'biopsies.': 'O'}]"
The objective of the study was to evaluate the impact of previously unrecognized systemic autoimmune rheumatic on the incidence of preeclampsia and fetal growth restriction (FGR).,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'previously': 'O'}, {'unrecognized': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'preeclampsia': 'I-Entity'}, {'and': 'O'}, {'fetal': 'B-Entity'}, {'growth': 'I-Entity'}, {'restriction': 'I-Entity'}, {'(FGR).': 'O'}]"
"The clinical presentation of pSS may vary from an asymptomatic condition to severe skin symptom, resulting in a difficult and challenging diagnosis and treatment.","[{'The': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'may': 'O'}, {'vary': 'O'}, {'from': 'O'}, {'an': 'O'}, {'asymptomatic': 'O'}, {'condition': 'O'}, {'to': 'O'}, {'severe': 'O'}, {'skin': 'O'}, {'symptom,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'a': 'O'}, {'difficult': 'O'}, {'and': 'O'}, {'challenging': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'treatment.': 'O'}]"
"Furthermore, composite indices such as the disease activity score (DAS)-28, which are widely used in everyday clinical practice and clinical trials, may be insufficient to evaluate real inflammatory activity in patients with RA associated with chronic pain syndromes such as FM, and can lead to an overestimate of disease activity in RA.","[{'Furthermore,': 'O'}, {'composite': 'O'}, {'indices': 'O'}, {'such': 'O'}, {'as': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'score': 'O'}, {'(DAS)-28,': 'O'}, {'which': 'O'}, {'are': 'O'}, {'widely': 'O'}, {'used': 'O'}, {'in': 'O'}, {'everyday': 'O'}, {'clinical': 'O'}, {'practice': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'trials,': 'O'}, {'may': 'O'}, {'be': 'O'}, {'insufficient': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'real': 'O'}, {'inflammatory': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'RA': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'chronic': 'B-Entity'}, {'pain': 'I-Entity'}, {'syndromes': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'FM,': 'I-Entity'}, {'and': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'an': 'O'}, {'overestimate': 'O'}, {'of': 'O'}, {'disease': 'O'}]"
Visual analog scale assessment showed a significant time-wise improvement (P < 0.05).,"[{'Visual': 'O'}, {'analog': 'O'}, {'scale': 'O'}, {'assessment': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'time-wise': 'O'}, {'improvement': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
We describe 7 patients that developed urticarial lesions in the context of a known or concurrently diagnosed autoimmune connective tissue disease.,"[{'We': 'O'}, {'describe': 'O'}, {'7': 'O'}, {'patients': 'O'}, {'that': 'O'}, {'developed': 'O'}, {'urticarial': 'B-Entity'}, {'lesions': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'context': 'O'}, {'of': 'O'}, {'a': 'O'}, {'known': 'O'}, {'or': 'O'}, {'concurrently': 'O'}, {'diagnosed': 'O'}, {'autoimmune': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"All patients with pSS-SFN, i-SFN, and hATTR-SFN confirmed by reduced intraepidermal nerve fiber density on skin biopsy were retrospectively included, and their characteristics were compared.","[{'All': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS-SFN,': 'I-Entity'}, {'i-SFN,': 'O'}, {'and': 'O'}, {'hATTR-SFN': 'O'}, {'confirmed': 'O'}, {'by': 'O'}, {'reduced': 'O'}, {'intraepidermal': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'density': 'O'}, {'on': 'O'}, {'skin': 'O'}, {'biopsy': 'O'}, {'were': 'O'}, {'retrospectively': 'O'}, {'included,': 'O'}, {'and': 'O'}, {'their': 'O'}, {'characteristics': 'O'}, {'were': 'O'}, {'compared.': 'O'}]"
No difference in percentage mutation in dominant clone-derived IGHV sequences was seen between pSS and non-pSS.,"[{'No': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'percentage': 'O'}, {'mutation': 'O'}, {'in': 'O'}, {'dominant': 'O'}, {'clone-derived': 'O'}, {'IGHV': 'O'}, {'sequences': 'O'}, {'was': 'O'}, {'seen': 'O'}, {'between': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'non-pSS.': 'O'}]"
"To describe clinical features and outcomes of seven patients with pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in the setting of underlying primary Sjogrens syndrome from a single center, we reviewed medical records of consecutive patients with pulmonary MALT lymphoma evaluated at our facility from January 1, 1999 to December 31, 2015 for clinical features, laboratory, pathologic and radiographic findings, management, and outcomes.","[{'To': 'O'}, {'describe': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'and': 'O'}, {'outcomes': 'O'}, {'of': 'O'}, {'seven': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pulmonary': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'I-Entity'}, {'tissue': 'I-Entity'}, {'(MALT)': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'setting': 'O'}, {'of': 'O'}, {'underlying': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'from': 'O'}, {'a': 'O'}, {'single': 'O'}, {'center,': 'O'}, {'we': 'O'}, {'reviewed': 'O'}, {'medical': 'O'}, {'records': 'O'}, {'of': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pulmonary': 'O'}, {'MALT': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'evaluated': 'O'}, {'at': 'O'}, {'our': 'O'}, {'facility': 'O'}, {'from': 'O'}]"
Renal involvement has been usually in the form of tubulointerstitial nephritis.,"[{'Renal': 'O'}, {'involvement': 'O'}, {'has': 'O'}, {'been': 'O'}, {'usually': 'O'}, {'in': 'O'}, {'the': 'O'}, {'form': 'O'}, {'of': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis.': 'I-Entity'}]"
We assessed whether interleukin (IL)-17 was present in the tears of various ocular surface inflammatory diseases and the tear IL-17 concentrations were clinically correlated with various ocular surface inflammatory diseases.,"[{'We': 'O'}, {'assessed': 'O'}, {'whether': 'O'}, {'interleukin': 'O'}, {'(IL)-17': 'O'}, {'was': 'O'}, {'present': 'O'}, {'in': 'O'}, {'the': 'O'}, {'tears': 'O'}, {'of': 'O'}, {'various': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'inflammatory': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'IL-17': 'O'}, {'concentrations': 'O'}, {'were': 'O'}, {'clinically': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'various': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'inflammatory': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"Our results describe the course and prognosis of SS-associated NHL and highlight the need for a risk-stratified treatment approach.Athens, Greece.","[{'Our': 'O'}, {'results': 'O'}, {'describe': 'O'}, {'the': 'O'}, {'course': 'O'}, {'and': 'O'}, {'prognosis': 'O'}, {'of': 'O'}, {'SS-associated': 'I-Entity'}, {'NHL': 'I-Entity'}, {'and': 'O'}, {'highlight': 'O'}, {'the': 'O'}, {'need': 'O'}, {'for': 'O'}, {'a': 'O'}, {'risk-stratified': 'O'}, {'treatment': 'O'}, {'approach.Athens,': 'O'}, {'Greece.': 'O'}]"
The monitoring of DED in SS is not uniform in optometric offices across North America.,"[{'The': 'O'}, {'monitoring': 'O'}, {'of': 'O'}, {'DED': 'I-Entity'}, {'in': 'O'}, {'SS': 'O'}, {'is': 'O'}, {'not': 'O'}, {'uniform': 'O'}, {'in': 'O'}, {'optometric': 'O'}, {'offices': 'O'}, {'across': 'O'}, {'North': 'O'}, {'America.': 'O'}]"
The clinical and laboratory findings were consistent with disseminated intravascular coagulation (DIC).,"[{'The': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'disseminated': 'B-Entity'}, {'intravascular': 'B-Entity'}, {'coagulation': 'I-Entity'}, {'(DIC).': 'O'}]"
"Initially, he was diagnosed with idiopathic autoimmune encephalitis and was treated with steroids.","[{'Initially,': 'O'}, {'he': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'idiopathic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'encephalitis': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'steroids.': 'I-Entity'}]"
"While serum BAFF was negatively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in GI lymphoma patient, IL14 was positively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in non-GI lymphoma patient.","[{'While': 'O'}, {'serum': 'O'}, {'BAFF': 'O'}, {'was': 'O'}, {'negatively': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'both': 'O'}, {'traditional': 'O'}, {'anti-SSA/Ro': 'O'}, {'and': 'O'}, {'novel': 'O'}, {'TSA': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'GI': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'patient,': 'O'}, {'IL14': 'O'}, {'was': 'O'}, {'positively': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'both': 'O'}, {'traditional': 'O'}, {'anti-SSA/Ro': 'O'}, {'and': 'O'}, {'novel': 'O'}, {'TSA': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'non-GI': 'O'}, {'lymphoma': 'I-Entity'}]"
(6) Preliminary detection of saliva TSAs showed that all the IgG levels of these three antibodies increased significantly in pSS patients.,"[{'(6)': 'O'}, {'Preliminary': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'saliva': 'O'}, {'TSAs': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'all': 'O'}, {'the': 'O'}, {'IgG': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'these': 'O'}, {'three': 'O'}, {'antibodies': 'O'}, {'increased': 'O'}, {'significantly': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"Low-dose RTX allows for reduction in corticosteroid doses and B-cells, while large-scale randomized double-blind controlled trials are needed to confirm the results.China.and are associated with disease severity.","[{'Low-dose': 'O'}, {'RTX': 'I-Entity'}, {'allows': 'O'}, {'for': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'corticosteroid': 'O'}, {'doses': 'O'}, {'and': 'O'}, {'B-cells,': 'O'}, {'while': 'O'}, {'large-scale': 'O'}, {'randomized': 'O'}, {'double-blind': 'O'}, {'controlled': 'O'}, {'trials': 'O'}, {'are': 'O'}, {'needed': 'O'}, {'to': 'O'}, {'confirm': 'O'}, {'the': 'O'}, {'results.China.and': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'severity.': 'O'}]"
"The association of SFN and pSS has been scarcely evaluated, probably because of its lack of awareness and the low availability of the required diagnostic procedures.","[{'The': 'O'}, {'association': 'O'}, {'of': 'O'}, {'SFN': 'I-Entity'}, {'and': 'O'}, {'pSS': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'scarcely': 'O'}, {'evaluated,': 'O'}, {'probably': 'O'}, {'because': 'O'}, {'of': 'O'}, {'its': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'awareness': 'O'}, {'and': 'O'}, {'the': 'O'}, {'low': 'O'}, {'availability': 'O'}, {'of': 'O'}, {'the': 'O'}, {'required': 'O'}, {'diagnostic': 'O'}, {'procedures.': 'O'}]"
"We report a 38-year-old woman diagnosed with tubulointerstitial nephritis (TIN) on renal biopsy, followed by being diagnosed with primary biliary cirrhosis (PBC) and Sjogrens syndrome (SS).","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'38-year-old': 'O'}, {'woman': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'(TIN)': 'O'}, {'on': 'O'}, {'renal': 'O'}, {'biopsy,': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'being': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cirrhosis': 'I-Entity'}, {'(PBC)': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"The paper presents new criteria for the diagnosis of dry eye secondary to the autoimmune Sjogrens syndrome and their high specificity (94.7% and 93.3%)‚Äö√†√∂‚Äö√†√á based on the results of clinical trials in 1618 patients, conducted by an international research team.Sjogrena.syndrome.","[{'The': 'O'}, {'paper': 'O'}, {'presents': 'O'}, {'new': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'the': 'O'}, {'autoimmune': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'their': 'O'}, {'high': 'O'}, {'specificity': 'O'}, {'(94.7%': 'O'}, {'and': 'O'}, {'93.3%)‚Äö√†√∂‚Äö√†√á': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'trials': 'O'}, {'in': 'O'}, {'1618': 'O'}]"
"Although the concentration of mucins MUC5B and MUC7 were similar between patients and controls, a comparison of protein Western blotting and glycan staining identified a reduction in mucin glycosylation in Sjogrens, particularly on MUC7.","[{'Although': 'O'}, {'the': 'O'}, {'concentration': 'O'}, {'of': 'O'}, {'mucins': 'O'}, {'MUC5B': 'O'}, {'and': 'O'}, {'MUC7': 'O'}, {'were': 'O'}, {'similar': 'O'}, {'between': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'controls,': 'O'}, {'a': 'O'}, {'comparison': 'O'}, {'of': 'O'}, {'protein': 'O'}, {'Western': 'O'}, {'blotting': 'O'}, {'and': 'O'}, {'glycan': 'O'}, {'staining': 'O'}, {'identified': 'O'}, {'a': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'mucin': 'O'}, {'glycosylation': 'O'}, {'in': 'O'}, {'Sjogrens,': 'I-Entity'}, {'particularly': 'O'}, {'on': 'O'}, {'MUC7.': 'O'}]"
Multivariate logistic regression analysis showed that BMI and fatty liver were mutually associated with LIPG independently from radiation dose.,"[{'Multivariate': 'O'}, {'logistic': 'O'}, {'regression': 'O'}, {'analysis': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'BMI': 'O'}, {'and': 'O'}, {'fatty': 'B-Entity'}, {'liver': 'I-Entity'}, {'were': 'O'}, {'mutually': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'LIPG': 'I-Entity'}, {'independently': 'O'}, {'from': 'O'}, {'radiation': 'O'}, {'dose.': 'O'}]"
"Laboratory results were as follows: ESR 44mm/h, C-reactive protein 4.35, normal levels of complement C3 and C4, negative rheumatoid factor and anticyclic citrullinated peptide antibodies, positive antinuclear antibodies with fine speckled pattern (1:320) and cytoplasm (1:160) pattern and negative anti-Smith, -double-stranded DNA, Sjogren's syndrome-antigen A and Sjogren's syndrome-antigen B. Histological report of cervical node tissue revealed granulomatous lesions compatible with tuberculosis.","[{'Laboratory': 'O'}, {'results': 'O'}, {'were': 'O'}, {'as': 'O'}, {'follows:': 'O'}, {'ESR': 'O'}, {'44mm/h,': 'O'}, {'C-reactive': 'O'}, {'protein': 'O'}, {'4.35,': 'O'}, {'normal': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'complement': 'O'}, {'C3': 'O'}, {'and': 'O'}, {'C4,': 'O'}, {'negative': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'and': 'O'}, {'anticyclic': 'O'}, {'citrullinated': 'I-Entity'}, {'peptide': 'I-Entity'}, {'antibodies,': 'O'}, {'positive': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'with': 'O'}, {'fine': 'O'}, {'speckled': 'O'}]"
Renal manifestation is characteristically chronic lymphocytic tubulointerstitial nephritis.,"[{'Renal': 'O'}, {'manifestation': 'O'}, {'is': 'O'}, {'characteristically': 'O'}, {'chronic': 'O'}, {'lymphocytic': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis.': 'I-Entity'}]"
"Earlier, systemic lupus erythematosus flared in about 50% of patients during pregnancy, but the flare rate has significantly decreased recently.","[{'Earlier,': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'flared': 'O'}, {'in': 'O'}, {'about': 'O'}, {'50%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'during': 'O'}, {'pregnancy,': 'O'}, {'but': 'O'}, {'the': 'O'}, {'flare': 'O'}, {'rate': 'O'}, {'has': 'O'}, {'significantly': 'O'}, {'decreased': 'O'}, {'recently.': 'O'}]"
"A 13-year-old Pacific Island girl presented complaining of fever, joint pain and dry mouth.","[{'A': 'O'}, {'13-year-old': 'O'}, {'Pacific': 'O'}, {'Island': 'O'}, {'girl': 'O'}, {'presented': 'O'}, {'complaining': 'O'}, {'of': 'O'}, {'fever,': 'I-Entity'}, {'joint': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"Simple univariate regression and multiple regression analyses with fatigue as a dependent variable revealed that depression, pain, and the biochemical variable IL-1Ra had a significant association with fatigue.","[{'Simple': 'O'}, {'univariate': 'O'}, {'regression': 'O'}, {'and': 'O'}, {'multiple': 'O'}, {'regression': 'O'}, {'analyses': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'dependent': 'O'}, {'variable': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'depression,': 'I-Entity'}, {'pain,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'biochemical': 'O'}, {'variable': 'O'}, {'IL-1Ra': 'O'}, {'had': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'association': 'O'}, {'with': 'O'}, {'fatigue.': 'I-Entity'}]"
"Interestingly, SGEC demethylation may be attributed in part to the infiltrating B cells as suspected in patients treated with anti-CD20 antibodies to deplete B cells.","[{'Interestingly,': 'O'}, {'SGEC': 'O'}, {'demethylation': 'O'}, {'may': 'O'}, {'be': 'O'}, {'attributed': 'O'}, {'in': 'O'}, {'part': 'O'}, {'to': 'O'}, {'the': 'O'}, {'infiltrating': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'as': 'O'}, {'suspected': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'anti-CD20': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'deplete': 'O'}, {'B': 'O'}, {'cells.': 'O'}]"
A 46-year-old female was admitted to our hospital because of an abnormal chest roentgenogram finding on a medical checkup.,"[{'A': 'O'}, {'46-year-old': 'O'}, {'female': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'to': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'because': 'O'}, {'of': 'O'}, {'an': 'O'}, {'abnormal': 'O'}, {'chest': 'O'}, {'roentgenogram': 'O'}, {'finding': 'O'}, {'on': 'O'}, {'a': 'O'}, {'medical': 'O'}, {'checkup.': 'O'}]"
"Fifty subjects with pSS and 300 with connective tissue diseases (CTD; systemic lupus erythematosus 100, rheumatoid arthritis 100, scleroderma 100) were selected randomly from our patient registry.","[{'Fifty': 'O'}, {'subjects': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'300': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(CTD;': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'100,': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'100,': 'O'}, {'scleroderma': 'I-Entity'}, {'100)': 'O'}, {'were': 'O'}, {'selected': 'O'}, {'randomly': 'O'}, {'from': 'O'}, {'our': 'O'}, {'patient': 'O'}, {'registry.': 'O'}]"
"This circulating biomarker was enumerated in SLE patients (n = 46), Sjogrens syndrome patients (n = 17), and healthy controls (n = 48) and was correlated with disease activity and end-organ involvement.","[{'This': 'O'}, {'circulating': 'O'}, {'biomarker': 'O'}, {'was': 'O'}, {'enumerated': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'patients': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'46),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'17),': 'O'}, {'and': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'48)': 'O'}, {'and': 'O'}, {'was': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'end-organ': 'O'}, {'involvement.': 'O'}]"
"Almost all patients (98%) had a history of dry eye for an average of 10.4 years (median, 7.9 years) before presentation.","[{'Almost': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'(98%)': 'O'}, {'had': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'for': 'O'}, {'an': 'O'}, {'average': 'O'}, {'of': 'O'}, {'10.4': 'O'}, {'years': 'O'}, {'(median,': 'O'}, {'7.9': 'O'}, {'years)': 'O'}, {'before': 'O'}, {'presentation.': 'O'}]"
"During surgery, the tumors were found to be well capsuled and had no adhesion or invasion to the surrounding tissues consistent with its characteristics of low grade malignancy.","[{'During': 'O'}, {'surgery,': 'O'}, {'the': 'O'}, {'tumors': 'I-Entity'}, {'were': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'well': 'O'}, {'capsuled': 'O'}, {'and': 'O'}, {'had': 'O'}, {'no': 'O'}, {'adhesion': 'O'}, {'or': 'O'}, {'invasion': 'O'}, {'to': 'O'}, {'the': 'O'}, {'surrounding': 'O'}, {'tissues': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'its': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'low': 'O'}, {'grade': 'O'}, {'malignancy.': 'I-Entity'}]"
"In addition to this, ELISA profiling of autoantibodies was carried out using patients' plasma and supernatant, collected post-mitogen stimulation of PBMC.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'this,': 'O'}, {'ELISA': 'O'}, {'profiling': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'was': 'O'}, {'carried': 'O'}, {'out': 'O'}, {'using': 'O'}, {""patients'"": 'O'}, {'plasma': 'O'}, {'and': 'O'}, {'supernatant,': 'O'}, {'collected': 'O'}, {'post-mitogen': 'O'}, {'stimulation': 'O'}, {'of': 'O'}, {'PBMC.': 'O'}]"
This addresses shortcomings of classical ANA analysis like false-negative ANA findings and lack of laboratory efficiency and standardization.,"[{'This': 'O'}, {'addresses': 'O'}, {'shortcomings': 'O'}, {'of': 'O'}, {'classical': 'O'}, {'ANA': 'O'}, {'analysis': 'O'}, {'like': 'O'}, {'false-negative': 'O'}, {'ANA': 'O'}, {'findings': 'O'}, {'and': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'laboratory': 'O'}, {'efficiency': 'O'}, {'and': 'O'}, {'standardization.': 'O'}]"
"Thus, ESSPRI was redefined as the mean of the three scales: dryness, limb pain and fatigue.","[{'Thus,': 'O'}, {'ESSPRI': 'O'}, {'was': 'O'}, {'redefined': 'O'}, {'as': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'of': 'O'}, {'the': 'O'}, {'three': 'O'}, {'scales:': 'O'}, {'dryness,': 'I-Entity'}, {'limb': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'fatigue.': 'I-Entity'}]"
"The most common clinical manifestations at diagnosis were: PMR features, often with atypical clinical presentation (n=23 patients, 72%); diffuse lower limb pain (n=16 patients, 50%); constitutional symptoms (n=12 patients, 37%), inflammatory low back pain (n=9 patients, 28%) and fever (n=7 patients, 22%).","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'at': 'O'}, {'diagnosis': 'O'}, {'were:': 'O'}, {'PMR': 'O'}, {'features,': 'O'}, {'often': 'O'}, {'with': 'O'}, {'atypical': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'(n=23': 'O'}, {'patients,': 'O'}, {'72%);': 'O'}, {'diffuse': 'O'}, {'lower': 'B-Entity'}, {'limb': 'O'}, {'pain': 'I-Entity'}, {'(n=16': 'O'}, {'patients,': 'O'}, {'50%);': 'O'}, {'constitutional': 'O'}, {'symptoms': 'O'}, {'(n=12': 'O'}, {'patients,': 'O'}, {'37%),': 'O'}, {'inflammatory': 'O'}, {'low': 'B-Entity'}, {'back': 'I-Entity'}]"
A familiarity with the numerous findings in commonly encountered systemic diseases is necessary for the radiologist interpreting any chest study.,"[{'A': 'O'}, {'familiarity': 'O'}, {'with': 'O'}, {'the': 'O'}, {'numerous': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'commonly': 'O'}, {'encountered': 'O'}, {'systemic': 'O'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'necessary': 'O'}, {'for': 'O'}, {'the': 'O'}, {'radiologist': 'O'}, {'interpreting': 'O'}, {'any': 'O'}, {'chest': 'O'}, {'study.': 'O'}]"
"Histologically this disease is characterized by a dense polyclonal lymphoplasmacytic infiltrate, and is frequently associated with germinal centers, fibrosis and obliterative phlebitis.","[{'Histologically': 'O'}, {'this': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'dense': 'O'}, {'polyclonal': 'O'}, {'lymphoplasmacytic': 'O'}, {'infiltrate,': 'O'}, {'and': 'O'}, {'is': 'O'}, {'frequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'germinal': 'O'}, {'centers,': 'O'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'obliterative': 'B-Entity'}, {'phlebitis.': 'I-Entity'}]"
The aim of this study was to evaluate the expression of persistence of mumps virus and some cells that interact with viral infection in the focus of the autoimmune epithelitis and peripheral blood of Sjogrens syndrome patients in comparison to patients with rheumatoid arthritis (RA) and nonautoimmune sicca syndrome (nSS).,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'persistence': 'O'}, {'of': 'O'}, {'mumps': 'B-Entity'}, {'virus': 'I-Entity'}, {'and': 'O'}, {'some': 'O'}, {'cells': 'O'}, {'that': 'O'}, {'interact': 'O'}, {'with': 'O'}, {'viral': 'B-Entity'}, {'infection': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'focus': 'O'}, {'of': 'O'}, {'the': 'O'}, {'autoimmune': 'B-Entity'}, {'epithelitis': 'I-Entity'}, {'and': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'to': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}]"
"This paper examines a 58-year-old man with SS, severe dyspnea and recurrent exacerbations associated with bronchiolitis-bronchiectasis.","[{'This': 'O'}, {'paper': 'O'}, {'examines': 'O'}, {'a': 'O'}, {'58-year-old': 'O'}, {'man': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'severe': 'O'}, {'dyspnea': 'I-Entity'}, {'and': 'O'}, {'recurrent': 'O'}, {'exacerbations': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'bronchiolitis-bronchiectasis.': 'I-Entity'}]"
"The association between positive fluorescein staining and diagnosis was significant for dry eye (P<0.0001), Sjogrens syndrome (P<0.0001), and glaucoma (P<0.05).","[{'The': 'O'}, {'association': 'O'}, {'between': 'O'}, {'positive': 'O'}, {'fluorescein': 'I-Entity'}, {'staining': 'O'}, {'and': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'significant': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(P<0.0001),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(P<0.0001),': 'O'}, {'and': 'O'}, {'glaucoma': 'I-Entity'}, {'(P<0.05).': 'O'}]"
This expression pattern makes CD38 an interesting target for a targeted therapy aiming to deplete antibody-producing plasma cells.,"[{'This': 'O'}, {'expression': 'O'}, {'pattern': 'O'}, {'makes': 'O'}, {'CD38': 'O'}, {'an': 'O'}, {'interesting': 'O'}, {'target': 'O'}, {'for': 'O'}, {'a': 'O'}, {'targeted': 'O'}, {'therapy': 'O'}, {'aiming': 'O'}, {'to': 'O'}, {'deplete': 'O'}, {'antibody-producing': 'O'}, {'plasma': 'O'}, {'cells.': 'O'}]"
"After rituximab therapy, all the patients showed a decrease of IgG4 levels to the normal levels and positive changes evidenced by visualization techniques (computed tomography, magnetic resonance imaging).","[{'After': 'O'}, {'rituximab': 'I-Entity'}, {'therapy,': 'O'}, {'all': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'of': 'O'}, {'IgG4': 'O'}, {'levels': 'O'}, {'to': 'O'}, {'the': 'O'}, {'normal': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'changes': 'O'}, {'evidenced': 'O'}, {'by': 'O'}, {'visualization': 'O'}, {'techniques': 'O'}, {'(computed': 'O'}, {'tomography,': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'imaging).': 'O'}]"
"New-onset systemic lupus erythematosus (SLE) during pregnancy and in the postpartum period is rare, especially when complicated with pre-eclampsia, which is difficult to diagnose accurately.","[{'New-onset': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'during': 'O'}, {'pregnancy': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'postpartum': 'O'}, {'period': 'O'}, {'is': 'O'}, {'rare,': 'O'}, {'especially': 'O'}, {'when': 'O'}, {'complicated': 'O'}, {'with': 'O'}, {'pre-eclampsia,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'accurately.': 'O'}]"
"He was eventually diagnosed with SS based on the examination results, such as inflammatory cell infiltration into the minor salivary glands and positive serum anti-SSA/Ro antibody.","[{'He': 'O'}, {'was': 'O'}, {'eventually': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'examination': 'O'}, {'results,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'into': 'O'}, {'the': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'serum': 'O'}, {'anti-SSA/Ro': 'O'}, {'antibody.': 'O'}]"
APL was found effective in the treatment of SS dry eye.,"[{'APL': 'I-Entity'}, {'was': 'O'}, {'found': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'SS': 'B-Entity'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"In this study, we sought to address changes in blood lymphocyte subpopulations and labial salivary gland (LSG) inflammation after belimumab treatment in patients with primary Sjogrens syndrome (pSS) and to identify predictors of response to treatment.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'sought': 'O'}, {'to': 'O'}, {'address': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'blood': 'O'}, {'lymphocyte': 'O'}, {'subpopulations': 'O'}, {'and': 'O'}, {'labial': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'(LSG)': 'O'}, {'inflammation': 'I-Entity'}, {'after': 'O'}, {'belimumab': 'I-Entity'}, {'treatment': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'predictors': 'O'}, {'of': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment.': 'O'}]"
The increase in systolic-diastolic ratio significantly correlates with neuropsychological impairment.,"[{'The': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'systolic-diastolic': 'O'}, {'ratio': 'O'}, {'significantly': 'O'}, {'correlates': 'O'}, {'with': 'O'}, {'neuropsychological': 'B-Entity'}, {'impairment.': 'I-Entity'}]"
"Furthermore, although inclusion body myositis has a low prevalence, it is the most common inflammatory myopathy in older adults and is unfortunately associated with long delays in diagnosis, so knowledge of this disorder is also crucial for practicing internists.Stanford, CA, USA.","[{'Furthermore,': 'O'}, {'although': 'O'}, {'inclusion': 'B-Entity'}, {'body': 'I-Entity'}, {'myositis': 'I-Entity'}, {'has': 'O'}, {'a': 'O'}, {'low': 'O'}, {'prevalence,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'inflammatory': 'B-Entity'}, {'myopathy': 'I-Entity'}, {'in': 'O'}, {'older': 'O'}, {'adults': 'O'}, {'and': 'O'}, {'is': 'O'}, {'unfortunately': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'long': 'O'}, {'delays': 'O'}, {'in': 'O'}, {'diagnosis,': 'O'}, {'so': 'O'}, {'knowledge': 'O'}, {'of': 'O'}, {'this': 'O'}, {'disorder': 'O'}, {'is': 'O'}, {'also': 'O'}, {'crucial': 'O'}, {'for': 'O'}, {'practicing': 'O'}, {'internists.Stanford,': 'O'}, {'CA,': 'O'}, {'USA.': 'O'}]"
We report 6 patients with an established diagnosis of primary Sjogren syndrome who developed severe rheumatoid arthritis (RA) requiring oral disease-modifying antirheumatic drug with or without biologic therapy.,"[{'We': 'O'}, {'report': 'O'}, {'6': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'an': 'O'}, {'established': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'who': 'O'}, {'developed': 'O'}, {'severe': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'requiring': 'O'}, {'oral': 'O'}, {'disease-modifying': 'O'}, {'antirheumatic': 'O'}, {'drug': 'O'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'biologic': 'O'}, {'therapy.': 'O'}]"
"All clinical and laboratory data were follow-up cumulative data, except for anti-Ku antibodies.","[{'All': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'data': 'O'}, {'were': 'O'}, {'follow-up': 'O'}, {'cumulative': 'O'}, {'data,': 'O'}, {'except': 'O'}, {'for': 'O'}, {'anti-Ku': 'O'}, {'antibodies.': 'O'}]"
"Both of the diseases have vague and nonspecific symptoms, causing difficulties for the clinicians to distinguish between the two diseases.","[{'Both': 'O'}, {'of': 'O'}, {'the': 'O'}, {'diseases': 'O'}, {'have': 'O'}, {'vague': 'O'}, {'and': 'O'}, {'nonspecific': 'O'}, {'symptoms,': 'O'}, {'causing': 'O'}, {'difficulties': 'O'}, {'for': 'O'}, {'the': 'O'}, {'clinicians': 'O'}, {'to': 'O'}, {'distinguish': 'O'}, {'between': 'O'}, {'the': 'O'}, {'two': 'O'}, {'diseases.': 'O'}]"
"Salivary epidermal growth factor (EGF) is considered an important cytoprotective factor against injuries, and it contributes to wound healing in the oral cavity.","[{'Salivary': 'O'}, {'epidermal': 'O'}, {'growth': 'O'}, {'factor': 'O'}, {'(EGF)': 'O'}, {'is': 'O'}, {'considered': 'O'}, {'an': 'O'}, {'important': 'O'}, {'cytoprotective': 'O'}, {'factor': 'O'}, {'against': 'O'}, {'injuries,': 'I-Entity'}, {'and': 'O'}, {'it': 'O'}, {'contributes': 'O'}, {'to': 'O'}, {'wound': 'O'}, {'healing': 'O'}, {'in': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'cavity.': 'O'}]"
"Importantly, ITPR3, a key component of calcium signaling in epithelial cells, that has previously shown to be downregulated in SS SG, was directly targeted and downregulated by miR-1248, inducing the same functional calcium signaling changes as observed in SS SGs.","[{'Importantly,': 'O'}, {'ITPR3,': 'O'}, {'a': 'O'}, {'key': 'O'}, {'component': 'O'}, {'of': 'O'}, {'calcium': 'I-Entity'}, {'signaling': 'O'}, {'in': 'O'}, {'epithelial': 'O'}, {'cells,': 'O'}, {'that': 'O'}, {'has': 'O'}, {'previously': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'be': 'O'}, {'downregulated': 'O'}, {'in': 'O'}, {'SS': 'O'}, {'SG,': 'O'}, {'was': 'O'}, {'directly': 'O'}, {'targeted': 'O'}, {'and': 'O'}, {'downregulated': 'O'}, {'by': 'O'}, {'miR-1248,': 'O'}, {'inducing': 'O'}, {'the': 'O'}, {'same': 'O'}, {'functional': 'O'}, {'calcium': 'I-Entity'}, {'signaling': 'O'}, {'changes': 'O'}, {'as': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'SS': 'O'}]"
Ten patients with pSS were reassessed after 3.1‚Äö√Ñ√∂‚àö√ë‚àö¬¢years (1.7-4.7); none developed large fiber neuropathy linked to pSS.,"[{'Ten': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'were': 'O'}, {'reassessed': 'O'}, {'after': 'O'}, {'3.1‚Äö√Ñ√∂‚àö√ë‚àö¬¢years': 'O'}, {'(1.7-4.7);': 'O'}, {'none': 'O'}, {'developed': 'O'}, {'large': 'O'}, {'fiber': 'O'}, {'neuropathy': 'I-Entity'}, {'linked': 'O'}, {'to': 'O'}, {'pSS.': 'I-Entity'}]"
"In RA and SLE, HCQ is preferred because of the lower incidence of gastrointestinal adverse reactions compared with CQ and it might have a lower risk of ocular adverse reactions.","[{'In': 'O'}, {'RA': 'I-Entity'}, {'and': 'O'}, {'SLE,': 'I-Entity'}, {'HCQ': 'I-Entity'}, {'is': 'O'}, {'preferred': 'O'}, {'because': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lower': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'gastrointestinal': 'B-Entity'}, {'adverse': 'I-Entity'}, {'reactions': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'CQ': 'I-Entity'}, {'and': 'O'}, {'it': 'O'}, {'might': 'O'}, {'have': 'O'}, {'a': 'O'}, {'lower': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'adverse': 'I-Entity'}, {'reactions.': 'O'}]"
"In fact, the involvement of lacrimal and salivary glands results in the typical features of dry eye and salivary dysfunction (xerostomia).","[{'In': 'O'}, {'fact,': 'O'}, {'the': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'results': 'O'}, {'in': 'O'}, {'the': 'O'}, {'typical': 'O'}, {'features': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'salivary': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'(xerostomia).': 'O'}]"
The MIECA and the mean N/C ratios were worse in dry eye subjects compared to controls both in impression cytology and in vivo confocal microscopy (p<0.0001) with no significant differences between these parameters when the two examination techniques were compared.,"[{'The': 'O'}, {'MIECA': 'O'}, {'and': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'N/C': 'O'}, {'ratios': 'O'}, {'were': 'O'}, {'worse': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'subjects': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'controls': 'O'}, {'both': 'O'}, {'in': 'O'}, {'impression': 'O'}, {'cytology': 'O'}, {'and': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'(p<0.0001)': 'O'}, {'with': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'between': 'O'}, {'these': 'O'}, {'parameters': 'O'}, {'when': 'O'}, {'the': 'O'}, {'two': 'O'}, {'examination': 'O'}, {'techniques': 'O'}, {'were': 'O'}, {'compared.': 'O'}]"
The coincidence of systemic autoimmune diseases and pregnancy may modify the outcome of the disease and the pregnancy due to the background immunologic and hormonal processes.,"[{'The': 'O'}, {'coincidence': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'pregnancy': 'O'}, {'may': 'O'}, {'modify': 'O'}, {'the': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'the': 'O'}, {'pregnancy': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'background': 'O'}, {'immunologic': 'O'}, {'and': 'O'}, {'hormonal': 'O'}, {'processes.': 'O'}]"
The role of recombinant IL-34 on isolated peripheral blood mononuclear cells was also evaluated.,"[{'The': 'O'}, {'role': 'O'}, {'of': 'O'}, {'recombinant': 'O'}, {'IL-34': 'O'}, {'on': 'O'}, {'isolated': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'was': 'O'}, {'also': 'O'}, {'evaluated.': 'O'}]"
Diagnosis of pSS is challenging even in tertiary care centers as patients present with myriad features to several specialties.,"[{'Diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'challenging': 'O'}, {'even': 'O'}, {'in': 'O'}, {'tertiary': 'O'}, {'care': 'O'}, {'centers': 'O'}, {'as': 'O'}, {'patients': 'O'}, {'present': 'O'}, {'with': 'O'}, {'myriad': 'O'}, {'features': 'O'}, {'to': 'O'}, {'several': 'O'}, {'specialties.': 'O'}]"
Lower levels of pro-inflammatory cytokines indicate a beneficial effect of oral steroids in this patient group.Norway.,"[{'Lower': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'pro-inflammatory': 'O'}, {'cytokines': 'O'}, {'indicate': 'O'}, {'a': 'O'}, {'beneficial': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'steroids': 'I-Entity'}, {'in': 'O'}, {'this': 'O'}, {'patient': 'O'}, {'group.Norway.': 'O'}]"
"5 out of the 11 patients had been diagnosed with an autoimmune disease, namely rheumatoid arthritis (RA), Sjogren's syndrome (SS) and antiphospholipid syndrome (APS).","[{'5': 'O'}, {'out': 'O'}, {'of': 'O'}, {'the': 'O'}, {'11': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'been': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'namely': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS).': 'O'}]"
"Sjogren's syndrome (SS) is characterized by infiltration of exocrine glands with T and B lymphocytes, leading to glandular dysfunction and frequently accompanied by hypergammaglobulinemia and autoantibodies.","[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'with': 'O'}, {'T': 'O'}, {'and': 'O'}, {'B': 'O'}, {'lymphocytes,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'glandular': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'and': 'O'}, {'frequently': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'hypergammaglobulinemia': 'I-Entity'}, {'and': 'O'}, {'autoantibodies.': 'O'}]"
Mucus plugs and debris were removed with irrigation or with a forceps if necessary.,"[{'Mucus': 'O'}, {'plugs': 'O'}, {'and': 'O'}, {'debris': 'O'}, {'were': 'O'}, {'removed': 'O'}, {'with': 'O'}, {'irrigation': 'O'}, {'or': 'O'}, {'with': 'O'}, {'a': 'O'}, {'forceps': 'O'}, {'if': 'O'}, {'necessary.': 'O'}]"
We report a case of aortic stenosis (AS) associated with SS in an elderly patient.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'aortic': 'B-Entity'}, {'stenosis': 'I-Entity'}, {'(AS)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'an': 'O'}, {'elderly': 'O'}, {'patient.': 'O'}]"
"We found leukocytosis, azygos fissure on chest X-ray along with normal pulmonary function tests and arterial blood gases.","[{'We': 'O'}, {'found': 'O'}, {'leukocytosis,': 'I-Entity'}, {'azygos': 'B-Entity'}, {'fissure': 'I-Entity'}, {'on': 'O'}, {'chest': 'O'}, {'X-ray': 'O'}, {'along': 'O'}, {'with': 'O'}, {'normal': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'and': 'O'}, {'arterial': 'O'}, {'blood': 'O'}, {'gases.': 'O'}]"
"Sjogrens syndrome is an autoimmune disease which targets the salivary and lacrimal glands in particular, causing sicca syndrome.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'which': 'O'}, {'targets': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'in': 'O'}, {'particular,': 'O'}, {'causing': 'O'}, {'sicca': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
The quadrivariate Disease Activity Score- 28 (DAS28) was used for measuring disease activity.,"[{'The': 'O'}, {'quadrivariate': 'O'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Score-': 'O'}, {'28': 'O'}, {'(DAS28)': 'O'}, {'was': 'O'}, {'used': 'O'}, {'for': 'O'}, {'measuring': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"For 790 patients from two large prospective cohorts, ESSDAI, physician evaluation of disease activity, ESSPRI and patients' satisfaction with their current health status were recorded.","[{'For': 'O'}, {'790': 'O'}, {'patients': 'O'}, {'from': 'O'}, {'two': 'O'}, {'large': 'O'}, {'prospective': 'O'}, {'cohorts,': 'O'}, {'ESSDAI,': 'O'}, {'physician': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'ESSPRI': 'O'}, {'and': 'O'}, {""patients'"": 'O'}, {'satisfaction': 'O'}, {'with': 'O'}, {'their': 'O'}, {'current': 'O'}, {'health': 'O'}, {'status': 'O'}, {'were': 'O'}, {'recorded.': 'O'}]"
"The present review of the MSGB using strict focus scoring guidelines yielded 95.4% sensitivity, 76.4% specificity, 63.6% PPV, and 97.5% NPV.","[{'The': 'O'}, {'present': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'MSGB': 'O'}, {'using': 'O'}, {'strict': 'O'}, {'focus': 'O'}, {'scoring': 'O'}, {'guidelines': 'O'}, {'yielded': 'O'}, {'95.4%': 'O'}, {'sensitivity,': 'O'}, {'76.4%': 'O'}, {'specificity,': 'O'}, {'63.6%': 'O'}, {'PPV,': 'O'}, {'and': 'O'}, {'97.5%': 'O'}, {'NPV.': 'O'}]"
"The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale.","[{'The': 'O'}, {'primary': 'O'}, {'end': 'O'}, {'point': 'O'}, {'was': 'O'}, {'the': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'achieving': 'O'}, {'a': 'O'}, {'30%': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'either': 'O'}, {'fatigue': 'I-Entity'}, {'or': 'O'}, {'oral': 'B-Entity'}, {'dryness': 'I-Entity'}, {'at': 'O'}, {'48': 'O'}, {'weeks,': 'O'}, {'as': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'visual': 'O'}, {'analog': 'O'}, {'scale.': 'O'}]"
"Mice cannulated with the Ad5-IL17R:Fc viral vector at either 7 or 16 weeks of age exhibited a rapid temporal, yet persistent, decrease in the levels of serum IL17 as well as the overall numbers of CD4+IL17+T cells present in their spleens.","[{'Mice': 'O'}, {'cannulated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'Ad5-IL17R:Fc': 'O'}, {'viral': 'O'}, {'vector': 'O'}, {'at': 'O'}, {'either': 'O'}, {'7': 'O'}, {'or': 'O'}, {'16': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'age': 'O'}, {'exhibited': 'O'}, {'a': 'O'}, {'rapid': 'O'}, {'temporal,': 'O'}, {'yet': 'O'}, {'persistent,': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'IL17': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'the': 'O'}, {'overall': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'CD4+IL17+T': 'O'}, {'cells': 'O'}, {'present': 'O'}, {'in': 'O'}, {'their': 'O'}, {'spleens.': 'O'}]"
The ability to both understand the information and to perceive the information as sufficient were significantly higher when someone trained in paediatric cardiology gave the information.,"[{'The': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'both': 'O'}, {'understand': 'O'}, {'the': 'O'}, {'information': 'O'}, {'and': 'O'}, {'to': 'O'}, {'perceive': 'O'}, {'the': 'O'}, {'information': 'O'}, {'as': 'O'}, {'sufficient': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'when': 'O'}, {'someone': 'O'}, {'trained': 'O'}, {'in': 'O'}, {'paediatric': 'O'}, {'cardiology': 'O'}, {'gave': 'O'}, {'the': 'O'}, {'information.': 'O'}]"
One-hundred and ninety-three patients and 70 SNPs in 11 genes were available for analysis after quality control.,"[{'One-hundred': 'O'}, {'and': 'O'}, {'ninety-three': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'70': 'O'}, {'SNPs': 'O'}, {'in': 'O'}, {'11': 'O'}, {'genes': 'O'}, {'were': 'O'}, {'available': 'O'}, {'for': 'O'}, {'analysis': 'O'}, {'after': 'O'}, {'quality': 'O'}, {'control.': 'O'}]"
"In 105 pSS patients (mean age 51.34 years, mean disease duration 5.98 years), 52 RA patients (mean age 51.37 years, mean disease duration 8.10 years) and 54 HC (mean age 51.35 years) clinical and sociodemographic characteristics were determined and results analyzed.","[{'In': 'O'}, {'105': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'(mean': 'O'}, {'age': 'O'}, {'51.34': 'O'}, {'years,': 'O'}, {'mean': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'5.98': 'O'}, {'years),': 'O'}, {'52': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'(mean': 'O'}, {'age': 'O'}, {'51.37': 'O'}, {'years,': 'O'}, {'mean': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'8.10': 'O'}, {'years)': 'O'}, {'and': 'O'}, {'54': 'O'}, {'HC': 'O'}, {'(mean': 'O'}, {'age': 'O'}, {'51.35': 'O'}, {'years)': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'sociodemographic': 'O'}, {'characteristics': 'O'}, {'were': 'O'}, {'determined': 'O'}, {'and': 'O'}]"
There was no history of dry eyes or dry mouth.,"[{'There': 'O'}, {'was': 'O'}, {'no': 'O'}, {'history': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'or': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
Poly(I:C) treatment significantly upregulated the expression of multiple chemokines within the submandibular glands.,"[{'Poly(I:C)': 'B-Entity'}, {'treatment': 'O'}, {'significantly': 'O'}, {'upregulated': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'multiple': 'O'}, {'chemokines': 'O'}, {'within': 'O'}, {'the': 'O'}, {'submandibular': 'O'}, {'glands.': 'O'}]"
"IL7R‚âà√≠¬¨¬± cells strongly correlated with the lymphocytic focus score, IL-7 expression, the decrease in percentage of IgA plasma cells and numbers of CD3 T cells, CD20 B cells, and CD1a and CD208 myeloid dendritic cells.","[{'IL7R‚âà√≠¬¨¬±': 'O'}, {'cells': 'O'}, {'strongly': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'lymphocytic': 'O'}, {'focus': 'O'}, {'score,': 'O'}, {'IL-7': 'O'}, {'expression,': 'O'}, {'the': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'percentage': 'O'}, {'of': 'O'}, {'IgA': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'CD3': 'O'}, {'T': 'O'}, {'cells,': 'O'}, {'CD20': 'O'}, {'B': 'O'}, {'cells,': 'O'}, {'and': 'O'}, {'CD1a': 'O'}, {'and': 'O'}, {'CD208': 'O'}, {'myeloid': 'O'}]"
"At 31 years of age, she was diagnosed with multiple sclerosis because of optic neuritis and myelitis.","[{'At': 'O'}, {'31': 'O'}, {'years': 'O'}, {'of': 'O'}, {'age,': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'because': 'O'}, {'of': 'O'}, {'optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'and': 'O'}, {'myelitis.': 'I-Entity'}]"
"Autonomic signs and symptoms in SS are potentially immunoresponsive, but immunotherapy in these patients may require repeated, ongoing, or adjunctive therapy for optimal and sustained improvement.steroid drops post routine cataract extraction.","[{'Autonomic': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'are': 'O'}, {'potentially': 'O'}, {'immunoresponsive,': 'O'}, {'but': 'O'}, {'immunotherapy': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'may': 'O'}, {'require': 'O'}, {'repeated,': 'O'}, {'ongoing,': 'O'}, {'or': 'O'}, {'adjunctive': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'optimal': 'O'}, {'and': 'O'}, {'sustained': 'O'}, {'improvement.steroid': 'O'}, {'drops': 'O'}, {'post': 'O'}, {'routine': 'O'}, {'cataract': 'I-Entity'}, {'extraction.': 'O'}]"
"This article details the various musculoskeletal imaging features of the other connective tissue diseases such as scleroderma and progressive systemic sclerosis, systemic lupus erythematosus, Still's disease, dermatomyositis and polymyositis, Sjogrens syndrome, and mixed connective tissue disease.France.Rehabilitation; Warsaw, Poland.Leeds, Leeds, United Kingdom.France.Epub 2018 Apr 19.severe autoimmune thrombocytopenia and hemolytic anemia in a patient with Sjogrens syndrome].","[{'This': 'O'}, {'article': 'O'}, {'details': 'O'}, {'the': 'O'}, {'various': 'O'}, {'musculoskeletal': 'O'}, {'imaging': 'O'}, {'features': 'O'}, {'of': 'O'}, {'the': 'O'}, {'other': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'scleroderma': 'I-Entity'}, {'and': 'O'}, {'progressive': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {""Still's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {'dermatomyositis': 'I-Entity'}, {'and': 'O'}, {'polymyositis,': 'I-Entity'}, {'Sjogrens': 'O'}]"
"A man in his thirties was admitted with a constellation of fatigue, flank pain, weight loss and bilateral acute anterior uveitis.","[{'A': 'O'}, {'man': 'O'}, {'in': 'O'}, {'his': 'O'}, {'thirties': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'with': 'O'}, {'a': 'O'}, {'constellation': 'O'}, {'of': 'O'}, {'fatigue,': 'I-Entity'}, {'flank': 'B-Entity'}, {'pain,': 'I-Entity'}, {'weight': 'B-Entity'}, {'loss': 'I-Entity'}, {'and': 'O'}, {'bilateral': 'O'}, {'acute': 'O'}, {'anterior': 'B-Entity'}, {'uveitis.': 'I-Entity'}]"
We demonstrated an increase of serum IL-21 with systemic activity.,"[{'We': 'O'}, {'demonstrated': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'IL-21': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'activity.': 'O'}]"
"The sensitivity of EliA CTD Screen for systemic lupus erythematosus, systemic sclerosis, primary Sjogrens syndrome, mixed connective tissue disease, and inflammatory myopathy was 74%, 72%, 89%, 100%, and 39%, respectively.","[{'The': 'O'}, {'sensitivity': 'O'}, {'of': 'O'}, {'EliA': 'O'}, {'CTD': 'O'}, {'Screen': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'mixed': 'B-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'inflammatory': 'B-Entity'}, {'myopathy': 'I-Entity'}, {'was': 'O'}, {'74%,': 'O'}, {'72%,': 'O'}, {'89%,': 'O'}, {'100%,': 'O'}, {'and': 'O'}, {'39%,': 'O'}, {'respectively.': 'O'}]"
"In a subset of SLE patients (14 of 46), but in none of the controls, the levels of circulating Tfh cells (defined as circulating CXCR5+CD4+ cells with high expression of Tfh-associated molecules, such as inducible T cell costimulator or programmed death 1) were increased.","[{'In': 'O'}, {'a': 'O'}, {'subset': 'O'}, {'of': 'O'}, {'SLE': 'I-Entity'}, {'patients': 'O'}, {'(14': 'O'}, {'of': 'O'}, {'46),': 'O'}, {'but': 'O'}, {'in': 'O'}, {'none': 'O'}, {'of': 'O'}, {'the': 'O'}, {'controls,': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'circulating': 'O'}, {'Tfh': 'O'}, {'cells': 'O'}, {'(defined': 'O'}, {'as': 'O'}, {'circulating': 'O'}, {'CXCR5+CD4+': 'O'}, {'cells': 'O'}, {'with': 'O'}, {'high': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'Tfh-associated': 'O'}, {'molecules,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'inducible': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'costimulator': 'O'}]"
Increased GRP78 and sXBP1 expression was found in experimental dry eye and Sjogren syndrome models and was GC specific.,"[{'Increased': 'O'}, {'GRP78': 'O'}, {'and': 'O'}, {'sXBP1': 'O'}, {'expression': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'experimental': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'models': 'O'}, {'and': 'O'}, {'was': 'O'}, {'GC': 'O'}, {'specific.': 'O'}]"
"Unlike bone marrow plugs where MSCs were initially isolated, compact bone has minimal (amount of) hematopoietic cells and thus facilitates the MSCs isolation process.","[{'Unlike': 'O'}, {'bone': 'O'}, {'marrow': 'O'}, {'plugs': 'O'}, {'where': 'O'}, {'MSCs': 'O'}, {'were': 'O'}, {'initially': 'O'}, {'isolated,': 'O'}, {'compact': 'O'}, {'bone': 'O'}, {'has': 'O'}, {'minimal': 'O'}, {'(amount': 'O'}, {'of)': 'O'}, {'hematopoietic': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'thus': 'O'}, {'facilitates': 'O'}, {'the': 'O'}, {'MSCs': 'O'}, {'isolation': 'O'}, {'process.': 'O'}]"
"A gynecologic evaluation is needed both in pSS and nS-SS to assess genital involvement and, eventually, to address a therapy targeted to genital symptoms.Division of Rheumatology Department of Science for Woman and Child Health (A.D.M.","[{'A': 'O'}, {'gynecologic': 'O'}, {'evaluation': 'O'}, {'is': 'O'}, {'needed': 'O'}, {'both': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'nS-SS': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'genital': 'O'}, {'involvement': 'O'}, {'and,': 'O'}, {'eventually,': 'O'}, {'to': 'O'}, {'address': 'O'}, {'a': 'O'}, {'therapy': 'O'}, {'targeted': 'O'}, {'to': 'O'}, {'genital': 'O'}, {'symptoms.Division': 'O'}, {'of': 'O'}, {'Rheumatology': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Science': 'O'}, {'for': 'O'}, {'Woman': 'O'}, {'and': 'O'}, {'Child': 'O'}, {'Health': 'O'}, {'(A.D.M.': 'O'}]"
No one autoantibody has been identified as the definite cause of pulmonary hypertension.,"[{'No': 'O'}, {'one': 'O'}, {'autoantibody': 'O'}, {'has': 'O'}, {'been': 'O'}, {'identified': 'O'}, {'as': 'O'}, {'the': 'O'}, {'definite': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension.': 'I-Entity'}]"
"People with pSS also described a range of ocular symptoms including pain, dryness, and itching, which were compounded by fatigue.","[{'People': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'also': 'O'}, {'described': 'O'}, {'a': 'O'}, {'range': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'including': 'O'}, {'pain,': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'and': 'O'}, {'itching,': 'I-Entity'}, {'which': 'O'}, {'were': 'O'}, {'compounded': 'O'}, {'by': 'O'}, {'fatigue.': 'I-Entity'}]"
"Salivary and serum FLCs were assayed in 15 patients and 13 patients, respectively, and in 15 controls.","[{'Salivary': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'FLCs': 'O'}, {'were': 'O'}, {'assayed': 'O'}, {'in': 'O'}, {'15': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'13': 'O'}, {'patients,': 'O'}, {'respectively,': 'O'}, {'and': 'O'}, {'in': 'O'}, {'15': 'O'}, {'controls.': 'O'}]"
To compare parotid diffusion-weighted images (DWIs) taken before and after abatacept therapy in patients with Sjogrens syndrome (SS) associated with rheumatoid arthritis (RA) and to examine the utility in evaluation and prediction of response to therapy.,"[{'To': 'O'}, {'compare': 'O'}, {'parotid': 'O'}, {'diffusion-weighted': 'O'}, {'images': 'O'}, {'(DWIs)': 'O'}, {'taken': 'O'}, {'before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'abatacept': 'I-Entity'}, {'therapy': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'utility': 'O'}, {'in': 'O'}, {'evaluation': 'O'}, {'and': 'O'}, {'prediction': 'O'}, {'of': 'O'}, {'response': 'O'}, {'to': 'O'}, {'therapy.': 'O'}]"
"Published data on the use of biological therapies in PSS, the possible roles for other biological therapies and the potential challenges for their use.","[{'Published': 'O'}, {'data': 'O'}, {'on': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'biological': 'O'}, {'therapies': 'O'}, {'in': 'O'}, {'PSS,': 'I-Entity'}, {'the': 'O'}, {'possible': 'O'}, {'roles': 'O'}, {'for': 'O'}, {'other': 'O'}, {'biological': 'O'}, {'therapies': 'O'}, {'and': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'challenges': 'O'}, {'for': 'O'}, {'their': 'O'}, {'use.': 'O'}]"
Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system that preferentially affects the optic nerves and spinal cord.,"[{'Neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'(NMO)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'demyelinating': 'B-Entity'}, {'disease': 'I-Entity'}, {'of': 'O'}, {'the': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'that': 'O'}, {'preferentially': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'optic': 'O'}, {'nerves': 'O'}, {'and': 'O'}, {'spinal': 'O'}, {'cord.': 'O'}]"
"Periocular lesions, such as eyelid involvement and orbital inflammation, are relatively rare and, in case of orbital masses, may require a biopsy control.","[{'Periocular': 'B-Entity'}, {'lesions,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'eyelid': 'B-Entity'}, {'involvement': 'I-Entity'}, {'and': 'O'}, {'orbital': 'B-Entity'}, {'inflammation,': 'I-Entity'}, {'are': 'O'}, {'relatively': 'O'}, {'rare': 'O'}, {'and,': 'O'}, {'in': 'O'}, {'case': 'O'}, {'of': 'O'}, {'orbital': 'B-Entity'}, {'masses,': 'I-Entity'}, {'may': 'O'}, {'require': 'O'}, {'a': 'O'}, {'biopsy': 'O'}, {'control.': 'O'}]"
"The duration of AST treatment was 1-6 months in 25%, 6-12 months in 24%, 1-2 years in 22%, and 2-3 years in 29% of the participants.","[{'The': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'AST': 'I-Entity'}, {'treatment': 'O'}, {'was': 'O'}, {'1-6': 'O'}, {'months': 'O'}, {'in': 'O'}, {'25%,': 'O'}, {'6-12': 'O'}, {'months': 'O'}, {'in': 'O'}, {'24%,': 'O'}, {'1-2': 'O'}, {'years': 'O'}, {'in': 'O'}, {'22%,': 'O'}, {'and': 'O'}, {'2-3': 'O'}, {'years': 'O'}, {'in': 'O'}, {'29%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'participants.': 'O'}]"
Antibodies to the SS-A level was 127U/ml.,"[{'Antibodies': 'O'}, {'to': 'O'}, {'the': 'O'}, {'SS-A': 'I-Entity'}, {'level': 'O'}, {'was': 'O'}, {'127U/ml.': 'O'}]"
"One year after the onset of symptoms acrocyanosis and digital necrosis, gastric adenocarcinoma was diagnosed, without metastatic disease, and surgical treatment was performed.","[{'One': 'O'}, {'year': 'O'}, {'after': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'symptoms': 'O'}, {'acrocyanosis': 'I-Entity'}, {'and': 'O'}, {'digital': 'B-Entity'}, {'necrosis,': 'I-Entity'}, {'gastric': 'B-Entity'}, {'adenocarcinoma': 'I-Entity'}, {'was': 'O'}, {'diagnosed,': 'O'}, {'without': 'O'}, {'metastatic': 'O'}, {'disease,': 'O'}, {'and': 'O'}, {'surgical': 'O'}, {'treatment': 'O'}, {'was': 'O'}, {'performed.': 'O'}]"
"Evidence was graded in categories I-IV and a treatment algorithm, comprising first line, second line and rescue therapies for ocular dryness associated with SS was proposed.","[{'Evidence': 'O'}, {'was': 'O'}, {'graded': 'O'}, {'in': 'O'}, {'categories': 'O'}, {'I-IV': 'O'}, {'and': 'O'}, {'a': 'O'}, {'treatment': 'O'}, {'algorithm,': 'O'}, {'comprising': 'O'}, {'first': 'O'}, {'line,': 'O'}, {'second': 'O'}, {'line': 'O'}, {'and': 'O'}, {'rescue': 'O'}, {'therapies': 'O'}, {'for': 'O'}, {'ocular': 'B-Entity'}, {'dryness': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'was': 'O'}, {'proposed.': 'O'}]"
"B cell subsets and function were analyzed in peripheral blood from 66 adult patients with primary SS (including 14 patients with B cell lymphoproliferative disease [LPD]) and 30 healthy donors, using flow cytometry, calcium mobilization, and gene array analysis.","[{'B': 'O'}, {'cell': 'O'}, {'subsets': 'O'}, {'and': 'O'}, {'function': 'O'}, {'were': 'O'}, {'analyzed': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'from': 'O'}, {'66': 'O'}, {'adult': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'(including': 'O'}, {'14': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'B': 'B-Entity'}, {'cell': 'I-Entity'}, {'lymphoproliferative': 'I-Entity'}, {'disease': 'I-Entity'}, {'[LPD])': 'O'}, {'and': 'O'}, {'30': 'O'}, {'healthy': 'O'}, {'donors,': 'O'}, {'using': 'O'}, {'flow': 'O'}, {'cytometry,': 'O'}, {'calcium': 'I-Entity'}, {'mobilization,': 'O'}, {'and': 'O'}, {'gene': 'O'}, {'array': 'O'}, {'analysis.': 'O'}]"
"We found that all of the costimulatory molecules were expressed in duct epithelial cells of salivary glands from MRL-Fas(lpr) mice, whereas immunoreactivity was absent or weak in the MRL/+ mice.","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'all': 'O'}, {'of': 'O'}, {'the': 'O'}, {'costimulatory': 'O'}, {'molecules': 'O'}, {'were': 'O'}, {'expressed': 'O'}, {'in': 'O'}, {'duct': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'MRL-Fas(lpr)': 'O'}, {'mice,': 'O'}, {'whereas': 'O'}, {'immunoreactivity': 'O'}, {'was': 'O'}, {'absent': 'O'}, {'or': 'O'}, {'weak': 'O'}, {'in': 'O'}, {'the': 'O'}, {'MRL/+': 'O'}, {'mice.': 'O'}]"
"The specific criteria for this diagnosis are reviewed including the symptoms, antinuclear antibodies (ANA), extractable nuclear antigen antibodies (ENA), abnormal salivary scintigraphy and positive Schirmer test.","[{'The': 'O'}, {'specific': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'this': 'O'}, {'diagnosis': 'O'}, {'are': 'O'}, {'reviewed': 'O'}, {'including': 'O'}, {'the': 'O'}, {'symptoms,': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANA),': 'O'}, {'extractable': 'O'}, {'nuclear': 'O'}, {'antigen': 'O'}, {'antibodies': 'O'}, {'(ENA),': 'O'}, {'abnormal': 'O'}, {'salivary': 'O'}, {'scintigraphy': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'Schirmer': 'O'}, {'test.': 'O'}]"
"We conducted a baseline assessment of salivary flow and saliva sampling for the measurement of sodium, chlorine, potassium, calcium and phosphate electrolytes, and the determination of anti-Ro/SSA and La/SSB antibodies; a serum sampling was made to assess antibody positivity.","[{'We': 'O'}, {'conducted': 'O'}, {'a': 'O'}, {'baseline': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'and': 'O'}, {'saliva': 'O'}, {'sampling': 'O'}, {'for': 'O'}, {'the': 'O'}, {'measurement': 'O'}, {'of': 'O'}, {'sodium,': 'I-Entity'}, {'chlorine,': 'I-Entity'}, {'potassium,': 'I-Entity'}, {'calcium': 'I-Entity'}, {'and': 'O'}, {'phosphate': 'I-Entity'}, {'electrolytes,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'determination': 'O'}, {'of': 'O'}, {'anti-Ro/SSA': 'O'}, {'and': 'O'}, {'La/SSB': 'O'}, {'antibodies;': 'O'}, {'a': 'O'}, {'serum': 'O'}, {'sampling': 'O'}, {'was': 'O'}, {'made': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'antibody': 'O'}, {'positivity.': 'O'}]"
"The prevalence of DES subjects with anxiety or depression symptoms was significantly higher than in the control group (P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.003, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001).","[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'DES': 'I-Entity'}, {'subjects': 'O'}, {'with': 'O'}, {'anxiety': 'I-Entity'}, {'or': 'O'}, {'depression': 'I-Entity'}, {'symptoms': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group': 'O'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.003,': 'O'}, {'P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001).': 'O'}]"
TO was increased in RA patients with or without sSS.,"[{'TO': 'O'}, {'was': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'sSS.': 'O'}]"
"Compared with primary SS, RA/SS patients were older, had more severe arthritis, anaemia and lung involvement; a lower incidence of fever, rash, leucopenia, thrombocytopenia and hyperthyroidism; and a higher frequency of RF, anti-keratin antibody, anti-perinuclear factor and anti-cyclic citrullinated antibodies (P < 0.05).","[{'Compared': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS,': 'I-Entity'}, {'RA/SS': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'older,': 'O'}, {'had': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'arthritis,': 'I-Entity'}, {'anaemia': 'I-Entity'}, {'and': 'O'}, {'lung': 'I-Entity'}, {'involvement;': 'O'}, {'a': 'O'}, {'lower': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'fever,': 'I-Entity'}, {'rash,': 'I-Entity'}, {'leucopenia,': 'I-Entity'}, {'thrombocytopenia': 'I-Entity'}, {'and': 'O'}, {'hyperthyroidism;': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'RF,': 'O'}, {'anti-keratin': 'O'}]"
Retrospective study based on the presence or absence of anti-Ro52 antibodies in patients with pSS.,"[{'Retrospective': 'O'}, {'study': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'or': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'anti-Ro52': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"From a cohort of 584 SS patients followed in our department from 1980 to 2010, we retrospectively analyzed 53 consecutive NHL cases.","[{'From': 'O'}, {'a': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'584': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'followed': 'O'}, {'in': 'O'}, {'our': 'O'}, {'department': 'O'}, {'from': 'O'}, {'1980': 'O'}, {'to': 'O'}, {'2010,': 'O'}, {'we': 'O'}, {'retrospectively': 'O'}, {'analyzed': 'O'}, {'53': 'O'}, {'consecutive': 'O'}, {'NHL': 'I-Entity'}, {'cases.': 'O'}]"
"Four months after the initiation of colchicine treatment, she presented with MCTD-related pulmonary artery hypertension.","[{'Four': 'O'}, {'months': 'O'}, {'after': 'O'}, {'the': 'O'}, {'initiation': 'O'}, {'of': 'O'}, {'colchicine': 'I-Entity'}, {'treatment,': 'O'}, {'she': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'MCTD-related': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'artery': 'I-Entity'}, {'hypertension.': 'I-Entity'}]"
"A total of 92 subjects who met American-European consensus criteria for the diagnosis of pSS completed a questionnaire that included health history, medication use, illness perceptions, pain severity, mood, fatigue, pain anxiety, and pain catastrophizing.","[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'92': 'O'}, {'subjects': 'O'}, {'who': 'O'}, {'met': 'O'}, {'American-European': 'O'}, {'consensus': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'completed': 'O'}, {'a': 'O'}, {'questionnaire': 'O'}, {'that': 'O'}, {'included': 'O'}, {'health': 'O'}, {'history,': 'O'}, {'medication': 'O'}, {'use,': 'O'}, {'illness': 'O'}, {'perceptions,': 'O'}, {'pain': 'I-Entity'}, {'severity,': 'O'}, {'mood,': 'O'}, {'fatigue,': 'I-Entity'}, {'pain': 'I-Entity'}, {'anxiety,': 'I-Entity'}, {'and': 'O'}, {'pain': 'I-Entity'}, {'catastrophizing.': 'O'}]"
"As discussed, overexpression of type I IFN and BAFF on one hand and IL-6 and IL-21 on the other hand are critically involved in the enhanced plasma cell formation in pSS patients.","[{'As': 'O'}, {'discussed,': 'O'}, {'overexpression': 'O'}, {'of': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'and': 'O'}, {'BAFF': 'O'}, {'on': 'O'}, {'one': 'O'}, {'hand': 'O'}, {'and': 'O'}, {'IL-6': 'O'}, {'and': 'O'}, {'IL-21': 'O'}, {'on': 'O'}, {'the': 'O'}, {'other': 'O'}, {'hand': 'O'}, {'are': 'O'}, {'critically': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'enhanced': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'formation': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
Altogether 13 patients were identified.,"[{'Altogether': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'identified.': 'O'}]"
"Its clinical diagnosis is not easy because FM-like symptoms are frequent, and its differential diagnosis with other causes of chronic diffuse pain is difficult.","[{'Its': 'O'}, {'clinical': 'O'}, {'diagnosis': 'O'}, {'is': 'O'}, {'not': 'O'}, {'easy': 'O'}, {'because': 'O'}, {'FM-like': 'I-Entity'}, {'symptoms': 'O'}, {'are': 'O'}, {'frequent,': 'O'}, {'and': 'O'}, {'its': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'with': 'O'}, {'other': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'chronic': 'O'}, {'diffuse': 'O'}, {'pain': 'I-Entity'}, {'is': 'O'}, {'difficult.': 'O'}]"
"Specifically, we compare the diagnostic accuracy of lung ultrasound with traditional imaging techniques and pulmonary functional tests.Pisa, Italy.","[{'Specifically,': 'O'}, {'we': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'diagnostic': 'O'}, {'accuracy': 'O'}, {'of': 'O'}, {'lung': 'O'}, {'ultrasound': 'O'}, {'with': 'O'}, {'traditional': 'O'}, {'imaging': 'O'}, {'techniques': 'O'}, {'and': 'O'}, {'pulmonary': 'O'}, {'functional': 'O'}, {'tests.Pisa,': 'O'}, {'Italy.': 'O'}]"
"MRI of left knee was highly consistent with tuberculous arthritis, which was further confirmed by positive blood culture of Mycobacterium tuberculosis and acid-fast stain of synovial fluid.and dental management with a 6-year follow-up.","[{'MRI': 'O'}, {'of': 'O'}, {'left': 'O'}, {'knee': 'O'}, {'was': 'O'}, {'highly': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'tuberculous': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'which': 'O'}, {'was': 'O'}, {'further': 'O'}, {'confirmed': 'O'}, {'by': 'O'}, {'positive': 'O'}, {'blood': 'O'}, {'culture': 'O'}, {'of': 'O'}, {'Mycobacterium': 'B-Entity'}, {'tuberculosis': 'I-Entity'}, {'and': 'O'}, {'acid-fast': 'O'}, {'stain': 'O'}, {'of': 'O'}, {'synovial': 'O'}, {'fluid.and': 'O'}, {'dental': 'O'}, {'management': 'O'}, {'with': 'O'}, {'a': 'O'}, {'6-year': 'O'}, {'follow-up.': 'O'}]"
We therefore hypothesized that EGF secretion would be diminished in SS and that this could affect gastric target cells.,"[{'We': 'O'}, {'therefore': 'O'}, {'hypothesized': 'O'}, {'that': 'O'}, {'EGF': 'O'}, {'secretion': 'O'}, {'would': 'O'}, {'be': 'O'}, {'diminished': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'that': 'O'}, {'this': 'O'}, {'could': 'O'}, {'affect': 'O'}, {'gastric': 'O'}, {'target': 'O'}, {'cells.': 'O'}]"
Several courses of different types of antibiotics could not relieve her urinary irritation symptoms.,"[{'Several': 'O'}, {'courses': 'O'}, {'of': 'O'}, {'different': 'O'}, {'types': 'O'}, {'of': 'O'}, {'antibiotics': 'O'}, {'could': 'O'}, {'not': 'O'}, {'relieve': 'O'}, {'her': 'O'}, {'urinary': 'B-Entity'}, {'irritation': 'I-Entity'}, {'symptoms.': 'O'}]"
Its typical renal manifestation shows high amount of proteinuria with microscopic hematuria and renal insufficiency.,"[{'Its': 'O'}, {'typical': 'O'}, {'renal': 'O'}, {'manifestation': 'O'}, {'shows': 'O'}, {'high': 'O'}, {'amount': 'O'}, {'of': 'O'}, {'proteinuria': 'I-Entity'}, {'with': 'O'}, {'microscopic': 'O'}, {'hematuria': 'I-Entity'}, {'and': 'O'}, {'renal': 'B-Entity'}, {'insufficiency.': 'I-Entity'}]"
"Mild or moderate synovial hypertrophy was found in 151 (15.7%) and 2 (0.2%) out of 960 hand joints, respectively, and power Doppler signals were present in 19 (2.0%) of the 960 joints.","[{'Mild': 'O'}, {'or': 'O'}, {'moderate': 'O'}, {'synovial': 'B-Entity'}, {'hypertrophy': 'I-Entity'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'151': 'O'}, {'(15.7%)': 'O'}, {'and': 'O'}, {'2': 'O'}, {'(0.2%)': 'O'}, {'out': 'O'}, {'of': 'O'}, {'960': 'O'}, {'hand': 'O'}, {'joints,': 'O'}, {'respectively,': 'O'}, {'and': 'O'}, {'power': 'O'}, {'Doppler': 'O'}, {'signals': 'O'}, {'were': 'O'}, {'present': 'O'}, {'in': 'O'}, {'19': 'O'}, {'(2.0%)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'960': 'O'}, {'joints.': 'O'}]"
The incidence of Sjogren's syndrome in patients with systemic sclerosis was still higher compared with control when stratified according to age.,"[{'The': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'was': 'O'}, {'still': 'O'}, {'higher': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'control': 'O'}, {'when': 'O'}, {'stratified': 'O'}, {'according': 'O'}, {'to': 'O'}, {'age.': 'O'}]"
"All patients had reduced carbon monoxide-diffusing capacity (DLCO; <75% of the predicted value); <60% of the predicted value of peak expiratory flow (PEF), of forced vital capacity (FVC), and of forced expiratory volume in the 1st second (FEV1) were noted in 15 (34.1%) patients, 13 (29.5%) patients, and 12 (27.3%) patients, respectively.","[{'All': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'reduced': 'O'}, {'carbon': 'B-Entity'}, {'monoxide-diffusing': 'I-Entity'}, {'capacity': 'O'}, {'(DLCO;': 'O'}, {'<75%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'predicted': 'O'}, {'value);': 'O'}, {'<60%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'predicted': 'O'}, {'value': 'O'}, {'of': 'O'}, {'peak': 'O'}, {'expiratory': 'O'}, {'flow': 'O'}, {'(PEF),': 'O'}, {'of': 'O'}, {'forced': 'O'}, {'vital': 'O'}, {'capacity': 'O'}, {'(FVC),': 'O'}, {'and': 'O'}, {'of': 'O'}, {'forced': 'O'}, {'expiratory': 'O'}, {'volume': 'O'}, {'in': 'O'}]"
The US examination was performed in suspected pSS only in studies in which the sensitivity ranged from 45.8 to 91.6% and specificity from 73 to 98.1%.,"[{'The': 'O'}, {'US': 'O'}, {'examination': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'suspected': 'O'}, {'pSS': 'I-Entity'}, {'only': 'O'}, {'in': 'O'}, {'studies': 'O'}, {'in': 'O'}, {'which': 'O'}, {'the': 'O'}, {'sensitivity': 'O'}, {'ranged': 'O'}, {'from': 'O'}, {'45.8': 'O'}, {'to': 'O'}, {'91.6%': 'O'}, {'and': 'O'}, {'specificity': 'O'}, {'from': 'O'}, {'73': 'O'}, {'to': 'O'}, {'98.1%.': 'O'}]"
"After systemic diagnosis, oral lesions benefit from specialized care by dentists in collaboration with the medical team.","[{'After': 'O'}, {'systemic': 'O'}, {'diagnosis,': 'O'}, {'oral': 'B-Entity'}, {'lesions': 'I-Entity'}, {'benefit': 'O'}, {'from': 'O'}, {'specialized': 'O'}, {'care': 'O'}, {'by': 'O'}, {'dentists': 'O'}, {'in': 'O'}, {'collaboration': 'O'}, {'with': 'O'}, {'the': 'O'}, {'medical': 'O'}, {'team.': 'O'}]"
Patients in this series treated with immune-modulating therapy experienced significant improvement.,"[{'Patients': 'O'}, {'in': 'O'}, {'this': 'O'}, {'series': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'immune-modulating': 'O'}, {'therapy': 'O'}, {'experienced': 'O'}, {'significant': 'O'}, {'improvement.': 'O'}]"
We also examined the intracellular expression of IDO.,"[{'We': 'O'}, {'also': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'intracellular': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'IDO.': 'O'}]"
The aim of the present study was to verify whether artificial neural networks (ANNs) might help to elucidate the mechanisms underlying the increased prevalence of cardiovascular events (CV) in primary Sjogrens syndrome (pSS).,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'verify': 'O'}, {'whether': 'O'}, {'artificial': 'O'}, {'neural': 'O'}, {'networks': 'O'}, {'(ANNs)': 'O'}, {'might': 'O'}, {'help': 'O'}, {'to': 'O'}, {'elucidate': 'O'}, {'the': 'O'}, {'mechanisms': 'O'}, {'underlying': 'O'}, {'the': 'O'}, {'increased': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'cardiovascular': 'B-Entity'}, {'events': 'I-Entity'}, {'(CV)': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"Autoimmune diseases, such as rheumatoid arthritis, systematic lupus erythematosus and Sjogrens syndrome, are a group of diseases characterized by the activation of immune cells and excessive production of autoantibodies.","[{'Autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'systematic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'are': 'O'}, {'a': 'O'}, {'group': 'O'}, {'of': 'O'}, {'diseases': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'the': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'immune': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'excessive': 'O'}, {'production': 'O'}, {'of': 'O'}, {'autoantibodies.': 'O'}]"
Adenocarcinoma was the most frequently seen lung cancer pathology in pSS patients.,"[{'Adenocarcinoma': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'seen': 'O'}, {'lung': 'B-Entity'}, {'cancer': 'I-Entity'}, {'pathology': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"These studies provide new insight to understand the diseases and also shed light on the development of novel therapy.Beijing, China; Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.","[{'These': 'O'}, {'studies': 'O'}, {'provide': 'O'}, {'new': 'O'}, {'insight': 'O'}, {'to': 'O'}, {'understand': 'O'}, {'the': 'O'}, {'diseases': 'O'}, {'and': 'O'}, {'also': 'O'}, {'shed': 'O'}, {'light': 'O'}, {'on': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'novel': 'O'}, {'therapy.Beijing,': 'O'}, {'China;': 'O'}, {'Beijing': 'O'}, {'Key': 'O'}, {'Laboratory': 'O'}, {'for': 'O'}, {'Rheumatism': 'I-Entity'}, {'Mechanism': 'O'}, {'and': 'O'}, {'Immune': 'O'}, {'Diagnosis': 'O'}, {'(BZ0135),': 'O'}, {'Beijing,': 'O'}, {'China.': 'O'}]"
We performed a review of the literature regarding pregnancy outcomes in women with Sjogren syndrome.,"[{'We': 'O'}, {'performed': 'O'}, {'a': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'regarding': 'O'}, {'pregnancy': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {'women': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Secondary Raynaud's phenomenon is common with rheumatic diseases (systemic sclerosis, systemic lupus erythematosus, primary Sjogrens syndrome, mixed connective tissue disease, etc.","[{'Secondary': 'B-Entity'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon': 'I-Entity'}, {'is': 'O'}, {'common': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(systemic': 'O'}, {'sclerosis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'mixed': 'B-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'etc.': 'O'}]"
To describe baseline characteristics of patients with primary Sjogren's syndrome (pSS) with right heart catheterization (RHC)-confirmed pulmonary arterial hypertension (PAH).,"[{'To': 'O'}, {'describe': 'O'}, {'baseline': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'with': 'O'}, {'right': 'O'}, {'heart': 'O'}, {'catheterization': 'O'}, {'(RHC)-confirmed': 'O'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'(PAH).': 'O'}]"
"HCQ and CQ have a good reputation for being effective and relatively safe treatments in SLE, mild-moderate RA and Sj‚Äö√†√∂‚Äö√†√®gren's syndrome.","[{'HCQ': 'I-Entity'}, {'and': 'O'}, {'CQ': 'I-Entity'}, {'have': 'O'}, {'a': 'O'}, {'good': 'O'}, {'reputation': 'O'}, {'for': 'O'}, {'being': 'O'}, {'effective': 'O'}, {'and': 'O'}, {'relatively': 'O'}, {'safe': 'O'}, {'treatments': 'O'}, {'in': 'O'}, {'SLE,': 'I-Entity'}, {'mild-moderate': 'O'}, {'RA': 'I-Entity'}, {'and': 'O'}, {""Sj‚Äö√†√∂‚Äö√†√®gren's"": 'O'}, {'syndrome.': 'I-Entity'}]"
To propose the Intense Pulsed Light (IPL) therapy as a helpful supplementary treatment in patients with dry eye disease.,"[{'To': 'O'}, {'propose': 'O'}, {'the': 'O'}, {'Intense': 'O'}, {'Pulsed': 'O'}, {'Light': 'O'}, {'(IPL)': 'O'}, {'therapy': 'O'}, {'as': 'O'}, {'a': 'O'}, {'helpful': 'O'}, {'supplementary': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease.': 'I-Entity'}]"
The numbers of lymphocytic foci decreased significantly (P = 0.041).,"[{'The': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'lymphocytic': 'O'}, {'foci': 'O'}, {'decreased': 'O'}, {'significantly': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.041).': 'O'}]"
"Presence of EAMs is not directly associated with disease activity and functional status, but influences negatively HRQoL including physical and emotional functioning.therapy/physiopathology/psychology16.Sjogrens syndrome in non-obese diabetic mice.","[{'Presence': 'O'}, {'of': 'O'}, {'EAMs': 'I-Entity'}, {'is': 'O'}, {'not': 'O'}, {'directly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'functional': 'O'}, {'status,': 'O'}, {'but': 'O'}, {'influences': 'O'}, {'negatively': 'O'}, {'HRQoL': 'O'}, {'including': 'O'}, {'physical': 'O'}, {'and': 'O'}, {'emotional': 'O'}, {'functioning.therapy/physiopathology/psychology16.Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'mice.': 'O'}]"
"The Brief Cognitive Symptoms Inventory (BCSI) is a short, self-report scale designed to measure cognitive symptomatology in patients with rheumatic disease.","[{'The': 'O'}, {'Brief': 'O'}, {'Cognitive': 'O'}, {'Symptoms': 'O'}, {'Inventory': 'O'}, {'(BCSI)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'short,': 'O'}, {'self-report': 'O'}, {'scale': 'O'}, {'designed': 'O'}, {'to': 'O'}, {'measure': 'O'}, {'cognitive': 'O'}, {'symptomatology': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'disease.': 'I-Entity'}]"
Their mother was found to have lupus erythematosus with positive anti-Ro/SSA antibodies and developed Sjogren syndrome.,"[{'Their': 'O'}, {'mother': 'O'}, {'was': 'O'}, {'found': 'O'}, {'to': 'O'}, {'have': 'O'}, {'lupus': 'B-Entity'}, {'erythematosus': 'I-Entity'}, {'with': 'O'}, {'positive': 'O'}, {'anti-Ro/SSA': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'developed': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
To diagnose a patient as having chronic hyposalivation is a challenge in clinical practice and methods of salivary flow assessment are little known by rheumatologists.,"[{'To': 'O'}, {'diagnose': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'as': 'O'}, {'having': 'O'}, {'chronic': 'O'}, {'hyposalivation': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'challenge': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'practice': 'O'}, {'and': 'O'}, {'methods': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'assessment': 'O'}, {'are': 'O'}, {'little': 'O'}, {'known': 'O'}, {'by': 'O'}, {'rheumatologists.': 'O'}]"
"The expression of CD163, CD68 and HIF-1‚âà√≠¬¨¬± were examined by immunohistochemistry or immunofluorescence.","[{'The': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'CD163,': 'O'}, {'CD68': 'O'}, {'and': 'O'}, {'HIF-1‚âà√≠¬¨¬±': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'immunohistochemistry': 'O'}, {'or': 'O'}, {'immunofluorescence.': 'O'}]"
"Histopathological examination showed lymphoplasmacytic infiltration with storiform fibrosis, lymphoplasmacytic inflammation and lymphoepithelial lesions, and dilatation of the duct with epithelial metaplasia in the three groups, respectively.","[{'Histopathological': 'O'}, {'examination': 'O'}, {'showed': 'O'}, {'lymphoplasmacytic': 'O'}, {'infiltration': 'O'}, {'with': 'O'}, {'storiform': 'O'}, {'fibrosis,': 'I-Entity'}, {'lymphoplasmacytic': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'lymphoepithelial': 'B-Entity'}, {'lesions,': 'I-Entity'}, {'and': 'O'}, {'dilatation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'duct': 'O'}, {'with': 'O'}, {'epithelial': 'B-Entity'}, {'metaplasia': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'three': 'O'}, {'groups,': 'O'}, {'respectively.': 'O'}]"
"Among the autoimmune rheumatic diseases with potential for oral manifestations, rheumatoid arthritis (RA), inflammatory myopathies (IM), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), relapsing polychondritis (RP) and Sjogrens syndrome (SS) can be cited.","[{'Among': 'O'}, {'the': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'with': 'O'}, {'potential': 'O'}, {'for': 'O'}, {'oral': 'O'}, {'manifestations,': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {'inflammatory': 'B-Entity'}, {'myopathies': 'I-Entity'}, {'(IM),': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(SSc),': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}]"
"MSC treatment directed T cells toward Treg and Th2, while suppressing Th17 and Tfh responses, and alleviated disease symptoms.","[{'MSC': 'O'}, {'treatment': 'O'}, {'directed': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'toward': 'O'}, {'Treg': 'O'}, {'and': 'O'}, {'Th2,': 'O'}, {'while': 'O'}, {'suppressing': 'O'}, {'Th17': 'O'}, {'and': 'O'}, {'Tfh': 'O'}, {'responses,': 'O'}, {'and': 'O'}, {'alleviated': 'O'}, {'disease': 'O'}, {'symptoms.': 'O'}]"
"A decreased saliva production occurs in primary Sjogrens syndrome (pSS), an autoimmune disease characterized by oral and ocular dryness due to dysfunction of the lacrimal and salivary glands (SGs).","[{'A': 'O'}, {'decreased': 'B-Entity'}, {'saliva': 'I-Entity'}, {'production': 'I-Entity'}, {'occurs': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'oral': 'B-Entity'}, {'and': 'I-Entity'}, {'ocular': 'I-Entity'}, {'dryness': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'dysfunction': 'B-Entity'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands': 'O'}, {'(SGs).': 'O'}]"
"Compared with RA without SS, RA/SS patients had more severe arthritis; a higher incidence of haematological abnormality, fever and rash; and a higher frequency of RF, ANAs and anti-SSA and anti-SSB antibodies (P < 0.05).","[{'Compared': 'O'}, {'with': 'O'}, {'RA': 'I-Entity'}, {'without': 'O'}, {'SS,': 'I-Entity'}, {'RA/SS': 'I-Entity'}, {'patients': 'O'}, {'had': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'arthritis;': 'I-Entity'}, {'a': 'O'}, {'higher': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'haematological': 'B-Entity'}, {'abnormality,': 'I-Entity'}, {'fever': 'I-Entity'}, {'and': 'O'}, {'rash;': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'RF,': 'O'}, {'ANAs': 'O'}, {'and': 'O'}, {'anti-SSA': 'O'}, {'and': 'O'}, {'anti-SSB': 'O'}, {'antibodies': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"The VAS-IBS consists of 7 VAS scales, namely, abdominal pain, diarrhoea, constipation, bloating and flatulence, vomiting and nausea, psychological well-being and the intestinal symptoms' influence on daily life.","[{'The': 'O'}, {'VAS-IBS': 'O'}, {'consists': 'O'}, {'of': 'O'}, {'7': 'O'}, {'VAS': 'O'}, {'scales,': 'O'}, {'namely,': 'O'}, {'abdominal': 'B-Entity'}, {'pain,': 'I-Entity'}, {'diarrhoea,': 'I-Entity'}, {'constipation,': 'I-Entity'}, {'bloating': 'I-Entity'}, {'and': 'O'}, {'flatulence,': 'I-Entity'}, {'vomiting': 'I-Entity'}, {'and': 'O'}, {'nausea,': 'I-Entity'}, {'psychological': 'O'}, {'well-being': 'O'}, {'and': 'O'}, {'the': 'O'}, {'intestinal': 'B-Entity'}, {""symptoms'"": 'I-Entity'}, {'influence': 'O'}, {'on': 'O'}, {'daily': 'O'}, {'life.': 'O'}]"
"In addition to cytokines, chemokines, chitinases, and lipid mediators, macrophages contribute to a proteolytic milieu, underlying tissue destruction, inappropriate repair, and compromised glandular functions.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'cytokines,': 'O'}, {'chemokines,': 'O'}, {'chitinases,': 'O'}, {'and': 'O'}, {'lipid': 'O'}, {'mediators,': 'O'}, {'macrophages': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'a': 'O'}, {'proteolytic': 'O'}, {'milieu,': 'O'}, {'underlying': 'O'}, {'tissue': 'B-Entity'}, {'destruction,': 'I-Entity'}, {'inappropriate': 'O'}, {'repair,': 'O'}, {'and': 'O'}, {'compromised': 'B-Entity'}, {'glandular': 'I-Entity'}, {'functions.': 'I-Entity'}]"
"Further studies should investigate the possibility of combining tests for different salivary autoantibodies as a method for diagnosing pSS.Beijing 100081, Honghua1968@yahoo.com.interest exist.syndrome.","[{'Further': 'O'}, {'studies': 'O'}, {'should': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'combining': 'O'}, {'tests': 'O'}, {'for': 'O'}, {'different': 'O'}, {'salivary': 'O'}, {'autoantibodies': 'O'}, {'as': 'O'}, {'a': 'O'}, {'method': 'O'}, {'for': 'O'}, {'diagnosing': 'O'}, {'pSS.Beijing': 'I-Entity'}, {'100081,': 'O'}, {'Honghua1968@yahoo.com.interest': 'O'}, {'exist.syndrome.': 'O'}]"
"During the follow-up period, there is a risk for acute exacerbation of interstitial pneumonia and development of malignant lymphoma.","[{'During': 'O'}, {'the': 'O'}, {'follow-up': 'O'}, {'period,': 'O'}, {'there': 'O'}, {'is': 'O'}, {'a': 'O'}, {'risk': 'O'}, {'for': 'O'}, {'acute': 'O'}, {'exacerbation': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'and': 'O'}, {'development': 'O'}, {'of': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma.': 'I-Entity'}]"
Renal biopsy revealed tubulointerstitial nephritis with a mild focal infiltration of lymphocytes and plasma cells.,"[{'Renal': 'O'}, {'biopsy': 'O'}, {'revealed': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'with': 'O'}, {'a': 'O'}, {'mild': 'O'}, {'focal': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'lymphocytes': 'O'}, {'and': 'O'}, {'plasma': 'O'}, {'cells.': 'O'}]"
"Calcinosis associated with systemic sclerosis is a well-recognized phenomenon, but a destructive paraspinal tumor in the cervical spine associated with overlap syndrome is extremely unique.","[{'Calcinosis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'well-recognized': 'O'}, {'phenomenon,': 'O'}, {'but': 'O'}, {'a': 'O'}, {'destructive': 'O'}, {'paraspinal': 'B-Entity'}, {'tumor': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'cervical': 'O'}, {'spine': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'overlap': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'extremely': 'O'}, {'unique.': 'O'}]"
The authors report a previously undescribed cause of multifocal chronic subdural haematoma in infancy which could result in a misdiagnosis of previous NAHI.,"[{'The': 'O'}, {'authors': 'O'}, {'report': 'O'}, {'a': 'O'}, {'previously': 'O'}, {'undescribed': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'multifocal': 'O'}, {'chronic': 'O'}, {'subdural': 'B-Entity'}, {'haematoma': 'I-Entity'}, {'in': 'O'}, {'infancy': 'O'}, {'which': 'O'}, {'could': 'O'}, {'result': 'O'}, {'in': 'O'}, {'a': 'O'}, {'misdiagnosis': 'O'}, {'of': 'O'}, {'previous': 'O'}, {'NAHI.': 'I-Entity'}]"
The patient was a 36-year-old woman presenting with a periodic short-duration (2-3 days) fever and pleural pain.,"[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'a': 'O'}, {'36-year-old': 'O'}, {'woman': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'a': 'O'}, {'periodic': 'O'}, {'short-duration': 'O'}, {'(2-3': 'O'}, {'days)': 'O'}, {'fever': 'I-Entity'}, {'and': 'O'}, {'pleural': 'B-Entity'}, {'pain.': 'I-Entity'}]"
We reported 2 cases: the first one was a 40-year-old woman who developed neuritis of the left optic nerve as presenting symptom few years before the diagnosis of SS; the second was a 54-year-old woman who presented a paralysis of the right phrenic nerve 7 years after the SS onset.,"[{'We': 'O'}, {'reported': 'O'}, {'2': 'O'}, {'cases:': 'O'}, {'the': 'O'}, {'first': 'O'}, {'one': 'O'}, {'was': 'O'}, {'a': 'O'}, {'40-year-old': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'developed': 'O'}, {'neuritis': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'left': 'O'}, {'optic': 'O'}, {'nerve': 'O'}, {'as': 'O'}, {'presenting': 'O'}, {'symptom': 'O'}, {'few': 'O'}, {'years': 'O'}, {'before': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS;': 'I-Entity'}, {'the': 'O'}, {'second': 'O'}, {'was': 'O'}, {'a': 'O'}, {'54-year-old': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'a': 'O'}, {'paralysis': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'right': 'I-Entity'}, {'phrenic': 'I-Entity'}]"
"Patients with SS may experience unorthodox patterns of burning pain not conforming to a traditional ""stocking-and-glove"" distribution, which can affect the face, torso, and proximal extremities.","[{'Patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'experience': 'O'}, {'unorthodox': 'O'}, {'patterns': 'O'}, {'of': 'O'}, {'burning': 'O'}, {'pain': 'I-Entity'}, {'not': 'O'}, {'conforming': 'O'}, {'to': 'O'}, {'a': 'O'}, {'traditional': 'O'}, {'""stocking-and-glove""': 'O'}, {'distribution,': 'O'}, {'which': 'O'}, {'can': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'face,': 'O'}, {'torso,': 'O'}, {'and': 'O'}, {'proximal': 'O'}, {'extremities.': 'O'}]"
Magnetic resonance imaging (MRI) revealed swelling and enhancement of intracanalicular and pre-chiasmatic segments of the right optic nerve and right side of the optic chiasm.,"[{'Magnetic': 'O'}, {'resonance': 'O'}, {'imaging': 'O'}, {'(MRI)': 'O'}, {'revealed': 'O'}, {'swelling': 'I-Entity'}, {'and': 'O'}, {'enhancement': 'O'}, {'of': 'O'}, {'intracanalicular': 'O'}, {'and': 'O'}, {'pre-chiasmatic': 'O'}, {'segments': 'O'}, {'of': 'O'}, {'the': 'O'}, {'right': 'O'}, {'optic': 'O'}, {'nerve': 'O'}, {'and': 'O'}, {'right': 'O'}, {'side': 'O'}, {'of': 'O'}, {'the': 'O'}, {'optic': 'O'}, {'chiasm.': 'O'}]"
"We found that the frequencies of newly emigrant/transitional B cells expressing polyreactive antibodies were significantly increased in SS patients compared to those in healthy donors, revealing defective central B cell tolerance in SS patients.","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'the': 'O'}, {'frequencies': 'O'}, {'of': 'O'}, {'newly': 'O'}, {'emigrant/transitional': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'expressing': 'O'}, {'polyreactive': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'those': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'donors,': 'O'}, {'revealing': 'O'}, {'defective': 'O'}, {'central': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'tolerance': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
"Besides glandular enlargement in Sjogrens syndrome, sarcoidosis, lymphoma and other diseases, the symptom can also be found in IgG4-related disease.","[{'Besides': 'O'}, {'glandular': 'B-Entity'}, {'enlargement': 'I-Entity'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'sarcoidosis,': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'diseases,': 'O'}, {'the': 'O'}, {'symptom': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'found': 'O'}, {'in': 'O'}, {'IgG4-related': 'O'}, {'disease.': 'O'}]"
"This is the first report of an IMT associated with Sjogrens disease, systemic lupus erythematosus and Non-Hodgkin lymphoma developing in the lungs.","[{'This': 'O'}, {'is': 'O'}, {'the': 'O'}, {'first': 'O'}, {'report': 'O'}, {'of': 'O'}, {'an': 'O'}, {'IMT': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'disease,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {'Non-Hodgkin': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'developing': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lungs.': 'O'}]"
"Sarcoidosis, tubulointerstitial nephritis and uveitis (TINU) syndrome, primary Sjogren's syndrome, and IgG4-related disease often show an interstitial nephritis when the kidneys are affected.","[{'Sarcoidosis,': 'I-Entity'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'and': 'I-Entity'}, {'uveitis': 'I-Entity'}, {'(TINU)': 'O'}, {'syndrome,': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'IgG4-related': 'O'}, {'disease': 'O'}, {'often': 'O'}, {'show': 'O'}, {'an': 'O'}, {'interstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'when': 'O'}, {'the': 'O'}, {'kidneys': 'O'}, {'are': 'O'}, {'affected.': 'O'}]"
"Setting the cut-off US inhomogeneity score at 6 resulted in the best ratio of specificity (90.0%) to sensitivity (95.1%), with a positive predictive value of 72% and a negative predictive value of 96%.","[{'Setting': 'O'}, {'the': 'O'}, {'cut-off': 'O'}, {'US': 'O'}, {'inhomogeneity': 'O'}, {'score': 'O'}, {'at': 'O'}, {'6': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'the': 'O'}, {'best': 'O'}, {'ratio': 'O'}, {'of': 'O'}, {'specificity': 'O'}, {'(90.0%)': 'O'}, {'to': 'O'}, {'sensitivity': 'O'}, {'(95.1%),': 'O'}, {'with': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'72%': 'O'}, {'and': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'96%.': 'O'}]"
To characterize a group of patients with IgG4-related disease (IgG4-RD) in a Russian population and to evaluate the efficiency of rituximab therapy.,"[{'To': 'O'}, {'characterize': 'O'}, {'a': 'O'}, {'group': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'in': 'O'}, {'a': 'O'}, {'Russian': 'O'}, {'population': 'O'}, {'and': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficiency': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'therapy.': 'O'}]"
The abnormal localization of AQP5 was associated with poor saliva secretion.,"[{'The': 'O'}, {'abnormal': 'O'}, {'localization': 'O'}, {'of': 'O'}, {'AQP5': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'poor': 'O'}, {'saliva': 'O'}, {'secretion.': 'O'}]"
"Surface expression of P2X7R on PBMC in patients with pSS was significantly higher than controls, suggesting P2X7R may contribute to the complex pathogenesis of pSS and also anxiety and/or depression.amour_87117825@163.com.","[{'Surface': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'P2X7R': 'O'}, {'on': 'O'}, {'PBMC': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'controls,': 'O'}, {'suggesting': 'O'}, {'P2X7R': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'complex': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'also': 'O'}, {'anxiety': 'I-Entity'}, {'and/or': 'O'}, {'depression.amour_87117825@163.com.': 'I-Entity'}]"
"salvatore.devita@asuiud.sanita.fvg.it.Udine, Italy.Udine, Italy.Udine, Italy.Udine, Italy.in systemic lupus erythematosus and Sjogrens syndrome: clinical implications and effects of B cell-targeted therapies.","[{'salvatore.devita@asuiud.sanita.fvg.it.Udine,': 'O'}, {'Italy.Udine,': 'O'}, {'Italy.Udine,': 'O'}, {'Italy.Udine,': 'O'}, {'Italy.in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome:': 'I-Entity'}, {'clinical': 'O'}, {'implications': 'O'}]"
The correlations between LB values and lacrimal function results were evaluated.,"[{'The': 'O'}, {'correlations': 'O'}, {'between': 'O'}, {'LB': 'O'}, {'values': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'function': 'O'}, {'results': 'O'}, {'were': 'O'}, {'evaluated.': 'O'}]"
"Our results showed pSS patients who are seropositive for one of the following markers: ANA, RF, anti-SS-A, or anti-SS-B are younger, predominantly female, and had more serological abnormalities than those with seronegativity of ANA, RF, anti-SS-A, or anti-SS-B.","[{'Our': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}, {'are': 'O'}, {'seropositive': 'O'}, {'for': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'following': 'O'}, {'markers:': 'O'}, {'ANA,': 'O'}, {'RF,': 'O'}, {'anti-SS-A,': 'O'}, {'or': 'O'}, {'anti-SS-B': 'O'}, {'are': 'O'}, {'younger,': 'O'}, {'predominantly': 'O'}, {'female,': 'O'}, {'and': 'O'}, {'had': 'O'}, {'more': 'O'}, {'serological': 'O'}, {'abnormalities': 'O'}, {'than': 'O'}, {'those': 'O'}, {'with': 'O'}, {'seronegativity': 'O'}, {'of': 'O'}, {'ANA,': 'O'}, {'RF,': 'O'}]"
"The salivary proteome has been characterised in several diseases: oral squamous cell carcinoma and oral leukoplakia, chronic graft-versus-host disease Sjogrens syndrome and other autoimmune disorders such as SAPHO, schizophrenia and bipolar disorder, and genetic diseases like Down's Syndrome and Wilson disease.","[{'The': 'O'}, {'salivary': 'O'}, {'proteome': 'O'}, {'has': 'O'}, {'been': 'O'}, {'characterised': 'O'}, {'in': 'O'}, {'several': 'O'}, {'diseases:': 'O'}, {'oral': 'B-Entity'}, {'squamous': 'I-Entity'}, {'cell': 'I-Entity'}, {'carcinoma': 'I-Entity'}, {'and': 'O'}, {'oral': 'B-Entity'}, {'leukoplakia,': 'I-Entity'}, {'chronic': 'B-Entity'}, {'graft-versus-host': 'I-Entity'}, {'disease': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'SAPHO,': 'I-Entity'}, {'schizophrenia': 'I-Entity'}, {'and': 'O'}, {'bipolar': 'I-Entity'}]"
"Furthermore, we quantified the Ro- and La-specific memory B cells in these individuals by a 6-day in vitro polyclonal stimulation of PBMC followed by an antigen-specific ELISPOT assay for the detection of memory B cells.","[{'Furthermore,': 'O'}, {'we': 'O'}, {'quantified': 'O'}, {'the': 'O'}, {'Ro-': 'I-Entity'}, {'and': 'O'}, {'La-specific': 'I-Entity'}, {'memory': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'these': 'O'}, {'individuals': 'O'}, {'by': 'O'}, {'a': 'O'}, {'6-day': 'O'}, {'in': 'O'}, {'vitro': 'O'}, {'polyclonal': 'O'}, {'stimulation': 'O'}, {'of': 'O'}, {'PBMC': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'an': 'O'}, {'antigen-specific': 'O'}, {'ELISPOT': 'O'}, {'assay': 'O'}, {'for': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'memory': 'O'}, {'B': 'O'}, {'cells.': 'O'}]"
"The ability to accurately detect elevated matrix metalloproteinase 9 levels may lead to earlier diagnosis, more appropriate treatment, and better management of ocular surface disease.","[{'The': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'accurately': 'O'}, {'detect': 'O'}, {'elevated': 'O'}, {'matrix': 'O'}, {'metalloproteinase': 'O'}, {'9': 'O'}, {'levels': 'O'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'earlier': 'O'}, {'diagnosis,': 'O'}, {'more': 'O'}, {'appropriate': 'O'}, {'treatment,': 'O'}, {'and': 'O'}, {'better': 'O'}, {'management': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Cryoglobulins are immunoglobulins that precipitate in vitro at temperatures less than 37¬¨¬®‚Äö√†√ªC and produce organ damage through two main pathways: vascular sludging (hyperviscosity syndrome, mainly in type I cryoglobulinaemia) and immune-mediated mechanisms (principally vasculitis, in mixed cryoglobulinaemia).","[{'Cryoglobulins': 'O'}, {'are': 'O'}, {'immunoglobulins': 'O'}, {'that': 'O'}, {'precipitate': 'O'}, {'in': 'O'}, {'vitro': 'O'}, {'at': 'O'}, {'temperatures': 'O'}, {'less': 'O'}, {'than': 'O'}, {'37¬¨¬®‚Äö√†√ªC': 'O'}, {'and': 'O'}, {'produce': 'O'}, {'organ': 'B-Entity'}, {'damage': 'I-Entity'}, {'through': 'O'}, {'two': 'O'}, {'main': 'O'}, {'pathways:': 'O'}, {'vascular': 'B-Entity'}, {'sludging': 'I-Entity'}, {'(hyperviscosity': 'O'}, {'syndrome,': 'I-Entity'}, {'mainly': 'O'}, {'in': 'O'}]"
Transcranial Doppler ultrasound findings were consistent with CV.,"[{'Transcranial': 'O'}, {'Doppler': 'O'}, {'ultrasound': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'CV.': 'I-Entity'}]"
A 47-year- old woman with an 8-year history of SS was admitted due to skin ecchymosis and bleeding gums.,"[{'A': 'O'}, {'47-year-': 'O'}, {'old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'an': 'O'}, {'8-year': 'O'}, {'history': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'was': 'O'}, {'admitted': 'O'}, {'due': 'O'}, {'to': 'O'}, {'skin': 'B-Entity'}, {'ecchymosis': 'I-Entity'}, {'and': 'O'}, {'bleeding': 'B-Entity'}, {'gums.': 'I-Entity'}]"
"The management of extraglandular features must be tailored to the specific organ or organs involved; however, limited data have been obtained from controlled trials in SS to guide the treatment of systemic symptoms using therapies including antimalarials, glucocorticoids, immunosuppressive drugs and biologic agents.","[{'The': 'O'}, {'management': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'features': 'O'}, {'must': 'O'}, {'be': 'O'}, {'tailored': 'O'}, {'to': 'O'}, {'the': 'O'}, {'specific': 'O'}, {'organ': 'O'}, {'or': 'O'}, {'organs': 'O'}, {'involved;': 'O'}, {'however,': 'O'}, {'limited': 'O'}, {'data': 'O'}, {'have': 'O'}, {'been': 'O'}, {'obtained': 'O'}, {'from': 'O'}, {'controlled': 'O'}, {'trials': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'to': 'O'}, {'guide': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'symptoms': 'O'}, {'using': 'O'}, {'therapies': 'O'}, {'including': 'O'}, {'antimalarials,': 'O'}, {'glucocorticoids,': 'O'}, {'immunosuppressive': 'O'}, {'drugs': 'O'}, {'and': 'O'}]"
"Clinical files for eight adult MAS patients treated at the Second Affiliated Hospital of Harbin Medical University were analyzed for clinical manifestations, laboratory investigations, therapeutic measurements and clinical outcomes.","[{'Clinical': 'O'}, {'files': 'O'}, {'for': 'O'}, {'eight': 'O'}, {'adult': 'O'}, {'MAS': 'I-Entity'}, {'patients': 'O'}, {'treated': 'O'}, {'at': 'O'}, {'the': 'O'}, {'Second': 'O'}, {'Affiliated': 'O'}, {'Hospital': 'O'}, {'of': 'O'}, {'Harbin': 'O'}, {'Medical': 'O'}, {'University': 'O'}, {'were': 'O'}, {'analyzed': 'O'}, {'for': 'O'}, {'clinical': 'O'}, {'manifestations,': 'O'}, {'laboratory': 'O'}, {'investigations,': 'O'}, {'therapeutic': 'O'}, {'measurements': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'outcomes.': 'O'}]"
Periodontal capillaroscopy has been used to investigate the features of microcirculation.,"[{'Periodontal': 'O'}, {'capillaroscopy': 'O'}, {'has': 'O'}, {'been': 'O'}, {'used': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'features': 'O'}, {'of': 'O'}, {'microcirculation.': 'O'}]"
"The patient was subsequently treated with plasma exchange, which resulted in a successful outcome without any complications.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'subsequently': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'plasma': 'O'}, {'exchange,': 'O'}, {'which': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'successful': 'O'}, {'outcome': 'O'}, {'without': 'O'}, {'any': 'O'}, {'complications.': 'O'}]"
These histopathological findings subsequently confirmed a diagnosis of marginal zone B cell lymphoma.,"[{'These': 'O'}, {'histopathological': 'O'}, {'findings': 'O'}, {'subsequently': 'O'}, {'confirmed': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'marginal': 'B-Entity'}, {'zone': 'O'}, {'B': 'I-Entity'}, {'cell': 'I-Entity'}, {'lymphoma.': 'I-Entity'}]"
"Female gender, family history of autoimmune disease, self-reported joint pain or dry mouth, external signs of orbital inflammation, and conjunctival chemosis were more common in patients with inflammatory systemic disease as compared with that in patients with no identifiable condition (P < 0.05 for all).","[{'Female': 'O'}, {'gender,': 'O'}, {'family': 'O'}, {'history': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'self-reported': 'O'}, {'joint': 'B-Entity'}, {'pain': 'I-Entity'}, {'or': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'external': 'O'}, {'signs': 'O'}, {'of': 'O'}, {'orbital': 'B-Entity'}, {'inflammation,': 'I-Entity'}, {'and': 'O'}, {'conjunctival': 'B-Entity'}, {'chemosis': 'I-Entity'}, {'were': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'inflammatory': 'B-Entity'}, {'systemic': 'I-Entity'}, {'disease': 'I-Entity'}, {'as': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'that': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'no': 'O'}, {'identifiable': 'O'}, {'condition': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05': 'O'}, {'for': 'O'}]"
DHEA-deficient female SS patients (n = 12) were treated with placebo for 4 months followed by DHEA 50 mg q.d.,"[{'DHEA-deficient': 'I-Entity'}, {'female': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'12)': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'placebo': 'O'}, {'for': 'O'}, {'4': 'O'}, {'months': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'DHEA': 'I-Entity'}, {'50': 'O'}, {'mg': 'O'}, {'q.d.': 'O'}]"
"MSUS was performed in all patients in both hands and wrists, evaluating the presence of inflammation within joints and periarticular tissues, and the existence of permanent joint damage.","[{'MSUS': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'both': 'O'}, {'hands': 'O'}, {'and': 'O'}, {'wrists,': 'O'}, {'evaluating': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'within': 'O'}, {'joints': 'O'}, {'and': 'O'}, {'periarticular': 'O'}, {'tissues,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'existence': 'O'}, {'of': 'O'}, {'permanent': 'O'}, {'joint': 'B-Entity'}, {'damage.': 'I-Entity'}]"
Interstitial lung disease (ILD) was identified on high-resolution computed tomography (HRCT).,"[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'was': 'O'}, {'identified': 'O'}, {'on': 'O'}, {'high-resolution': 'O'}, {'computed': 'O'}, {'tomography': 'O'}, {'(HRCT).': 'O'}]"
Understanding the various forms of ocular involvement in these conditions is important as untreated ophthalmic involvement can lead to severe vision loss.,"[{'Understanding': 'O'}, {'the': 'O'}, {'various': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'ocular': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'these': 'O'}, {'conditions': 'O'}, {'is': 'O'}, {'important': 'O'}, {'as': 'O'}, {'untreated': 'O'}, {'ophthalmic': 'O'}, {'involvement': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'severe': 'O'}, {'vision': 'B-Entity'}, {'loss.': 'I-Entity'}]"
The expression and localization of aquaporin-5 (AQP-5) was examined by Western blot and immunofluorescent staining.,"[{'The': 'O'}, {'expression': 'O'}, {'and': 'O'}, {'localization': 'O'}, {'of': 'O'}, {'aquaporin-5': 'O'}, {'(AQP-5)': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'Western': 'O'}, {'blot': 'O'}, {'and': 'O'}, {'immunofluorescent': 'O'}, {'staining.': 'O'}]"
"On the basis of several tests, she was diagnosed with ataxic sensory neuronopathy due to dorsal root ganglionitis associated with Sjogrens syndrome.","[{'On': 'O'}, {'the': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'several': 'O'}, {'tests,': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'ataxic': 'B-Entity'}, {'sensory': 'I-Entity'}, {'neuronopathy': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'dorsal': 'B-Entity'}, {'root': 'I-Entity'}, {'ganglionitis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
These data demonstrate that TGF-‚âà√≠‚Äö√¢¬ß1 is an important key factor in the transition phase from SG chronic inflammation to fibrotic disease.,"[{'These': 'O'}, {'data': 'O'}, {'demonstrate': 'O'}, {'that': 'O'}, {'TGF-‚âà√≠‚Äö√¢¬ß1': 'O'}, {'is': 'O'}, {'an': 'O'}, {'important': 'O'}, {'key': 'O'}, {'factor': 'O'}, {'in': 'O'}, {'the': 'O'}, {'transition': 'O'}, {'phase': 'O'}, {'from': 'O'}, {'SG': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'to': 'O'}, {'fibrotic': 'B-Entity'}, {'disease.': 'I-Entity'}]"
Validation results indicate high levels of sensitivity and specificity for the criteria.,"[{'Validation': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'high': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'sensitivity': 'O'}, {'and': 'O'}, {'specificity': 'O'}, {'for': 'O'}, {'the': 'O'}, {'criteria.': 'O'}]"
These APCs may contribute to the generation of the pathogenic Th1 cells that cause goblet cell loss in KCS.stevenp@bcm.edu.Fang.Bian@bcm.edu.dkorayg@hotmail.com.Turkey.,"[{'These': 'O'}, {'APCs': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'generation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pathogenic': 'O'}, {'Th1': 'O'}, {'cells': 'O'}, {'that': 'O'}, {'cause': 'O'}, {'goblet': 'O'}, {'cell': 'O'}, {'loss': 'I-Entity'}, {'in': 'O'}, {'KCS.stevenp@bcm.edu.Fang.Bian@bcm.edu.dkorayg@hotmail.com.Turkey.': 'O'}]"
"lung, esophageal, prostate or ovarian cancer).","[{'lung,': 'B-Entity'}, {'esophageal,': 'I-Entity'}, {'prostate': 'I-Entity'}, {'or': 'I-Entity'}, {'ovarian': 'I-Entity'}, {'cancer).': 'I-Entity'}]"
"Presumably, specific autoantibodies may directly induce injury of the nervous system.Shinjuku-Ku Tokyo 162-0054, Japan.syndrome.","[{'Presumably,': 'O'}, {'specific': 'O'}, {'autoantibodies': 'O'}, {'may': 'O'}, {'directly': 'O'}, {'induce': 'O'}, {'injury': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system.Shinjuku-Ku': 'I-Entity'}, {'Tokyo': 'O'}, {'162-0054,': 'O'}, {'Japan.syndrome.': 'O'}]"
"The patient was then treated with 8 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy, which resulted in histological and functional improvement of her salivary glands.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'then': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'8': 'O'}, {'cycles': 'O'}, {'of': 'O'}, {'R-CHOP': 'O'}, {'(rituximab,': 'O'}, {'cyclophosphamide,': 'I-Entity'}, {'doxorubicin,': 'I-Entity'}, {'vincristine,': 'I-Entity'}, {'and': 'O'}, {'prednisone)': 'I-Entity'}, {'therapy,': 'O'}, {'which': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'histological': 'O'}, {'and': 'O'}, {'functional': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'her': 'O'}, {'salivary': 'O'}]"
"At the clinical examination, 91,7% of SS had at least one oral sign respect to 75 % of controls.","[{'At': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'examination,': 'O'}, {'91,7%': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'had': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'oral': 'O'}, {'sign': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'75': 'O'}, {'%': 'O'}, {'of': 'O'}, {'controls.': 'O'}]"
A computerised tomography scan showed atrophy of her salivary glands and a skin lesion biopsied by her GP in the past had been histologically characterised as anetoderma.,"[{'A': 'O'}, {'computerised': 'O'}, {'tomography': 'O'}, {'scan': 'O'}, {'showed': 'O'}, {'atrophy': 'B-Entity'}, {'of': 'I-Entity'}, {'her': 'O'}, {'salivary': 'I-Entity'}, {'glands': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'skin': 'O'}, {'lesion': 'I-Entity'}, {'biopsied': 'O'}, {'by': 'O'}, {'her': 'O'}, {'GP': 'O'}, {'in': 'O'}, {'the': 'O'}, {'past': 'O'}, {'had': 'O'}, {'been': 'O'}, {'histologically': 'O'}, {'characterised': 'O'}, {'as': 'O'}, {'anetoderma.': 'I-Entity'}]"
"The secondary endpoints were dry eyes/mouth/skin/nose/throat/vagina visual analogue scale (VAS), pain and discomfort VAS, fatigue VAS, mental discomfort VAS, patient global assessment (PGA), EULAR Sjogrens Syndrome Disease Activity Index (ESSDAI), Schirmer's test, basal/stimulated salivary flow-rate values, and erythrocyte sedimentation rate (ESR).","[{'The': 'O'}, {'secondary': 'O'}, {'endpoints': 'O'}, {'were': 'O'}, {'dry': 'B-Entity'}, {'eyes/mouth/skin/nose/throat/vagina': 'I-Entity'}, {'visual': 'O'}, {'analogue': 'O'}, {'scale': 'O'}, {'(VAS),': 'O'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'discomfort': 'I-Entity'}, {'VAS,': 'O'}, {'fatigue': 'I-Entity'}, {'VAS,': 'O'}, {'mental': 'O'}, {'discomfort': 'O'}, {'VAS,': 'O'}, {'patient': 'O'}, {'global': 'O'}, {'assessment': 'O'}, {'(PGA),': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}]"
A 13-year-old girl was initially observed for several months due to elevated sedimentation rate (ESR 75-90 mm/h) without signs of inflammation or other symptoms and disease signs.,"[{'A': 'O'}, {'13-year-old': 'O'}, {'girl': 'O'}, {'was': 'O'}, {'initially': 'O'}, {'observed': 'O'}, {'for': 'O'}, {'several': 'O'}, {'months': 'O'}, {'due': 'O'}, {'to': 'O'}, {'elevated': 'O'}, {'sedimentation': 'O'}, {'rate': 'O'}, {'(ESR': 'O'}, {'75-90': 'O'}, {'mm/h)': 'O'}, {'without': 'O'}, {'signs': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'or': 'O'}, {'other': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'signs.': 'O'}]"
Two patients had OLP associated with secondary SS (25%).,"[{'Two': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'OLP': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'secondary': 'O'}, {'SS': 'I-Entity'}, {'(25%).': 'O'}]"
To evaluate whether major salivary-gland ultrasonography (SGUS) abnormalities change over time in patients with suspected primary Sjogrens syndrome (pSS) during the natural course of the disease.,"[{'To': 'O'}, {'evaluate': 'O'}, {'whether': 'O'}, {'major': 'O'}, {'salivary-gland': 'O'}, {'ultrasonography': 'O'}, {'(SGUS)': 'O'}, {'abnormalities': 'O'}, {'change': 'O'}, {'over': 'O'}, {'time': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'suspected': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'during': 'O'}, {'the': 'O'}, {'natural': 'O'}, {'course': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"The emphasis is on the contribution of these techniques to the diagnosis of pSS, their potential in assessing disease activity and disease progression in pSS, and their contribution to diagnosing and staging of pSS-associated lymphomas.","[{'The': 'O'}, {'emphasis': 'O'}, {'is': 'O'}, {'on': 'O'}, {'the': 'O'}, {'contribution': 'O'}, {'of': 'O'}, {'these': 'O'}, {'techniques': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'their': 'O'}, {'potential': 'O'}, {'in': 'O'}, {'assessing': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'in': 'O'}, {'pSS,': 'I-Entity'}, {'and': 'O'}, {'their': 'O'}, {'contribution': 'O'}, {'to': 'O'}, {'diagnosing': 'O'}, {'and': 'O'}, {'staging': 'O'}, {'of': 'O'}, {'pSS-associated': 'I-Entity'}, {'lymphomas.': 'I-Entity'}]"
"On examination, he had a corneal ulcer and stromal thinning in his right eye which progressed to a full thickness perforation 12 hours later.","[{'On': 'O'}, {'examination,': 'O'}, {'he': 'O'}, {'had': 'O'}, {'a': 'O'}, {'corneal': 'B-Entity'}, {'ulcer': 'I-Entity'}, {'and': 'O'}, {'stromal': 'O'}, {'thinning': 'O'}, {'in': 'O'}, {'his': 'O'}, {'right': 'O'}, {'eye': 'O'}, {'which': 'O'}, {'progressed': 'O'}, {'to': 'O'}, {'a': 'O'}, {'full': 'O'}, {'thickness': 'O'}, {'perforation': 'I-Entity'}, {'12': 'O'}, {'hours': 'O'}, {'later.': 'O'}]"
"The patient was diagnosed with her rheumatological condition in 2005 and started on disease-modifying antirheumatoid drugs, which were taken intermittently due to a concern over medication side-effects.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'her': 'O'}, {'rheumatological': 'B-Entity'}, {'condition': 'O'}, {'in': 'O'}, {'2005': 'O'}, {'and': 'O'}, {'started': 'O'}, {'on': 'O'}, {'disease-modifying': 'O'}, {'antirheumatoid': 'O'}, {'drugs,': 'O'}, {'which': 'O'}, {'were': 'O'}, {'taken': 'O'}, {'intermittently': 'O'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'concern': 'O'}, {'over': 'O'}, {'medication': 'O'}, {'side-effects.': 'O'}]"
"Together with the family history, the presence of musculoskeletal manifestations can lead to the correct diagnosis by prompting alpha-galactosidase assays in males and genetic testing in females.","[{'Together': 'O'}, {'with': 'O'}, {'the': 'O'}, {'family': 'O'}, {'history,': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'musculoskeletal': 'B-Entity'}, {'manifestations': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'the': 'O'}, {'correct': 'O'}, {'diagnosis': 'O'}, {'by': 'O'}, {'prompting': 'O'}, {'alpha-galactosidase': 'O'}, {'assays': 'O'}, {'in': 'O'}, {'males': 'O'}, {'and': 'O'}, {'genetic': 'O'}, {'testing': 'O'}, {'in': 'O'}, {'females.': 'O'}]"
"These are the first reported cases linking the presence of anti-Ro antibodies and external hydrocephalus with subdural fluid collections in infancy.Frenchay Park Road, Bristol, UK.","[{'These': 'O'}, {'are': 'O'}, {'the': 'O'}, {'first': 'O'}, {'reported': 'O'}, {'cases': 'O'}, {'linking': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-Ro': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'external': 'O'}, {'hydrocephalus': 'I-Entity'}, {'with': 'O'}, {'subdural': 'O'}, {'fluid': 'O'}, {'collections': 'O'}, {'in': 'O'}, {'infancy.Frenchay': 'O'}, {'Park': 'O'}, {'Road,': 'O'}, {'Bristol,': 'O'}, {'UK.': 'O'}]"
"The severity of fatigue was correlated with the duration of RA, the intensity of joint pain, the activity of disease, the importance of structural damage, the degree of functional impairment, and the rate of anti-cyclic citrullinated protein (CCP) antibodies (P < 0.05).","[{'The': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'was': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'RA,': 'I-Entity'}, {'the': 'O'}, {'intensity': 'O'}, {'of': 'O'}, {'joint': 'B-Entity'}, {'pain,': 'I-Entity'}, {'the': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'disease,': 'O'}, {'the': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'structural': 'O'}, {'damage,': 'O'}, {'the': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'functional': 'O'}, {'impairment,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'anti-cyclic': 'O'}, {'citrullinated': 'I-Entity'}, {'protein': 'O'}, {'(CCP)': 'O'}, {'antibodies': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a new disease entity characterized by high serum IgG4 levels, IgG4-positive plasmacytic infiltration, and fibrosis in various organs.","[{'Immunoglobulin': 'B-Entity'}, {'G4': 'I-Entity'}, {'(IgG4)-related': 'O'}, {'disease': 'O'}, {'(IgG4-RD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'new': 'O'}, {'disease': 'O'}, {'entity': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'high': 'O'}, {'serum': 'O'}, {'IgG4': 'O'}, {'levels,': 'O'}, {'IgG4-positive': 'O'}, {'plasmacytic': 'O'}, {'infiltration,': 'O'}, {'and': 'O'}, {'fibrosis': 'I-Entity'}, {'in': 'O'}, {'various': 'O'}, {'organs.': 'O'}]"
"Further; networks, pathways, and interaction analyses showed that LRP1 is functionally related to the HLA-B and IL10 genes and it has a substantial impact within immunological pathways and/or reaction to bacterial and other foreign proteins (phagocytosis, regulation of phospholipase A2 activity, negative regulation of apoptosis and response to lipopolysaccharides).","[{'Further;': 'O'}, {'networks,': 'O'}, {'pathways,': 'O'}, {'and': 'O'}, {'interaction': 'O'}, {'analyses': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'LRP1': 'O'}, {'is': 'O'}, {'functionally': 'O'}, {'related': 'O'}, {'to': 'O'}, {'the': 'O'}, {'HLA-B': 'O'}, {'and': 'O'}, {'IL10': 'O'}, {'genes': 'O'}, {'and': 'O'}, {'it': 'O'}, {'has': 'O'}, {'a': 'O'}, {'substantial': 'O'}, {'impact': 'O'}, {'within': 'O'}, {'immunological': 'O'}, {'pathways': 'O'}, {'and/or': 'O'}, {'reaction': 'O'}, {'to': 'O'}, {'bacterial': 'O'}, {'and': 'O'}, {'other': 'O'}, {'foreign': 'O'}, {'proteins': 'O'}, {'(phagocytosis,': 'O'}, {'regulation': 'O'}, {'of': 'O'}, {'phospholipase': 'O'}]"
The useful combination of the US grey-scale and the colour/power Doppler technique provides more valuable details regarding the presence and degree of soft tissues blood perfusion and may be valuable in narrowing the differential diagnosis.,"[{'The': 'O'}, {'useful': 'O'}, {'combination': 'O'}, {'of': 'O'}, {'the': 'O'}, {'US': 'O'}, {'grey-scale': 'O'}, {'and': 'O'}, {'the': 'O'}, {'colour/power': 'O'}, {'Doppler': 'O'}, {'technique': 'O'}, {'provides': 'O'}, {'more': 'O'}, {'valuable': 'O'}, {'details': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'and': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'soft': 'O'}, {'tissues': 'O'}, {'blood': 'O'}, {'perfusion': 'O'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'valuable': 'O'}, {'in': 'O'}, {'narrowing': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis.': 'O'}]"
"In the paper, we also study the performance achieved by fusing the best methods, finding that a recognition rate of 85.60% is reached when the top seven methods are employed.","[{'In': 'O'}, {'the': 'O'}, {'paper,': 'O'}, {'we': 'O'}, {'also': 'O'}, {'study': 'O'}, {'the': 'O'}, {'performance': 'O'}, {'achieved': 'O'}, {'by': 'O'}, {'fusing': 'O'}, {'the': 'O'}, {'best': 'O'}, {'methods,': 'O'}, {'finding': 'O'}, {'that': 'O'}, {'a': 'O'}, {'recognition': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'85.60%': 'O'}, {'is': 'O'}, {'reached': 'O'}, {'when': 'O'}, {'the': 'O'}, {'top': 'O'}, {'seven': 'O'}, {'methods': 'O'}, {'are': 'O'}, {'employed.': 'O'}]"
"Vitamin D deficiency does not play a role on IMT of pSS, whereas it plays a role in disease damage and activity.","[{'Vitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'deficiency': 'O'}, {'does': 'O'}, {'not': 'O'}, {'play': 'O'}, {'a': 'O'}, {'role': 'O'}, {'on': 'O'}, {'IMT': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'whereas': 'O'}, {'it': 'O'}, {'plays': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'damage': 'O'}, {'and': 'O'}, {'activity.': 'O'}]"
A 65-year-old woman with a limited form of systematic sclerosis (SSc) and Sjogrens syndrome (SS) was admitted to our hospital for the evaluation of renal dysfunction.,"[{'A': 'O'}, {'65-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'a': 'O'}, {'limited': 'O'}, {'form': 'O'}, {'of': 'O'}, {'systematic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(SSc)': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'to': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'for': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'renal': 'B-Entity'}, {'dysfunction.': 'I-Entity'}]"
"Linear regression, Durbin-Watson (DW), and Pearson tests were evaluated to investigate the relationship between ‚âà√≠¬¨¬±-L-FUCA-1 plasma levels and autoimmune manifestations.","[{'Linear': 'O'}, {'regression,': 'O'}, {'Durbin-Watson': 'O'}, {'(DW),': 'O'}, {'and': 'O'}, {'Pearson': 'O'}, {'tests': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'‚âà√≠¬¨¬±-L-FUCA-1': 'O'}, {'plasma': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'manifestations.': 'O'}]"
"For Permissions, please email: journals.permissions@oup.com.Biomedical Sciences and.Biomedical Sciences and.taku@nagasaki-u.ac.jp.2015 Sep 2.idiopathic pulmonary fibrosis.","[{'For': 'O'}, {'Permissions,': 'O'}, {'please': 'O'}, {'email:': 'O'}, {'journals.permissions@oup.com.Biomedical': 'O'}, {'Sciences': 'O'}, {'and.Biomedical': 'O'}, {'Sciences': 'O'}, {'and.taku@nagasaki-u.ac.jp.2015': 'O'}, {'Sep': 'O'}, {'2.idiopathic': 'O'}, {'pulmonary': 'I-Entity'}, {'fibrosis.': 'I-Entity'}]"
The development and implementation of a method for analyzing polymorphic gene variants used to diagnose dry keratoconjunctivitis in rheumatoid arthritis and Sjogren's syndrome will allow assessment of the possibility of developing dry keratoconjunctivitis and/or its progression in patients with autoimmune diseases or in people at risk.,"[{'The': 'O'}, {'development': 'O'}, {'and': 'O'}, {'implementation': 'O'}, {'of': 'O'}, {'a': 'O'}, {'method': 'O'}, {'for': 'O'}, {'analyzing': 'O'}, {'polymorphic': 'O'}, {'gene': 'O'}, {'variants': 'O'}, {'used': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'dry': 'B-Entity'}, {'keratoconjunctivitis': 'I-Entity'}, {'in': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'will': 'O'}, {'allow': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'dry': 'B-Entity'}, {'keratoconjunctivitis': 'I-Entity'}, {'and/or': 'O'}]"
Almost half of the pregnancies assessed in women with pSS were associated with complications not attributable to factors other than the disease.Colegio Mexicano de Reumatolog‚Äö√†√∂‚Äö√¢‚Ä†a.,"[{'Almost': 'O'}, {'half': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pregnancies': 'O'}, {'assessed': 'O'}, {'in': 'O'}, {'women': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'complications': 'O'}, {'not': 'O'}, {'attributable': 'O'}, {'to': 'O'}, {'factors': 'O'}, {'other': 'O'}, {'than': 'O'}, {'the': 'O'}, {'disease.Colegio': 'O'}, {'Mexicano': 'O'}, {'de': 'O'}, {'Reumatolog‚Äö√†√∂‚Äö√¢‚Ä†a.': 'O'}]"
"In this article, we summarise the clinical manifestations, diagnosis and management of SS relevant to dental practitioners.Newcastle Dental Hospital, Newcastle upon Tyne.","[{'In': 'O'}, {'this': 'O'}, {'article,': 'O'}, {'we': 'O'}, {'summarise': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'manifestations,': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'management': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'relevant': 'O'}, {'to': 'O'}, {'dental': 'O'}, {'practitioners.Newcastle': 'O'}, {'Dental': 'O'}, {'Hospital,': 'O'}, {'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne.': 'O'}]"
"POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a paraneoplastic syndrome driven by plasma cell dyscrasias.","[{'POEMS': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(polyneuropathy,': 'O'}, {'organomegaly,': 'I-Entity'}, {'endocrinopathy,': 'I-Entity'}, {'monoclonal': 'B-Entity'}, {'gammopathy,': 'I-Entity'}, {'and': 'O'}, {'skin': 'B-Entity'}, {'changes)': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'paraneoplastic': 'B-Entity'}, {'syndrome': 'O'}, {'driven': 'O'}, {'by': 'O'}, {'plasma': 'B-Entity'}, {'cell': 'I-Entity'}, {'dyscrasias.': 'I-Entity'}]"
"Vigilance for the development of new neurologic symptoms is imperative even in chronic, apparently stable patients.","[{'Vigilance': 'O'}, {'for': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'new': 'O'}, {'neurologic': 'O'}, {'symptoms': 'O'}, {'is': 'O'}, {'imperative': 'O'}, {'even': 'O'}, {'in': 'O'}, {'chronic,': 'O'}, {'apparently': 'O'}, {'stable': 'O'}, {'patients.': 'O'}]"
We compared the hearing thresholds of both ears of patients with pSS versus the healthy control group and observed a significant difference in frequencies above 500¬¨¬®‚Äö√Ñ‚Ä†Hz.,"[{'We': 'O'}, {'compared': 'O'}, {'the': 'O'}, {'hearing': 'O'}, {'thresholds': 'O'}, {'of': 'O'}, {'both': 'O'}, {'ears': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'versus': 'O'}, {'the': 'O'}, {'healthy': 'O'}, {'control': 'O'}, {'group': 'O'}, {'and': 'O'}, {'observed': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'frequencies': 'O'}, {'above': 'O'}, {'500¬¨¬®‚Äö√Ñ‚Ä†Hz.': 'O'}]"
"This case report demonstrates the successful medical treatment of an autoimmune-related sterile corneal perforation without surgical intervention, highlighting the fact that early diagnosis and rigorous medical treatment with autologous serum and regenerating agent eye drops can effectively aid tissue regeneration and favorable visual rehabilitation.Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.clinical and immunological associations.","[{'This': 'O'}, {'case': 'O'}, {'report': 'O'}, {'demonstrates': 'O'}, {'the': 'O'}, {'successful': 'O'}, {'medical': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'an': 'O'}, {'autoimmune-related': 'O'}, {'sterile': 'O'}, {'corneal': 'B-Entity'}, {'perforation': 'I-Entity'}, {'without': 'O'}, {'surgical': 'O'}, {'intervention,': 'O'}, {'highlighting': 'O'}, {'the': 'O'}, {'fact': 'O'}, {'that': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'rigorous': 'O'}, {'medical': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'autologous': 'O'}, {'serum': 'O'}, {'and': 'O'}, {'regenerating': 'O'}, {'agent': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'can': 'O'}, {'effectively': 'O'}, {'aid': 'O'}, {'tissue': 'O'}, {'regeneration': 'O'}, {'and': 'O'}, {'favorable': 'O'}, {'visual': 'O'}, {'rehabilitation.Thessaloniki,': 'O'}]"
"Plasma Gas6 concentrations were determined, and Gas6 expressions in labial salivary gland (LSG) tissues from controls and pSS and sSS patients were also evaluated.","[{'Plasma': 'O'}, {'Gas6': 'O'}, {'concentrations': 'O'}, {'were': 'O'}, {'determined,': 'O'}, {'and': 'O'}, {'Gas6': 'O'}, {'expressions': 'O'}, {'in': 'O'}, {'labial': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'(LSG)': 'O'}, {'tissues': 'O'}, {'from': 'O'}, {'controls': 'O'}, {'and': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'sSS': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'also': 'O'}, {'evaluated.': 'O'}]"
"In the follow-up, the onset, and/or worsening of either the peripheral nervous system (PNS) domain (by multivariate and univariate analysis), or the biological domain (only by univariate analysis) correlated with a higher disease activity at the last visit [PNS domain: OR 5.9 (2.4-14.5), p < 0.0001; biological domain: OR 1.9 (1.0-3.8), p = 0.043].","[{'In': 'O'}, {'the': 'O'}, {'follow-up,': 'O'}, {'the': 'O'}, {'onset,': 'O'}, {'and/or': 'O'}, {'worsening': 'O'}, {'of': 'O'}, {'either': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(PNS)': 'I-Entity'}, {'domain': 'O'}, {'(by': 'O'}, {'multivariate': 'O'}, {'and': 'O'}, {'univariate': 'O'}, {'analysis),': 'O'}, {'or': 'O'}, {'the': 'O'}, {'biological': 'O'}, {'domain': 'O'}, {'(only': 'O'}, {'by': 'O'}, {'univariate': 'O'}, {'analysis)': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'at': 'O'}, {'the': 'O'}, {'last': 'O'}, {'visit': 'O'}, {'[PNS': 'O'}]"
"There are numerous non-ocular manifestations of SS, and monitoring for SS-related comorbid findings can aid in diagnosis, ideally in collaboration with a rheumatologist.","[{'There': 'O'}, {'are': 'O'}, {'numerous': 'O'}, {'non-ocular': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'monitoring': 'O'}, {'for': 'O'}, {'SS-related': 'I-Entity'}, {'comorbid': 'O'}, {'findings': 'O'}, {'can': 'O'}, {'aid': 'O'}, {'in': 'O'}, {'diagnosis,': 'O'}, {'ideally': 'O'}, {'in': 'O'}, {'collaboration': 'O'}, {'with': 'O'}, {'a': 'O'}, {'rheumatologist.': 'O'}]"
"Clinical, immunological and histological characteristics were surveyed, and potential risk factors for neurological complications were examined by multivariate analysis.","[{'Clinical,': 'O'}, {'immunological': 'O'}, {'and': 'O'}, {'histological': 'O'}, {'characteristics': 'O'}, {'were': 'O'}, {'surveyed,': 'O'}, {'and': 'O'}, {'potential': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'neurological': 'B-Entity'}, {'complications': 'I-Entity'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'multivariate': 'O'}, {'analysis.': 'O'}]"
"Patients whose main complaint is persistent parotid gland swelling may have a parotid biopsy in order to diagnose non-Hodgkin lymphoma.26953, Valence cedex 9, France.","[{'Patients': 'O'}, {'whose': 'O'}, {'main': 'O'}, {'complaint': 'O'}, {'is': 'O'}, {'persistent': 'O'}, {'parotid': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling': 'I-Entity'}, {'may': 'O'}, {'have': 'O'}, {'a': 'O'}, {'parotid': 'O'}, {'biopsy': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'non-Hodgkin': 'B-Entity'}, {'lymphoma.26953,': 'I-Entity'}, {'Valence': 'O'}, {'cedex': 'O'}, {'9,': 'O'}, {'France.': 'O'}]"
It is widely accepted that autoantibodies provide crucial diagnostic and prognostic information for autoimmune diseases.,"[{'It': 'O'}, {'is': 'O'}, {'widely': 'O'}, {'accepted': 'O'}, {'that': 'O'}, {'autoantibodies': 'O'}, {'provide': 'O'}, {'crucial': 'O'}, {'diagnostic': 'O'}, {'and': 'O'}, {'prognostic': 'O'}, {'information': 'O'}, {'for': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
The occurrence of NLM after LM was statistically significant in some studies and a NLM represented the most frequent cause of death.,"[{'The': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'NLM': 'I-Entity'}, {'after': 'O'}, {'LM': 'I-Entity'}, {'was': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'in': 'O'}, {'some': 'O'}, {'studies': 'O'}, {'and': 'O'}, {'a': 'O'}, {'NLM': 'I-Entity'}, {'represented': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'death.': 'I-Entity'}]"
"From the Registry of Catastrophic Illness database in the National Health Insurance Research Database in Taiwan, we identified 389 patients who were diagnosed with pSS from 2005 to 2010.","[{'From': 'O'}, {'the': 'O'}, {'Registry': 'O'}, {'of': 'O'}, {'Catastrophic': 'B-Entity'}, {'Illness': 'I-Entity'}, {'database': 'O'}, {'in': 'O'}, {'the': 'O'}, {'National': 'O'}, {'Health': 'O'}, {'Insurance': 'O'}, {'Research': 'O'}, {'Database': 'O'}, {'in': 'O'}, {'Taiwan,': 'O'}, {'we': 'O'}, {'identified': 'O'}, {'389': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'were': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'from': 'O'}, {'2005': 'O'}, {'to': 'O'}, {'2010.': 'O'}]"
On subsequent investigations she was found to have normal anion-gap metabolic acidosis with positive urine anion gap consistent with the diagnosis of distal renal tubular acidosis (RTA).,"[{'On': 'O'}, {'subsequent': 'O'}, {'investigations': 'O'}, {'she': 'O'}, {'was': 'O'}, {'found': 'O'}, {'to': 'O'}, {'have': 'O'}, {'normal': 'O'}, {'anion-gap': 'O'}, {'metabolic': 'O'}, {'acidosis': 'I-Entity'}, {'with': 'O'}, {'positive': 'O'}, {'urine': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'distal': 'B-Entity'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA).': 'O'}]"
The conception that multiple sclerosis may be challenging to distinguish from demyelinating manifestations of Sjogrens syndrome (SS) was introduced more than 30 years ago.,"[{'The': 'O'}, {'conception': 'O'}, {'that': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'challenging': 'O'}, {'to': 'O'}, {'distinguish': 'O'}, {'from': 'O'}, {'demyelinating': 'I-Entity'}, {'manifestations': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'was': 'O'}, {'introduced': 'O'}, {'more': 'O'}, {'than': 'O'}, {'30': 'O'}, {'years': 'O'}, {'ago.': 'O'}]"
This group of patients was divided in two subgroups: four patients with normal tear production and eight patients with low tear production.,"[{'This': 'O'}, {'group': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'was': 'O'}, {'divided': 'O'}, {'in': 'O'}, {'two': 'O'}, {'subgroups:': 'O'}, {'four': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'normal': 'O'}, {'tear': 'O'}, {'production': 'O'}, {'and': 'O'}, {'eight': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'low': 'O'}, {'tear': 'I-Entity'}, {'production.': 'O'}]"
"To assess the correlation between scintigraphic results and disease severity, semi-quantitative parameters were plotted versus Sjogrens syndrome disease activity index (ESSDAI).","[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'correlation': 'O'}, {'between': 'O'}, {'scintigraphic': 'O'}, {'results': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'severity,': 'O'}, {'semi-quantitative': 'O'}, {'parameters': 'O'}, {'were': 'O'}, {'plotted': 'O'}, {'versus': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI).': 'O'}]"
"For patient reported outcomes, there were no differences in EULAR Sjogrens syndrome patient reported index (ESSPRI), fatigue or dryness between groups, but pain scores were lower in the IFN active groups.","[{'For': 'O'}, {'patient': 'O'}, {'reported': 'O'}, {'outcomes,': 'O'}, {'there': 'O'}, {'were': 'O'}, {'no': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'patient': 'O'}, {'reported': 'O'}, {'index': 'O'}, {'(ESSPRI),': 'O'}, {'fatigue': 'I-Entity'}, {'or': 'O'}, {'dryness': 'I-Entity'}, {'between': 'O'}, {'groups,': 'O'}, {'but': 'O'}, {'pain': 'I-Entity'}, {'scores': 'O'}, {'were': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'the': 'O'}, {'IFN': 'I-Entity'}, {'active': 'O'}, {'groups.': 'O'}]"
The veins appear as dark areas.,"[{'The': 'O'}, {'veins': 'O'}, {'appear': 'O'}, {'as': 'O'}, {'dark': 'O'}, {'areas.': 'O'}]"
It remains uncertain whether the administration of a low dose of steroids before the onset of autoimmune hepatitis might have prevented the development of liver dysfunction in our patient.autoimmune dacryoadenitis.,"[{'It': 'O'}, {'remains': 'O'}, {'uncertain': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'a': 'O'}, {'low': 'O'}, {'dose': 'O'}, {'of': 'O'}, {'steroids': 'I-Entity'}, {'before': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'hepatitis': 'I-Entity'}, {'might': 'O'}, {'have': 'O'}, {'prevented': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'liver': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'our': 'O'}, {'patient.autoimmune': 'O'}, {'dacryoadenitis.': 'I-Entity'}]"
Escalation of prednisone did not improve the pain and swelling of left knee.,"[{'Escalation': 'O'}, {'of': 'O'}, {'prednisone': 'I-Entity'}, {'did': 'O'}, {'not': 'O'}, {'improve': 'O'}, {'the': 'O'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'swelling': 'I-Entity'}, {'of': 'O'}, {'left': 'O'}, {'knee.': 'O'}]"
The inferior tarsal conjunctiva of each patient was examined in vivo by LSCM.,"[{'The': 'O'}, {'inferior': 'O'}, {'tarsal': 'O'}, {'conjunctiva': 'O'}, {'of': 'O'}, {'each': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'by': 'O'}, {'LSCM.': 'O'}]"
"We describe a case of 72-year-old woman with Hashimoto disease, autoimmune hepatitis, Sjogrens syndrome, and immune-related pancytopenia complicated by cryoglobulinemic glomerulonephritis.","[{'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'72-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Hashimoto': 'B-Entity'}, {'disease,': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'hepatitis,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'immune-related': 'O'}, {'pancytopenia': 'I-Entity'}, {'complicated': 'O'}, {'by': 'O'}, {'cryoglobulinemic': 'B-Entity'}, {'glomerulonephritis.': 'I-Entity'}]"
Only one clinical trial used oral care sessions as control group.,"[{'Only': 'O'}, {'one': 'O'}, {'clinical': 'O'}, {'trial': 'O'}, {'used': 'O'}, {'oral': 'O'}, {'care': 'O'}, {'sessions': 'O'}, {'as': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
The method chosen was to define histopathological profiles reported in renal biopsies performed on patients with renal involvement due to different rheumatic diseases.,"[{'The': 'O'}, {'method': 'O'}, {'chosen': 'O'}, {'was': 'O'}, {'to': 'O'}, {'define': 'O'}, {'histopathological': 'O'}, {'profiles': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'renal': 'O'}, {'biopsies': 'O'}, {'performed': 'O'}, {'on': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'renal': 'O'}, {'involvement': 'O'}, {'due': 'O'}, {'to': 'O'}, {'different': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Reduced TBUT was seen more frequently in patients with dry eye (57%), ocular allergy (16%), and chronic blepharitis (15%).","[{'Reduced': 'O'}, {'TBUT': 'I-Entity'}, {'was': 'O'}, {'seen': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(57%),': 'O'}, {'ocular': 'B-Entity'}, {'allergy': 'I-Entity'}, {'(16%),': 'O'}, {'and': 'O'}, {'chronic': 'B-Entity'}, {'blepharitis': 'I-Entity'}, {'(15%).': 'O'}]"
"Then, we performed cross-listing in a group of independent gene expression datasets from patients with SS to identify consensus gene list of differentially expressed genes.","[{'Then,': 'O'}, {'we': 'O'}, {'performed': 'O'}, {'cross-listing': 'O'}, {'in': 'O'}, {'a': 'O'}, {'group': 'O'}, {'of': 'O'}, {'independent': 'O'}, {'gene': 'O'}, {'expression': 'O'}, {'datasets': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'to': 'O'}, {'identify': 'O'}, {'consensus': 'O'}, {'gene': 'O'}, {'list': 'O'}, {'of': 'O'}, {'differentially': 'O'}, {'expressed': 'O'}, {'genes.': 'O'}]"
"There were no significant differences in articular involvement, myopathy, tendon friction rubs and gastrointestinal, pulmonary, cardiac and renal involvements.","[{'There': 'O'}, {'were': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'articular': 'O'}, {'involvement,': 'O'}, {'myopathy,': 'I-Entity'}, {'tendon': 'O'}, {'friction': 'I-Entity'}, {'rubs': 'I-Entity'}, {'and': 'O'}, {'gastrointestinal,': 'B-Entity'}, {'pulmonary,': 'I-Entity'}, {'cardiac': 'I-Entity'}, {'and': 'I-Entity'}, {'renal': 'I-Entity'}, {'involvements.': 'O'}]"
"Sjogrens syndrome is a complex and heterogeneous autoimmune disease characterised by ocular and oral dryness (1), which mainly affects the exocrine glands.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'complex': 'O'}, {'and': 'O'}, {'heterogeneous': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterised': 'O'}, {'by': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness': 'I-Entity'}, {'(1),': 'O'}, {'which': 'O'}, {'mainly': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands.': 'O'}]"
The central nervous system involvement of Sjogrens Syndrome and the difficulty of differential diagnosis with neurological diseases such as Multiple sclerosis is discussed.catiacmduarte@gmail.comaccompanied by vitamin D deficiency.,"[{'The': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'difficulty': 'O'}, {'of': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'with': 'O'}, {'neurological': 'B-Entity'}, {'diseases': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'Multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'is': 'O'}, {'discussed.catiacmduarte@gmail.comaccompanied': 'O'}, {'by': 'O'}, {'vitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'deficiency.': 'I-Entity'}]"
The objective of this work was to determine the presence of HHV-8 viral DNA in whole blood from patients suffering from different systemic autoimmune diseases (SAD).,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'work': 'O'}, {'was': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'HHV-8': 'B-Entity'}, {'viral': 'O'}, {'DNA': 'O'}, {'in': 'O'}, {'whole': 'O'}, {'blood': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'different': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(SAD).': 'O'}]"
"However, there remains no systematic review to assess the effectiveness and safety of CHM.","[{'However,': 'O'}, {'there': 'O'}, {'remains': 'O'}, {'no': 'O'}, {'systematic': 'O'}, {'review': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'effectiveness': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'CHM.': 'I-Entity'}]"
Cranial magnetic resonance imaging revealed multiple lesions compatible with acute cerebral infarction.,"[{'Cranial': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'imaging': 'O'}, {'revealed': 'O'}, {'multiple': 'O'}, {'lesions': 'O'}, {'compatible': 'O'}, {'with': 'O'}, {'acute': 'B-Entity'}, {'cerebral': 'I-Entity'}, {'infarction.': 'I-Entity'}]"
"In this paper, we aimed to highlight the potential value of US imaging in the management of the elderly with a wide spectrum of musculoskeletal conditions (degenerative/rheumatic joint diseases, falls/trauma, nursing care, peripheral nerve problems, sarcopenia, and interventions).","[{'In': 'O'}, {'this': 'O'}, {'paper,': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'highlight': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'value': 'O'}, {'of': 'O'}, {'US': 'O'}, {'imaging': 'O'}, {'in': 'O'}, {'the': 'O'}, {'management': 'O'}, {'of': 'O'}, {'the': 'O'}, {'elderly': 'O'}, {'with': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'musculoskeletal': 'B-Entity'}, {'conditions': 'O'}, {'(degenerative/rheumatic': 'O'}, {'joint': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'falls/trauma,': 'I-Entity'}, {'nursing': 'O'}, {'care,': 'O'}, {'peripheral': 'B-Entity'}, {'nerve': 'I-Entity'}, {'problems,': 'I-Entity'}, {'sarcopenia,': 'I-Entity'}, {'and': 'O'}, {'interventions).': 'O'}]"
"We enrolled 101 pSS patients with normal liver function and structures, and without significant liver diseases or other conditions affecting liver fibrosis.","[{'We': 'O'}, {'enrolled': 'O'}, {'101': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'normal': 'O'}, {'liver': 'O'}, {'function': 'O'}, {'and': 'O'}, {'structures,': 'O'}, {'and': 'O'}, {'without': 'O'}, {'significant': 'O'}, {'liver': 'B-Entity'}, {'diseases': 'I-Entity'}, {'or': 'O'}, {'other': 'O'}, {'conditions': 'O'}, {'affecting': 'O'}, {'liver': 'B-Entity'}, {'fibrosis.': 'I-Entity'}]"
"Thus, the potential of aluminum-based adjuvants for induction of autoimmunity should be closely monitored in individuals genetically susceptible to developing autoimmune disorders.and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.","[{'Thus,': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'of': 'O'}, {'aluminum-based': 'I-Entity'}, {'adjuvants': 'O'}, {'for': 'O'}, {'induction': 'O'}, {'of': 'O'}, {'autoimmunity': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'closely': 'O'}, {'monitored': 'O'}, {'in': 'O'}, {'individuals': 'O'}, {'genetically': 'O'}, {'susceptible': 'O'}, {'to': 'O'}, {'developing': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders.and': 'I-Entity'}, {'Clinical': 'O'}, {'Immunology': 'O'}, {'Program,': 'O'}, {'Oklahoma': 'O'}, {'Medical': 'O'}, {'Research': 'O'}, {'Foundation,': 'O'}, {'Oklahoma': 'O'}, {'City,': 'O'}, {'OK,': 'O'}, {'USA.': 'O'}]"
SSc patients with such clinical features may be at high risk of AITD and require regular follow up of thyroid function including ultrasonography and the examination of serum hormone levels to start an early treatment.Japan.with lung cancer: An analysis of ten cases in China and literature review.,"[{'SSc': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'such': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'may': 'O'}, {'be': 'O'}, {'at': 'O'}, {'high': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'AITD': 'I-Entity'}, {'and': 'O'}, {'require': 'O'}, {'regular': 'O'}, {'follow': 'O'}, {'up': 'O'}, {'of': 'O'}, {'thyroid': 'O'}, {'function': 'O'}, {'including': 'O'}, {'ultrasonography': 'O'}, {'and': 'O'}, {'the': 'O'}, {'examination': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'hormone': 'O'}, {'levels': 'O'}, {'to': 'O'}, {'start': 'O'}, {'an': 'O'}, {'early': 'O'}, {'treatment.Japan.with': 'O'}, {'lung': 'B-Entity'}, {'cancer:': 'I-Entity'}, {'An': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'ten': 'O'}, {'cases': 'O'}, {'in': 'O'}, {'China': 'O'}, {'and': 'O'}, {'literature': 'O'}, {'review.': 'O'}]"
18F-Fluorodeoxyglucose (FDG) PET/CT scanning may be of interest for this purpose by detection of metabolic activity in lung tissue.,"[{'18F-Fluorodeoxyglucose': 'B-Entity'}, {'(FDG)': 'O'}, {'PET/CT': 'O'}, {'scanning': 'O'}, {'may': 'O'}, {'be': 'O'}, {'of': 'O'}, {'interest': 'O'}, {'for': 'O'}, {'this': 'O'}, {'purpose': 'O'}, {'by': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'metabolic': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'lung': 'O'}, {'tissue.': 'O'}]"
"In multivariate logistic regression, white blood cells count ‚Äö√Ñ√∂‚àö¬¢¬¨√ü4000.0/mm(3) (Odds ratio [OR] 9.821), serum albumin‚Äö√Ñ√∂‚àö√ë‚àö¬¢‚Äö√Ñ√∂‚àö¬¢¬¨√ü3.8‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg/dL (OR 16.770) and aspartate aminotransferase (AST) ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢‚Äö√Ñ√∂‚àö√ë‚àö¬¢27.0 IU/L (OR 20.858) independently predicted silent but substantial liver fibrosis in pSS patients.","[{'In': 'O'}, {'multivariate': 'O'}, {'logistic': 'O'}, {'regression,': 'O'}, {'white': 'O'}, {'blood': 'O'}, {'cells': 'O'}, {'count': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢¬¨√ü4000.0/mm(3)': 'O'}, {'(Odds': 'O'}, {'ratio': 'O'}, {'[OR]': 'O'}, {'9.821),': 'O'}, {'serum': 'O'}, {'albumin‚Äö√Ñ√∂‚àö√ë‚àö¬¢‚Äö√Ñ√∂‚àö¬¢¬¨√ü3.8‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg/dL': 'O'}]"
"Elevated levels of IL-17F were associated with increased IgG and IgM, higher titers of ANA and anti-SSA antibodies, and reduction of C3 and C4.","[{'Elevated': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'IL-17F': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'IgG': 'O'}, {'and': 'O'}, {'IgM,': 'O'}, {'higher': 'O'}, {'titers': 'O'}, {'of': 'O'}, {'ANA': 'O'}, {'and': 'O'}, {'anti-SSA': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'reduction': 'O'}, {'of': 'O'}, {'C3': 'O'}, {'and': 'O'}, {'C4.': 'O'}]"
"To date evidence based guidelines for the management of pSS are lacking, hence the therapeutic approach is mainly based on expert opinion and data from other connective tissue diseases.","[{'To': 'O'}, {'date': 'O'}, {'evidence': 'O'}, {'based': 'O'}, {'guidelines': 'O'}, {'for': 'O'}, {'the': 'O'}, {'management': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'are': 'O'}, {'lacking,': 'O'}, {'hence': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'approach': 'O'}, {'is': 'O'}, {'mainly': 'O'}, {'based': 'O'}, {'on': 'O'}, {'expert': 'O'}, {'opinion': 'O'}, {'and': 'O'}, {'data': 'O'}, {'from': 'O'}, {'other': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and theInstitute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, Unive","[{'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne': 'O'}, {'Hospitals': 'O'}, {'NHS': 'O'}, {'Foundation': 'O'}, {'Trust,': 'O'}, {'Musculoskeletal': 'O'}, {'Research': 'O'}, {'Group,': 'O'}, {'Institute': 'O'}, {'of': 'O'}, {'Cellular': 'O'}, {'Medicine': 'O'}, {'&': 'O'}, {'NIHR': 'O'}, {'Biomedical': 'O'}, {'Research': 'O'}, {'Centre': 'O'}, {'for': 'O'}, {'Ageing': 'O'}, {'and': 'O'}, {'Chronic': 'B-Entity'}, {'Diseases,': 'I-Entity'}, {'Institute': 'O'}, {'of': 'O'}, {'Health': 'O'}, {'and': 'O'}, {'Society,': 'O'}, {'Newcastle': 'O'}, {'University,': 'O'}, {'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne,': 'O'}, {'Musgrove': 'O'}, {'Park': 'O'}, {'Hospital,': 'O'}, {'Taunton': 'O'}]"
"Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and theInstitute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.Institute of Cellular Medicine & NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, University Hospital Birmingham, Birmingham, Great Western Hospitals NHS Foundation Trust, Swindon, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, Nottingham University Hospital, Nottingham, Gartnavel General Hospital, Glasgow, Barts and the London NHS Trust & Barts and the London School of Medicine and Dentistry, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, Royal Hampshire County Hospital, Winchester, Royal Derby Hospital, Derby, University College London Hospitals NHS Foundation Trust, London, Queen Elizabeth Hospital, Gateshead, Sunderland Royal Hospital, Sunderland, Southend University Hospital, Royal National Hospital for Rheumatic Diseases, Bath, Portsmouth Hospitals NHS Trust, Aintree University Hospitals, Liverpool, Basildon Hospital, Basildon, Royal Hallamshire Hospital, Sheffield, UK.","[{'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne': 'O'}, {'Hospitals': 'O'}, {'NHS': 'O'}, {'Foundation': 'O'}, {'Trust,': 'O'}, {'Musculoskeletal': 'O'}, {'Research': 'O'}, {'Group,': 'O'}, {'Institute': 'O'}, {'of': 'O'}, {'Cellular': 'O'}, {'Medicine': 'O'}, {'&': 'O'}, {'NIHR': 'O'}, {'Biomedical': 'O'}, {'Research': 'O'}, {'Centre': 'O'}, {'for': 'O'}, {'Ageing': 'O'}, {'and': 'O'}, {'Chronic': 'B-Entity'}, {'Diseases,': 'I-Entity'}, {'Institute': 'O'}, {'of': 'O'}, {'Health': 'O'}, {'and': 'O'}, {'Society,': 'O'}, {'Newcastle': 'O'}, {'University,': 'O'}, {'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne,': 'O'}, {'Musgrove': 'O'}, {'Park': 'O'}, {'Hospital,': 'O'}, {'Taunton': 'O'}]"
"Although the role of hypovitaminosis D in pSS pathogenesis remains controversial, the results of this study encourage the assessment of vitamin D in specific pSS subsets that could mostly benefit from a supplementation.chiara.baldini74@gmail.com.6.activating blood on the Th1/Th2 immune balance in peripheral blood in patients with primary Sjogren's syndrome.","[{'Although': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'hypovitaminosis': 'B-Entity'}, {'D': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'pathogenesis': 'O'}, {'remains': 'O'}, {'controversial,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'encourage': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'vitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'in': 'O'}, {'specific': 'O'}, {'pSS': 'I-Entity'}, {'subsets': 'O'}, {'that': 'O'}, {'could': 'O'}, {'mostly': 'O'}, {'benefit': 'O'}, {'from': 'O'}, {'a': 'O'}, {'supplementation.chiara.baldini74@gmail.com.6.activating': 'O'}]"
"The objective of this study was to evaluate, in TN patients, if rheumatologic clinical and laboratory findings could contribute to the early diagnosis of rheumatic diseases.","[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate,': 'O'}, {'in': 'O'}, {'TN': 'I-Entity'}, {'patients,': 'O'}, {'if': 'O'}, {'rheumatologic': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'findings': 'O'}, {'could': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Symptoms are often nonspecific and develop gradually, making diagnosis difficult.","[{'Symptoms': 'O'}, {'are': 'O'}, {'often': 'O'}, {'nonspecific': 'O'}, {'and': 'O'}, {'develop': 'O'}, {'gradually,': 'O'}, {'making': 'O'}, {'diagnosis': 'O'}, {'difficult.': 'O'}]"
In this Attending Rounds a patient with hypokalemia and metabolic acidosis is presented to emphasize the role of routine laboratory studies in the assessment of such patients so that a correct diagnosis can be made and appropriate treatment can be initiated promptly.Sep 15.,"[{'In': 'O'}, {'this': 'O'}, {'Attending': 'O'}, {'Rounds': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'hypokalemia': 'I-Entity'}, {'and': 'O'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'is': 'O'}, {'presented': 'O'}, {'to': 'O'}, {'emphasize': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'routine': 'O'}, {'laboratory': 'O'}, {'studies': 'O'}, {'in': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'such': 'O'}, {'patients': 'O'}, {'so': 'O'}, {'that': 'O'}, {'a': 'O'}, {'correct': 'O'}, {'diagnosis': 'O'}, {'can': 'O'}, {'be': 'O'}, {'made': 'O'}, {'and': 'O'}, {'appropriate': 'O'}, {'treatment': 'O'}, {'can': 'O'}, {'be': 'O'}, {'initiated': 'O'}, {'promptly.Sep': 'O'}, {'15.': 'O'}]"
"Eye and/or mouth dryness is a frequent complaint in clinical setting, and its frequency increases with age.","[{'Eye': 'B-Entity'}, {'and/or': 'I-Entity'}, {'mouth': 'I-Entity'}, {'dryness': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'frequent': 'O'}, {'complaint': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'setting,': 'O'}, {'and': 'O'}, {'its': 'O'}, {'frequency': 'O'}, {'increases': 'O'}, {'with': 'O'}, {'age.': 'O'}]"
"Monitoring disease activity using imaging modalities (including positron emission tomography) and serum markers is imperative, as relapses are common.","[{'Monitoring': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'using': 'O'}, {'imaging': 'O'}, {'modalities': 'O'}, {'(including': 'O'}, {'positron': 'O'}, {'emission': 'O'}, {'tomography)': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'markers': 'O'}, {'is': 'O'}, {'imperative,': 'O'}, {'as': 'O'}, {'relapses': 'O'}, {'are': 'O'}, {'common.': 'O'}]"
"During a single study visit, subjects underwent blinded rheumatologic evaluation, DAS-28, health assessment questionnaires, autoantibodies, inflammatory markers, hand X-ray, and hand Duplex ultrasound.","[{'During': 'O'}, {'a': 'O'}, {'single': 'O'}, {'study': 'O'}, {'visit,': 'O'}, {'subjects': 'O'}, {'underwent': 'O'}, {'blinded': 'O'}, {'rheumatologic': 'O'}, {'evaluation,': 'O'}, {'DAS-28,': 'O'}, {'health': 'O'}, {'assessment': 'O'}, {'questionnaires,': 'O'}, {'autoantibodies,': 'O'}, {'inflammatory': 'O'}, {'markers,': 'O'}, {'hand': 'O'}, {'X-ray,': 'O'}, {'and': 'O'}, {'hand': 'O'}, {'Duplex': 'O'}, {'ultrasound.': 'O'}]"
All samples were tested by enzyme-linked immunosorbent assay according to the Inflammatory Neuropathy Cause and Treatment protocol.,"[{'All': 'O'}, {'samples': 'O'}, {'were': 'O'}, {'tested': 'O'}, {'by': 'O'}, {'enzyme-linked': 'O'}, {'immunosorbent': 'O'}, {'assay': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'Inflammatory': 'B-Entity'}, {'Neuropathy': 'I-Entity'}, {'Cause': 'O'}, {'and': 'O'}, {'Treatment': 'O'}, {'protocol.': 'O'}]"
"However, it is way more complex when the disease begins with extraglandular features, such as non erosive polyarticular arthritis, Raynaud's phenomenon, peripheral or central nervous system involvement, kidney disease or interstitial pneumonary disease, or even vasculitis.","[{'However,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'way': 'O'}, {'more': 'O'}, {'complex': 'O'}, {'when': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'begins': 'O'}, {'with': 'O'}, {'extraglandular': 'O'}, {'features,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'non': 'O'}, {'erosive': 'O'}, {'polyarticular': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon,': 'I-Entity'}, {'peripheral': 'O'}, {'or': 'O'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'involvement,': 'O'}, {'kidney': 'B-Entity'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonary': 'I-Entity'}, {'disease,': 'I-Entity'}, {'or': 'O'}, {'even': 'O'}]"
We reported the first case of IgG4-related Mikulicz¬¨¬®¬¨‚Ä¢s disease in Serbia.,"[{'We': 'O'}, {'reported': 'O'}, {'the': 'O'}, {'first': 'O'}, {'case': 'O'}, {'of': 'O'}, {'IgG4-related': 'O'}, {'Mikulicz¬¨¬®¬¨‚Ä¢s': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'Serbia.': 'O'}]"
"Iguratimod was discontinued immediately, and methylprednisolone was used for acute liver injury and Sjogren's syndrome.","[{'Iguratimod': 'I-Entity'}, {'was': 'O'}, {'discontinued': 'O'}, {'immediately,': 'O'}, {'and': 'O'}, {'methylprednisolone': 'I-Entity'}, {'was': 'O'}, {'used': 'O'}, {'for': 'O'}, {'acute': 'B-Entity'}, {'liver': 'I-Entity'}, {'injury': 'I-Entity'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"The prevalence of ANA was increased in most patients with systemic especially in neuropathy (NP), hemolytic anemia (HA), primary Sjogren's syndrome (pSS), dermatomyositis (DM), thrombocytopenia (Tb), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), AP, Renal impairment (RI), SLE, and mixed connective tissue disease (MCTD).","[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'ANA': 'O'}, {'was': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'most': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'neuropathy': 'I-Entity'}, {'(NP),': 'O'}, {'hemolytic': 'B-Entity'}, {'anemia': 'I-Entity'}, {'(HA),': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'dermatomyositis': 'I-Entity'}, {'(DM),': 'O'}, {'thrombocytopenia': 'I-Entity'}, {'(Tb),': 'O'}]"
Lymphoma diagnoses were evaluated by tissue review.,"[{'Lymphoma': 'I-Entity'}, {'diagnoses': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'tissue': 'O'}, {'review.': 'O'}]"
"Systemic sclerosis is a rare disease, for this reason the amount of available data on this disorder are scanty.","[{'Systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'disease,': 'O'}, {'for': 'O'}, {'this': 'O'}, {'reason': 'O'}, {'the': 'O'}, {'amount': 'O'}, {'of': 'O'}, {'available': 'O'}, {'data': 'O'}, {'on': 'O'}, {'this': 'O'}, {'disorder': 'O'}, {'are': 'O'}, {'scanty.': 'O'}]"
These results show association titles dilution ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1/320 in ANA's first test requested by a Rheumatology Unit with patients with systemic connective tissue disease.,"[{'These': 'O'}, {'results': 'O'}, {'show': 'O'}, {'association': 'O'}, {'titles': 'O'}, {'dilution': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1/320': 'O'}, {'in': 'O'}, {""ANA's"": 'O'}, {'first': 'O'}, {'test': 'O'}, {'requested': 'O'}, {'by': 'O'}, {'a': 'O'}, {'Rheumatology': 'O'}, {'Unit': 'O'}, {'with': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
Understanding the formation of Sjogren's lymphocytic infiltrates could permit earlier diagnosis and better outcomes.,"[{'Understanding': 'O'}, {'the': 'O'}, {'formation': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'lymphocytic': 'O'}, {'infiltrates': 'O'}, {'could': 'O'}, {'permit': 'O'}, {'earlier': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'better': 'O'}, {'outcomes.': 'O'}]"
No proven benefit of immunosuppressive agents over steroid therapy alone was found in this study.,"[{'No': 'O'}, {'proven': 'O'}, {'benefit': 'O'}, {'of': 'O'}, {'immunosuppressive': 'O'}, {'agents': 'O'}, {'over': 'O'}, {'steroid': 'I-Entity'}, {'therapy': 'O'}, {'alone': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'this': 'O'}, {'study.': 'O'}]"
The purpose of our study was to define the clinical characteristics of anti-centromere antibody and anti-SS-A/Ro antibody (ACA/SS-A) double positive Sjogrens syndrome (SS) and to clarify the clinical impact of these antibodies.,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'our': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'define': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'anti-centromere': 'O'}, {'antibody': 'O'}, {'and': 'O'}, {'anti-SS-A/Ro': 'O'}, {'antibody': 'O'}, {'(ACA/SS-A)': 'O'}, {'double': 'O'}, {'positive': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'clarify': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'these': 'O'}, {'antibodies.': 'O'}]"
"Even though most evidence comes from small and uncontrolled studies with few randomised controlled trials, CyA should be still regarded as a valid therapeutic tool in 2016 rheumatology.Italiano, piazzale Brescia 20, 20149, Milan, Italy.Istituto Auxologico Italiano, Via Zucchi 18, 20095, Cusano Milanino, Milan, Italy.del Perdono 7, 20122, Milan, Italy.UK.Istituto Auxologico Italiano, Via Zucchi 18, 20095, Cusano Milanino, Milan, Italy.","[{'Even': 'O'}, {'though': 'O'}, {'most': 'O'}, {'evidence': 'O'}, {'comes': 'O'}, {'from': 'O'}, {'small': 'O'}, {'and': 'O'}, {'uncontrolled': 'O'}, {'studies': 'O'}, {'with': 'O'}, {'few': 'O'}, {'randomised': 'O'}, {'controlled': 'O'}, {'trials,': 'O'}, {'CyA': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'still': 'O'}, {'regarded': 'O'}, {'as': 'O'}, {'a': 'O'}, {'valid': 'O'}, {'therapeutic': 'O'}, {'tool': 'O'}, {'in': 'O'}, {'2016': 'O'}, {'rheumatology.Italiano,': 'O'}, {'piazzale': 'O'}, {'Brescia': 'O'}, {'20,': 'O'}, {'20149,': 'O'}, {'Milan,': 'O'}, {'Italy.Istituto': 'O'}, {'Auxologico': 'O'}]"
A total of 48 postmenopausal women with stage I-III breast cancer and hand pain were recruited from the Lombardi Comprehensive Cancer Center.,"[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'48': 'O'}, {'postmenopausal': 'O'}, {'women': 'O'}, {'with': 'O'}, {'stage': 'O'}, {'I-III': 'O'}, {'breast': 'B-Entity'}, {'cancer': 'I-Entity'}, {'and': 'O'}, {'hand': 'B-Entity'}, {'pain': 'I-Entity'}, {'were': 'O'}, {'recruited': 'O'}, {'from': 'O'}, {'the': 'O'}, {'Lombardi': 'O'}, {'Comprehensive': 'O'}, {'Cancer': 'I-Entity'}, {'Center.': 'O'}]"
Overexpression of Syt-1 was associated with salivary gland alterations revealing that the secretory dysfunction in SS-patients is linked to altered expression and/or localization of secretory machinery components together with impaired epithelial cell polarity.,"[{'Overexpression': 'O'}, {'of': 'O'}, {'Syt-1': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'alterations': 'O'}, {'revealing': 'O'}, {'that': 'O'}, {'the': 'O'}, {'secretory': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'SS-patients': 'I-Entity'}, {'is': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'altered': 'O'}, {'expression': 'O'}, {'and/or': 'O'}, {'localization': 'O'}, {'of': 'O'}, {'secretory': 'O'}, {'machinery': 'O'}, {'components': 'O'}, {'together': 'O'}, {'with': 'O'}, {'impaired': 'O'}, {'epithelial': 'O'}, {'cell': 'O'}, {'polarity.': 'O'}]"
Two Cochrane systematic literature reviews (SLRs) have reported that topical treatments for dry mouth and dry eye are safe and effective.,"[{'Two': 'O'}, {'Cochrane': 'O'}, {'systematic': 'O'}, {'literature': 'O'}, {'reviews': 'O'}, {'(SLRs)': 'O'}, {'have': 'O'}, {'reported': 'O'}, {'that': 'O'}, {'topical': 'O'}, {'treatments': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'are': 'O'}, {'safe': 'O'}, {'and': 'O'}, {'effective.': 'O'}]"
"Compared with controls, a significant decrease was observed in the average, inferior, and temporal thicknesses of pRNFL and in the minimum, superotemporal, inferonasal, inferior, and inferotemporal thicknesses of mGCIPL of eyes with pSS (all P¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.05).","[{'Compared': 'O'}, {'with': 'O'}, {'controls,': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'decrease': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'average,': 'O'}, {'inferior,': 'O'}, {'and': 'O'}, {'temporal': 'O'}, {'thicknesses': 'O'}, {'of': 'O'}, {'pRNFL': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'minimum,': 'O'}, {'superotemporal,': 'O'}, {'inferonasal,': 'O'}, {'inferior,': 'O'}, {'and': 'O'}, {'inferotemporal': 'O'}, {'thicknesses': 'O'}, {'of': 'O'}, {'mGCIPL': 'O'}, {'of': 'O'}, {'eyes': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'(all': 'O'}, {'P¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.05).': 'O'}]"
"The recent discovery of auto-antibodies to cN-1A provides a serological tool to aid the differentiation between inflammatory myopathies and supports the idea that apart from degeneration, an adaptive immune response may also play a role in sIBM pathophysiology.","[{'The': 'O'}, {'recent': 'O'}, {'discovery': 'O'}, {'of': 'O'}, {'auto-antibodies': 'O'}, {'to': 'O'}, {'cN-1A': 'O'}, {'provides': 'O'}, {'a': 'O'}, {'serological': 'O'}, {'tool': 'O'}, {'to': 'O'}, {'aid': 'O'}, {'the': 'O'}, {'differentiation': 'O'}, {'between': 'O'}, {'inflammatory': 'O'}, {'myopathies': 'I-Entity'}, {'and': 'O'}, {'supports': 'O'}, {'the': 'O'}, {'idea': 'O'}, {'that': 'O'}, {'apart': 'O'}, {'from': 'O'}, {'degeneration,': 'O'}, {'an': 'O'}, {'adaptive': 'O'}, {'immune': 'O'}, {'response': 'O'}, {'may': 'O'}, {'also': 'O'}, {'play': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'sIBM': 'I-Entity'}, {'pathophysiology.': 'O'}]"
"IgG4-related disease has been recently defined as a distinct clinic-pathologic entity, characterized by dense IgG-4 plasmacytic infiltration of diverse organs, fibrosis, and tumefactive lesions.","[{'IgG4-related': 'O'}, {'disease': 'O'}, {'has': 'O'}, {'been': 'O'}, {'recently': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'a': 'O'}, {'distinct': 'O'}, {'clinic-pathologic': 'O'}, {'entity,': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'dense': 'O'}, {'IgG-4': 'O'}, {'plasmacytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'diverse': 'O'}, {'organs,': 'O'}, {'fibrosis,': 'I-Entity'}, {'and': 'O'}, {'tumefactive': 'O'}, {'lesions.': 'O'}]"
Renal biopsy showed chronic plasma cell-rich TIN with IgG4 + PC infiltration.,"[{'Renal': 'O'}, {'biopsy': 'O'}, {'showed': 'O'}, {'chronic': 'O'}, {'plasma': 'O'}, {'cell-rich': 'O'}, {'TIN': 'I-Entity'}, {'with': 'O'}, {'IgG4': 'O'}, {'+': 'O'}, {'PC': 'O'}, {'infiltration.': 'O'}]"
"73 patients were studied, divided into the following experimental groups: primary Sjogren syndrome (SSp) (n=15), secondary SS (SSs) (n=17), dry mouth, dry eye without Sjogrens syndrome (BO) (n=20) and healthy controls (C) (n=21).","[{'73': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'studied,': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'the': 'O'}, {'following': 'O'}, {'experimental': 'O'}, {'groups:': 'O'}, {'primary': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SSp)': 'O'}, {'(n=15),': 'O'}, {'secondary': 'O'}, {'SS': 'I-Entity'}, {'(SSs)': 'O'}, {'(n=17),': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'without': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(BO)': 'O'}, {'(n=20)': 'O'}, {'and': 'O'}, {'healthy': 'O'}, {'controls': 'O'}]"
"This uncontrolled study suggests the need for a full epidemiologic analysis of all individuals working with such occupational exposure, including full clinical and immunological examination.bmr@ku.eduJun 11.","[{'This': 'O'}, {'uncontrolled': 'O'}, {'study': 'O'}, {'suggests': 'O'}, {'the': 'O'}, {'need': 'O'}, {'for': 'O'}, {'a': 'O'}, {'full': 'O'}, {'epidemiologic': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'all': 'O'}, {'individuals': 'O'}, {'working': 'O'}, {'with': 'O'}, {'such': 'O'}, {'occupational': 'O'}, {'exposure,': 'O'}, {'including': 'O'}, {'full': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'immunological': 'O'}, {'examination.bmr@ku.eduJun': 'O'}, {'11.': 'O'}]"
"To identify independent contributors of fatigue in primary Sjogrens syndrome (SS) patients, taking into account clinical, laboratory, and psychological features, and to explore the potential role of interferon (IFN)-induced gene indoleamine 2,3-dioxygenase (IDO-1), anti-21-hydroxylase (anti-21[OH]) antibodies, and soluble BAFF.","[{'To': 'O'}, {'identify': 'O'}, {'independent': 'O'}, {'contributors': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'patients,': 'O'}, {'taking': 'O'}, {'into': 'O'}, {'account': 'O'}, {'clinical,': 'O'}, {'laboratory,': 'O'}, {'and': 'O'}, {'psychological': 'O'}, {'features,': 'O'}, {'and': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'role': 'O'}, {'of': 'O'}, {'interferon': 'I-Entity'}, {'(IFN)-induced': 'O'}, {'gene': 'O'}, {'indoleamine': 'B-Entity'}, {'2,3-dioxygenase': 'I-Entity'}, {'(IDO-1),': 'O'}]"
Fine needle aspiration of the salivary glands (SG) showed nonspecific findings that led to delayed diagnosis of SS.,"[{'Fine': 'O'}, {'needle': 'O'}, {'aspiration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(SG)': 'O'}, {'showed': 'O'}, {'nonspecific': 'O'}, {'findings': 'O'}, {'that': 'O'}, {'led': 'O'}, {'to': 'O'}, {'delayed': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
"Extracellular high mobility group box 1 (HMGB1) acts as a damage associated molecular pattern molecule through the Toll-like receptor to promote autoreactive B cell activation, which may be involved in the pathogenesis of Sj‚Äö√Ñ√π‚àö√ºgren's syndrome.","[{'Extracellular': 'O'}, {'high': 'O'}, {'mobility': 'O'}, {'group': 'O'}, {'box': 'O'}, {'1': 'O'}, {'(HMGB1)': 'O'}, {'acts': 'O'}, {'as': 'O'}, {'a': 'O'}, {'damage': 'O'}, {'associated': 'O'}, {'molecular': 'O'}, {'pattern': 'O'}, {'molecule': 'O'}, {'through': 'O'}, {'the': 'O'}, {'Toll-like': 'O'}, {'receptor': 'O'}, {'to': 'O'}, {'promote': 'O'}, {'autoreactive': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'be': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {""Sj‚Äö√Ñ√π‚àö√ºgren's"": 'O'}]"
B cells isolated from peripheral blood of 21 pSS patients and 18 healthy controls were stimulated with TLR-7 and -9 ligands for 24 h before being analysed for the expression of certain surface markers and intracellular cytokine levels by flow cytometry.,"[{'B': 'O'}, {'cells': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'21': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'18': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'stimulated': 'O'}, {'with': 'O'}, {'TLR-7': 'O'}, {'and': 'O'}, {'-9': 'O'}, {'ligands': 'O'}, {'for': 'O'}, {'24': 'O'}, {'h': 'O'}, {'before': 'O'}, {'being': 'O'}, {'analysed': 'O'}, {'for': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'certain': 'O'}, {'surface': 'O'}, {'markers': 'O'}, {'and': 'O'}, {'intracellular': 'O'}, {'cytokine': 'O'}, {'levels': 'O'}, {'by': 'O'}, {'flow': 'O'}, {'cytometry.': 'O'}]"
The St George's Respiratory Questionnaire (SGRQ) was used to assess respiratory symptoms.,"[{'The': 'O'}, {'St': 'O'}, {""George's"": 'O'}, {'Respiratory': 'O'}, {'Questionnaire': 'O'}, {'(SGRQ)': 'O'}, {'was': 'O'}, {'used': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'respiratory': 'B-Entity'}, {'symptoms.': 'O'}]"
Lung transplantation should be considered in patients with advanced disease but is not always feasible because of other manifestations of CTD and comorbidities.,"[{'Lung': 'O'}, {'transplantation': 'O'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'advanced': 'O'}, {'disease': 'O'}, {'but': 'O'}, {'is': 'O'}, {'not': 'O'}, {'always': 'O'}, {'feasible': 'O'}, {'because': 'O'}, {'of': 'O'}, {'other': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'CTD': 'I-Entity'}, {'and': 'O'}, {'comorbidities.': 'O'}]"
"The frequency of constitutional symptoms (such as fever and fatigue) and lung involvement was significantly higher (p< 0,05) and the articular symptoms were significantly less frequent (p< 0,05) in pSS with neurological involvement.","[{'The': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'constitutional': 'O'}, {'symptoms': 'O'}, {'(such': 'O'}, {'as': 'O'}, {'fever': 'I-Entity'}, {'and': 'O'}, {'fatigue)': 'I-Entity'}, {'and': 'O'}, {'lung': 'O'}, {'involvement': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'(p<': 'O'}, {'0,05)': 'O'}, {'and': 'O'}, {'the': 'O'}, {'articular': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'less': 'O'}, {'frequent': 'O'}, {'(p<': 'O'}, {'0,05)': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'with': 'O'}, {'neurological': 'O'}, {'involvement.': 'O'}]"
Sjogrens syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration and destruction of salivary and lacrimal glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"At the same time, she was diagnosed with pSS, based on dry mouth, xerophthalmia, positive anti-Ro/La antibodies, and scintigraphic finding of salivary glands.","[{'At': 'O'}, {'the': 'O'}, {'same': 'O'}, {'time,': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'xerophthalmia,': 'I-Entity'}, {'positive': 'O'}, {'anti-Ro/La': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'scintigraphic': 'O'}, {'finding': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
"In 303 pSS patients, disease activity was assessed by the European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI), the EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), the Sjogren's Syndrome Disease Activity Index (SSDAI) and the Sjogren's Syndrome Disease Damage Index (SSDDI).","[{'In': 'O'}, {'303': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'assessed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'European': 'O'}, {'League': 'O'}, {'Against': 'O'}, {'Rheumatism': 'I-Entity'}, {'(EULAR)': 'O'}, {""Sjogren's"": 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI),': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {""Sjogren's"": 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Patient': 'O'}, {'Reported': 'O'}, {'Index': 'O'}, {'(ESSPRI),': 'O'}]"
"These results demonstrate a novel chimeric mouse model of human SjS that provides a unique in vivo environment to test experimental therapeutics and investigate T-cell disease pathology.43210, USA; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.43210, USA; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.43210, USA; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.43210, USA; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.43210, USA; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.Phenotyping Shared Resource, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.43210, USA; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.","[{'These': 'O'}, {'results': 'O'}, {'demonstrate': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'chimeric': 'O'}, {'mouse': 'O'}, {'model': 'O'}, {'of': 'O'}, {'human': 'O'}, {'SjS': 'I-Entity'}, {'that': 'O'}, {'provides': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'environment': 'O'}, {'to': 'O'}, {'test': 'O'}, {'experimental': 'O'}, {'therapeutics': 'O'}, {'and': 'O'}, {'investigate': 'O'}, {'T-cell': 'O'}, {'disease': 'O'}, {'pathology.43210,': 'O'}, {'USA;': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Internal': 'O'}, {'Medicine,': 'O'}, {'The': 'O'}, {'Ohio': 'O'}, {'State': 'O'}, {'University,': 'O'}, {'Columbus,': 'O'}, {'OH': 'O'}, {'43210,': 'O'}, {'USA;': 'O'}]"
A total of 25 patients affected by SS and 25 healthy controls were examined.,"[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'25': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'25': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'examined.': 'O'}]"
"This article encompasses a collection and analysis of all the criteria of diseases affecting the oral cavity, which will be beneficial for an oral physician in their routine clinics.College and Hospital, India.Dental College, Barwala, India.Bhilai, Chhattisgarh, India.10.1016/j.jobcr.2015.12.012.","[{'This': 'O'}, {'article': 'O'}, {'encompasses': 'O'}, {'a': 'O'}, {'collection': 'O'}, {'and': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'all': 'O'}, {'the': 'O'}, {'criteria': 'O'}, {'of': 'O'}, {'diseases': 'I-Entity'}, {'affecting': 'I-Entity'}, {'the': 'I-Entity'}, {'oral': 'I-Entity'}, {'cavity,': 'I-Entity'}, {'which': 'O'}, {'will': 'O'}, {'be': 'O'}, {'beneficial': 'O'}, {'for': 'O'}, {'an': 'O'}, {'oral': 'O'}, {'physician': 'O'}, {'in': 'O'}, {'their': 'O'}, {'routine': 'O'}, {'clinics.College': 'O'}, {'and': 'O'}, {'Hospital,': 'O'}, {'India.Dental': 'O'}, {'College,': 'O'}, {'Barwala,': 'O'}, {'India.Bhilai,': 'O'}, {'Chhattisgarh,': 'O'}, {'India.10.1016/j.jobcr.2015.12.012.': 'O'}]"
"According to the results of the examination, the following diagnoses were verified: 4 - primary SS, 9 - systemic lupus erythematosus with SS, 10 - juvenile rheumatoid arthritis with SS, 3 - mixed connective tissue disease, 3 - overlap syndrome, 1 - systemic sclerosis with SS.","[{'According': 'O'}, {'to': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'the': 'O'}, {'examination,': 'O'}, {'the': 'O'}, {'following': 'O'}, {'diagnoses': 'O'}, {'were': 'O'}, {'verified:': 'O'}, {'4': 'O'}, {'-': 'O'}, {'primary': 'O'}, {'SS,': 'I-Entity'}, {'9': 'O'}, {'-': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'10': 'O'}, {'-': 'O'}, {'juvenile': 'B-Entity'}, {'rheumatoid': 'I-Entity'}, {'arthritis': 'I-Entity'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'3': 'O'}, {'-': 'O'}, {'mixed': 'B-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'3': 'O'}, {'-': 'O'}, {'overlap': 'B-Entity'}, {'syndrome,': 'I-Entity'}]"
"The SS risk allele of rs10774671 has been shown by others to be associated with reduced OAS1 enzymatic activity and ability to clear viral infections, as well as reduced responsiveness to IFN treatment.","[{'The': 'O'}, {'SS': 'O'}, {'risk': 'O'}, {'allele': 'O'}, {'of': 'O'}, {'rs10774671': 'O'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'by': 'O'}, {'others': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'reduced': 'O'}, {'OAS1': 'O'}, {'enzymatic': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'clear': 'O'}, {'viral': 'B-Entity'}, {'infections,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'reduced': 'O'}, {'responsiveness': 'O'}, {'to': 'O'}, {'IFN': 'I-Entity'}, {'treatment.': 'O'}]"
We now demonstrate a critical role for lymphotoxin ‚âà√≠¬¨¬± (LTA) in the pathogenesis of Sjogrens disease in IL14‚âà√≠¬¨¬±TG mice.,"[{'We': 'O'}, {'now': 'O'}, {'demonstrate': 'O'}, {'a': 'O'}, {'critical': 'O'}, {'role': 'O'}, {'for': 'O'}, {'lymphotoxin': 'O'}, {'‚âà√≠¬¨¬±': 'O'}, {'(LTA)': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'IL14‚âà√≠¬¨¬±TG': 'O'}, {'mice.': 'O'}]"
"Its clinical characteristics along with the relatively easy access to the target tissue and its product makes Sjogrens syndrome appealing to study many aspects of microRNAs in a systemic autoimmune disease, such as their potential as diagnostic or prognostic biomarkers and their role in pathogenesis of autoimmunity, inflammation or organ dysfunction.","[{'Its': 'O'}, {'clinical': 'O'}, {'characteristics': 'O'}, {'along': 'O'}, {'with': 'O'}, {'the': 'O'}, {'relatively': 'O'}, {'easy': 'O'}, {'access': 'O'}, {'to': 'O'}, {'the': 'O'}, {'target': 'O'}, {'tissue': 'O'}, {'and': 'O'}, {'its': 'O'}, {'product': 'O'}, {'makes': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'appealing': 'O'}, {'to': 'O'}, {'study': 'O'}, {'many': 'O'}, {'aspects': 'O'}, {'of': 'O'}, {'microRNAs': 'O'}, {'in': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'their': 'O'}, {'potential': 'O'}, {'as': 'O'}, {'diagnostic': 'O'}, {'or': 'O'}, {'prognostic': 'O'}, {'biomarkers': 'O'}, {'and': 'O'}, {'their': 'O'}, {'role': 'O'}, {'in': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'autoimmunity,': 'B-Entity'}]"
"The definition of scleroderma overlap syndrome is important, especially in patients who need high-dose corticosteroids for complications of a CTD.","[{'The': 'O'}, {'definition': 'O'}, {'of': 'O'}, {'scleroderma': 'B-Entity'}, {'overlap': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'important,': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'need': 'O'}, {'high-dose': 'O'}, {'corticosteroids': 'O'}, {'for': 'O'}, {'complications': 'O'}, {'of': 'O'}, {'a': 'O'}, {'CTD.': 'I-Entity'}]"
The E-FABP concentration in tears significantly correlated with the results of dry eye parameters.,"[{'The': 'O'}, {'E-FABP': 'O'}, {'concentration': 'O'}, {'in': 'O'}, {'tears': 'O'}, {'significantly': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'parameters.': 'O'}]"
The sensitivity of B cells to epratuzumab as measured by the mean concentration producing 50% of the maximum B cell count depletion was lower for patients with associated SS (9.5 ‚âà√≠¬¨‚à´g/ml) versus the total EMBODY population (87.1 ‚âà√≠¬¨‚à´g/ml).,"[{'The': 'O'}, {'sensitivity': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'to': 'O'}, {'epratuzumab': 'I-Entity'}, {'as': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'concentration': 'O'}, {'producing': 'O'}, {'50%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'maximum': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'count': 'O'}, {'depletion': 'O'}, {'was': 'O'}, {'lower': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'associated': 'O'}, {'SS': 'I-Entity'}, {'(9.5': 'O'}, {'‚âà√≠¬¨‚à´g/ml)': 'O'}, {'versus': 'O'}, {'the': 'O'}, {'total': 'O'}, {'EMBODY': 'O'}]"
To describe baseline characteristics of patients with primary Sjogrens syndrome (pSS) with right heart catheterization (RHC)-confirmed pulmonary arterial hypertension (PAH) and explore risk factors for PAH in pSS.,"[{'To': 'O'}, {'describe': 'O'}, {'baseline': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'with': 'O'}, {'right': 'O'}, {'heart': 'O'}, {'catheterization': 'O'}, {'(RHC)-confirmed': 'O'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'(PAH)': 'O'}, {'and': 'O'}, {'explore': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'PAH': 'I-Entity'}, {'in': 'O'}, {'pSS.': 'I-Entity'}]"
"We here report, to the best of our knowledge, the first description of an association between thymoma and Reynolds syndrome (systemic sclerosis associated with primary biliary cirrhosis) in an 80-year-old woman.","[{'We': 'O'}, {'here': 'O'}, {'report,': 'O'}, {'to': 'O'}, {'the': 'O'}, {'best': 'O'}, {'of': 'O'}, {'our': 'O'}, {'knowledge,': 'O'}, {'the': 'O'}, {'first': 'O'}, {'description': 'O'}, {'of': 'O'}, {'an': 'O'}, {'association': 'O'}, {'between': 'O'}, {'thymoma': 'I-Entity'}, {'and': 'O'}, {'Reynolds': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(systemic': 'O'}, {'sclerosis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cirrhosis)': 'I-Entity'}, {'in': 'O'}, {'an': 'O'}, {'80-year-old': 'O'}, {'woman.': 'O'}]"
"Using multiple regression analysis, we modelled the relationship between Profile of Fatigue and Discomfort physical and mental fatigue scores and potentially related variables.","[{'Using': 'O'}, {'multiple': 'O'}, {'regression': 'O'}, {'analysis,': 'O'}, {'we': 'O'}, {'modelled': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'Profile': 'O'}, {'of': 'O'}, {'Fatigue': 'I-Entity'}, {'and': 'O'}, {'Discomfort': 'O'}, {'physical': 'O'}, {'and': 'O'}, {'mental': 'O'}, {'fatigue': 'I-Entity'}, {'scores': 'O'}, {'and': 'O'}, {'potentially': 'O'}, {'related': 'O'}, {'variables.': 'O'}]"
PSS is not associated with an increased risk of ischemic stroke subsequent to diagnosis.Taiwan.21.Sjogren syndrome.,"[{'PSS': 'I-Entity'}, {'is': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'ischemic': 'B-Entity'}, {'stroke': 'I-Entity'}, {'subsequent': 'O'}, {'to': 'O'}, {'diagnosis.Taiwan.21.Sjogren': 'O'}, {'syndrome.': 'I-Entity'}]"
"We aimed to compare illness perceptions and psychological distress in patients with pSS, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and to test whether their associations with health-related quality of life (HRQoL) are similar in these groups of patients.","[{'We': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'illness': 'O'}, {'perceptions': 'O'}, {'and': 'O'}, {'psychological': 'O'}, {'distress': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'test': 'O'}, {'whether': 'O'}, {'their': 'O'}, {'associations': 'O'}, {'with': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(HRQoL)': 'O'}, {'are': 'O'}]"
There is a well-established association of Sjogren's syndrome with renal tubular acidosis (RTA).¬¨¬®‚Äö√Ñ‚Ä†Rarely there is a retrospective diagnosis where the patient presents with RTA and the workup reveals Sjogren's syndrome.,"[{'There': 'O'}, {'is': 'O'}, {'a': 'O'}, {'well-established': 'O'}, {'association': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA).¬¨¬®‚Äö√Ñ‚Ä†Rarely': 'O'}, {'there': 'O'}, {'is': 'O'}, {'a': 'O'}, {'retrospective': 'O'}, {'diagnosis': 'O'}, {'where': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'presents': 'O'}, {'with': 'O'}, {'RTA': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'workup': 'O'}, {'reveals': 'O'}, {""Sjogren's"": 'B-Entity'}]"
The patient remained symptom-free for 6 months postoperatively.10.1097/IOP.0b013e31827bda76.of cyclosporin 0.1¬¨¬®‚Äö√Ñ‚Ä†% for severe dry eye syndrome].,"[{'The': 'O'}, {'patient': 'O'}, {'remained': 'O'}, {'symptom-free': 'O'}, {'for': 'O'}, {'6': 'O'}, {'months': 'O'}, {'postoperatively.10.1097/IOP.0b013e31827bda76.of': 'O'}, {'cyclosporin': 'I-Entity'}, {'0.1¬¨¬®‚Äö√Ñ‚Ä†%': 'O'}, {'for': 'O'}]"
"These disorders, which may become symptomatic before or after the development of NMO, are often diagnosed long after the diagnosis of NMO, as symptoms may be wrongly attributed to NMO, its residual effects or medication side effects.","[{'These': 'O'}, {'disorders,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'become': 'O'}, {'symptomatic': 'O'}, {'before': 'O'}, {'or': 'O'}, {'after': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'NMO,': 'I-Entity'}, {'are': 'O'}, {'often': 'O'}, {'diagnosed': 'O'}, {'long': 'O'}, {'after': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'NMO,': 'I-Entity'}, {'as': 'O'}, {'symptoms': 'O'}, {'may': 'O'}, {'be': 'O'}, {'wrongly': 'O'}, {'attributed': 'O'}, {'to': 'O'}, {'NMO,': 'I-Entity'}, {'its': 'O'}, {'residual': 'O'}, {'effects': 'O'}, {'or': 'O'}, {'medication': 'O'}, {'side': 'O'}, {'effects.': 'O'}]"
They are liable to form a centrocecal scotoma and tubular vision.,"[{'They': 'O'}, {'are': 'O'}, {'liable': 'O'}, {'to': 'O'}, {'form': 'O'}, {'a': 'O'}, {'centrocecal': 'B-Entity'}, {'scotoma': 'I-Entity'}, {'and': 'O'}, {'tubular': 'B-Entity'}, {'vision.': 'I-Entity'}]"
One of the main characteristics of primary Sjogrens syndrome (pSS) is chronic dysfunction and destruction of the salivary and lacrimal glands; their secretory biofluids should reflect the glandular biological status.,"[{'One': 'O'}, {'of': 'O'}, {'the': 'O'}, {'main': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'chronic': 'O'}, {'dysfunction': 'I-Entity'}, {'and': 'O'}, {'destruction': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'I-Entity'}, {'lacrimal': 'O'}, {'glands;': 'O'}, {'their': 'O'}, {'secretory': 'O'}, {'biofluids': 'O'}, {'should': 'O'}, {'reflect': 'O'}, {'the': 'O'}, {'glandular': 'O'}, {'biological': 'O'}, {'status.': 'O'}]"
"Based on the investigations performed, a diagnosis was made of bullous pemphigoid.","[{'Based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'investigations': 'O'}, {'performed,': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'made': 'O'}, {'of': 'O'}, {'bullous': 'B-Entity'}, {'pemphigoid.': 'I-Entity'}]"
To assess the efficacy and safety of abatacept in patients with early and active primary Sjogrens syndrome (pSS).,"[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'abatacept': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'early': 'O'}, {'and': 'O'}, {'active': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"Bronchoalveolar lavage fluid revealed an increase of the total number of cells (35 x 10(4)/ml), including elevated lymphocyte level (69%) and decreased CD4/CD8 ratio (0.45).","[{'Bronchoalveolar': 'O'}, {'lavage': 'O'}, {'fluid': 'O'}, {'revealed': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'of': 'O'}, {'the': 'O'}, {'total': 'O'}, {'number': 'O'}, {'of': 'O'}, {'cells': 'O'}, {'(35': 'O'}, {'x': 'O'}, {'10(4)/ml),': 'O'}, {'including': 'O'}, {'elevated': 'O'}, {'lymphocyte': 'O'}, {'level': 'O'}, {'(69%)': 'O'}, {'and': 'O'}, {'decreased': 'O'}, {'CD4/CD8': 'O'}, {'ratio': 'O'}, {'(0.45).': 'O'}]"
"A 74-year-old Japanese woman with an overlap of rheumatoid arthritis, Sjogrens syndrome, and systemic sclerosis developed a huge tumor-like mass at the atlanto-axial vertebral joint region that caused severe cervical pain and difficulty in activities of daily living.","[{'A': 'O'}, {'74-year-old': 'O'}, {'Japanese': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'an': 'O'}, {'overlap': 'O'}, {'of': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'developed': 'O'}, {'a': 'O'}, {'huge': 'O'}, {'tumor-like': 'I-Entity'}, {'mass': 'O'}, {'at': 'O'}, {'the': 'O'}, {'atlanto-axial': 'O'}, {'vertebral': 'O'}, {'joint': 'O'}, {'region': 'O'}, {'that': 'O'}, {'caused': 'O'}, {'severe': 'O'}, {'cervical': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}]"
"Because we wanted to include only patients with full work availability potential, eligible patients were aged 18-62 years.","[{'Because': 'O'}, {'we': 'O'}, {'wanted': 'O'}, {'to': 'O'}, {'include': 'O'}, {'only': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'full': 'O'}, {'work': 'O'}, {'availability': 'O'}, {'potential,': 'O'}, {'eligible': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'aged': 'O'}, {'18-62': 'O'}, {'years.': 'O'}]"
"Improving physician education of pSS may help to alleviate frustrations and delays associated with diagnosis; the advent of novel effective treatments would be welcomed by patients with pSS.Collegeville, PA, USA.Jul 28.arthritis].","[{'Improving': 'O'}, {'physician': 'O'}, {'education': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'may': 'O'}, {'help': 'O'}, {'to': 'O'}, {'alleviate': 'O'}, {'frustrations': 'O'}, {'and': 'O'}, {'delays': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'diagnosis;': 'O'}, {'the': 'O'}, {'advent': 'O'}, {'of': 'O'}, {'novel': 'O'}, {'effective': 'O'}, {'treatments': 'O'}, {'would': 'O'}, {'be': 'O'}, {'welcomed': 'O'}, {'by': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.Collegeville,': 'I-Entity'}, {'PA,': 'O'}, {'USA.Jul': 'O'}, {'28.arthritis].': 'O'}]"
CASE: A 38-years old woman was treated in our department for diffuse systemic sclerosis and associated Sjogren syndrome.,"[{'CASE:': 'O'}, {'A': 'O'}, {'38-years': 'O'}, {'old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'in': 'O'}, {'our': 'O'}, {'department': 'O'}, {'for': 'O'}, {'diffuse': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'and': 'O'}, {'associated': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
It is known that 5% to 34% of Sjogrens syndrome (SS) cases are complicated by neuropathy in the form of myelitis.,"[{'It': 'O'}, {'is': 'O'}, {'known': 'O'}, {'that': 'O'}, {'5%': 'O'}, {'to': 'O'}, {'34%': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'cases': 'O'}, {'are': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'neuropathy': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'form': 'O'}, {'of': 'O'}, {'myelitis.': 'I-Entity'}]"
"Anti-Ro and anti-La were found by immunodiffusion in 12 patients, and 8 of these 12 had neuropathy (‚âà√¨‚àö¬∞(2) = 8.46, P = 0.0036, odds ratio = 6.0 compared to those without precipitating anti-Ro and anti-La).","[{'Anti-Ro': 'O'}, {'and': 'O'}, {'anti-La': 'O'}, {'were': 'O'}, {'found': 'O'}, {'by': 'O'}, {'immunodiffusion': 'O'}, {'in': 'O'}, {'12': 'O'}, {'patients,': 'O'}, {'and': 'O'}, {'8': 'O'}, {'of': 'O'}, {'these': 'O'}, {'12': 'O'}, {'had': 'O'}, {'neuropathy': 'I-Entity'}, {'(‚âà√¨‚àö¬∞(2)': 'O'}, {'=': 'O'}, {'8.46,': 'O'}, {'P': 'O'}, {'=': 'O'}, {'0.0036,': 'O'}, {'odds': 'O'}, {'ratio': 'O'}, {'=': 'O'}, {'6.0': 'O'}]"
"Thrombotic thrombocytopenic purpura (TTP) is an uncommon, serious disease that involves multiple organs and is rapidly fatal if left untreated.","[{'Thrombotic': 'B-Entity'}, {'thrombocytopenic': 'I-Entity'}, {'purpura': 'I-Entity'}, {'(TTP)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'uncommon,': 'O'}, {'serious': 'O'}, {'disease': 'O'}, {'that': 'O'}, {'involves': 'O'}, {'multiple': 'O'}, {'organs': 'O'}, {'and': 'O'}, {'is': 'O'}, {'rapidly': 'O'}, {'fatal': 'O'}, {'if': 'O'}, {'left': 'O'}, {'untreated.': 'O'}]"
"Proteomic techniques have become popular in medicine and dentistry because of their widespread use in analyzing bodily fluids such as blood, saliva, urine, and gingival crevicular fluids as well as hard tissues such as enamel, dentine, and cementum.","[{'Proteomic': 'O'}, {'techniques': 'O'}, {'have': 'O'}, {'become': 'O'}, {'popular': 'O'}, {'in': 'O'}, {'medicine': 'O'}, {'and': 'O'}, {'dentistry': 'O'}, {'because': 'O'}, {'of': 'O'}, {'their': 'O'}, {'widespread': 'O'}, {'use': 'O'}, {'in': 'O'}, {'analyzing': 'O'}, {'bodily': 'O'}, {'fluids': 'O'}, {'such': 'O'}, {'as': 'O'}, {'blood,': 'O'}, {'saliva,': 'O'}, {'urine,': 'O'}, {'and': 'O'}, {'gingival': 'O'}, {'crevicular': 'O'}, {'fluids': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'hard': 'O'}, {'tissues': 'O'}, {'such': 'O'}, {'as': 'O'}, {'enamel,': 'O'}, {'dentine,': 'O'}, {'and': 'O'}, {'cementum.': 'O'}]"
Tumoral calcinosis (TC) is a difficult-to-treat complication that can occur during several diseases such as dermatomyositis or genetic hyperphosphatemia.,"[{'Tumoral': 'B-Entity'}, {'calcinosis': 'I-Entity'}, {'(TC)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'difficult-to-treat': 'O'}, {'complication': 'O'}, {'that': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'during': 'O'}, {'several': 'O'}, {'diseases': 'O'}, {'such': 'O'}, {'as': 'O'}, {'dermatomyositis': 'I-Entity'}, {'or': 'O'}, {'genetic': 'O'}, {'hyperphosphatemia.': 'I-Entity'}]"
"Lymphoma-associated biomarkers were defined in a multicentre series of well-characterized patients with pSS, by dissecting the cohort in the pSS-associated prelymphomatous conditions.","[{'Lymphoma-associated': 'I-Entity'}, {'biomarkers': 'O'}, {'were': 'O'}, {'defined': 'O'}, {'in': 'O'}, {'a': 'O'}, {'multicentre': 'O'}, {'series': 'O'}, {'of': 'O'}, {'well-characterized': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'by': 'O'}, {'dissecting': 'O'}, {'the': 'O'}, {'cohort': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pSS-associated': 'I-Entity'}, {'prelymphomatous': 'O'}, {'conditions.': 'O'}]"
"Because of the well-established role of B-lymphocytes in the pathogenesis of pSS, a B-cell targeting therapy may represent a new and intriguing therapeutic approach; in this context, growing evidence suggests that B-cell depletion by rituximab (RTX) is also effective in pSS.","[{'Because': 'O'}, {'of': 'O'}, {'the': 'O'}, {'well-established': 'O'}, {'role': 'O'}, {'of': 'O'}, {'B-lymphocytes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'a': 'O'}, {'B-cell': 'O'}, {'targeting': 'O'}, {'therapy': 'O'}, {'may': 'O'}, {'represent': 'O'}, {'a': 'O'}, {'new': 'O'}, {'and': 'O'}, {'intriguing': 'O'}, {'therapeutic': 'O'}, {'approach;': 'O'}, {'in': 'O'}, {'this': 'O'}, {'context,': 'O'}, {'growing': 'O'}, {'evidence': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'B-cell': 'O'}, {'depletion': 'O'}, {'by': 'O'}, {'rituximab': 'I-Entity'}, {'(RTX)': 'O'}]"
"In a comparative, observational case series study, 34 normal volunteers (group 1) and 34 patients with dry eye disease (DED) associated with Sjogren syndrome (group 2) were included in the study.","[{'In': 'O'}, {'a': 'O'}, {'comparative,': 'O'}, {'observational': 'O'}, {'case': 'O'}, {'series': 'O'}, {'study,': 'O'}, {'34': 'O'}, {'normal': 'O'}, {'volunteers': 'O'}, {'(group': 'O'}, {'1)': 'O'}, {'and': 'O'}, {'34': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(group': 'O'}, {'2)': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study.': 'O'}]"
"Phenotypic expression of various mononuclear cells present in the affected tissue offers additional insight into cellular proliferation, survival, migration, antibody secretion and also the potential of forming tertiary lymphoid tissue, i.e., germinal centers.","[{'Phenotypic': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'various': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'present': 'O'}, {'in': 'O'}, {'the': 'O'}, {'affected': 'O'}, {'tissue': 'O'}, {'offers': 'O'}, {'additional': 'O'}, {'insight': 'O'}, {'into': 'O'}, {'cellular': 'O'}, {'proliferation,': 'O'}, {'survival,': 'O'}, {'migration,': 'O'}, {'antibody': 'O'}, {'secretion': 'O'}, {'and': 'O'}, {'also': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'of': 'O'}, {'forming': 'O'}, {'tertiary': 'O'}, {'lymphoid': 'O'}, {'tissue,': 'O'}, {'i.e.,': 'O'}, {'germinal': 'O'}, {'centers.': 'O'}]"
Changes of parameters after treatment in all the patients and differences of changes in SS and non-SS were evaluated.,"[{'Changes': 'O'}, {'of': 'O'}, {'parameters': 'O'}, {'after': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'all': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'differences': 'O'}, {'of': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'non-SS': 'O'}, {'were': 'O'}, {'evaluated.': 'O'}]"
BACKGROUND/Chromium and nickel are important soil pollutants in Taiwan.,"[{'BACKGROUND/Chromium': 'O'}, {'and': 'O'}, {'nickel': 'I-Entity'}, {'are': 'O'}, {'important': 'O'}, {'soil': 'O'}, {'pollutants': 'O'}, {'in': 'O'}, {'Taiwan.': 'O'}]"
"Therapeutic options include mainly symptomatic and supportive measures, and traditional immunosuppressant drugs have shown no effectiveness in randomized trials.","[{'Therapeutic': 'O'}, {'options': 'O'}, {'include': 'O'}, {'mainly': 'O'}, {'symptomatic': 'O'}, {'and': 'O'}, {'supportive': 'O'}, {'measures,': 'O'}, {'and': 'O'}, {'traditional': 'O'}, {'immunosuppressant': 'O'}, {'drugs': 'O'}, {'have': 'O'}, {'shown': 'O'}, {'no': 'O'}, {'effectiveness': 'O'}, {'in': 'O'}, {'randomized': 'O'}, {'trials.': 'O'}]"
Sensory function was not affected in 11% of patients indicating that Sjogrens syndrome associated neuropathy can present as a pure motor syndrome.,"[{'Sensory': 'O'}, {'function': 'O'}, {'was': 'O'}, {'not': 'O'}, {'affected': 'O'}, {'in': 'O'}, {'11%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'indicating': 'O'}, {'that': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'neuropathy': 'I-Entity'}, {'can': 'O'}, {'present': 'O'}, {'as': 'O'}, {'a': 'O'}, {'pure': 'O'}, {'motor': 'O'}, {'syndrome.': 'I-Entity'}]"
L1 ORF2p was expressed in 17/20 SS patients and all controls.,"[{'L1': 'O'}, {'ORF2p': 'O'}, {'was': 'O'}, {'expressed': 'O'}, {'in': 'O'}, {'17/20': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'all': 'O'}, {'controls.': 'O'}]"
"PAH was the initial manifestation of pSS in 12 patients (41.4%), and shortness of breath was the most common symptom (29/29, 100%).","[{'PAH': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'initial': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'in': 'O'}, {'12': 'O'}, {'patients': 'O'}, {'(41.4%),': 'O'}, {'and': 'O'}, {'shortness': 'B-Entity'}, {'of': 'I-Entity'}, {'breath': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'symptom': 'O'}, {'(29/29,': 'O'}, {'100%).': 'O'}]"
"Furthermore, unsupervised analysis based on gene expression modification before and after treatment allowed identification of 8 genes that were differentially expressed between responders and nonresponders, with the difference remaining significant after Bonferroni correction.","[{'Furthermore,': 'O'}, {'unsupervised': 'O'}, {'analysis': 'O'}, {'based': 'O'}, {'on': 'O'}, {'gene': 'O'}, {'expression': 'O'}, {'modification': 'O'}, {'before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'treatment': 'O'}, {'allowed': 'O'}, {'identification': 'O'}, {'of': 'O'}, {'8': 'O'}, {'genes': 'O'}, {'that': 'O'}, {'were': 'O'}, {'differentially': 'O'}, {'expressed': 'O'}, {'between': 'O'}, {'responders': 'O'}, {'and': 'O'}, {'nonresponders,': 'O'}, {'with': 'O'}, {'the': 'O'}, {'difference': 'O'}, {'remaining': 'O'}, {'significant': 'O'}, {'after': 'O'}, {'Bonferroni': 'O'}, {'correction.': 'O'}]"
"Vascular and tenosynovial structures, as well as the salivary glands, can be assessed with US in vasculitis and connective tissue disorders, including systemic lupus erythematosus and Sjogrens syndrome.","[{'Vascular': 'O'}, {'and': 'O'}, {'tenosynovial': 'O'}, {'structures,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'can': 'O'}, {'be': 'O'}, {'assessed': 'O'}, {'with': 'O'}, {'US': 'O'}, {'in': 'O'}, {'vasculitis': 'I-Entity'}, {'and': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disorders,': 'I-Entity'}, {'including': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"However, the disease-specific mechanisms for premature atherosclerosis in pSS are not fully understood.","[{'However,': 'O'}, {'the': 'O'}, {'disease-specific': 'O'}, {'mechanisms': 'O'}, {'for': 'O'}, {'premature': 'B-Entity'}, {'atherosclerosis': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'are': 'O'}, {'not': 'O'}, {'fully': 'O'}, {'understood.': 'O'}]"
"We found a female predominance, younger age at disease onset, lower frequency of extra articular manifestations, more frequent polyarticular pattern at disease onset and less erosive disease, denoting changing referral patterns, earlier diagnosis, improved disease control in Egyptian RA patients over 2 decades.","[{'We': 'O'}, {'found': 'O'}, {'a': 'O'}, {'female': 'O'}, {'predominance,': 'O'}, {'younger': 'O'}, {'age': 'O'}, {'at': 'O'}, {'disease': 'O'}, {'onset,': 'O'}, {'lower': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'extra': 'O'}, {'articular': 'O'}, {'manifestations,': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'polyarticular': 'O'}, {'pattern': 'O'}, {'at': 'O'}, {'disease': 'O'}, {'onset': 'O'}, {'and': 'O'}, {'less': 'O'}, {'erosive': 'O'}, {'disease,': 'O'}, {'denoting': 'O'}, {'changing': 'O'}, {'referral': 'O'}, {'patterns,': 'O'}, {'earlier': 'O'}, {'diagnosis,': 'O'}, {'improved': 'O'}, {'disease': 'O'}, {'control': 'O'}, {'in': 'O'}, {'Egyptian': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'over': 'O'}, {'2': 'O'}, {'decades.': 'O'}]"
"Over the past two decades, there have been several advances in the assessment and management of connective tissue disease-related pulmonary arterial hypertension (CTD-PAH) that improved outcomes of the treatment of this lethal disease, and this will be the focus of this study.","[{'Over': 'O'}, {'the': 'O'}, {'past': 'O'}, {'two': 'O'}, {'decades,': 'O'}, {'there': 'O'}, {'have': 'O'}, {'been': 'O'}, {'several': 'O'}, {'advances': 'O'}, {'in': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'and': 'O'}, {'management': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease-related': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'(CTD-PAH)': 'O'}, {'that': 'O'}, {'improved': 'O'}, {'outcomes': 'O'}, {'of': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'this': 'O'}, {'lethal': 'O'}, {'disease,': 'O'}, {'and': 'O'}, {'this': 'O'}, {'will': 'O'}, {'be': 'O'}, {'the': 'O'}, {'focus': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study.': 'O'}]"
"Work-up excluded sarcoidosis, Sjogrens syndrome, systemic lupus erythematosus, ANCA-associated vasculitides, Beh‚Äö√†√∂‚àö√ºet disease, spondyloarthritis and infection.","[{'Work-up': 'O'}, {'excluded': 'O'}, {'sarcoidosis,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'ANCA-associated': 'O'}, {'vasculitides,': 'I-Entity'}, {'Beh‚Äö√†√∂‚àö√ºet': 'O'}, {'disease,': 'I-Entity'}, {'spondyloarthritis': 'I-Entity'}, {'and': 'O'}, {'infection.': 'I-Entity'}]"
This meta-analysis aimed to explore the association of subclinical atherosclerosis and arterial stiffness in primary Sjogren's syndrome.,"[{'This': 'O'}, {'meta-analysis': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'subclinical': 'O'}, {'atherosclerosis': 'I-Entity'}, {'and': 'O'}, {'arterial': 'B-Entity'}, {'stiffness': 'I-Entity'}, {'in': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
After a follow up of mean 8.2 years a significant correlation was found between disease duration and the prevalence of EGOD.,"[{'After': 'O'}, {'a': 'O'}, {'follow': 'O'}, {'up': 'O'}, {'of': 'O'}, {'mean': 'O'}, {'8.2': 'O'}, {'years': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'correlation': 'O'}, {'was': 'O'}, {'found': 'O'}, {'between': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'and': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'EGOD.': 'I-Entity'}]"
GTW is as effective as HCQ in the treatment of Sjogrens syndrome in the NOD mouse model.Section of the Chinese Stomatological Association (CSA)Sjogrens syndrome.,"[{'GTW': 'I-Entity'}, {'is': 'O'}, {'as': 'O'}, {'effective': 'O'}, {'as': 'O'}, {'HCQ': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'NOD': 'O'}, {'mouse': 'O'}, {'model.Section': 'O'}, {'of': 'O'}, {'the': 'O'}, {'Chinese': 'O'}, {'Stomatological': 'O'}, {'Association': 'O'}, {'(CSA)Sjogrens': 'O'}, {'syndrome.': 'I-Entity'}]"
"IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS) is characterized by bilateral swelling of glandular tissues with extensive fibrosis, and is immunologically considered a Th2-predominant disease.","[{'IgG4-related': 'O'}, {'dacryoadenitis': 'I-Entity'}, {'and': 'O'}, {'sialoadenitis': 'I-Entity'}, {'(IgG4-DS)': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'bilateral': 'O'}, {'swelling': 'O'}, {'of': 'O'}, {'glandular': 'O'}, {'tissues': 'O'}, {'with': 'O'}, {'extensive': 'O'}, {'fibrosis,': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'immunologically': 'O'}, {'considered': 'O'}, {'a': 'O'}, {'Th2-predominant': 'O'}, {'disease.': 'O'}]"
"There was a preponderance of dendritic cells and NK cells in the initial inflammatory cell infiltrates, and these were followed by CD4+ T cells.","[{'There': 'O'}, {'was': 'O'}, {'a': 'O'}, {'preponderance': 'O'}, {'of': 'O'}, {'dendritic': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'NK': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'initial': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltrates,': 'O'}, {'and': 'O'}, {'these': 'O'}, {'were': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'CD4+': 'O'}, {'T': 'O'}, {'cells.': 'O'}]"
Nuclear medicine studies evaluate physiology on a molecular level providing earlier detection of lesions before morphologic change is evident.,"[{'Nuclear': 'O'}, {'medicine': 'O'}, {'studies': 'O'}, {'evaluate': 'O'}, {'physiology': 'O'}, {'on': 'O'}, {'a': 'O'}, {'molecular': 'O'}, {'level': 'O'}, {'providing': 'O'}, {'earlier': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'lesions': 'O'}, {'before': 'O'}, {'morphologic': 'O'}, {'change': 'O'}, {'is': 'O'}, {'evident.': 'O'}]"
Evidence has indicated that exosomes may play roles in processes such as the modulation of the immune response and activation of inflammation.,"[{'Evidence': 'O'}, {'has': 'O'}, {'indicated': 'O'}, {'that': 'O'}, {'exosomes': 'O'}, {'may': 'O'}, {'play': 'O'}, {'roles': 'O'}, {'in': 'O'}, {'processes': 'O'}, {'such': 'O'}, {'as': 'O'}, {'the': 'O'}, {'modulation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'response': 'O'}, {'and': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'inflammation.': 'I-Entity'}]"
"Diagnostic criteria for Sjogrens syndrome are required both by healthcare professionals and patients, namely in order to provide a rational basis for the assessment of the symptoms, establish an individual disease prognosis, and orientate the therapeutic intervention.","[{'Diagnostic': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'are': 'O'}, {'required': 'O'}, {'both': 'O'}, {'by': 'O'}, {'healthcare': 'O'}, {'professionals': 'O'}, {'and': 'O'}, {'patients,': 'O'}, {'namely': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'provide': 'O'}, {'a': 'O'}, {'rational': 'O'}, {'basis': 'O'}, {'for': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'the': 'O'}, {'symptoms,': 'O'}, {'establish': 'O'}, {'an': 'O'}, {'individual': 'O'}, {'disease': 'O'}, {'prognosis,': 'O'}, {'and': 'O'}, {'orientate': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'intervention.': 'O'}]"
"In our cohort, no clinical manifestation or disease score could clearly select patients with subsequent lymphoma development.","[{'In': 'O'}, {'our': 'O'}, {'cohort,': 'O'}, {'no': 'O'}, {'clinical': 'O'}, {'manifestation': 'O'}, {'or': 'O'}, {'disease': 'O'}, {'score': 'O'}, {'could': 'O'}, {'clearly': 'O'}, {'select': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'subsequent': 'O'}, {'lymphoma': 'I-Entity'}, {'development.': 'O'}]"
"MRI spinal-cord lesions have similar appearances in the earlier as well as chronic phases of a sensory neuronopathy, and therefore suggest that such dorsal column lesions may reflect inflammatory as well as a gliotic burden of injury.","[{'MRI': 'O'}, {'spinal-cord': 'B-Entity'}, {'lesions': 'I-Entity'}, {'have': 'O'}, {'similar': 'O'}, {'appearances': 'O'}, {'in': 'O'}, {'the': 'O'}, {'earlier': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'chronic': 'O'}, {'phases': 'O'}, {'of': 'O'}, {'a': 'O'}, {'sensory': 'B-Entity'}, {'neuronopathy,': 'I-Entity'}, {'and': 'O'}, {'therefore': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'such': 'O'}, {'dorsal': 'O'}, {'column': 'O'}, {'lesions': 'O'}, {'may': 'O'}, {'reflect': 'O'}, {'inflammatory': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'a': 'O'}, {'gliotic': 'I-Entity'}, {'burden': 'O'}, {'of': 'O'}, {'injury.': 'I-Entity'}]"
"Compared to 413 adult SS patients, childhood SS was more commonly associated with parotitis, positive serologies, neurologic and nephrologic manifestations, and non-specific features (fever, lymphadenopathy) but less commonly associated with dry mouth and dry eyes.","[{'Compared': 'O'}, {'to': 'O'}, {'413': 'O'}, {'adult': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'childhood': 'O'}, {'SS': 'I-Entity'}, {'was': 'O'}, {'more': 'O'}, {'commonly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'parotitis,': 'I-Entity'}, {'positive': 'O'}, {'serologies,': 'O'}, {'neurologic': 'O'}, {'and': 'O'}, {'nephrologic': 'O'}, {'manifestations,': 'O'}, {'and': 'O'}, {'non-specific': 'O'}, {'features': 'O'}, {'(fever,': 'O'}, {'lymphadenopathy)': 'I-Entity'}, {'but': 'O'}, {'less': 'O'}, {'commonly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes.': 'I-Entity'}]"
"Patients and controls were comparable in age and education, but differed significantly in the prevalence of depression (38.1 vs 7.9%, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001), the number of physician visits [17.0 (10.0) vs 6.5 (4.5); P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001] and gainful employment (‚Äö√Ñ√∂‚àö¬¢¬¨√ü64 years: 52.8 vs 77.1% P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001).","[{'Patients': 'O'}, {'and': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'comparable': 'O'}, {'in': 'O'}, {'age': 'O'}, {'and': 'O'}, {'education,': 'O'}, {'but': 'O'}, {'differed': 'O'}, {'significantly': 'O'}, {'in': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'depression': 'I-Entity'}, {'(38.1': 'O'}, {'vs': 'O'}, {'7.9%,': 'O'}, {'P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001),': 'O'}]"
"Conversely, more rarely extra-digestive features during follow-up in patients with EGID may lead to a diagnosis of an associated CTD.","[{'Conversely,': 'O'}, {'more': 'O'}, {'rarely': 'O'}, {'extra-digestive': 'O'}, {'features': 'O'}, {'during': 'O'}, {'follow-up': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'EGID': 'I-Entity'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'an': 'O'}, {'associated': 'O'}, {'CTD.': 'I-Entity'}]"
"Based on this study, the authors believe that fine-needle aspiration biopsy or intraoperative biopsy and frozen section diagnosis may help reduce unnecessary lacrimal gland excision.Australian Institute of Ophthalmology, Adelaide, SA 5000, Australia.update.","[{'Based': 'O'}, {'on': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'the': 'O'}, {'authors': 'O'}, {'believe': 'O'}, {'that': 'O'}, {'fine-needle': 'O'}, {'aspiration': 'O'}, {'biopsy': 'O'}, {'or': 'O'}, {'intraoperative': 'O'}, {'biopsy': 'O'}, {'and': 'O'}, {'frozen': 'O'}, {'section': 'O'}, {'diagnosis': 'O'}, {'may': 'O'}, {'help': 'O'}, {'reduce': 'O'}, {'unnecessary': 'O'}, {'lacrimal': 'O'}, {'gland': 'O'}, {'excision.Australian': 'O'}, {'Institute': 'O'}, {'of': 'O'}, {'Ophthalmology,': 'O'}, {'Adelaide,': 'O'}, {'SA': 'O'}, {'5000,': 'O'}, {'Australia.update.': 'O'}]"
"In multivariate logistic regression analysis, after adjustment for white blood cell count, hemoglobin level, platelet count, lymphocyte count, and C3 and C4 levels, lower plasma Gas6 concentrations were significantly associated with an increased risk of SS.","[{'In': 'O'}, {'multivariate': 'O'}, {'logistic': 'O'}, {'regression': 'O'}, {'analysis,': 'O'}, {'after': 'O'}, {'adjustment': 'O'}, {'for': 'O'}, {'white': 'O'}, {'blood': 'O'}, {'cell': 'O'}, {'count,': 'O'}, {'hemoglobin': 'O'}, {'level,': 'O'}, {'platelet': 'O'}, {'count,': 'O'}, {'lymphocyte': 'O'}, {'count,': 'O'}, {'and': 'O'}, {'C3': 'O'}, {'and': 'O'}, {'C4': 'O'}, {'levels,': 'O'}, {'lower': 'O'}, {'plasma': 'O'}, {'Gas6': 'O'}, {'concentrations': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
"Overall, SLE-related RSV showed a decreasing trend from January 2004 to December 2013 and then demonstrated a slowly increasing trend from January 2014 to December 2018.","[{'Overall,': 'O'}, {'SLE-related': 'I-Entity'}, {'RSV': 'I-Entity'}, {'showed': 'O'}, {'a': 'O'}, {'decreasing': 'O'}, {'trend': 'O'}, {'from': 'O'}, {'January': 'O'}, {'2004': 'O'}, {'to': 'O'}, {'December': 'O'}, {'2013': 'O'}, {'and': 'O'}, {'then': 'O'}, {'demonstrated': 'O'}, {'a': 'O'}, {'slowly': 'O'}, {'increasing': 'O'}, {'trend': 'O'}, {'from': 'O'}, {'January': 'O'}, {'2014': 'O'}, {'to': 'O'}, {'December': 'O'}, {'2018.': 'O'}]"
Anti-Ro/SSA antibodies were tested by qualitative ELISA using a commercial assay.,"[{'Anti-Ro/SSA': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'tested': 'O'}, {'by': 'O'}, {'qualitative': 'O'}, {'ELISA': 'O'}, {'using': 'O'}, {'a': 'O'}, {'commercial': 'O'}, {'assay.': 'O'}]"
"We retrospectively analyzed the manifestations, treatments, and outcomes in patients with pSS-cerebellar complication in Peking Union Medical College Hospital and cases reported in literature.","[{'We': 'O'}, {'retrospectively': 'O'}, {'analyzed': 'O'}, {'the': 'O'}, {'manifestations,': 'O'}, {'treatments,': 'O'}, {'and': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS-cerebellar': 'I-Entity'}, {'complication': 'I-Entity'}, {'in': 'O'}, {'Peking': 'O'}, {'Union': 'O'}, {'Medical': 'O'}, {'College': 'O'}, {'Hospital': 'O'}, {'and': 'O'}, {'cases': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'literature.': 'O'}]"
"The reactivity in blood donors, in patients with chronic fatigue syndrome, and in diseased controls was <4%.","[{'The': 'O'}, {'reactivity': 'O'}, {'in': 'O'}, {'blood': 'O'}, {'donors,': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'chronic': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'in': 'O'}, {'diseased': 'O'}, {'controls': 'O'}, {'was': 'O'}, {'<4%.': 'O'}]"
Kidney and liver involvement was confirmed morphologically and immunomorphologically.,"[{'Kidney': 'B-Entity'}, {'and': 'I-Entity'}, {'liver': 'I-Entity'}, {'involvement': 'I-Entity'}, {'was': 'O'}, {'confirmed': 'O'}, {'morphologically': 'O'}, {'and': 'O'}, {'immunomorphologically.': 'O'}]"
"In addition, CCL22 enhanced IFN-‚âà√≠‚Äö√¢‚Ä¢ production of T cells of the SS model, thereby suggesting that CCL22 may impair the local immune tolerance in the target organ of the SS model.","[{'In': 'O'}, {'addition,': 'O'}, {'CCL22': 'O'}, {'enhanced': 'O'}, {'IFN-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'production': 'O'}, {'of': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'of': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'model,': 'O'}, {'thereby': 'O'}, {'suggesting': 'O'}, {'that': 'O'}, {'CCL22': 'O'}, {'may': 'O'}, {'impair': 'O'}, {'the': 'O'}, {'local': 'O'}, {'immune': 'O'}, {'tolerance': 'O'}, {'in': 'O'}, {'the': 'O'}, {'target': 'O'}, {'organ': 'O'}, {'of': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'model.': 'O'}]"
"To date, only cases of MALT lymphoma of the salivary glands, thymus and stomach associated with Sjogren syndrome have been published.","[{'To': 'O'}, {'date,': 'O'}, {'only': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'I-Entity'}, {'glands,': 'I-Entity'}, {'thymus': 'O'}, {'and': 'O'}, {'stomach': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'published.': 'O'}]"
The discovery of this particular histologic appearance in a muscle biopsy independent of the final diagnosis should indicate the possibility of SS.Electronic address: alexandra.espitiathibault@chu-nantes.fr.Dec 15.involvement: results from the AIR registry.,"[{'The': 'O'}, {'discovery': 'O'}, {'of': 'O'}, {'this': 'O'}, {'particular': 'O'}, {'histologic': 'O'}, {'appearance': 'O'}, {'in': 'O'}, {'a': 'O'}, {'muscle': 'O'}, {'biopsy': 'O'}, {'independent': 'O'}, {'of': 'O'}, {'the': 'O'}, {'final': 'O'}, {'diagnosis': 'O'}, {'should': 'O'}, {'indicate': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'SS.Electronic': 'I-Entity'}, {'address:': 'O'}, {'alexandra.espitiathibault@chu-nantes.fr.Dec': 'O'}, {'15.involvement:': 'O'}, {'results': 'O'}, {'from': 'O'}, {'the': 'O'}, {'AIR': 'O'}, {'registry.': 'O'}]"
"In patients with pSS, disease activity was estimated using the European League Against Rheumatism (EULAR) Sjogrens Syndrome Disease Activity Index (ESSDAI), and patient-reported outcomes were evaluated with the EULAR Sjogrens Syndrome Patient-Reported Index.","[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'estimated': 'O'}, {'using': 'O'}, {'the': 'O'}, {'European': 'O'}, {'League': 'O'}, {'Against': 'O'}, {'Rheumatism': 'I-Entity'}, {'(EULAR)': 'O'}, {'Sjogrens': 'O'}, {'Syndrome': 'O'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI),': 'O'}, {'and': 'O'}, {'patient-reported': 'O'}, {'outcomes': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Patient-Reported': 'O'}]"
"However, the large majority of patients still experienced physical fatigue at an unsatisfactory level, above the cut-off value for PASS.","[{'However,': 'O'}, {'the': 'O'}, {'large': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'still': 'O'}, {'experienced': 'O'}, {'physical': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'at': 'O'}, {'an': 'O'}, {'unsatisfactory': 'O'}, {'level,': 'O'}, {'above': 'O'}, {'the': 'O'}, {'cut-off': 'O'}, {'value': 'O'}, {'for': 'O'}, {'PASS.': 'O'}]"
"Cesarean section rates, gestational age, body measurements at birth, and the incidence of CHB in these 212 pregnancies were analyzed in relation to fetal atrioventricular conduction and maternal diagnosis and compared with data from the Medical Birth Registry on 352,104 pregnancies in the Stockholm County.","[{'Cesarean': 'O'}, {'section': 'O'}, {'rates,': 'O'}, {'gestational': 'O'}, {'age,': 'O'}, {'body': 'O'}, {'measurements': 'O'}, {'at': 'O'}, {'birth,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'CHB': 'I-Entity'}, {'in': 'O'}, {'these': 'O'}, {'212': 'O'}, {'pregnancies': 'O'}, {'were': 'O'}, {'analyzed': 'O'}, {'in': 'O'}, {'relation': 'O'}, {'to': 'O'}, {'fetal': 'O'}, {'atrioventricular': 'O'}, {'conduction': 'O'}, {'and': 'O'}, {'maternal': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'data': 'O'}, {'from': 'O'}, {'the': 'O'}, {'Medical': 'O'}, {'Birth': 'O'}, {'Registry': 'O'}, {'on': 'O'}, {'352,104': 'O'}, {'pregnancies': 'O'}]"
"The high mortality rates are in part due to a delay in the diagnosis, and therefore clinicians must maintain a high index of suspicion.","[{'The': 'O'}, {'high': 'O'}, {'mortality': 'O'}, {'rates': 'O'}, {'are': 'O'}, {'in': 'O'}, {'part': 'O'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'delay': 'O'}, {'in': 'O'}, {'the': 'O'}, {'diagnosis,': 'O'}, {'and': 'O'}, {'therefore': 'O'}, {'clinicians': 'O'}, {'must': 'O'}, {'maintain': 'O'}, {'a': 'O'}, {'high': 'O'}, {'index': 'O'}, {'of': 'O'}, {'suspicion.': 'O'}]"
"Solid phase assay (EliA CTD Screen, Phadia, in which antibodies to 17 antigens are detected) was compared to indirect immunofluorescence for the detection of antinuclear antibodies in diagnostic samples of 236 patients with autoimmune connective tissue diseases, in 149 healthy blood donors, 139 patients with chronic fatigue syndrome, and 134 diseased controls.","[{'Solid': 'O'}, {'phase': 'O'}, {'assay': 'O'}, {'(EliA': 'O'}, {'CTD': 'O'}, {'Screen,': 'O'}, {'Phadia,': 'O'}, {'in': 'O'}, {'which': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'17': 'O'}, {'antigens': 'O'}, {'are': 'O'}, {'detected)': 'O'}, {'was': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'for': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'diagnostic': 'O'}, {'samples': 'O'}, {'of': 'O'}, {'236': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'in': 'O'}, {'149': 'O'}]"
"However, because she remained febrile, a thorough investigation resulted in the challenging diagnosis of SS.","[{'However,': 'O'}, {'because': 'O'}, {'she': 'O'}, {'remained': 'O'}, {'febrile,': 'I-Entity'}, {'a': 'O'}, {'thorough': 'O'}, {'investigation': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'the': 'O'}, {'challenging': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
"Participants were assessed as healthy controls or for a clinical diagnosis of dry eye using the Ocular Surface Disease Index, Schirmer tear test, tear breakup time, and keratoconjunctival staining.","[{'Participants': 'O'}, {'were': 'O'}, {'assessed': 'O'}, {'as': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'or': 'O'}, {'for': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'using': 'O'}, {'the': 'O'}, {'Ocular': 'O'}, {'Surface': 'O'}, {'Disease': 'O'}, {'Index,': 'O'}, {'Schirmer': 'O'}, {'tear': 'O'}, {'test,': 'O'}, {'tear': 'O'}, {'breakup': 'O'}, {'time,': 'O'}, {'and': 'O'}, {'keratoconjunctival': 'O'}, {'staining.': 'O'}]"
"In part II of this review, we present an overview of the diffuse cystic lung diseases caused by lymphoproliferative disorders, genetic mutations, or aberrant lung development and provide an approach to aid in their diagnosis and management.Rochester, Minnesota; and.Cincinnati, Ohio.Cincinnati, Ohio.","[{'In': 'O'}, {'part': 'O'}, {'II': 'O'}, {'of': 'O'}, {'this': 'O'}, {'review,': 'O'}, {'we': 'O'}, {'present': 'O'}, {'an': 'O'}, {'overview': 'O'}, {'of': 'O'}, {'the': 'O'}, {'diffuse': 'O'}, {'cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'diseases': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'lymphoproliferative': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'genetic': 'O'}, {'mutations,': 'O'}, {'or': 'O'}, {'aberrant': 'B-Entity'}, {'lung': 'I-Entity'}, {'development': 'I-Entity'}, {'and': 'O'}, {'provide': 'O'}, {'an': 'O'}, {'approach': 'O'}, {'to': 'O'}, {'aid': 'O'}, {'in': 'O'}, {'their': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'management.Rochester,': 'O'}, {'Minnesota;': 'O'}, {'and.Cincinnati,': 'O'}, {'Ohio.Cincinnati,': 'O'}]"
"Although there was an association between ATD and the presence of anti-Ro/SSA and/or anti-La/SSB antibodies, the absence of sicca symptoms and negative Schirmer's tests suggest a lack of association with secondary Sjogren's syndrome.","[{'Although': 'O'}, {'there': 'O'}, {'was': 'O'}, {'an': 'O'}, {'association': 'O'}, {'between': 'O'}, {'ATD': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-Ro/SSA': 'O'}, {'and/or': 'O'}, {'anti-La/SSB': 'O'}, {'antibodies,': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'O'}, {'and': 'O'}, {'negative': 'O'}, {""Schirmer's"": 'O'}, {'tests': 'O'}, {'suggest': 'O'}, {'a': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'association': 'O'}, {'with': 'O'}, {'secondary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
The basal cytoplasmatic calcium levels were lower in both Th1 and Th2 lymphocytes in pSS compared to controls.,"[{'The': 'O'}, {'basal': 'O'}, {'cytoplasmatic': 'O'}, {'calcium': 'I-Entity'}, {'levels': 'O'}, {'were': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'both': 'O'}, {'Th1': 'O'}, {'and': 'O'}, {'Th2': 'O'}, {'lymphocytes': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'compared': 'O'}, {'to': 'O'}, {'controls.': 'O'}]"
"We present a case of a 49-year-old female patient with a history of systemic lupus erythematosus, Sjogren's syndrome, and gastroesophageal reflux disease.","[{'We': 'O'}, {'present': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'49-year-old': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'gastroesophageal': 'B-Entity'}, {'reflux': 'I-Entity'}, {'disease.': 'I-Entity'}]"
Sjogrens syndrome (SS) has a varied clinical spectrum and has been associated with various chest computed tomography (CT) findings.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'has': 'O'}, {'a': 'O'}, {'varied': 'O'}, {'clinical': 'O'}, {'spectrum': 'O'}, {'and': 'O'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'various': 'O'}, {'chest': 'O'}, {'computed': 'O'}, {'tomography': 'O'}, {'(CT)': 'O'}, {'findings.': 'O'}]"
"Demographic characteristics, clinical manifestations, serial CD4 and CD8 lymphocyte counts and plasma HIV viral loads, HLA-B27 status, and treatment response to HIV and rheumatic diseases were recorded.","[{'Demographic': 'O'}, {'characteristics,': 'O'}, {'clinical': 'O'}, {'manifestations,': 'O'}, {'serial': 'O'}, {'CD4': 'O'}, {'and': 'O'}, {'CD8': 'O'}, {'lymphocyte': 'O'}, {'counts': 'O'}, {'and': 'O'}, {'plasma': 'O'}, {'HIV': 'I-Entity'}, {'viral': 'O'}, {'loads,': 'O'}, {'HLA-B27': 'O'}, {'status,': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'response': 'O'}, {'to': 'O'}, {'HIV': 'I-Entity'}, {'and': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'were': 'O'}, {'recorded.': 'O'}]"
"The majority of subjects who were ""false-positive"" for a given rheumatic disease on administrative data had a true diagnosis of a similar rheumatic disease.","[{'The': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'subjects': 'O'}, {'who': 'O'}, {'were': 'O'}, {'""false-positive""': 'O'}, {'for': 'O'}, {'a': 'O'}, {'given': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'on': 'O'}, {'administrative': 'O'}, {'data': 'O'}, {'had': 'O'}, {'a': 'O'}, {'true': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'rheumatic': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Secondly, the criteria recognize the systemic nature of SS, namely that patients without salivary or ocular glandular symptoms, but with extraglandular manifestations and B cell activation markers were also included in the SS classification.","[{'Secondly,': 'O'}, {'the': 'O'}, {'criteria': 'O'}, {'recognize': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'nature': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'namely': 'O'}, {'that': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'salivary': 'O'}, {'or': 'I-Entity'}, {'ocular': 'I-Entity'}, {'glandular': 'I-Entity'}, {'symptoms,': 'I-Entity'}, {'but': 'O'}, {'with': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation': 'O'}, {'markers': 'O'}, {'were': 'O'}, {'also': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'classification.': 'O'}]"
"In a sub-group of patients with both SLE and SS, Kaplan-Meier analysis showed that lymphopenia and interstitial lung disease were associated with increased mortality (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.024 and P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.023, respectively).","[{'In': 'O'}, {'a': 'O'}, {'sub-group': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'both': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'SS,': 'I-Entity'}, {'Kaplan-Meier': 'O'}, {'analysis': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'lymphopenia': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'mortality': 'O'}, {'(P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.024': 'O'}]"
The evaluation of the response was assessed using the disability Modified Rankin Scale (MRS) and a global evaluation by the practitioner.,"[{'The': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'response': 'O'}, {'was': 'O'}, {'assessed': 'O'}, {'using': 'O'}, {'the': 'O'}, {'disability': 'O'}, {'Modified': 'O'}, {'Rankin': 'O'}, {'Scale': 'O'}, {'(MRS)': 'O'}, {'and': 'O'}, {'a': 'O'}, {'global': 'O'}, {'evaluation': 'O'}, {'by': 'O'}, {'the': 'O'}, {'practitioner.': 'O'}]"
Some studies had also a selection bias because patients were hospitalized (data were obtained from hospital discharge registries) and therefore the more severe cases were considered.,"[{'Some': 'O'}, {'studies': 'O'}, {'had': 'O'}, {'also': 'O'}, {'a': 'O'}, {'selection': 'O'}, {'bias': 'O'}, {'because': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'hospitalized': 'O'}, {'(data': 'O'}, {'were': 'O'}, {'obtained': 'O'}, {'from': 'O'}, {'hospital': 'O'}, {'discharge': 'O'}, {'registries)': 'O'}, {'and': 'O'}, {'therefore': 'O'}, {'the': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'considered.': 'O'}]"
"Xerostomia (34 vs 4 subjects), xerophtalmia (23 vs 3) and dry skin (32 vs 12) were reported more often by the recipients than donors (P<0.001).","[{'Xerostomia': 'I-Entity'}, {'(34': 'O'}, {'vs': 'O'}, {'4': 'O'}, {'subjects),': 'O'}, {'xerophtalmia': 'I-Entity'}, {'(23': 'O'}, {'vs': 'O'}, {'3)': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'skin': 'I-Entity'}, {'(32': 'O'}, {'vs': 'O'}, {'12)': 'O'}, {'were': 'O'}, {'reported': 'O'}, {'more': 'O'}, {'often': 'O'}, {'by': 'O'}, {'the': 'O'}, {'recipients': 'O'}, {'than': 'O'}, {'donors': 'O'}, {'(P<0.001).': 'O'}]"
"Fatigue and depression deserve more recognition as treatment targets in pSS.Berlin, Germany.","[{'Fatigue': 'I-Entity'}, {'and': 'O'}, {'depression': 'I-Entity'}, {'deserve': 'O'}, {'more': 'O'}, {'recognition': 'O'}, {'as': 'O'}, {'treatment': 'O'}, {'targets': 'O'}, {'in': 'O'}, {'pSS.Berlin,': 'O'}, {'Germany.': 'O'}]"
"Androgens increased INT alpha1 and alpha2 subunits in tubuloepithelial cells and in healthy LSG, but in SS salivary glands this androgen regulation was defective, which is likely to contribute to defective outside-in signaling, acinar atrophy, and ductal cell hyperplasia.Hospital, PO Box 700, FIN-00029 HUS, Helsinki, Finland.presentation and outcome.","[{'Androgens': 'O'}, {'increased': 'O'}, {'INT': 'O'}, {'alpha1': 'O'}, {'and': 'O'}, {'alpha2': 'O'}, {'subunits': 'O'}, {'in': 'O'}, {'tubuloepithelial': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'LSG,': 'O'}, {'but': 'O'}, {'in': 'O'}, {'SS': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'this': 'O'}, {'androgen': 'O'}, {'regulation': 'O'}, {'was': 'O'}, {'defective,': 'O'}, {'which': 'O'}, {'is': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'defective': 'O'}, {'outside-in': 'O'}, {'signaling,': 'O'}, {'acinar': 'B-Entity'}, {'atrophy,': 'I-Entity'}]"
We aimed to evaluate the usefulness of anti-‚âà√≠¬¨¬±-fodrin antibodies (AFA) in combination with rheumatoid factor (RF) and/or antinuclear antibodies (ANA) as an alternative immunological criterion for Sjogren syndrome (SS) among patients with negative anti-Ro/La serology.,"[{'We': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'usefulness': 'O'}, {'of': 'O'}, {'anti-‚âà√≠¬¨¬±-fodrin': 'O'}, {'antibodies': 'O'}, {'(AFA)': 'O'}, {'in': 'O'}, {'combination': 'O'}, {'with': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'(RF)': 'O'}, {'and/or': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANA)': 'O'}, {'as': 'O'}, {'an': 'O'}, {'alternative': 'O'}, {'immunological': 'O'}, {'criterion': 'O'}, {'for': 'O'}, {'Sjogren': 'O'}]"
"The clinical presentation of a patient with LETM is often dramatic and can consist of paraparesis or tetraparesis, sensory disturbances, and gait, bladder, bowel and/or sexual dysfunction.","[{'The': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'LETM': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'dramatic': 'O'}, {'and': 'O'}, {'can': 'O'}, {'consist': 'O'}, {'of': 'O'}, {'paraparesis': 'I-Entity'}, {'or': 'O'}, {'tetraparesis,': 'I-Entity'}, {'sensory': 'B-Entity'}, {'disturbances,': 'I-Entity'}, {'and': 'O'}, {'gait,': 'B-Entity'}, {'bladder,': 'B-Entity'}, {'bowel': 'I-Entity'}, {'and/or': 'I-Entity'}, {'sexual': 'I-Entity'}, {'dysfunction.': 'I-Entity'}]"
"Our findings have provided new therapeutic targets for SS., Nishinomiya, Hyogo , Japan.Nov 5.French multicenter retrospective study.","[{'Our': 'O'}, {'findings': 'O'}, {'have': 'O'}, {'provided': 'O'}, {'new': 'O'}, {'therapeutic': 'O'}, {'targets': 'O'}, {'for': 'O'}, {'SS.,': 'I-Entity'}, {'Nishinomiya,': 'O'}, {'Hyogo': 'O'}, {',': 'O'}, {'Japan.Nov': 'O'}, {'5.French': 'O'}, {'multicenter': 'O'}, {'retrospective': 'O'}, {'study.': 'O'}]"
Cyclophosphamide has led to the development of treatment protocols using alternative immunosuppressive agents in patients with SS showing a poor response to plasmapheresis and potentially life-threatening manifestations.,"[{'Cyclophosphamide': 'I-Entity'}, {'has': 'O'}, {'led': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'protocols': 'O'}, {'using': 'O'}, {'alternative': 'O'}, {'immunosuppressive': 'O'}, {'agents': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'showing': 'O'}, {'a': 'O'}, {'poor': 'O'}, {'response': 'O'}, {'to': 'O'}, {'plasmapheresis': 'O'}, {'and': 'O'}, {'potentially': 'O'}, {'life-threatening': 'O'}, {'manifestations.': 'O'}]"
"The pattern of cutaneous lesions and associated autoantibodies also allow the distinction of different phenotypes, either more prone to life-threatening interstitial lung disease (MDA-5) or with higher risk for neoplasia (TIF1-‚âà√≠‚Äö√¢‚Ä¢).","[{'The': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'cutaneous': 'O'}, {'lesions': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'autoantibodies': 'O'}, {'also': 'O'}, {'allow': 'O'}, {'the': 'O'}, {'distinction': 'O'}, {'of': 'O'}, {'different': 'O'}, {'phenotypes,': 'O'}, {'either': 'O'}, {'more': 'O'}, {'prone': 'O'}, {'to': 'O'}, {'life-threatening': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(MDA-5)': 'O'}, {'or': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'risk': 'O'}, {'for': 'O'}, {'neoplasia': 'I-Entity'}, {'(TIF1-‚âà√≠‚Äö√¢‚Ä¢).': 'O'}]"
The altered function of MAIT cells in target tissues from pSS patients may result in dysregulation of mucosal immunity leading to microbial damage of mucosal surfaces and subsequent initiation of autoimmune response.in the USA.Australia.Australia.Australia.Australia.Australia.,"[{'The': 'O'}, {'altered': 'O'}, {'function': 'O'}, {'of': 'O'}, {'MAIT': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'target': 'O'}, {'tissues': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'may': 'O'}, {'result': 'O'}, {'in': 'O'}, {'dysregulation': 'O'}, {'of': 'O'}, {'mucosal': 'O'}, {'immunity': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'microbial': 'O'}, {'damage': 'O'}, {'of': 'O'}, {'mucosal': 'O'}, {'surfaces': 'O'}, {'and': 'O'}, {'subsequent': 'O'}, {'initiation': 'O'}, {'of': 'O'}, {'autoimmune': 'O'}, {'response.in': 'O'}, {'the': 'O'}, {'USA.Australia.Australia.Australia.Australia.Australia.': 'O'}]"
Recent studies suggested a potential of rituximab (RTX) in treating autoimmune thrombocytopenia (AITP) secondary to autoimmune diseases.,"[{'Recent': 'O'}, {'studies': 'O'}, {'suggested': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'(RTX)': 'O'}, {'in': 'O'}, {'treating': 'O'}, {'autoimmune': 'B-Entity'}, {'thrombocytopenia': 'I-Entity'}, {'(AITP)': 'O'}, {'secondary': 'O'}, {'to': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"There are contradictory opinions if late-onset systemic lupus erythematosus (SLE) is associated with a different, more benign disease course and better prognosis than early-onset SLE.","[{'There': 'O'}, {'are': 'O'}, {'contradictory': 'O'}, {'opinions': 'O'}, {'if': 'O'}, {'late-onset': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'different,': 'O'}, {'more': 'O'}, {'benign': 'O'}, {'disease': 'O'}, {'course': 'O'}, {'and': 'O'}, {'better': 'O'}, {'prognosis': 'O'}, {'than': 'O'}, {'early-onset': 'O'}, {'SLE.': 'I-Entity'}]"
Novel discoveries and substantial advancements have revealed that saliva may contain real-time information describing our overall physiological condition.,"[{'Novel': 'O'}, {'discoveries': 'O'}, {'and': 'O'}, {'substantial': 'O'}, {'advancements': 'O'}, {'have': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'saliva': 'O'}, {'may': 'O'}, {'contain': 'O'}, {'real-time': 'O'}, {'information': 'O'}, {'describing': 'O'}, {'our': 'O'}, {'overall': 'O'}, {'physiological': 'O'}, {'condition.': 'O'}]"
"The patient was treated with antimycotics, high doses of glucocorticoids and intravenous immunoglobulins with a significant clinical and radiological improvement.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'antimycotics,': 'O'}, {'high': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'glucocorticoids': 'O'}, {'and': 'O'}, {'intravenous': 'O'}, {'immunoglobulins': 'O'}, {'with': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'radiological': 'O'}, {'improvement.': 'O'}]"
A young lady with a history of repeated episodes of generalised weakness and fatigue presented to our hospital with similar symptoms and was found to have severe hypokalaemia.,"[{'A': 'O'}, {'young': 'O'}, {'lady': 'O'}, {'with': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'repeated': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'generalised': 'O'}, {'weakness': 'I-Entity'}, {'and': 'O'}, {'fatigue': 'I-Entity'}, {'presented': 'O'}, {'to': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'with': 'O'}, {'similar': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'was': 'O'}, {'found': 'O'}, {'to': 'O'}, {'have': 'O'}, {'severe': 'O'}, {'hypokalaemia.': 'I-Entity'}]"
Anti-52kD and 60kD SS-A/Ro antibodies were measured by ELISA kit in rheumatic disease patients.,"[{'Anti-52kD': 'O'}, {'and': 'O'}, {'60kD': 'O'}, {'SS-A/Ro': 'B-Entity'}, {'antibodies': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'ELISA': 'O'}, {'kit': 'O'}, {'in': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'patients.': 'O'}]"
"Detailed clinical features, testing, treatment, and outcomes were recorded.","[{'Detailed': 'O'}, {'clinical': 'O'}, {'features,': 'O'}, {'testing,': 'O'}, {'treatment,': 'O'}, {'and': 'O'}, {'outcomes': 'O'}, {'were': 'O'}, {'recorded.': 'O'}]"
Salivary-gland ultrasonography (SGUS) was recently shown to assist in the diagnosis and therapeutic monitoring of pSS.,"[{'Salivary-gland': 'O'}, {'ultrasonography': 'O'}, {'(SGUS)': 'O'}, {'was': 'O'}, {'recently': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'assist': 'O'}, {'in': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'monitoring': 'O'}, {'of': 'O'}, {'pSS.': 'I-Entity'}]"
Pilocarpine is more effective than artificial saliva for enhancing salivary and lacrimal secretion in patients with SS.,"[{'Pilocarpine': 'I-Entity'}, {'is': 'O'}, {'more': 'O'}, {'effective': 'O'}, {'than': 'O'}, {'artificial': 'O'}, {'saliva': 'O'}, {'for': 'O'}, {'enhancing': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'secretion': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
Here we report two cases of immune mediated cytopenias that were diagnosed to be due to Sjogren's syndrome.,"[{'Here': 'O'}, {'we': 'O'}, {'report': 'O'}, {'two': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'immune': 'O'}, {'mediated': 'O'}, {'cytopenias': 'I-Entity'}, {'that': 'O'}, {'were': 'O'}, {'diagnosed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'due': 'O'}, {'to': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"The patient's red blood cells showed spontaneous agglutination in saline at room temperature, and immunoglobulin M (IgM) was detected on the surface of red blood cells by flow cytometry, indicating that autoimmune hemolytic anemia was caused by warm reactive IgM antibodies.","[{'The': 'O'}, {""patient's"": 'O'}, {'red': 'O'}, {'blood': 'O'}, {'cells': 'O'}, {'showed': 'O'}, {'spontaneous': 'O'}, {'agglutination': 'O'}, {'in': 'O'}, {'saline': 'O'}, {'at': 'O'}, {'room': 'O'}, {'temperature,': 'O'}, {'and': 'O'}, {'immunoglobulin': 'O'}, {'M': 'O'}, {'(IgM)': 'O'}, {'was': 'O'}, {'detected': 'O'}, {'on': 'O'}, {'the': 'O'}, {'surface': 'O'}, {'of': 'O'}, {'red': 'O'}, {'blood': 'O'}, {'cells': 'O'}, {'by': 'O'}, {'flow': 'O'}, {'cytometry,': 'O'}, {'indicating': 'O'}, {'that': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia': 'I-Entity'}, {'was': 'O'}]"
"The patient health questionnaire-9 (PHQ-9) and generalized anxiety disorder (GAD)-7 questionnaires were used to detect depression and anxiety symptoms, respectively.","[{'The': 'O'}, {'patient': 'O'}, {'health': 'O'}, {'questionnaire-9': 'O'}, {'(PHQ-9)': 'O'}, {'and': 'O'}, {'generalized': 'B-Entity'}, {'anxiety': 'I-Entity'}, {'disorder': 'I-Entity'}, {'(GAD)-7': 'O'}, {'questionnaires': 'O'}, {'were': 'O'}, {'used': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'depression': 'I-Entity'}, {'and': 'O'}, {'anxiety': 'I-Entity'}, {'symptoms,': 'O'}, {'respectively.': 'O'}]"
"To asses the possibility of an endoscopic technique to diagnose, treat, and maintain the salivary glands in patients with Sjogren syndrome and systemic lupus erythematosus.","[{'To': 'O'}, {'asses': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'an': 'O'}, {'endoscopic': 'O'}, {'technique': 'O'}, {'to': 'O'}, {'diagnose,': 'O'}, {'treat,': 'O'}, {'and': 'O'}, {'maintain': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus.': 'I-Entity'}]"
SS should be considerd as a possible cause of trigeminal nerve disturbances.,"[{'SS': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'considerd': 'O'}, {'as': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'trigeminal': 'B-Entity'}, {'nerve': 'I-Entity'}, {'disturbances.': 'I-Entity'}]"
"Administration of a neutralizing anti-TNF-‚âà√≠¬¨¬± antibody to female NOD mice during the stage prior to disease onset significantly improved salivary secretion, indicating a remission of clinical symptoms of SS.","[{'Administration': 'O'}, {'of': 'O'}, {'a': 'O'}, {'neutralizing': 'O'}, {'anti-TNF-‚âà√≠¬¨¬±': 'O'}, {'antibody': 'O'}, {'to': 'O'}, {'female': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'during': 'O'}, {'the': 'O'}, {'stage': 'O'}, {'prior': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'onset': 'O'}, {'significantly': 'O'}, {'improved': 'O'}, {'salivary': 'O'}, {'secretion,': 'O'}, {'indicating': 'O'}, {'a': 'O'}, {'remission': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
Patients with mixed monoclonal cryoglobulinemia often developed clinical manifestations of Sjogrens syndrome (23%) and malignant lymphoproliferative diseases (14%).,"[{'Patients': 'O'}, {'with': 'O'}, {'mixed': 'O'}, {'monoclonal': 'O'}, {'cryoglobulinemia': 'I-Entity'}, {'often': 'O'}, {'developed': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(23%)': 'O'}, {'and': 'O'}, {'malignant': 'B-Entity'}, {'lymphoproliferative': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(14%).': 'O'}]"
Hierarchical regression analyses identified the strongest predictor of ocular dryness sensitivity to be self-reported pain and that of oral dryness sensitivity to be self-reported fatigue.,"[{'Hierarchical': 'O'}, {'regression': 'O'}, {'analyses': 'O'}, {'identified': 'O'}, {'the': 'O'}, {'strongest': 'O'}, {'predictor': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'dryness': 'I-Entity'}, {'sensitivity': 'O'}, {'to': 'O'}, {'be': 'O'}, {'self-reported': 'O'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'that': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'dryness': 'I-Entity'}, {'sensitivity': 'O'}, {'to': 'O'}, {'be': 'O'}, {'self-reported': 'O'}, {'fatigue.': 'I-Entity'}]"
"To describe changes in the 2001-2014 mortality of 6 autoimmune systemic diseases (AISDs), namely Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathies (IIM), Sjogrens Syndrome (SS), Mixed Connective Tissue Disease (MCTD) and ANCA-associated vasculitis (AAV) at the country-, continent-, and world-levels.","[{'To': 'O'}, {'describe': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'2001-2014': 'O'}, {'mortality': 'O'}, {'of': 'O'}, {'6': 'O'}, {'autoimmune': 'B-Entity'}, {'systemic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(AISDs),': 'O'}, {'namely': 'O'}, {'Systemic': 'B-Entity'}, {'Lupus': 'I-Entity'}, {'Erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'Systemic': 'B-Entity'}, {'Sclerosis': 'I-Entity'}, {'(SSc),': 'O'}, {'Idiopathic': 'B-Entity'}, {'Inflammatory': 'I-Entity'}, {'Myopathies': 'I-Entity'}, {'(IIM),': 'O'}]"
"Therefore, clinicians who treat patients with burning mouth symptoms should evaluate laboratory findings and salivary functions to identify patients with SS.2017 Dec 15.","[{'Therefore,': 'O'}, {'clinicians': 'O'}, {'who': 'O'}, {'treat': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'burning': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'O'}, {'should': 'O'}, {'evaluate': 'O'}, {'laboratory': 'O'}, {'findings': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'functions': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.2017': 'I-Entity'}, {'Dec': 'O'}, {'15.': 'O'}]"
"In the study, a statistically significant difference was found between the control group,SjS and RA+SjS groups.","[{'In': 'O'}, {'the': 'O'}, {'study,': 'O'}, {'a': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'was': 'O'}, {'found': 'O'}, {'between': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group,SjS': 'O'}, {'and': 'O'}, {'RA+SjS': 'I-Entity'}, {'groups.': 'O'}]"
The percentages of CD4+CXCR5+Tfh cells and B cell subsets were examined by flow cytometry.,"[{'The': 'O'}, {'percentages': 'O'}, {'of': 'O'}, {'CD4+CXCR5+Tfh': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'subsets': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'flow': 'O'}, {'cytometry.': 'O'}]"
Gastric neuroendocrine tumors (GNETs) with spindle cell morphology are extremely rare.,"[{'Gastric': 'B-Entity'}, {'neuroendocrine': 'I-Entity'}, {'tumors': 'I-Entity'}, {'(GNETs)': 'O'}, {'with': 'O'}, {'spindle': 'O'}, {'cell': 'O'}, {'morphology': 'O'}, {'are': 'O'}, {'extremely': 'O'}, {'rare.': 'O'}]"
"Titer of anit-MDM2 was negatively associated with hemoglobin level, platelet count, complement 3 level and complement 4 level, positively associated with European Sjogren's syndrome disease activity index (ESSDAI) and level of IgG.","[{'Titer': 'O'}, {'of': 'O'}, {'anit-MDM2': 'O'}, {'was': 'O'}, {'negatively': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'hemoglobin': 'O'}, {'level,': 'O'}, {'platelet': 'O'}, {'count,': 'O'}, {'complement': 'O'}, {'3': 'O'}, {'level': 'O'}, {'and': 'O'}, {'complement': 'O'}, {'4': 'O'}, {'level,': 'O'}, {'positively': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'European': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI)': 'O'}, {'and': 'O'}, {'level': 'O'}, {'of': 'O'}, {'IgG.': 'O'}]"
The objective of the study is to investigate the effect of hydroxychloroquine (HCQ) on subjective and objective parameters of dry eye in patients with primary Sjogren's disease and to evaluate the association of tear fluid B-cell activating factor (BAFF) level with the response.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'(HCQ)': 'O'}, {'on': 'O'}, {'subjective': 'O'}, {'and': 'O'}, {'objective': 'O'}, {'parameters': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'tear': 'O'}, {'fluid': 'O'}, {'B-cell': 'O'}, {'activating': 'O'}, {'factor': 'O'}, {'(BAFF)': 'O'}, {'level': 'O'}, {'with': 'O'}, {'the': 'O'}]"
"Relationships among clinical, physiological, imaging and pathological findings of small airway disease associated with Sjogrens syndrome have remained unclear.","[{'Relationships': 'O'}, {'among': 'O'}, {'clinical,': 'O'}, {'physiological,': 'O'}, {'imaging': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'small': 'B-Entity'}, {'airway': 'I-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'have': 'O'}, {'remained': 'O'}, {'unclear.': 'O'}]"
"The prevalence of ANA, anti-Ro/SSA, and anti-La/SSB was much higher in patients with anemia than those without anemia.","[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'ANA,': 'O'}, {'anti-Ro/SSA,': 'O'}, {'and': 'O'}, {'anti-La/SSB': 'O'}, {'was': 'O'}, {'much': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'anemia': 'I-Entity'}, {'than': 'O'}, {'those': 'O'}, {'without': 'O'}, {'anemia.': 'I-Entity'}]"
"Pneumoparotitis is a rare affection that belongs to differential diagnoses of parotitis, along with infections, lymphadenitis, autoimmune disorders, inflammatory conditions, vascular malformations or neoplasms.","[{'Pneumoparotitis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'affection': 'O'}, {'that': 'O'}, {'belongs': 'O'}, {'to': 'O'}, {'differential': 'O'}, {'diagnoses': 'O'}, {'of': 'O'}, {'parotitis,': 'I-Entity'}, {'along': 'O'}, {'with': 'O'}, {'infections,': 'I-Entity'}, {'lymphadenitis,': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'inflammatory': 'B-Entity'}, {'conditions,': 'O'}, {'vascular': 'B-Entity'}, {'malformations': 'I-Entity'}, {'or': 'O'}, {'neoplasms.': 'I-Entity'}]"
"+82/31/219-5948, Fax +82/31/219-5950, E-mail: aysays77@naver.com.Feb 26.disease and a more frequent muscular and pulmonary involvement.","[{'+82/31/219-5948,': 'O'}, {'Fax': 'O'}, {'+82/31/219-5950,': 'O'}, {'E-mail:': 'O'}, {'aysays77@naver.com.Feb': 'O'}, {'26.disease': 'O'}, {'and': 'O'}, {'a': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'muscular': 'B-Entity'}, {'and': 'I-Entity'}, {'pulmonary': 'I-Entity'}, {'involvement.': 'O'}]"
Formation of large bullae in SS is a rare complication with potential for confusion with other diseases.,"[{'Formation': 'O'}, {'of': 'O'}, {'large': 'O'}, {'bullae': 'I-Entity'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'with': 'O'}, {'potential': 'O'}, {'for': 'O'}, {'confusion': 'O'}, {'with': 'O'}, {'other': 'O'}, {'diseases.': 'O'}]"
"A noteworthy proportion of patients also features extraglandular manifestations, sometimes severe and life-threatening.","[{'A': 'O'}, {'noteworthy': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'also': 'O'}, {'features': 'O'}, {'extraglandular': 'O'}, {'manifestations,': 'O'}, {'sometimes': 'O'}, {'severe': 'O'}, {'and': 'O'}, {'life-threatening.': 'O'}]"
Many different lesions may mimic the clinicoradiological features of LGPA.,"[{'Many': 'O'}, {'different': 'O'}, {'lesions': 'O'}, {'may': 'O'}, {'mimic': 'O'}, {'the': 'O'}, {'clinicoradiological': 'O'}, {'features': 'O'}, {'of': 'O'}, {'LGPA.': 'I-Entity'}]"
"Primary Sjogrens Syndrome (pSS) is an autoimmune disease involving salivary and other exocrine glands that leads to progressive lymphocytic infiltration into the gland, tissue damage, and secretory defects.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'involving': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'other': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'that': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'progressive': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'into': 'O'}, {'the': 'O'}, {'gland,': 'O'}, {'tissue': 'B-Entity'}, {'damage,': 'I-Entity'}, {'and': 'O'}, {'secretory': 'B-Entity'}, {'defects.': 'I-Entity'}]"
"Those with known features suggestive of RTA including hypokalemic paralysis, hyperchloremia and nephrocalcinosis without acidosis were defined as incomplete RTA.","[{'Those': 'O'}, {'with': 'O'}, {'known': 'O'}, {'features': 'O'}, {'suggestive': 'O'}, {'of': 'O'}, {'RTA': 'I-Entity'}, {'including': 'O'}, {'hypokalemic': 'O'}, {'paralysis,': 'I-Entity'}, {'hyperchloremia': 'I-Entity'}, {'and': 'O'}, {'nephrocalcinosis': 'I-Entity'}, {'without': 'O'}, {'acidosis': 'I-Entity'}, {'were': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'incomplete': 'O'}, {'RTA.': 'I-Entity'}]"
"It is suggested that clinicians should focus more on the clinical symptoms in these patients, rather than undertaking invasive diagnostic interventions to rule out Sjogrens syndrome.resolve the long debate on the issue.","[{'It': 'O'}, {'is': 'O'}, {'suggested': 'O'}, {'that': 'O'}, {'clinicians': 'O'}, {'should': 'O'}, {'focus': 'O'}, {'more': 'O'}, {'on': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients,': 'O'}, {'rather': 'O'}, {'than': 'O'}, {'undertaking': 'O'}, {'invasive': 'O'}, {'diagnostic': 'O'}, {'interventions': 'O'}, {'to': 'O'}, {'rule': 'O'}, {'out': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.resolve': 'I-Entity'}, {'the': 'O'}, {'long': 'O'}, {'debate': 'O'}, {'on': 'O'}, {'the': 'O'}, {'issue.': 'O'}]"
"Probably this is the correct way to reach a long lasting symptoms relief treatment that may allow an actual improvement of patients' quality of life.Rome , Italy.Rome , Italy.Rome , Italy.Rome , Italy.Rome , Italy.Rome , Italy.10.1080/13543784.2016.1249564.","[{'Probably': 'O'}, {'this': 'O'}, {'is': 'O'}, {'the': 'O'}, {'correct': 'O'}, {'way': 'O'}, {'to': 'O'}, {'reach': 'O'}, {'a': 'O'}, {'long': 'O'}, {'lasting': 'O'}, {'symptoms': 'O'}, {'relief': 'O'}, {'treatment': 'O'}, {'that': 'O'}, {'may': 'O'}, {'allow': 'O'}, {'an': 'O'}, {'actual': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {""patients'"": 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.Rome': 'O'}, {',': 'O'}, {'Italy.Rome': 'O'}, {',': 'O'}, {'Italy.Rome': 'O'}, {',': 'O'}, {'Italy.Rome': 'O'}, {',': 'O'}, {'Italy.Rome': 'O'}, {',': 'O'}, {'Italy.Rome': 'O'}, {',': 'O'}, {'Italy.10.1080/13543784.2016.1249564.': 'O'}]"
"In March 2009, she commenced an elimination diet protocol, eliminating gluten, beef, eggs, dairy products, nightshade vegetables, refined sugars, and citrus fruit for 4 months.","[{'In': 'O'}, {'March': 'O'}, {'2009,': 'O'}, {'she': 'O'}, {'commenced': 'O'}, {'an': 'O'}, {'elimination': 'O'}, {'diet': 'O'}, {'protocol,': 'O'}, {'eliminating': 'O'}, {'gluten,': 'I-Entity'}, {'beef,': 'O'}, {'eggs,': 'O'}, {'dairy': 'O'}, {'products,': 'O'}, {'nightshade': 'O'}, {'vegetables,': 'I-Entity'}, {'refined': 'B-Entity'}, {'sugars,': 'I-Entity'}, {'and': 'O'}, {'citrus': 'I-Entity'}, {'fruit': 'I-Entity'}, {'for': 'O'}, {'4': 'O'}, {'months.': 'O'}]"
Relapsing polychondritis (RP) is a very rare autoimmune disorder characterized by recurrent episodes of inflammation and destruction of cartilaginous tissues.,"[{'Relapsing': 'O'}, {'polychondritis': 'I-Entity'}, {'(RP)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'very': 'O'}, {'rare': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'recurrent': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'destruction': 'I-Entity'}, {'of': 'O'}, {'cartilaginous': 'O'}, {'tissues.': 'O'}]"
"Two small double blind randomized studies have been conducted and now published, demonstrating its efficacy on fatigue and sicca syndrome in early disease.","[{'Two': 'O'}, {'small': 'O'}, {'double': 'O'}, {'blind': 'O'}, {'randomized': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'conducted': 'O'}, {'and': 'O'}, {'now': 'O'}, {'published,': 'O'}, {'demonstrating': 'O'}, {'its': 'O'}, {'efficacy': 'O'}, {'on': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'early': 'O'}, {'disease.': 'O'}]"
"This review article provides an overview of normal and pathological SGs in the context of rheumatic diseases, identifying key elements in the tissue as diagnostic and prognostic biomarkers, useful in the current clinical practice.Department of Biotechnological and Applied Clinical Science, University of L'Aquila.","[{'This': 'O'}, {'review': 'O'}, {'article': 'O'}, {'provides': 'O'}, {'an': 'O'}, {'overview': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'SGs': 'O'}, {'in': 'O'}, {'the': 'O'}, {'context': 'O'}, {'of': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'identifying': 'O'}, {'key': 'O'}, {'elements': 'O'}, {'in': 'O'}, {'the': 'O'}, {'tissue': 'O'}, {'as': 'O'}, {'diagnostic': 'O'}, {'and': 'O'}, {'prognostic': 'O'}, {'biomarkers,': 'O'}, {'useful': 'O'}, {'in': 'O'}, {'the': 'O'}, {'current': 'O'}, {'clinical': 'O'}, {'practice.Department': 'O'}, {'of': 'O'}, {'Biotechnological': 'O'}, {'and': 'O'}, {'Applied': 'O'}, {'Clinical': 'O'}, {'Science,': 'O'}, {'University': 'O'}, {'of': 'O'}, {""L'Aquila."": 'O'}]"
The patient was consequently treated with an intra-oral electrostimulating device in order to stimulate the saliva secretion rate and reduce the feeling of a dry mouth.,"[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'consequently': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'intra-oral': 'O'}, {'electrostimulating': 'O'}, {'device': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'stimulate': 'O'}, {'the': 'O'}, {'saliva': 'O'}, {'secretion': 'O'}, {'rate': 'O'}, {'and': 'O'}, {'reduce': 'O'}, {'the': 'O'}, {'feeling': 'O'}, {'of': 'O'}, {'a': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"This latter event represents in all of these diseases the final result of an antigen-driven chronic stimulation of B lymphocytes.57025 Piombino, Italy.","[{'This': 'O'}, {'latter': 'O'}, {'event': 'O'}, {'represents': 'O'}, {'in': 'O'}, {'all': 'O'}, {'of': 'O'}, {'these': 'O'}, {'diseases': 'O'}, {'the': 'O'}, {'final': 'O'}, {'result': 'O'}, {'of': 'O'}, {'an': 'O'}, {'antigen-driven': 'O'}, {'chronic': 'O'}, {'stimulation': 'O'}, {'of': 'O'}, {'B': 'O'}, {'lymphocytes.57025': 'O'}, {'Piombino,': 'O'}, {'Italy.': 'O'}]"
Distal sensory and sensorimotor neuropathies are the most common manifestations of peripheral nerve disease in primary Sjogren syndrome.,"[{'Distal': 'B-Entity'}, {'sensory': 'I-Entity'}, {'and': 'I-Entity'}, {'sensorimotor': 'I-Entity'}, {'neuropathies': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'peripheral': 'B-Entity'}, {'nerve': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Demographic characteristics, association with CVD and lymphoproliferative disorders, pulmonary function, and pathology results were reviewed.","[{'Demographic': 'O'}, {'characteristics,': 'O'}, {'association': 'O'}, {'with': 'O'}, {'CVD': 'I-Entity'}, {'and': 'O'}, {'lymphoproliferative': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'pulmonary': 'O'}, {'function,': 'O'}, {'and': 'O'}, {'pathology': 'O'}, {'results': 'O'}, {'were': 'O'}, {'reviewed.': 'O'}]"
Sjogrens syndrome (SS) is an autoimmune inflammatory disorder of exocrine glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'of': 'I-Entity'}, {'exocrine': 'I-Entity'}, {'glands.': 'I-Entity'}]"
We describe a 39-year-old man who manifested flaccid paralysis of 4 limbs.,"[{'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'39-year-old': 'O'}, {'man': 'O'}, {'who': 'O'}, {'manifested': 'O'}, {'flaccid': 'B-Entity'}, {'paralysis': 'I-Entity'}, {'of': 'O'}, {'4': 'O'}, {'limbs.': 'O'}]"
The other 5 (3 MS and 2 NMO) patients were complicated with neuropathy caused by concomitant diabetes mellitus and Sjogrens syndrome.,"[{'The': 'O'}, {'other': 'O'}, {'5': 'O'}, {'(3': 'O'}, {'MS': 'I-Entity'}, {'and': 'O'}, {'2': 'O'}, {'NMO)': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'complicated': 'O'}, {'with': 'O'}, {'neuropathy': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'concomitant': 'O'}, {'diabetes': 'B-Entity'}, {'mellitus': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Patients with an early disease onset are more frequently positive for rheumatoid factor (RF) and/or anti-Ro/SS-A.,"[{'Patients': 'O'}, {'with': 'O'}, {'an': 'O'}, {'early': 'O'}, {'disease': 'O'}, {'onset': 'O'}, {'are': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor': 'O'}, {'(RF)': 'O'}, {'and/or': 'O'}, {'anti-Ro/SS-A.': 'O'}]"
"Hashimoto's thyroiditis was diagnosed in 63 patients, subacute thyroiditis in 23, subclinical hypothyroidism in five, and Graves' disease in one.","[{""Hashimoto's"": 'B-Entity'}, {'thyroiditis': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'in': 'O'}, {'63': 'O'}, {'patients,': 'O'}, {'subacute': 'O'}, {'thyroiditis': 'I-Entity'}, {'in': 'O'}, {'23,': 'O'}, {'subclinical': 'O'}, {'hypothyroidism': 'I-Entity'}, {'in': 'O'}, {'five,': 'O'}, {'and': 'O'}, {""Graves'"": 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'one.': 'O'}]"
"T cell hybridomas generated from HLA-DR3 transgenic mice recognized 3 regions on Ro60, with core epitopes mapped to amino acids 228-238, 246-256 and 371-381.","[{'T': 'O'}, {'cell': 'O'}, {'hybridomas': 'O'}, {'generated': 'O'}, {'from': 'O'}, {'HLA-DR3': 'O'}, {'transgenic': 'O'}, {'mice': 'O'}, {'recognized': 'O'}, {'3': 'O'}, {'regions': 'O'}, {'on': 'O'}, {'Ro60,': 'I-Entity'}, {'with': 'O'}, {'core': 'O'}, {'epitopes': 'O'}, {'mapped': 'O'}, {'to': 'O'}, {'amino': 'O'}, {'acids': 'O'}, {'228-238,': 'O'}, {'246-256': 'O'}, {'and': 'O'}, {'371-381.': 'O'}]"
"Therefore, SjS was thought to be the primary reason of hyperglobulinemia in this patient, which induced HVS, eventually causing CRVO.","[{'Therefore,': 'O'}, {'SjS': 'I-Entity'}, {'was': 'O'}, {'thought': 'O'}, {'to': 'O'}, {'be': 'O'}, {'the': 'O'}, {'primary': 'O'}, {'reason': 'O'}, {'of': 'O'}, {'hyperglobulinemia': 'I-Entity'}, {'in': 'O'}, {'this': 'O'}, {'patient,': 'O'}, {'which': 'O'}, {'induced': 'O'}, {'HVS,': 'I-Entity'}, {'eventually': 'O'}, {'causing': 'O'}, {'CRVO.': 'I-Entity'}]"
Results showed that salivary secretion increased by about 65% in patients treated with DCEL as compared with the control group.,"[{'Results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'salivary': 'O'}, {'secretion': 'O'}, {'increased': 'O'}, {'by': 'O'}, {'about': 'O'}, {'65%': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'DCEL': 'I-Entity'}, {'as': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
Diabetes mellitus in Sjogren's syndrome has also been described in literature.,"[{'Diabetes': 'B-Entity'}, {'mellitus': 'I-Entity'}, {'in': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'also': 'O'}, {'been': 'O'}, {'described': 'O'}, {'in': 'O'}, {'literature.': 'O'}]"
"To conclude, although central and peripheral complications of primary Sjogrens syndrome are difficult to assess, partly because of the wide spectrum of possible manifestations, it is around 20%.","[{'To': 'O'}, {'conclude,': 'O'}, {'although': 'O'}, {'central': 'O'}, {'and': 'O'}, {'peripheral': 'O'}, {'complications': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'are': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'assess,': 'O'}, {'partly': 'O'}, {'because': 'O'}, {'of': 'O'}, {'the': 'O'}, {'wide': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'possible': 'O'}, {'manifestations,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'around': 'O'}, {'20%.': 'O'}]"
"Levels of Flt3L were measured in cerebrospinal fluid (CSF) and serum of patients with pSS (n = 15), FM (n = 29), and AD (n = 39) and related to CNS symptoms and to markers of inflammation and degeneration.","[{'Levels': 'O'}, {'of': 'O'}, {'Flt3L': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'in': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'(CSF)': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'15),': 'O'}, {'FM': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'29),': 'O'}, {'and': 'O'}, {'AD': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'39)': 'O'}, {'and': 'O'}, {'related': 'O'}, {'to': 'O'}, {'CNS': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'to': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'degeneration.': 'O'}]"
"We describe two patients with pSS associated with ACA, initially diagnosed as limited systemic sclerosis.","[{'We': 'O'}, {'describe': 'O'}, {'two': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'ACA,': 'I-Entity'}, {'initially': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'limited': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis.': 'I-Entity'}]"
We report a case of a 40-year-old woman with Sjogrens syndrome and atopic dermatitis who presented with discoid lupus erythematosus on the forearms and lupus erythematosus profundus with alopecia involving the scalp.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'40-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'atopic': 'B-Entity'}, {'dermatitis': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'discoid': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'forearms': 'O'}, {'and': 'O'}, {'lupus': 'B-Entity'}, {'erythematosus': 'I-Entity'}, {'profundus': 'O'}, {'with': 'O'}, {'alopecia': 'I-Entity'}, {'involving': 'O'}, {'the': 'O'}, {'scalp.': 'O'}]"
"To compare the presence of subclinical atherosclerosis measured by means of pulse wave velocity (PWV) in women with primary Sjogrens syndrome (SS) versus a healthy age- and sex-matched control group, and to identify factors independently associated with PWV in primary SS.","[{'To': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'subclinical': 'O'}, {'atherosclerosis': 'I-Entity'}, {'measured': 'O'}, {'by': 'O'}, {'means': 'O'}, {'of': 'O'}, {'pulse': 'O'}, {'wave': 'O'}, {'velocity': 'O'}, {'(PWV)': 'O'}, {'in': 'O'}, {'women': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'versus': 'O'}, {'a': 'O'}, {'healthy': 'O'}, {'age-': 'O'}, {'and': 'O'}, {'sex-matched': 'O'}, {'control': 'O'}, {'group,': 'O'}, {'and': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'factors': 'O'}, {'independently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'PWV': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}]"
"Among the 19 NP syndromes, serum/plasma anti-NR2A/B antibodies were not specifically associated with any NP syndrome, including cognitive dysfunction (p=0.259) and mood disorder (p=0.503).","[{'Among': 'O'}, {'the': 'O'}, {'19': 'O'}, {'NP': 'B-Entity'}, {'syndromes,': 'O'}, {'serum/plasma': 'O'}, {'anti-NR2A/B': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'not': 'O'}, {'specifically': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'any': 'O'}, {'NP': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'including': 'O'}, {'cognitive': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'(p=0.259)': 'O'}, {'and': 'O'}, {'mood': 'B-Entity'}, {'disorder': 'I-Entity'}, {'(p=0.503).': 'O'}]"
"Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, rheumatoid vasculitis, cryoglobulinemia, Sjogren's syndrome, and non-systemic vasculitic neuropathy are disorders frequently associated with vasculitic neuropathy.","[{'Antineutrophil': 'O'}, {'cytoplasmic': 'O'}, {'antibody': 'O'}, {'(ANCA)-associated': 'O'}, {'vasculitis,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}, {'vasculitis,': 'I-Entity'}, {'cryoglobulinemia,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'non-systemic': 'O'}, {'vasculitic': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'are': 'O'}]"
"Associated procedures included sialodochoplasty (41%), steroid infusion (39%), and ductal stenting (8%).","[{'Associated': 'O'}, {'procedures': 'O'}, {'included': 'O'}, {'sialodochoplasty': 'O'}, {'(41%),': 'O'}, {'steroid': 'I-Entity'}, {'infusion': 'O'}, {'(39%),': 'O'}, {'and': 'O'}, {'ductal': 'O'}, {'stenting': 'O'}, {'(8%).': 'O'}]"
Histopathologic examination and immunohistochemistry of the thymus tumor and cytologic analysis of the pulmonary tissue were both consistent with mucosa-associated lymphoid tissue (MALT) lymphoma.,"[{'Histopathologic': 'O'}, {'examination': 'O'}, {'and': 'O'}, {'immunohistochemistry': 'O'}, {'of': 'O'}, {'the': 'O'}, {'thymus': 'B-Entity'}, {'tumor': 'I-Entity'}, {'and': 'O'}, {'cytologic': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pulmonary': 'O'}, {'tissue': 'O'}, {'were': 'O'}, {'both': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'I-Entity'}, {'tissue': 'I-Entity'}, {'(MALT)': 'O'}, {'lymphoma.': 'I-Entity'}]"
"Ultrasound M-mode and fetal echocardiogram revealed the etiology of the bradycardia to be a complete fetal congenital heart block, likely due to transplacental passage of autoimmune anti-Ro/SSA and anti-La/SSB antibodies.","[{'Ultrasound': 'O'}, {'M-mode': 'O'}, {'and': 'O'}, {'fetal': 'O'}, {'echocardiogram': 'O'}, {'revealed': 'O'}, {'the': 'O'}, {'etiology': 'O'}, {'of': 'O'}, {'the': 'O'}, {'bradycardia': 'I-Entity'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'complete': 'O'}, {'fetal': 'O'}, {'congenital': 'B-Entity'}, {'heart': 'I-Entity'}, {'block,': 'I-Entity'}, {'likely': 'O'}, {'due': 'O'}, {'to': 'O'}, {'transplacental': 'O'}, {'passage': 'O'}, {'of': 'O'}, {'autoimmune': 'O'}, {'anti-Ro/SSA': 'O'}, {'and': 'O'}, {'anti-La/SSB': 'O'}, {'antibodies.': 'O'}]"
To investigate the role of IL-2 in the balance of Th17 and Tregs and elucidate the underlying mechanisms of enhanced Th17 differentiation in primary Sjogrens syndrome (pSS) patients.,"[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'IL-2': 'O'}, {'in': 'O'}, {'the': 'O'}, {'balance': 'O'}, {'of': 'O'}, {'Th17': 'O'}, {'and': 'O'}, {'Tregs': 'O'}, {'and': 'O'}, {'elucidate': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'mechanisms': 'O'}, {'of': 'O'}, {'enhanced': 'O'}, {'Th17': 'O'}, {'differentiation': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'patients.': 'O'}]"
"To evaluate subclinical carotid atherosclerosis in an elderly group of patients with primary Sjogren syndrome compared with a control group matched for age, sex, ethnicity and cardiovascular risk factors, we enrolled 18 patients with Primary Sjogren Syndrome (mean age 65 ¬¨¬®¬¨¬± 5.93 SD) and 18 mild Ostheoarthritic patients (mean age 66 ¬¨¬®¬¨¬± 5.94 SD) from the outpatient department of Rheumatology, University ¬¨¬®‚àö¬®Campus Bio-Medico, Rome, Italy, matched for age, sex, ethnicity and cardiovascular risk factors.","[{'To': 'O'}, {'evaluate': 'O'}, {'subclinical': 'O'}, {'carotid': 'B-Entity'}, {'atherosclerosis': 'I-Entity'}, {'in': 'O'}, {'an': 'O'}, {'elderly': 'O'}, {'group': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'a': 'O'}, {'control': 'O'}, {'group': 'O'}, {'matched': 'O'}, {'for': 'O'}, {'age,': 'O'}, {'sex,': 'O'}, {'ethnicity': 'O'}, {'and': 'O'}, {'cardiovascular': 'O'}, {'risk': 'O'}, {'factors,': 'O'}, {'we': 'O'}, {'enrolled': 'O'}, {'18': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(mean': 'O'}, {'age': 'O'}, {'65': 'O'}, {'¬¨¬®¬¨¬±': 'O'}]"
"However, some progress has been achieved in characterizing typical clinical features and potential disease associated autoantibodies, which may lead to a better management of these patients.Hannover, Germany.symptoms: Real-world experience at a medical center.","[{'However,': 'O'}, {'some': 'O'}, {'progress': 'O'}, {'has': 'O'}, {'been': 'O'}, {'achieved': 'O'}, {'in': 'O'}, {'characterizing': 'O'}, {'typical': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'and': 'O'}, {'potential': 'O'}, {'disease': 'O'}, {'associated': 'O'}, {'autoantibodies,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'better': 'O'}, {'management': 'O'}, {'of': 'O'}, {'these': 'O'}, {'patients.Hannover,': 'O'}, {'Germany.symptoms:': 'O'}, {'Real-world': 'O'}, {'experience': 'O'}, {'at': 'O'}, {'a': 'O'}, {'medical': 'O'}, {'center.': 'O'}]"
"If PRT1 alone was ineffective to screen SGS from control patients, the comparison between PRT1 and PRT2 (so-called ""DeltaPRT"") was found as a good marker to detect patients with persistent tear reflex.","[{'If': 'O'}, {'PRT1': 'O'}, {'alone': 'O'}, {'was': 'O'}, {'ineffective': 'O'}, {'to': 'O'}, {'screen': 'O'}, {'SGS': 'I-Entity'}, {'from': 'O'}, {'control': 'O'}, {'patients,': 'O'}, {'the': 'O'}, {'comparison': 'O'}, {'between': 'O'}, {'PRT1': 'O'}, {'and': 'O'}, {'PRT2': 'O'}, {'(so-called': 'O'}, {'""DeltaPRT"")': 'O'}, {'was': 'O'}, {'found': 'O'}, {'as': 'O'}, {'a': 'O'}, {'good': 'O'}, {'marker': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'persistent': 'O'}, {'tear': 'B-Entity'}, {'reflex.': 'O'}]"
"Pathologic processes in the mouth, jaws, and contiguous structures could have a direct and indirect impact on the patient's overall systemic condition.","[{'Pathologic': 'O'}, {'processes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'mouth,': 'O'}, {'jaws,': 'O'}, {'and': 'O'}, {'contiguous': 'O'}, {'structures': 'O'}, {'could': 'O'}, {'have': 'O'}, {'a': 'O'}, {'direct': 'O'}, {'and': 'O'}, {'indirect': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'overall': 'O'}, {'systemic': 'O'}, {'condition.': 'O'}]"
"Differentiating physiological sicca complaints from SS in the elderly can be challenging, since apparently healthy individuals might present with auto-antibodies and lymphocytic infiltrates in salivary glands might be present as well.","[{'Differentiating': 'O'}, {'physiological': 'O'}, {'sicca': 'B-Entity'}, {'complaints': 'O'}, {'from': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'elderly': 'O'}, {'can': 'O'}, {'be': 'O'}, {'challenging,': 'O'}, {'since': 'O'}, {'apparently': 'O'}, {'healthy': 'O'}, {'individuals': 'O'}, {'might': 'O'}, {'present': 'O'}, {'with': 'O'}, {'auto-antibodies': 'O'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'infiltrates': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'might': 'O'}, {'be': 'O'}, {'present': 'O'}, {'as': 'O'}, {'well.': 'O'}]"
"To clarify the clinical characteristics of respiratory involvement associated with IgG4-related MD, we retrospectively assessed 25 patients with MD, 11 (44%) of whom had allergic symptoms, and 7 (28%) of whom complained of respiratory problems.","[{'To': 'O'}, {'clarify': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'respiratory': 'O'}, {'involvement': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'IgG4-related': 'O'}, {'MD,': 'I-Entity'}, {'we': 'O'}, {'retrospectively': 'O'}, {'assessed': 'O'}, {'25': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'MD,': 'I-Entity'}, {'11': 'O'}, {'(44%)': 'O'}, {'of': 'O'}, {'whom': 'O'}, {'had': 'O'}, {'allergic': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'and': 'O'}, {'7': 'O'}, {'(28%)': 'O'}, {'of': 'O'}, {'whom': 'O'}, {'complained': 'O'}, {'of': 'O'}, {'respiratory': 'B-Entity'}, {'problems.': 'I-Entity'}]"
Oral symptom scores and unstimulated whole salivary flow were recorded at baseline and after 4 weeks' use of the product.,"[{'Oral': 'O'}, {'symptom': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'unstimulated': 'O'}, {'whole': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'were': 'O'}, {'recorded': 'O'}, {'at': 'O'}, {'baseline': 'O'}, {'and': 'O'}, {'after': 'O'}, {'4': 'O'}, {""weeks'"": 'O'}, {'use': 'O'}, {'of': 'O'}, {'the': 'O'}, {'product.': 'O'}]"
Classically it has been postulated that sicca symptoms in SS patients are a double step process whereby lymphocytic infiltration of lacrimal and salivary glands (SG) is followed by epithelial cell destruction resulting in keratoconjunctivitis sicca and xerostomia.,"[{'Classically': 'O'}, {'it': 'O'}, {'has': 'O'}, {'been': 'O'}, {'postulated': 'O'}, {'that': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'are': 'O'}, {'a': 'O'}, {'double': 'O'}, {'step': 'O'}, {'process': 'O'}, {'whereby': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(SG)': 'O'}, {'is': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'epithelial': 'O'}, {'cell': 'O'}, {'destruction': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'and': 'O'}, {'xerostomia.': 'I-Entity'}]"
"In addition, it is the first study to investigate the relationship between the presence of enthesopathy and disease activity by means of US.Sakarya University Medical Faculty, Sakarya, Turkey.","[{'In': 'O'}, {'addition,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'the': 'O'}, {'first': 'O'}, {'study': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'enthesopathy': 'I-Entity'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'by': 'O'}, {'means': 'O'}, {'of': 'O'}, {'US.Sakarya': 'O'}, {'University': 'O'}, {'Medical': 'O'}, {'Faculty,': 'O'}, {'Sakarya,': 'O'}, {'Turkey.': 'O'}]"
"Although most reported patients with immunoglobulin G4-related disease (IgG4-RD) are from the Far East, we aimed to identify patients suffering from IgG4-RD in our University Centre in Debrecen, Hungary.","[{'Although': 'O'}, {'most': 'O'}, {'reported': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'immunoglobulin': 'B-Entity'}, {'G4-related': 'I-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'are': 'O'}, {'from': 'O'}, {'the': 'O'}, {'Far': 'O'}, {'East,': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'IgG4-RD': 'B-Entity'}, {'in': 'O'}, {'our': 'O'}, {'University': 'O'}, {'Centre': 'O'}, {'in': 'O'}, {'Debrecen,': 'O'}, {'Hungary.': 'O'}]"
"However, whether the elevated IL-17 in SS affects TJ integrity and thereby alters the function of salivary gland is unknown.","[{'However,': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'elevated': 'O'}, {'IL-17': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'affects': 'O'}, {'TJ': 'O'}, {'integrity': 'O'}, {'and': 'O'}, {'thereby': 'O'}, {'alters': 'O'}, {'the': 'O'}, {'function': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'is': 'O'}, {'unknown.': 'O'}]"
Two of these 5 SS patients whose neuropathic pain resolved with intravenous immunoglobulin (IVIg) therapy had improvement of MRN DRG abnormalities.We have developed a novel MRN protocol that can detect DRG abnormalities in SS patients with neuropathic pain who do not have markers of peripheral neuropathy.,"[{'Two': 'O'}, {'of': 'O'}, {'these': 'O'}, {'5': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'whose': 'O'}, {'neuropathic': 'B-Entity'}, {'pain': 'I-Entity'}, {'resolved': 'O'}, {'with': 'O'}, {'intravenous': 'O'}, {'immunoglobulin': 'O'}, {'(IVIg)': 'O'}, {'therapy': 'O'}, {'had': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'MRN': 'O'}, {'DRG': 'I-Entity'}, {'abnormalities.We': 'I-Entity'}, {'have': 'O'}, {'developed': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'MRN': 'O'}, {'protocol': 'O'}, {'that': 'O'}, {'can': 'O'}, {'detect': 'O'}, {'DRG': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'neuropathic': 'B-Entity'}]"
"Fourteen patients developed ANA-associated auto-immune disease during the follow-up: 5 polymyositis (mean apparition delay 78months), 6 systemic lupus erythematosus (mean occurrence delay 77months) and 2 systemic sclerosis (mean occurrence delay 133+/-64months).","[{'Fourteen': 'O'}, {'patients': 'O'}, {'developed': 'O'}, {'ANA-associated': 'I-Entity'}, {'auto-immune': 'B-Entity'}, {'disease': 'I-Entity'}, {'during': 'O'}, {'the': 'O'}, {'follow-up:': 'O'}, {'5': 'O'}, {'polymyositis': 'I-Entity'}, {'(mean': 'O'}, {'apparition': 'O'}, {'delay': 'O'}, {'78months),': 'O'}, {'6': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(mean': 'O'}, {'occurrence': 'O'}, {'delay': 'O'}, {'77months)': 'O'}, {'and': 'O'}, {'2': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(mean': 'O'}, {'occurrence': 'O'}, {'delay': 'O'}]"
We identified 107 patients with pSS as the reason for an SS diagnosis code and a verified lymphoma.,"[{'We': 'O'}, {'identified': 'O'}, {'107': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'reason': 'O'}, {'for': 'O'}, {'an': 'O'}, {'SS': 'I-Entity'}, {'diagnosis': 'O'}, {'code': 'O'}, {'and': 'O'}, {'a': 'O'}, {'verified': 'O'}, {'lymphoma.': 'I-Entity'}]"
The tear matrix metalloproteinase-9 (MMP-9) immunoassay (Inflammadry) exhibits variable results in dry eye (DE) patients.,"[{'The': 'O'}, {'tear': 'O'}, {'matrix': 'O'}, {'metalloproteinase-9': 'O'}, {'(MMP-9)': 'O'}, {'immunoassay': 'O'}, {'(Inflammadry)': 'O'}, {'exhibits': 'O'}, {'variable': 'O'}, {'results': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(DE)': 'O'}, {'patients.': 'O'}]"
"A 52-year-old woman with Sjogrens syndrome presented with multiple cerebral aneurysms, which resulted in recurrent subarachnoid hemorrhage (SAH) manifesting as severe headache.","[{'A': 'O'}, {'52-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'presented': 'O'}, {'with': 'O'}, {'multiple': 'O'}, {'cerebral': 'B-Entity'}, {'aneurysms,': 'I-Entity'}, {'which': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'recurrent': 'O'}, {'subarachnoid': 'B-Entity'}, {'hemorrhage': 'I-Entity'}, {'(SAH)': 'O'}, {'manifesting': 'O'}, {'as': 'O'}, {'severe': 'O'}, {'headache.': 'I-Entity'}]"
To describe the characteristics and the outcome of primary Sjogren Syndrome (pSS) associated arthritis and to compare the efficacy of different therapeutic regimen.,"[{'To': 'O'}, {'describe': 'O'}, {'the': 'O'}, {'characteristics': 'O'}, {'and': 'O'}, {'the': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'associated': 'O'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'different': 'O'}, {'therapeutic': 'O'}, {'regimen.': 'O'}]"
"This highlights the continuum between chronic B cell activation, disease activity, and lymphomagenesis in patients with primary SS.Paris-Sud, Le Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.Paris-Sud, Le Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.manifestation of cryoglobulinemic glomerulonephritis in the course of autoimmune diseases including Sjogrens syndrome.","[{'This': 'O'}, {'highlights': 'O'}, {'the': 'O'}, {'continuum': 'O'}, {'between': 'O'}, {'chronic': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation,': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'and': 'O'}, {'lymphomagenesis': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'SS.Paris-Sud,': 'I-Entity'}, {'Le': 'O'}, {'Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre,': 'O'}, {'France.Paris-Sud,': 'O'}, {'Le': 'O'}, {'Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre,': 'O'}]"
"To investigate the value of 3 novel autoantibodies [salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP)] in differentiating Sjogrens syndrome (SS)-related dry eye from non-SS dry eye.","[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'value': 'O'}, {'of': 'O'}, {'3': 'O'}, {'novel': 'O'}, {'autoantibodies': 'O'}, {'[salivary': 'O'}, {'protein': 'O'}, {'1': 'O'}, {'(SP1),': 'O'}, {'carbonic': 'O'}, {'anhydrase': 'O'}, {'6': 'O'}, {'(CA6),': 'O'}, {'and': 'O'}, {'parotid': 'O'}, {'secretory': 'O'}, {'protein': 'O'}, {'(PSP)]': 'O'}, {'in': 'O'}, {'differentiating': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)-related': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'from': 'O'}]"
We described earlier a simultaneously increased that the increased expression of miRNA-146a/b was accompanied by an increase in the expression of and TRAF6 and a decrease in the expression of IRAK1 genes in the peripheral mononuclear cells (PBMCs) of patients with primary Sjogren's syndrome (pSS) patients.,"[{'We': 'O'}, {'described': 'O'}, {'earlier': 'O'}, {'a': 'O'}, {'simultaneously': 'O'}, {'increased': 'O'}, {'that': 'O'}, {'the': 'O'}, {'increased': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'miRNA-146a/b': 'O'}, {'was': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'and': 'O'}, {'TRAF6': 'O'}, {'and': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'IRAK1': 'O'}, {'genes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'(PBMCs)': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}]"
"Eleven IS patients were recruited, of whom 8 (72.72%) were females with a mean age 47.87 years (DS‚Äö√Ñ√∂‚àö√ë‚àö¬¢¬¨¬®¬¨¬±‚Äö√Ñ√∂‚àö√ë‚àö¬¢13.95) and presented associated lower tract urinary symptoms (LUTS).","[{'Eleven': 'O'}, {'IS': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'recruited,': 'O'}, {'of': 'O'}, {'whom': 'O'}, {'8': 'O'}, {'(72.72%)': 'O'}, {'were': 'O'}, {'females': 'O'}, {'with': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'47.87': 'O'}, {'years': 'O'}, {'(DS‚Äö√Ñ√∂‚àö√ë‚àö¬¢¬¨¬®¬¨¬±‚Äö√Ñ√∂‚àö√ë‚àö¬¢13.95)': 'O'}]"
Clinical diagnosis by the treating physician was used as the gold standard.,"[{'Clinical': 'O'}, {'diagnosis': 'O'}, {'by': 'O'}, {'the': 'O'}, {'treating': 'O'}, {'physician': 'O'}, {'was': 'O'}, {'used': 'O'}, {'as': 'O'}, {'the': 'O'}, {'gold': 'O'}, {'standard.': 'O'}]"
Diminished Act1mRNA expression in SS may be associated with B cell hyperactivity and elevated immunoglobulin production in SS by uncontrolled B cell activation signal through CD40 and BAFFR.Historical Cohort Study Using Administrative Health Data.,"[{'Diminished': 'O'}, {'Act1mRNA': 'O'}, {'expression': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'hyperactivity': 'I-Entity'}, {'and': 'O'}, {'elevated': 'O'}, {'immunoglobulin': 'O'}, {'production': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'by': 'O'}, {'uncontrolled': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation': 'O'}, {'signal': 'O'}, {'through': 'O'}, {'CD40': 'O'}, {'and': 'O'}, {'BAFFR.Historical': 'O'}, {'Cohort': 'O'}, {'Study': 'O'}, {'Using': 'O'}, {'Administrative': 'O'}, {'Health': 'O'}, {'Data.': 'O'}]"
The objective of this study was to assess the prevalence of sicca complex (SC) in patients with chronic hepatitis C virus (HCV) infection and its association with clinical and laboratory features of liver disease.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'complex': 'I-Entity'}, {'(SC)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'chronic': 'O'}, {'hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'virus': 'I-Entity'}, {'(HCV)': 'I-Entity'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'its': 'O'}, {'association': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'features': 'O'}, {'of': 'O'}, {'liver': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Unfortunately we found that the body of evidence relied predominantly on information retrieved from individual cases, and the scientific information provided was heterogeneous.","[{'Unfortunately': 'O'}, {'we': 'O'}, {'found': 'O'}, {'that': 'O'}, {'the': 'O'}, {'body': 'O'}, {'of': 'O'}, {'evidence': 'O'}, {'relied': 'O'}, {'predominantly': 'O'}, {'on': 'O'}, {'information': 'O'}, {'retrieved': 'O'}, {'from': 'O'}, {'individual': 'O'}, {'cases,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'scientific': 'O'}, {'information': 'O'}, {'provided': 'O'}, {'was': 'O'}, {'heterogeneous.': 'O'}]"
"The odds ratio of arthritis detected by MSUS in ACPA-positivity was significant high (3.7, 95%CI 1.5-11.6), although odds ratio in RF-positivity had no statistical significance and a similar trend was seen in odds ratios of subclinical arthritis (4.9, 95%CI 1.6-18.0).","[{'The': 'O'}, {'odds': 'O'}, {'ratio': 'O'}, {'of': 'O'}, {'arthritis': 'I-Entity'}, {'detected': 'O'}, {'by': 'O'}, {'MSUS': 'O'}, {'in': 'O'}, {'ACPA-positivity': 'O'}, {'was': 'O'}, {'significant': 'O'}, {'high': 'O'}, {'(3.7,': 'O'}, {'95%CI': 'O'}, {'1.5-11.6),': 'O'}, {'although': 'O'}, {'odds': 'O'}, {'ratio': 'O'}, {'in': 'O'}, {'RF-positivity': 'I-Entity'}, {'had': 'O'}, {'no': 'O'}, {'statistical': 'O'}, {'significance': 'O'}, {'and': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'trend': 'O'}, {'was': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'odds': 'O'}]"
Amiloride 5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg daily was added to her regimen as a potassium sparing treatment with dramatic improvement in her symptoms and electrolyte levels (as shown in the figures).,"[{'Amiloride': 'I-Entity'}, {'5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg': 'O'}, {'daily': 'O'}, {'was': 'O'}, {'added': 'O'}, {'to': 'O'}, {'her': 'O'}, {'regimen': 'O'}, {'as': 'O'}, {'a': 'O'}, {'potassium': 'I-Entity'}, {'sparing': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'dramatic': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'her': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'electrolyte': 'O'}, {'levels': 'O'}, {'(as': 'O'}, {'shown': 'O'}, {'in': 'O'}, {'the': 'O'}, {'figures).': 'O'}]"
Sixty-three patients with pSS with pre-diagnostic data from the health surveys were identified.,"[{'Sixty-three': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'with': 'O'}, {'pre-diagnostic': 'O'}, {'data': 'O'}, {'from': 'O'}, {'the': 'O'}, {'health': 'O'}, {'surveys': 'O'}, {'were': 'O'}, {'identified.': 'O'}]"
"The main drug-based therapeutic approaches for systemic pSS during follow-up were HCQ in 282 (25%) patients, GCS in 475 (42%, at doses >20mg/day in 255-23%), immunosuppressive agents in 148 (13%), IVIG in 25 (2%) and RTX in 35 (3%) patients.","[{'The': 'O'}, {'main': 'O'}, {'drug-based': 'O'}, {'therapeutic': 'O'}, {'approaches': 'O'}, {'for': 'O'}, {'systemic': 'O'}, {'pSS': 'I-Entity'}, {'during': 'O'}, {'follow-up': 'O'}, {'were': 'O'}, {'HCQ': 'I-Entity'}, {'in': 'O'}, {'282': 'O'}, {'(25%)': 'O'}, {'patients,': 'O'}, {'GCS': 'I-Entity'}, {'in': 'O'}, {'475': 'O'}, {'(42%,': 'O'}, {'at': 'O'}, {'doses': 'O'}, {'>20mg/day': 'O'}, {'in': 'O'}, {'255-23%),': 'O'}, {'immunosuppressive': 'O'}, {'agents': 'O'}, {'in': 'O'}, {'148': 'O'}, {'(13%),': 'O'}]"
Patients with primary SS who display high frequencies of autoreactive and unresponsive CD21-/low B cells are susceptible to developing lymphoproliferation.,"[{'Patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'who': 'O'}, {'display': 'O'}, {'high': 'O'}, {'frequencies': 'O'}, {'of': 'O'}, {'autoreactive': 'O'}, {'and': 'O'}, {'unresponsive': 'O'}, {'CD21-/low': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'susceptible': 'O'}, {'to': 'O'}, {'developing': 'O'}, {'lymphoproliferation.': 'I-Entity'}]"
"In conclusion, our analyses indicate significant alterations in the cellular profiles of peripheral blood leucocytes in patients with pSS and may help to stratify the patients according to disease severity.Bergen, Bergen, Norway.Bergen, Bergen, Norway.Bergen, Bergen, Norway.Bergen, Bergen, Norway.Bergen, Bergen, Norway.Bergen, Bergen, Norway.Karolinska University Hospital Huddinge, Stockholm, Sweden.Bergen, Bergen, Norway.Bergen, Bergen, Norway.","[{'In': 'O'}, {'conclusion,': 'O'}, {'our': 'O'}, {'analyses': 'O'}, {'indicate': 'O'}, {'significant': 'O'}, {'alterations': 'O'}, {'in': 'O'}, {'the': 'O'}, {'cellular': 'O'}, {'profiles': 'O'}, {'of': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'leucocytes': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'help': 'O'}, {'to': 'O'}, {'stratify': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'according': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'severity.Bergen,': 'O'}, {'Bergen,': 'O'}, {'Norway.Bergen,': 'O'}, {'Bergen,': 'O'}, {'Norway.Bergen,': 'O'}, {'Bergen,': 'O'}, {'Norway.Bergen,': 'O'}, {'Bergen,': 'O'}, {'Norway.Bergen,': 'O'}]"
Similar trends were observed when more restrictive case definitions were applied.,"[{'Similar': 'O'}, {'trends': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'when': 'O'}, {'more': 'O'}, {'restrictive': 'O'}, {'case': 'O'}, {'definitions': 'O'}, {'were': 'O'}, {'applied.': 'O'}]"
Antimalarial medications are basal active drugs used for the treatment of various rheumatological conditions.,"[{'Antimalarial': 'O'}, {'medications': 'O'}, {'are': 'O'}, {'basal': 'O'}, {'active': 'O'}, {'drugs': 'O'}, {'used': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'various': 'O'}, {'rheumatological': 'B-Entity'}, {'conditions.': 'I-Entity'}]"
"Even though novel therapeutic tools have emerged, CyA still represents a suitable option in several clinical rheumatology settings.","[{'Even': 'O'}, {'though': 'O'}, {'novel': 'O'}, {'therapeutic': 'O'}, {'tools': 'O'}, {'have': 'O'}, {'emerged,': 'O'}, {'CyA': 'I-Entity'}, {'still': 'O'}, {'represents': 'O'}, {'a': 'O'}, {'suitable': 'O'}, {'option': 'O'}, {'in': 'O'}, {'several': 'O'}, {'clinical': 'O'}, {'rheumatology': 'O'}, {'settings.': 'O'}]"
We observe enhanced serological responses and higher frequencies of lymphoma-related extraglandular manifestations in men with pSS.,"[{'We': 'O'}, {'observe': 'O'}, {'enhanced': 'O'}, {'serological': 'O'}, {'responses': 'O'}, {'and': 'O'}, {'higher': 'O'}, {'frequencies': 'O'}, {'of': 'O'}, {'lymphoma-related': 'I-Entity'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'men': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"In conclusion, IL-17F was correlated with increased autoantibody levels and disease activity in pSS and is more clinically relevant than IL-17A.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China; Center of Clinical Immunology, Peking University, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, China.sialadenitis and secretory dysfunction in non-obese diabetic mice.","[{'In': 'O'}, {'conclusion,': 'O'}, {'IL-17F': 'O'}, {'was': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'autoantibody': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'more': 'O'}, {'clinically': 'O'}, {'relevant': 'O'}, {'than': 'O'}, {'IL-17A.Beijing': 'O'}, {'Key': 'O'}, {'Laboratory': 'O'}, {'for': 'O'}, {'Rheumatism': 'I-Entity'}, {'Mechanism': 'O'}, {'and': 'O'}, {'Immune': 'O'}, {'Diagnosis': 'O'}, {'(BZ0135),': 'O'}, {'Beijing,': 'O'}, {'China;': 'O'}]"
Lymphocytosis >2.6% in induced sputum was observed in 69% of all sputa.,"[{'Lymphocytosis': 'I-Entity'}, {'>2.6%': 'O'}, {'in': 'O'}, {'induced': 'O'}, {'sputum': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'69%': 'O'}, {'of': 'O'}, {'all': 'O'}, {'sputa.': 'O'}]"
Immunologic congenital atrioventricular block is due to the presence of anti-SSA and anti-SSB antibodies in maternal blood.,"[{'Immunologic': 'O'}, {'congenital': 'B-Entity'}, {'atrioventricular': 'I-Entity'}, {'block': 'I-Entity'}, {'is': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-SSA': 'O'}, {'and': 'O'}, {'anti-SSB': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'maternal': 'O'}, {'blood.': 'O'}]"
"The Fisher Exact test was used to evaluate the association between anti-Ku antibodies and diagnosis, gender, clinical signs, and other observed antibodies.","[{'The': 'O'}, {'Fisher': 'O'}, {'Exact': 'O'}, {'test': 'O'}, {'was': 'O'}, {'used': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'anti-Ku': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'diagnosis,': 'O'}, {'gender,': 'O'}, {'clinical': 'O'}, {'signs,': 'O'}, {'and': 'O'}, {'other': 'O'}, {'observed': 'O'}, {'antibodies.': 'O'}]"
Flow cytometry and immunofluorescence analysis for autoreactive B lymphocytes and ELISA for anti-SSA antibodies (Ab) detection were also performed.,"[{'Flow': 'O'}, {'cytometry': 'O'}, {'and': 'O'}, {'immunofluorescence': 'O'}, {'analysis': 'O'}, {'for': 'O'}, {'autoreactive': 'O'}, {'B': 'O'}, {'lymphocytes': 'O'}, {'and': 'O'}, {'ELISA': 'O'}, {'for': 'O'}, {'anti-SSA': 'O'}, {'antibodies': 'O'}, {'(Ab)': 'O'}, {'detection': 'O'}, {'were': 'O'}, {'also': 'O'}, {'performed.': 'O'}]"
We are presenting the case of a 53-year-old woman with a history of Sjogren syndrome and a secondary antiphospholipid syndrome admitted at the Nephrology department for the evaluation of renal failure.,"[{'We': 'O'}, {'are': 'O'}, {'presenting': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'53-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'secondary': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'admitted': 'O'}, {'at': 'O'}, {'the': 'O'}, {'Nephrology': 'O'}, {'department': 'O'}, {'for': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'renal': 'B-Entity'}, {'failure.': 'I-Entity'}]"
"HLH was described in systemic lupus erythematosus in 94 patients, in Still's disease in 37 patients, in rheumatoid arthritis in 13 patients, in systemic juvenile arthritis in 219 patients, in dermatomyositis in 7 patients, in Kawasaki disease in 25 patients, in systemic sclerosis in 5 patients, in Behcet disease in one patient, in polyarteritis nodosa in 6 patients, in ankylosing spondylitis in 2 patients, in mixed connective tissue disease in one patient, in sarcoidosis in 5 patients, in Sjogrens syndrome in 3 patients, in Wegener's granulomatosis in one patient, and in unclassifiable disorders in two patients.","[{'HLH': 'I-Entity'}, {'was': 'O'}, {'described': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'in': 'O'}, {'94': 'O'}, {'patients,': 'O'}, {'in': 'O'}, {""Still's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'37': 'O'}, {'patients,': 'O'}, {'in': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'in': 'O'}, {'13': 'O'}, {'patients,': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'juvenile': 'I-Entity'}, {'arthritis': 'I-Entity'}, {'in': 'O'}, {'219': 'O'}, {'patients,': 'O'}, {'in': 'O'}, {'dermatomyositis': 'I-Entity'}, {'in': 'O'}, {'7': 'O'}, {'patients,': 'O'}, {'in': 'O'}]"
The parotid and submandibular salivary glands were examined by ultrasonography using two different scoring systems proposed by Hocevar et al.,"[{'The': 'O'}, {'parotid': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'ultrasonography': 'O'}, {'using': 'O'}, {'two': 'O'}, {'different': 'O'}, {'scoring': 'O'}, {'systems': 'O'}, {'proposed': 'O'}, {'by': 'O'}, {'Hocevar': 'O'}, {'et': 'O'}, {'al.': 'O'}]"
"Medical records were screened for data regarding (1) the number of patients diagnosed with hydrocephalus associated with autoimmune diseases, (2) the clinical manifestation of hydrocephalus associated with autoimmune disease, and (3) the outcomes of these patients treated with medication or ventriculoperitoneal shunt (VPS).","[{'Medical': 'O'}, {'records': 'O'}, {'were': 'O'}, {'screened': 'O'}, {'for': 'O'}, {'data': 'O'}, {'regarding': 'O'}, {'(1)': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'hydrocephalus': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'(2)': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'hydrocephalus': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'(3)': 'O'}, {'the': 'O'}, {'outcomes': 'O'}, {'of': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'medication': 'O'}]"
Idiopathic lymphocytic pleuritis (ILP) is a rare form of diffuse pleural inflammation characterized by extensive lymphocytic infiltration for which no cause is found.,"[{'Idiopathic': 'B-Entity'}, {'lymphocytic': 'I-Entity'}, {'pleuritis': 'I-Entity'}, {'(ILP)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'form': 'O'}, {'of': 'O'}, {'diffuse': 'O'}, {'pleural': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'extensive': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'for': 'O'}, {'which': 'O'}, {'no': 'O'}, {'cause': 'O'}, {'is': 'O'}, {'found.': 'O'}]"
"APOBEC3B expression was observed in 15/20 Sjogrens syndrome patients, 5/5 chronic sialadenitis, and 3/5 normal minor salivary glands.","[{'APOBEC3B': 'O'}, {'expression': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'15/20': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients,': 'O'}, {'5/5': 'O'}, {'chronic': 'B-Entity'}, {'sialadenitis,': 'I-Entity'}, {'and': 'O'}, {'3/5': 'O'}, {'normal': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
"Scleredema adultorum of Buschke is a rare disorder characterized by diffuse swelling and non-pitting induration of the skin usually involving the face, neck, arms and upper trunk.","[{'Scleredema': 'B-Entity'}, {'adultorum': 'I-Entity'}, {'of': 'O'}, {'Buschke': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'disorder': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'diffuse': 'O'}, {'swelling': 'O'}, {'and': 'O'}, {'non-pitting': 'O'}, {'induration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'skin': 'O'}, {'usually': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'face,': 'O'}, {'neck,': 'O'}, {'arms': 'O'}, {'and': 'O'}, {'upper': 'O'}, {'trunk.': 'O'}]"
Superficial parotidectomy is indicated for diagnostic purposes and can be therapeutic in limited circumstances.,"[{'Superficial': 'O'}, {'parotidectomy': 'O'}, {'is': 'O'}, {'indicated': 'O'}, {'for': 'O'}, {'diagnostic': 'O'}, {'purposes': 'O'}, {'and': 'O'}, {'can': 'O'}, {'be': 'O'}, {'therapeutic': 'O'}, {'in': 'O'}, {'limited': 'O'}, {'circumstances.': 'O'}]"
LESSON: We provide the first example of severely decreased visual acuity in a NMOSD patient due to cortical blindness and not bilateral optic neuritis.,"[{'LESSON:': 'O'}, {'We': 'O'}, {'provide': 'O'}, {'the': 'O'}, {'first': 'O'}, {'example': 'O'}, {'of': 'O'}, {'severely': 'O'}, {'decreased': 'B-Entity'}, {'visual': 'I-Entity'}, {'acuity': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'NMOSD': 'I-Entity'}, {'patient': 'O'}, {'due': 'O'}, {'to': 'O'}, {'cortical': 'B-Entity'}, {'blindness': 'I-Entity'}, {'and': 'O'}, {'not': 'O'}, {'bilateral': 'O'}, {'optic': 'B-Entity'}, {'neuritis.': 'I-Entity'}]"
"When evaluating a patient with suspected pSS, the first step is to rule out its differential diagnoses, before looking for positive arguments for the disease.","[{'When': 'O'}, {'evaluating': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'suspected': 'O'}, {'pSS,': 'I-Entity'}, {'the': 'O'}, {'first': 'O'}, {'step': 'O'}, {'is': 'O'}, {'to': 'O'}, {'rule': 'O'}, {'out': 'O'}, {'its': 'O'}, {'differential': 'O'}, {'diagnoses,': 'O'}, {'before': 'O'}, {'looking': 'O'}, {'for': 'O'}, {'positive': 'O'}, {'arguments': 'O'}, {'for': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
Primary biliary cirrhosis (PBC) often is associated with this syndrome.,"[{'Primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cirrhosis': 'I-Entity'}, {'(PBC)': 'O'}, {'often': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'this': 'O'}, {'syndrome.': 'O'}]"
We present a middle-aged woman with a prior history of central nervous system (CNS) demyelinating disorder who presented with an acute onset quadriparesis and respiratory failure.,"[{'We': 'O'}, {'present': 'O'}, {'a': 'O'}, {'middle-aged': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'a': 'O'}, {'prior': 'O'}, {'history': 'O'}, {'of': 'O'}, {'central': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(CNS)': 'I-Entity'}, {'demyelinating': 'I-Entity'}, {'disorder': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'an': 'O'}, {'acute': 'O'}, {'onset': 'O'}, {'quadriparesis': 'I-Entity'}, {'and': 'O'}, {'respiratory': 'B-Entity'}, {'failure.': 'I-Entity'}]"
"ykaneko.z6@keio.jp.Medicine, Tokyo, Japan.Medicine, Tokyo, Japan.Medicine, Tokyo, Japan.Medicine, Tokyo, Japan.analogue scale for irritable bowel syndrome (VAS-IBS).","[{'ykaneko.z6@keio.jp.Medicine,': 'O'}, {'Tokyo,': 'O'}, {'Japan.Medicine,': 'O'}, {'Tokyo,': 'O'}, {'Japan.Medicine,': 'O'}, {'Tokyo,': 'O'}, {'Japan.Medicine,': 'O'}, {'Tokyo,': 'O'}, {'Japan.analogue': 'O'}, {'scale': 'O'}, {'for': 'O'}, {'irritable': 'B-Entity'}, {'bowel': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(VAS-IBS).': 'O'}]"
"This article aims to list out the diagnostic methods to diagnose autoimmune conditions and focuses on various diagnostic methods to effectively evaluate autoimmune disease of orofacial region.Dental Sciences and Research Centre, PMVIDS, Hyderabad, India.Dental Sciences and Research Centre, Hyderabad, India.Dental Sciences and Research Centre, PMVIDS, Hyderabad, India.2019 Oct 23.pemphigoid, Sjogren syndrome and gastric MALT lymphoma].","[{'This': 'O'}, {'article': 'O'}, {'aims': 'O'}, {'to': 'O'}, {'list': 'O'}, {'out': 'O'}, {'the': 'O'}, {'diagnostic': 'O'}, {'methods': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'autoimmune': 'B-Entity'}, {'conditions': 'I-Entity'}, {'and': 'O'}, {'focuses': 'O'}, {'on': 'O'}, {'various': 'O'}, {'diagnostic': 'O'}, {'methods': 'O'}, {'to': 'O'}, {'effectively': 'O'}, {'evaluate': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'of': 'O'}, {'orofacial': 'O'}, {'region.Dental': 'O'}, {'Sciences': 'O'}, {'and': 'O'}, {'Research': 'O'}, {'Centre,': 'O'}, {'PMVIDS,': 'O'}, {'Hyderabad,': 'O'}, {'India.Dental': 'O'}, {'Sciences': 'O'}, {'and': 'O'}, {'Research': 'O'}, {'Centre,': 'O'}, {'Hyderabad,': 'O'}, {'India.Dental': 'O'}]"
"Based on these clinical presentations, interstitial nephritis due to Sjogrens syndrome was strongly suspected.","[{'Based': 'O'}, {'on': 'O'}, {'these': 'O'}, {'clinical': 'O'}, {'presentations,': 'O'}, {'interstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'strongly': 'O'}, {'suspected.': 'O'}]"
"The etiology of primary Sjogrens syndrome is unknown, but the interaction between genetic and environmental factors (viruses, hormones, vitamins, stress) is important.","[{'The': 'O'}, {'etiology': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'unknown,': 'O'}, {'but': 'O'}, {'the': 'O'}, {'interaction': 'O'}, {'between': 'O'}, {'genetic': 'O'}, {'and': 'O'}, {'environmental': 'O'}, {'factors': 'O'}, {'(viruses,': 'O'}, {'hormones,': 'O'}, {'vitamins,': 'O'}, {'stress)': 'O'}, {'is': 'O'}, {'important.': 'O'}]"
"The diagnosis of primary Sjogrens syndrome was based on the presence of ocular dryness, salivary gland secretory and excretory dysfunction confirmed with dynamic tracer emission CT, and positive anti-Sjogrens syndrome A and anti-Sjogrens syndrome B antibodies.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'salivary': 'O'}, {'gland': 'O'}, {'secretory': 'O'}, {'and': 'O'}, {'excretory': 'O'}, {'dysfunction': 'O'}, {'confirmed': 'O'}, {'with': 'O'}, {'dynamic': 'O'}, {'tracer': 'O'}, {'emission': 'O'}, {'CT,': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'A': 'O'}, {'and': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'B': 'O'}, {'antibodies.': 'O'}]"
Pathway analysis and existing literature indicates that differential expression of these miRNAs may dysregulate pathways involved in inflammation.,"[{'Pathway': 'O'}, {'analysis': 'O'}, {'and': 'O'}, {'existing': 'O'}, {'literature': 'O'}, {'indicates': 'O'}, {'that': 'O'}, {'differential': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'these': 'O'}, {'miRNAs': 'O'}, {'may': 'O'}, {'dysregulate': 'O'}, {'pathways': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'inflammation.': 'I-Entity'}]"
It should be remembered that renal amyloidosis occurs as a clinical presentation of interstitial nephritis.15.syndrome and non-autoimmune sicca syndrome: a pilot study.,"[{'It': 'O'}, {'should': 'O'}, {'be': 'O'}, {'remembered': 'O'}, {'that': 'O'}, {'renal': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'occurs': 'O'}, {'as': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'nephritis.15.syndrome': 'I-Entity'}, {'and': 'O'}, {'non-autoimmune': 'O'}, {'sicca': 'I-Entity'}, {'syndrome:': 'I-Entity'}, {'a': 'O'}, {'pilot': 'O'}, {'study.': 'O'}]"
"Moreover, IFI16 positivity was associated with concurrent positivity for rheumatoid factor.","[{'Moreover,': 'O'}, {'IFI16': 'O'}, {'positivity': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'concurrent': 'O'}, {'positivity': 'O'}, {'for': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor.': 'O'}]"
"From these findings, a diagnosis of multiple dermatofibromas was made.","[{'From': 'O'}, {'these': 'O'}, {'findings,': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'multiple': 'O'}, {'dermatofibromas': 'I-Entity'}, {'was': 'O'}, {'made.': 'O'}]"
"The Waldeyer's ring is one of the most common sites of occurrence, but MALT lymphoma may also arise in salivary glands, lung, stomach, or lacrimal glands.","[{'The': 'O'}, {""Waldeyer's"": 'O'}, {'ring': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'sites': 'O'}, {'of': 'O'}, {'occurrence,': 'O'}, {'but': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'may': 'O'}, {'also': 'O'}, {'arise': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'lung,': 'O'}, {'stomach,': 'O'}, {'or': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"Based on these results, it is essential to emphasize the importance of close monitoring in patients receiving antimalarial medications and evaluation of visual findings before treatment initiation.","[{'Based': 'O'}, {'on': 'O'}, {'these': 'O'}, {'results,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'essential': 'O'}, {'to': 'O'}, {'emphasize': 'O'}, {'the': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'close': 'O'}, {'monitoring': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'receiving': 'O'}, {'antimalarial': 'O'}, {'medications': 'O'}, {'and': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'visual': 'O'}, {'findings': 'O'}, {'before': 'O'}, {'treatment': 'O'}, {'initiation.': 'O'}]"
"The disease overwhelmingly affects women around 30-60 years old, and more than 95% of patients present with oral and/or ocular dryness, although they may also develop a wide number of organ-specific systemic manifestations.","[{'The': 'O'}, {'disease': 'O'}, {'overwhelmingly': 'O'}, {'affects': 'O'}, {'women': 'O'}, {'around': 'O'}, {'30-60': 'O'}, {'years': 'O'}, {'old,': 'O'}, {'and': 'O'}, {'more': 'O'}, {'than': 'O'}, {'95%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'present': 'O'}, {'with': 'O'}, {'oral': 'B-Entity'}, {'and/or': 'I-Entity'}, {'ocular': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'although': 'O'}, {'they': 'O'}, {'may': 'O'}, {'also': 'O'}, {'develop': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'number': 'O'}, {'of': 'O'}, {'organ-specific': 'O'}, {'systemic': 'O'}, {'manifestations.': 'O'}]"
She was diagnosed by surgical lung biopsy to have mucosa-associated lymphoid tissue (MALT) lymphoma.,"[{'She': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'by': 'O'}, {'surgical': 'O'}, {'lung': 'O'}, {'biopsy': 'O'}, {'to': 'O'}, {'have': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'I-Entity'}, {'tissue': 'I-Entity'}, {'(MALT)': 'O'}, {'lymphoma.': 'I-Entity'}]"
m.bombardieri@qmul.ac.uk.monoclonal antibodies and establishment of a sandwich ELISA for autoimmune diseases detection.,"[{'m.bombardieri@qmul.ac.uk.monoclonal': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'establishment': 'O'}, {'of': 'O'}, {'a': 'O'}, {'sandwich': 'O'}, {'ELISA': 'O'}, {'for': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'detection.': 'O'}]"
"These results suggest that we should be vigilant with the pSS patients who have all these mentioned clinical and laboratory characteristics, and are more likely to develop SS/SLE.League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.of Medical Sciences, Beijing, China.","[{'These': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'we': 'O'}, {'should': 'O'}, {'be': 'O'}, {'vigilant': 'O'}, {'with': 'O'}, {'the': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}, {'have': 'O'}, {'all': 'O'}, {'these': 'O'}, {'mentioned': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'characteristics,': 'O'}, {'and': 'O'}, {'are': 'O'}, {'more': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'develop': 'O'}, {'SS/SLE.League': 'I-Entity'}, {'of': 'O'}, {'Associations': 'O'}, {'for': 'O'}, {'Rheumatology': 'O'}, {'and': 'O'}, {'Wiley': 'O'}, {'Publishing': 'O'}, {'Asia': 'O'}, {'Pty': 'O'}, {'Ltd.of': 'O'}, {'Medical': 'O'}, {'Sciences,': 'O'}, {'Beijing,': 'O'}, {'China.': 'O'}]"
"TNF-‚âà√≠¬¨¬± and LT-‚âà√≠¬¨¬± have an inverse relationship with fatigue severity in pSS challenging the notion that proinflammatory cytokines directly mediate fatigue in chronic immunological conditions.University, Newcastle upon Tyne, NE2 4HH, UK.","[{'TNF-‚âà√≠¬¨¬±': 'O'}, {'and': 'O'}, {'LT-‚âà√≠¬¨¬±': 'O'}, {'have': 'O'}, {'an': 'O'}, {'inverse': 'O'}, {'relationship': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'severity': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'challenging': 'O'}, {'the': 'O'}, {'notion': 'O'}, {'that': 'O'}, {'proinflammatory': 'O'}, {'cytokines': 'O'}, {'directly': 'O'}, {'mediate': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'chronic': 'O'}, {'immunological': 'O'}, {'conditions.University,': 'O'}]"
SLE-related eye involvement can be diagnosed in approximately one-third of the patients and is usually indicative of disease activity.,"[{'SLE-related': 'I-Entity'}, {'eye': 'B-Entity'}, {'involvement': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'diagnosed': 'O'}, {'in': 'O'}, {'approximately': 'O'}, {'one-third': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'is': 'O'}, {'usually': 'O'}, {'indicative': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"Neurological features were progressive multiple sclerosis-like manifestations (n=6), transverse myelitis (n=1), anxiety and depression disorder (n=1) and cognitive dysfunction (n=3).","[{'Neurological': 'O'}, {'features': 'O'}, {'were': 'O'}, {'progressive': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis-like': 'I-Entity'}, {'manifestations': 'O'}, {'(n=6),': 'O'}, {'transverse': 'B-Entity'}, {'myelitis': 'I-Entity'}, {'(n=1),': 'O'}, {'anxiety': 'B-Entity'}, {'and': 'I-Entity'}, {'depression': 'I-Entity'}, {'disorder': 'I-Entity'}, {'(n=1)': 'O'}, {'and': 'O'}, {'cognitive': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'(n=3).': 'O'}]"
"Sensory neuronopathies or ganglionopathies, or dorsal root ganglion disorders, represent a subgroup of peripheral nervous system diseases, frequently associated with dysinmune or neoplastic disorders and with toxic agents.","[{'Sensory': 'B-Entity'}, {'neuronopathies': 'I-Entity'}, {'or': 'O'}, {'ganglionopathies,': 'I-Entity'}, {'or': 'O'}, {'dorsal': 'B-Entity'}, {'root': 'I-Entity'}, {'ganglion': 'I-Entity'}, {'disorders,': 'I-Entity'}, {'represent': 'O'}, {'a': 'O'}, {'subgroup': 'O'}, {'of': 'O'}, {'peripheral': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'frequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'dysinmune': 'B-Entity'}, {'or': 'I-Entity'}, {'neoplastic': 'I-Entity'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'with': 'O'}, {'toxic': 'O'}, {'agents.': 'O'}]"
Topical medication and lid heating also may be advantageous for sleep quality in DED.10.1167/iovs.17-23467.epidemiology study.,"[{'Topical': 'O'}, {'medication': 'O'}, {'and': 'O'}, {'lid': 'O'}, {'heating': 'O'}, {'also': 'O'}, {'may': 'O'}, {'be': 'O'}, {'advantageous': 'O'}, {'for': 'O'}, {'sleep': 'O'}, {'quality': 'O'}, {'in': 'O'}, {'DED.10.1167/iovs.17-23467.epidemiology': 'I-Entity'}, {'study.': 'O'}]"
"She was then treated with alkalinization, steroids, neutral phosphate, calcium supplements together with activated vitamin D. So far, she recovered uneventfully with relieved pain and increased serum phosphorus level.","[{'She': 'O'}, {'was': 'O'}, {'then': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'alkalinization,': 'O'}, {'steroids,': 'I-Entity'}, {'neutral': 'O'}, {'phosphate,': 'I-Entity'}, {'calcium': 'I-Entity'}, {'supplements': 'O'}, {'together': 'O'}, {'with': 'O'}, {'activated': 'O'}, {'vitamin': 'B-Entity'}, {'D.': 'I-Entity'}, {'So': 'O'}, {'far,': 'O'}, {'she': 'O'}, {'recovered': 'O'}, {'uneventfully': 'O'}, {'with': 'O'}, {'relieved': 'O'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'increased': 'O'}, {'serum': 'O'}, {'phosphorus': 'I-Entity'}, {'level.': 'O'}]"
"The neuropathy was axonal in all, in five pure sensory and in four sensorimotor.","[{'The': 'O'}, {'neuropathy': 'I-Entity'}, {'was': 'O'}, {'axonal': 'O'}, {'in': 'O'}, {'all,': 'O'}, {'in': 'O'}, {'five': 'O'}, {'pure': 'O'}, {'sensory': 'O'}, {'and': 'O'}, {'in': 'O'}, {'four': 'O'}, {'sensorimotor.': 'O'}]"
"We, therefore, examined the possible association between BTLA and rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjogrens syndrome (SS) by conducting a case-control genetic association study.","[{'We,': 'O'}, {'therefore,': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'association': 'O'}, {'between': 'O'}, {'BTLA': 'O'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'by': 'O'}, {'conducting': 'O'}, {'a': 'O'}, {'case-control': 'O'}, {'genetic': 'O'}, {'association': 'O'}, {'study.': 'O'}]"
"In conclusion, we report the first case of pulmonary cryptococcosis in Sjogrens and C-SLE patient with a satisfactory clinical response to antifungal therapy.","[{'In': 'O'}, {'conclusion,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'the': 'O'}, {'first': 'O'}, {'case': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'cryptococcosis': 'I-Entity'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'and': 'I-Entity'}, {'C-SLE': 'I-Entity'}, {'patient': 'O'}, {'with': 'O'}, {'a': 'O'}, {'satisfactory': 'O'}, {'clinical': 'O'}, {'response': 'O'}, {'to': 'O'}, {'antifungal': 'O'}, {'therapy.': 'O'}]"
"Twenty-eight patients with primary SS included in the multicenter, randomized, double-blind, placebo-controlled Tolerance and Efficacy of Rituximab in Primary Sjogrens Syndrome (TEARS) trial underwent salivary gland ultrasonography before the first placebo or rituximab infusion and then 6 months later.","[{'Twenty-eight': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'multicenter,': 'O'}, {'randomized,': 'O'}, {'double-blind,': 'O'}, {'placebo-controlled': 'O'}, {'Tolerance': 'O'}, {'and': 'O'}, {'Efficacy': 'O'}, {'of': 'O'}, {'Rituximab': 'I-Entity'}, {'in': 'O'}, {'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(TEARS)': 'O'}, {'trial': 'O'}, {'underwent': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'ultrasonography': 'O'}]"
Large pericardial effusion (LPE) with cardiac tamponade is a rare but life-threatening complication in adults undergoing hematopoietic stem cell transplantation (HSCT).,"[{'Large': 'O'}, {'pericardial': 'B-Entity'}, {'effusion': 'I-Entity'}, {'(LPE)': 'O'}, {'with': 'O'}, {'cardiac': 'B-Entity'}, {'tamponade': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'but': 'O'}, {'life-threatening': 'O'}, {'complication': 'O'}, {'in': 'O'}, {'adults': 'O'}, {'undergoing': 'O'}, {'hematopoietic': 'O'}, {'stem': 'O'}, {'cell': 'O'}, {'transplantation': 'O'}, {'(HSCT).': 'O'}]"
"In about 30% of cases the RP is secondary, accompanied by other systemic connective tissue disorders as RA, SLE, Sjogrens syndrome, thyroiditis, ulcerative colitis, psoriasis and Beh‚àÜ√≠‚àö¬∞et's syndrome.","[{'In': 'O'}, {'about': 'O'}, {'30%': 'O'}, {'of': 'O'}, {'cases': 'O'}, {'the': 'O'}, {'RP': 'I-Entity'}, {'is': 'O'}, {'secondary,': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'other': 'O'}, {'systemic': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disorders': 'I-Entity'}, {'as': 'O'}, {'RA,': 'I-Entity'}, {'SLE,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'thyroiditis,': 'I-Entity'}, {'ulcerative': 'B-Entity'}, {'colitis,': 'I-Entity'}, {'psoriasis': 'I-Entity'}, {'and': 'O'}, {""Beh‚àÜ√≠‚àö¬∞et's"": 'O'}]"
"The diagnosis is easy to establish when the patient presents with sicca complex as a main symptom, or recurring attacks of parotitis.","[{'The': 'O'}, {'diagnosis': 'O'}, {'is': 'O'}, {'easy': 'O'}, {'to': 'O'}, {'establish': 'O'}, {'when': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'presents': 'O'}, {'with': 'O'}, {'sicca': 'B-Entity'}, {'complex': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'main': 'O'}, {'symptom,': 'O'}, {'or': 'O'}, {'recurring': 'O'}, {'attacks': 'O'}, {'of': 'O'}, {'parotitis.': 'I-Entity'}]"
"The advantages of using these models include the ability to study different stages of the disease with particular respect to specific target organs, to focus on the role of specific pathogenic factors and to investigate the effect of possible therapeutic interventions.","[{'The': 'O'}, {'advantages': 'O'}, {'of': 'O'}, {'using': 'O'}, {'these': 'O'}, {'models': 'O'}, {'include': 'O'}, {'the': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'study': 'O'}, {'different': 'O'}, {'stages': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'with': 'O'}, {'particular': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'specific': 'O'}, {'target': 'O'}, {'organs,': 'O'}, {'to': 'O'}, {'focus': 'O'}, {'on': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'specific': 'O'}, {'pathogenic': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'possible': 'O'}, {'therapeutic': 'O'}, {'interventions.': 'O'}]"
"Interrelationships between Sjogrens syndrome, lymphadenopathy and Lyme disease are discussed.University, Ukraine.University, Ukraine.University, Ukraine.University, Ukraine.University, Ukraine.University, Ukraine.","[{'Interrelationships': 'O'}, {'between': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'lymphadenopathy': 'I-Entity'}, {'and': 'O'}, {'Lyme': 'B-Entity'}, {'disease': 'I-Entity'}, {'are': 'O'}, {'discussed.University,': 'O'}, {'Ukraine.University,': 'O'}, {'Ukraine.University,': 'O'}, {'Ukraine.University,': 'O'}, {'Ukraine.University,': 'O'}, {'Ukraine.University,': 'O'}, {'Ukraine.': 'O'}]"
"The patient also tested positive for myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA), with changes in the MPO-ANCA titer that paralleled changes in the symptoms.","[{'The': 'O'}, {'patient': 'O'}, {'also': 'O'}, {'tested': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'myeloperoxidase-antineutrophil': 'O'}, {'cytoplasmic': 'O'}, {'antibodies': 'O'}, {'(MPO-ANCA),': 'O'}, {'with': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'MPO-ANCA': 'O'}, {'titer': 'O'}, {'that': 'O'}, {'paralleled': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'symptoms.': 'O'}]"
"Clinical features, immunological profile, acid-base balance and electrolyte status, 25-hydroxyvitamin D (25(OH) D3) levels, histopathological changes in minor salivary gland biopsy samples and radiological findings were retrieved.","[{'Clinical': 'O'}, {'features,': 'O'}, {'immunological': 'O'}, {'profile,': 'O'}, {'acid-base': 'O'}, {'balance': 'O'}, {'and': 'O'}, {'electrolyte': 'O'}, {'status,': 'O'}, {'25-hydroxyvitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'(25(OH)': 'O'}, {'D3)': 'I-Entity'}, {'levels,': 'O'}, {'histopathological': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy': 'O'}, {'samples': 'O'}, {'and': 'O'}, {'radiological': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'retrieved.': 'O'}]"
"Speckled pattern was significantly associated with anti-ENA (p < 0.05).The most commonly identified antinuclear autoreactivity was directed towards anti-RNP (25.7%) then anti-Scl-70 (20%), anti-SSA (14.2%) and anti-SSB (5.7%).","[{'Speckled': 'O'}, {'pattern': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'anti-ENA': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.05).The': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'identified': 'O'}, {'antinuclear': 'O'}, {'autoreactivity': 'O'}, {'was': 'O'}, {'directed': 'O'}, {'towards': 'O'}, {'anti-RNP': 'O'}, {'(25.7%)': 'O'}, {'then': 'O'}, {'anti-Scl-70': 'O'}, {'(20%),': 'O'}, {'anti-SSA': 'O'}, {'(14.2%)': 'O'}]"
A 53-year-old female developed epigastric discomfort and back pain in 2007.,"[{'A': 'O'}, {'53-year-old': 'O'}, {'female': 'O'}, {'developed': 'O'}, {'epigastric': 'B-Entity'}, {'discomfort': 'I-Entity'}, {'and': 'O'}, {'back': 'B-Entity'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'2007.': 'O'}]"
"The clinical, histopathologic, and radiologic disease manifestations of primary pulmonary or disseminated nontuberculous mycobacterial disease were compared in an autopsy series.","[{'The': 'O'}, {'clinical,': 'O'}, {'histopathologic,': 'O'}, {'and': 'O'}, {'radiologic': 'O'}, {'disease': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'pulmonary': 'O'}, {'or': 'O'}, {'disseminated': 'O'}, {'nontuberculous': 'O'}, {'mycobacterial': 'B-Entity'}, {'disease': 'I-Entity'}, {'were': 'O'}, {'compared': 'O'}, {'in': 'O'}, {'an': 'O'}, {'autopsy': 'O'}, {'series.': 'O'}]"
"When CQ had been administered for 4 weeks from week 13 and then maintained untreated for 4 weeks, tear secretion, corneal staining score, foci formation in the LG, conjunctival goblet cells and proinflammatory cytokine expressions were significantly better than untreated mice.","[{'When': 'O'}, {'CQ': 'I-Entity'}, {'had': 'O'}, {'been': 'O'}, {'administered': 'O'}, {'for': 'O'}, {'4': 'O'}, {'weeks': 'O'}, {'from': 'O'}, {'week': 'O'}, {'13': 'O'}, {'and': 'O'}, {'then': 'O'}, {'maintained': 'O'}, {'untreated': 'O'}, {'for': 'O'}, {'4': 'O'}, {'weeks,': 'O'}, {'tear': 'O'}, {'secretion,': 'O'}, {'corneal': 'O'}, {'staining': 'O'}, {'score,': 'O'}, {'foci': 'O'}, {'formation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'LG,': 'O'}, {'conjunctival': 'O'}, {'goblet': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'proinflammatory': 'O'}, {'cytokine': 'O'}, {'expressions': 'O'}, {'were': 'O'}, {'significantly': 'O'}]"
"From as early as the eighteenth century, a constellation of perplexing symptoms was observed that resembled symptoms of CFS.","[{'From': 'O'}, {'as': 'O'}, {'early': 'O'}, {'as': 'O'}, {'the': 'O'}, {'eighteenth': 'O'}, {'century,': 'O'}, {'a': 'O'}, {'constellation': 'O'}, {'of': 'O'}, {'perplexing': 'O'}, {'symptoms': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'that': 'O'}, {'resembled': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'CFS.': 'I-Entity'}]"
"Diagnosis is difficult, because the clinical presentation of patients is diverse, from mild to severe disease.","[{'Diagnosis': 'O'}, {'is': 'O'}, {'difficult,': 'O'}, {'because': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'is': 'O'}, {'diverse,': 'O'}, {'from': 'O'}, {'mild': 'O'}, {'to': 'O'}, {'severe': 'O'}, {'disease.': 'O'}]"
A thorough and systematic approach is required for accurate diagnosis and evaluation of such patients to enable appropriate management of the vasculitis and any associated condition.,"[{'A': 'O'}, {'thorough': 'O'}, {'and': 'O'}, {'systematic': 'O'}, {'approach': 'O'}, {'is': 'O'}, {'required': 'O'}, {'for': 'O'}, {'accurate': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'such': 'O'}, {'patients': 'O'}, {'to': 'O'}, {'enable': 'O'}, {'appropriate': 'O'}, {'management': 'O'}, {'of': 'O'}, {'the': 'O'}, {'vasculitis': 'I-Entity'}, {'and': 'O'}, {'any': 'O'}, {'associated': 'O'}, {'condition.': 'O'}]"
"Primary Sjogrens syndrome (PSS) is a chronic autoimmune disease characterized by lymphoplasmacytic infiltration of the exocrine glands, which results in multiple organs damage.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphoplasmacytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'which': 'O'}, {'results': 'O'}, {'in': 'O'}, {'multiple': 'O'}, {'organs': 'B-Entity'}, {'damage.': 'I-Entity'}]"
"Days later, she presented to the emergency room with an acute flare of her lupus and a constellation of symptoms that lead to new diagnoses of antiphospholipid syndrome (APS), Raynaud phenomenon, acute lower left extremity deep vein thrombosis (DVT), and diffuse bilateral pulmonary emboli (PEs).","[{'Days': 'O'}, {'later,': 'O'}, {'she': 'O'}, {'presented': 'O'}, {'to': 'O'}, {'the': 'O'}, {'emergency': 'O'}, {'room': 'O'}, {'with': 'O'}, {'an': 'O'}, {'acute': 'O'}, {'flare': 'O'}, {'of': 'O'}, {'her': 'O'}, {'lupus': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'constellation': 'O'}, {'of': 'O'}, {'symptoms': 'O'}, {'that': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'new': 'O'}, {'diagnoses': 'O'}, {'of': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS),': 'O'}, {'Raynaud': 'B-Entity'}, {'phenomenon,': 'I-Entity'}, {'acute': 'O'}, {'lower': 'O'}, {'left': 'O'}, {'extremity': 'O'}, {'deep': 'B-Entity'}, {'vein': 'I-Entity'}, {'thrombosis': 'I-Entity'}, {'(DVT),': 'O'}]"
This observational case-control study was designed to discover new cellular biomarkers and therapeutic targets in patients with pSS.,"[{'This': 'O'}, {'observational': 'O'}, {'case-control': 'O'}, {'study': 'O'}, {'was': 'O'}, {'designed': 'O'}, {'to': 'O'}, {'discover': 'O'}, {'new': 'O'}, {'cellular': 'O'}, {'biomarkers': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'targets': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"Differential diagnosis from other distinct disorders, such as sarcoidosis, Castleman's disease, Wegener's granulomatosis, lymphoma, cancer, and other existing conditions associated with high serum IgG4 level or abundant IgG4-bearing plasma cells in tissues is necessary.","[{'Differential': 'O'}, {'diagnosis': 'O'}, {'from': 'O'}, {'other': 'O'}, {'distinct': 'O'}, {'disorders,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'sarcoidosis,': 'I-Entity'}, {""Castleman's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {""Wegener's"": 'B-Entity'}, {'granulomatosis,': 'I-Entity'}, {'lymphoma,': 'I-Entity'}, {'cancer,': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'existing': 'O'}, {'conditions': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'high': 'O'}, {'serum': 'O'}, {'IgG4': 'O'}, {'level': 'O'}, {'or': 'O'}, {'abundant': 'O'}, {'IgG4-bearing': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'in': 'O'}]"
"A 62-year-old woman with rheumatoid arthritis and secondary Sjogrens syndrome took methotrexate (MTX) 5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg three times a week regularly but gradually developed an intermittent fever, oral ulcers and productive cough with mucopurulent sputum for about 2 weeks.","[{'A': 'O'}, {'62-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'secondary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'took': 'O'}, {'methotrexate': 'I-Entity'}, {'(MTX)': 'O'}, {'5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg': 'O'}, {'three': 'O'}, {'times': 'O'}, {'a': 'O'}, {'week': 'O'}, {'regularly': 'O'}, {'but': 'O'}, {'gradually': 'O'}, {'developed': 'O'}]"
"The concentrations of these cytokines/chemokines were significantly higher in the saliva from SS patients than those from controls, and the concentrations of Th2 cytokines/chemokines were associated closely with strong lymphocytic accumulation in LSGs.","[{'The': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'these': 'O'}, {'cytokines/chemokines': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'saliva': 'O'}, {'from': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'than': 'O'}, {'those': 'O'}, {'from': 'O'}, {'controls,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'Th2': 'O'}, {'cytokines/chemokines': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'closely': 'O'}, {'with': 'O'}, {'strong': 'O'}, {'lymphocytic': 'O'}, {'accumulation': 'O'}, {'in': 'O'}, {'LSGs.': 'O'}]"
Primary Sjogrens Syndrome (pSS) is a systemic autoimmune disease that involves the exocrine glands and internal organs.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'involves': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'internal': 'O'}, {'organs.': 'O'}]"
"pSS with SFN appeared to have no clinically abnormal features, including muscle weakness and decreasing deep tendon reflex.","[{'pSS': 'I-Entity'}, {'with': 'O'}, {'SFN': 'I-Entity'}, {'appeared': 'O'}, {'to': 'O'}, {'have': 'O'}, {'no': 'O'}, {'clinically': 'O'}, {'abnormal': 'O'}, {'features,': 'O'}, {'including': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'and': 'O'}, {'decreasing': 'B-Entity'}, {'deep': 'O'}, {'tendon': 'I-Entity'}, {'reflex.': 'I-Entity'}]"
"Specific voice symptoms significantly correlated with reduced SF-36 scores included frequent throat-clearing, throat soreness, difficulty projecting, and vocal discomfort.","[{'Specific': 'O'}, {'voice': 'B-Entity'}, {'symptoms': 'O'}, {'significantly': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'reduced': 'O'}, {'SF-36': 'O'}, {'scores': 'O'}, {'included': 'O'}, {'frequent': 'O'}, {'throat-clearing,': 'I-Entity'}, {'throat': 'B-Entity'}, {'soreness,': 'I-Entity'}, {'difficulty': 'B-Entity'}, {'projecting,': 'I-Entity'}, {'and': 'O'}, {'vocal': 'B-Entity'}, {'discomfort.': 'I-Entity'}]"
"The technique of skin biopsy, assessing for the intraepidermal nerve fiber density of unmyelinated nerves, provides a useful technique for neurologists to diagnose small-fiber neuropathies, especially when there is such a non-length-dependent distribution.","[{'The': 'O'}, {'technique': 'O'}, {'of': 'O'}, {'skin': 'O'}, {'biopsy,': 'O'}, {'assessing': 'O'}, {'for': 'O'}, {'the': 'O'}, {'intraepidermal': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'density': 'O'}, {'of': 'O'}, {'unmyelinated': 'O'}, {'nerves,': 'O'}, {'provides': 'O'}, {'a': 'O'}, {'useful': 'O'}, {'technique': 'O'}, {'for': 'O'}, {'neurologists': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'small-fiber': 'O'}, {'neuropathies,': 'I-Entity'}, {'especially': 'O'}, {'when': 'O'}, {'there': 'O'}, {'is': 'O'}, {'such': 'O'}, {'a': 'O'}, {'non-length-dependent': 'O'}, {'distribution.': 'O'}]"
The lip biopsy is essential for the diagnosis of primary Sjogren's syndrome (SS) but an invasive method can cause some disadvantages.,"[{'The': 'O'}, {'lip': 'O'}, {'biopsy': 'O'}, {'is': 'O'}, {'essential': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'but': 'O'}, {'an': 'O'}, {'invasive': 'O'}, {'method': 'O'}, {'can': 'O'}, {'cause': 'O'}, {'some': 'O'}, {'disadvantages.': 'O'}]"
"JSLE patients have more severe disease activity and more frequent renal involvement and LSLE patients have milder disease activity, more commonly accompanied by Sjogrens syndrome, at disease onset.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea.Gwangju, Korea.University Medical School & Hospital, Gwangju, Korea shinseok@chonnam.ac.kr.Sjogrens Syndrome and Systemic Sclerosis.","[{'JSLE': 'I-Entity'}, {'patients': 'O'}, {'have': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'renal': 'O'}, {'involvement': 'O'}, {'and': 'O'}, {'LSLE': 'I-Entity'}, {'patients': 'O'}, {'have': 'O'}, {'milder': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'more': 'O'}, {'commonly': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'at': 'O'}, {'disease': 'O'}, {'onset.University': 'O'}, {'Medical': 'O'}, {'School': 'O'}, {'&': 'O'}, {'Hospital,': 'O'}, {'Gwangju,': 'O'}, {'Korea.University': 'O'}, {'Medical': 'O'}, {'School': 'O'}, {'&': 'O'}, {'Hospital,': 'O'}, {'Gwangju,': 'O'}]"
"We present the case of woman in her 50s who developed numerous red-brown telangiectatic macules on her trunk and extremities, as well as persistent dry eyes and dry mouth.","[{'We': 'O'}, {'present': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'woman': 'O'}, {'in': 'O'}, {'her': 'O'}, {'50s': 'O'}, {'who': 'O'}, {'developed': 'O'}, {'numerous': 'O'}, {'red-brown': 'O'}, {'telangiectatic': 'I-Entity'}, {'macules': 'O'}, {'on': 'O'}, {'her': 'O'}, {'trunk': 'O'}, {'and': 'O'}, {'extremities,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'persistent': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"salivary gland enlargement, low C4, leukocytopenia, cryoglobulins, monoclonal gammopathy, disease duration), rheumatoid factor was strongly associated to MALT-NHLs development.","[{'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'enlargement,': 'I-Entity'}, {'low': 'O'}, {'C4,': 'O'}, {'leukocytopenia,': 'I-Entity'}, {'cryoglobulins,': 'O'}, {'monoclonal': 'B-Entity'}, {'gammopathy,': 'I-Entity'}, {'disease': 'O'}, {'duration),': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'was': 'O'}, {'strongly': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'MALT-NHLs': 'B-Entity'}, {'development.': 'O'}]"
"CyA is used even in paediatric rheumatology, in particular in the management of juvenile dermatomyositis and macrophage activation syndrome associated with systemic juvenile idiopathic arthritis.","[{'CyA': 'I-Entity'}, {'is': 'O'}, {'used': 'O'}, {'even': 'O'}, {'in': 'O'}, {'paediatric': 'O'}, {'rheumatology,': 'O'}, {'in': 'O'}, {'particular': 'O'}, {'in': 'O'}, {'the': 'O'}, {'management': 'O'}, {'of': 'O'}, {'juvenile': 'B-Entity'}, {'dermatomyositis': 'I-Entity'}, {'and': 'O'}, {'macrophage': 'O'}, {'activation': 'O'}, {'syndrome': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'juvenile': 'B-Entity'}, {'idiopathic': 'I-Entity'}, {'arthritis.': 'I-Entity'}]"
Autoimmune diseases-related arthritis has been rarely reported in HIV-1-infected patients.,"[{'Autoimmune': 'B-Entity'}, {'diseases-related': 'I-Entity'}, {'arthritis': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'rarely': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'HIV-1-infected': 'B-Entity'}, {'patients.': 'O'}]"
The arterial spin labeling (ASL) technique allows noninvasive quantitative assessment of tissue perfusion without the need for contrast agent.,"[{'The': 'O'}, {'arterial': 'O'}, {'spin': 'O'}, {'labeling': 'O'}, {'(ASL)': 'O'}, {'technique': 'O'}, {'allows': 'O'}, {'noninvasive': 'O'}, {'quantitative': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'tissue': 'O'}, {'perfusion': 'O'}, {'without': 'O'}, {'the': 'O'}, {'need': 'O'}, {'for': 'O'}, {'contrast': 'O'}, {'agent.': 'O'}]"
"The heterogeneity of neurologic manifestations in pSS complicates the diagnosis and approach to treatment, which should be directed toward the underlying neuro-pathologic mechanism.","[{'The': 'O'}, {'heterogeneity': 'O'}, {'of': 'O'}, {'neurologic': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'complicates': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'approach': 'O'}, {'to': 'O'}, {'treatment,': 'O'}, {'which': 'O'}, {'should': 'O'}, {'be': 'O'}, {'directed': 'O'}, {'toward': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'neuro-pathologic': 'O'}, {'mechanism.': 'O'}]"
"When a case with thymic lymphoid hyperplasia without myasthenia gravis is encountered, it is essential to consider the presence of another autoimmune disease including Sjogren syndrome.Daigaku, Uchinada, Kahoku, Ishikawa, 9200293, Japan.","[{'When': 'O'}, {'a': 'O'}, {'case': 'O'}, {'with': 'O'}, {'thymic': 'O'}, {'lymphoid': 'I-Entity'}, {'hyperplasia': 'I-Entity'}, {'without': 'O'}, {'myasthenia': 'B-Entity'}, {'gravis': 'I-Entity'}, {'is': 'O'}, {'encountered,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'essential': 'O'}, {'to': 'O'}, {'consider': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'another': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'including': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.Daigaku,': 'I-Entity'}, {'Uchinada,': 'O'}, {'Kahoku,': 'O'}, {'Ishikawa,': 'O'}, {'9200293,': 'O'}]"
"Polymerase chain reaction (PCR) and nested PCR were used to amplify viral DNA from peripheral blood mononuclear cells (PBMC) in 53 patients with SS, using primers from the HTLV-1 pX, p19, pol, and tax regions.","[{'Polymerase': 'O'}, {'chain': 'O'}, {'reaction': 'O'}, {'(PCR)': 'O'}, {'and': 'O'}, {'nested': 'O'}, {'PCR': 'O'}, {'were': 'O'}, {'used': 'O'}, {'to': 'O'}, {'amplify': 'O'}, {'viral': 'O'}, {'DNA': 'O'}, {'from': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'(PBMC)': 'O'}, {'in': 'O'}, {'53': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'using': 'O'}, {'primers': 'O'}, {'from': 'O'}, {'the': 'O'}, {'HTLV-1': 'O'}, {'pX,': 'O'}, {'p19,': 'O'}, {'pol,': 'O'}, {'and': 'O'}]"
"The present 9 cases were characterized by : (i) prominent lymphoplasmacytic and B-immunoblastic infiltration ; (ii) absence of pronounced arborizing vascular proliferation ; (iii) absence of CD10(+) ""clear cells"" ; (iv) presence of hyperplastic germinal center in 7 cases ; (v) immunohistochemistry, flow cytometry, and polymerase chain reaction demonstrated a reactive nature of the T- and B-lymphocytes ; and (vi) on in situ hybridization, there were no Epstein-Barr virus -infected lymphoid cells in any of the 9 cases.","[{'The': 'O'}, {'present': 'O'}, {'9': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {':': 'O'}, {'(i)': 'O'}, {'prominent': 'O'}, {'lymphoplasmacytic': 'O'}, {'and': 'O'}, {'B-immunoblastic': 'O'}, {'infiltration': 'O'}, {';': 'O'}, {'(ii)': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'pronounced': 'O'}, {'arborizing': 'O'}, {'vascular': 'O'}, {'proliferation': 'O'}, {';': 'O'}, {'(iii)': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'CD10(+)': 'O'}, {'""clear': 'O'}, {'cells""': 'O'}, {';': 'O'}, {'(iv)': 'O'}]"
We stress the important role of liver biopsy when imaging indicates HCC in patients without underlying cirrhosis.fg.foschi@ausl.ra.itUltrasound in Medicine,"[{'We': 'O'}, {'stress': 'O'}, {'the': 'O'}, {'important': 'O'}, {'role': 'O'}, {'of': 'O'}, {'liver': 'O'}, {'biopsy': 'O'}, {'when': 'O'}, {'imaging': 'O'}, {'indicates': 'O'}, {'HCC': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'underlying': 'O'}, {'cirrhosis.fg.foschi@ausl.ra.itUltrasound': 'I-Entity'}, {'in': 'O'}, {'Medicine': 'O'}]"
"Key recommendations include a decision tree for the use of oral disease-modifying antirheumatic drugs for inflammatory musculoskeletal pain, use of self-care measures and advice regarding exercise to reduce fatigue, and the use of rituximab in selected clinical settings for oral and ocular dryness and for certain extraglandular manifestations, including vasculitis, severe parotid swelling, inflammatory arthritis, pulmonary disease, and mononeuritis multiplex.","[{'Key': 'O'}, {'recommendations': 'O'}, {'include': 'O'}, {'a': 'O'}, {'decision': 'O'}, {'tree': 'O'}, {'for': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'disease-modifying': 'O'}, {'antirheumatic': 'O'}, {'drugs': 'O'}, {'for': 'O'}, {'inflammatory': 'B-Entity'}, {'musculoskeletal': 'B-Entity'}, {'pain,': 'I-Entity'}, {'use': 'O'}, {'of': 'O'}, {'self-care': 'O'}, {'measures': 'O'}, {'and': 'O'}, {'advice': 'O'}, {'regarding': 'O'}, {'exercise': 'O'}, {'to': 'O'}, {'reduce': 'O'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'in': 'O'}, {'selected': 'O'}, {'clinical': 'O'}, {'settings': 'O'}, {'for': 'O'}, {'oral': 'O'}, {'and': 'O'}, {'ocular': 'O'}]"
"Metformin, a first-line anti-diabetic drug, exerts anti-inflammatory and immunomodulatory effects by activating AMPK.","[{'Metformin,': 'I-Entity'}, {'a': 'O'}, {'first-line': 'O'}, {'anti-diabetic': 'O'}, {'drug,': 'O'}, {'exerts': 'O'}, {'anti-inflammatory': 'O'}, {'and': 'O'}, {'immunomodulatory': 'O'}, {'effects': 'O'}, {'by': 'O'}, {'activating': 'O'}, {'AMPK.': 'O'}]"
Advances in the role of infectious agents as triggers for SLE and Sjogrens syndrome have provided new insights into disease development.,"[{'Advances': 'O'}, {'in': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'infectious': 'O'}, {'agents': 'O'}, {'as': 'O'}, {'triggers': 'O'}, {'for': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'have': 'O'}, {'provided': 'O'}, {'new': 'O'}, {'insights': 'O'}, {'into': 'O'}, {'disease': 'O'}, {'development.': 'O'}]"
"Only one study evaluated the lissamine green test and reported a statistically significant difference between the groups at week 24 (MD -2.00, 95% CI -3.52 to -0.48).","[{'Only': 'O'}, {'one': 'O'}, {'study': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'lissamine': 'B-Entity'}, {'green': 'I-Entity'}, {'test': 'O'}, {'and': 'O'}, {'reported': 'O'}, {'a': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'between': 'O'}, {'the': 'O'}, {'groups': 'O'}, {'at': 'O'}, {'week': 'O'}, {'24': 'O'}, {'(MD': 'O'}, {'-2.00,': 'O'}, {'95%': 'O'}, {'CI': 'O'}, {'-3.52': 'O'}, {'to': 'O'}, {'-0.48).': 'O'}]"
SFN diagnosis was based on intraepidermal nerve fiber density on skin biopsies in patients with no abnormality on EMG.,"[{'SFN': 'I-Entity'}, {'diagnosis': 'O'}, {'was': 'O'}, {'based': 'O'}, {'on': 'O'}, {'intraepidermal': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'density': 'O'}, {'on': 'O'}, {'skin': 'O'}, {'biopsies': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'no': 'O'}, {'abnormality': 'O'}, {'on': 'O'}, {'EMG.': 'O'}]"
Disease-modifying therapy is reserved for patients with systemic involvement; there is limited evidence for its efficacy.,"[{'Disease-modifying': 'O'}, {'therapy': 'O'}, {'is': 'O'}, {'reserved': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'involvement;': 'O'}, {'there': 'O'}, {'is': 'O'}, {'limited': 'O'}, {'evidence': 'O'}, {'for': 'O'}, {'its': 'O'}, {'efficacy.': 'O'}]"
"However, in spite of stabilized findings in the 5 eyes with perforated ulcers, the visual acuity was in this case only between light perception and 0.05.","[{'However,': 'O'}, {'in': 'O'}, {'spite': 'O'}, {'of': 'O'}, {'stabilized': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'the': 'O'}, {'5': 'O'}, {'eyes': 'O'}, {'with': 'O'}, {'perforated': 'O'}, {'ulcers,': 'I-Entity'}, {'the': 'O'}, {'visual': 'O'}, {'acuity': 'O'}, {'was': 'O'}, {'in': 'O'}, {'this': 'O'}, {'case': 'O'}, {'only': 'O'}, {'between': 'O'}, {'light': 'O'}, {'perception': 'O'}, {'and': 'O'}, {'0.05.': 'O'}]"
The suggested approach for lip MSGB includes a specifically designed instrument whose performance during lip biopsy may contribute to minimize post-operative complications.interest exist.,"[{'The': 'O'}, {'suggested': 'O'}, {'approach': 'O'}, {'for': 'O'}, {'lip': 'O'}, {'MSGB': 'I-Entity'}, {'includes': 'O'}, {'a': 'O'}, {'specifically': 'O'}, {'designed': 'O'}, {'instrument': 'O'}, {'whose': 'O'}, {'performance': 'O'}, {'during': 'O'}, {'lip': 'O'}, {'biopsy': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'minimize': 'O'}, {'post-operative': 'O'}, {'complications.interest': 'O'}, {'exist.': 'O'}]"
A prospective observational study was conducted in At-Risk of AI-CTD (defined as antinuclear antibody (ANA) positive; ‚Äö√Ñ√∂‚àö¬¢¬¨√ü1‚Äö√Ñ√∂‚àö√ë‚àö¬¢clinical systemic lupus erythematosus (SLE) criterion; symptom duration <12 months and treatment-na‚Äö√†√∂‚àö√≤ve).,"[{'A': 'O'}, {'prospective': 'O'}, {'observational': 'O'}, {'study': 'O'}, {'was': 'O'}, {'conducted': 'O'}, {'in': 'O'}, {'At-Risk': 'O'}, {'of': 'O'}, {'AI-CTD': 'I-Entity'}, {'(defined': 'O'}, {'as': 'O'}, {'antinuclear': 'O'}, {'antibody': 'O'}, {'(ANA)': 'O'}, {'positive;': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢¬¨√ü1‚Äö√Ñ√∂‚àö√ë‚àö¬¢clinical': 'O'}]"
The frequencies of subpopulations of CD14(+) monocytes were evaluated by flow cytometry among isolated mononuclear cells from peripheral blood and salivary glands from both patients and controls.,"[{'The': 'O'}, {'frequencies': 'O'}, {'of': 'O'}, {'subpopulations': 'O'}, {'of': 'O'}, {'CD14(+)': 'O'}, {'monocytes': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'flow': 'O'}, {'cytometry': 'O'}, {'among': 'O'}, {'isolated': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'both': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'controls.': 'O'}]"
"We validated the enumeration of circulating T cells resembling Tfh cells as a biomarker of this expansion in sanroque mice, and we performed a comprehensive comparison of the surface phenotype of circulating and tonsillar Tfh cells in humans.","[{'We': 'O'}, {'validated': 'O'}, {'the': 'O'}, {'enumeration': 'O'}, {'of': 'O'}, {'circulating': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'resembling': 'O'}, {'Tfh': 'O'}, {'cells': 'O'}, {'as': 'O'}, {'a': 'O'}, {'biomarker': 'O'}, {'of': 'O'}, {'this': 'O'}, {'expansion': 'O'}, {'in': 'O'}, {'sanroque': 'O'}, {'mice,': 'O'}, {'and': 'O'}, {'we': 'O'}, {'performed': 'O'}, {'a': 'O'}, {'comprehensive': 'O'}, {'comparison': 'O'}, {'of': 'O'}, {'the': 'O'}, {'surface': 'O'}, {'phenotype': 'O'}, {'of': 'O'}, {'circulating': 'O'}, {'and': 'O'}, {'tonsillar': 'O'}, {'Tfh': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'humans.': 'O'}]"
"Clinical data as well as findings from experimental disease were summarized in categories addressing the presence of aab against M3R in SS patients, the function of anti-M3R aab, the association of aab against M3R with SS-related phenotypes, in vivo pathogenicity of transferred aab against M3R in mice, and mouse models induced via immunization with M3R.","[{'Clinical': 'O'}, {'data': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'findings': 'O'}, {'from': 'O'}, {'experimental': 'O'}, {'disease': 'O'}, {'were': 'O'}, {'summarized': 'O'}, {'in': 'O'}, {'categories': 'O'}, {'addressing': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'aab': 'O'}, {'against': 'O'}, {'M3R': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'the': 'O'}, {'function': 'O'}, {'of': 'O'}, {'anti-M3R': 'O'}, {'aab,': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'aab': 'O'}, {'against': 'O'}, {'M3R': 'O'}, {'with': 'O'}, {'SS-related': 'I-Entity'}, {'phenotypes,': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'pathogenicity': 'O'}]"
"After reviewing in detail the cutaneous manifestations of the most frequent inflammatory rheumatic diseases, we describe a topographic and morphological approach to skin rashes, calling attention to facial rashes, hand involvement, scalp, nail, or leg lesions or to some morphological aspects of skin lesions (annular, pustular, urticarial, or exanthematous) that may be the initial manifestations of inflammatory rheumatic diseases.","[{'After': 'O'}, {'reviewing': 'O'}, {'in': 'O'}, {'detail': 'O'}, {'the': 'O'}, {'cutaneous': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'we': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'topographic': 'O'}, {'and': 'O'}, {'morphological': 'O'}, {'approach': 'O'}, {'to': 'O'}, {'skin': 'B-Entity'}, {'rashes,': 'I-Entity'}, {'calling': 'O'}, {'attention': 'O'}, {'to': 'O'}, {'facial': 'O'}, {'rashes,': 'I-Entity'}, {'hand': 'O'}, {'involvement,': 'O'}, {'scalp,': 'O'}, {'nail,': 'O'}, {'or': 'O'}, {'leg': 'O'}, {'lesions': 'O'}, {'or': 'O'}, {'to': 'O'}, {'some': 'O'}, {'morphological': 'O'}, {'aspects': 'O'}, {'of': 'O'}, {'skin': 'O'}]"
Type I interferons (IFN) are a class of inducible and protective cytokines best known for immune defence against viruses and intracellular bacteria.,"[{'Type': 'O'}, {'I': 'O'}, {'interferons': 'O'}, {'(IFN)': 'O'}, {'are': 'O'}, {'a': 'O'}, {'class': 'O'}, {'of': 'O'}, {'inducible': 'O'}, {'and': 'O'}, {'protective': 'O'}, {'cytokines': 'O'}, {'best': 'O'}, {'known': 'O'}, {'for': 'O'}, {'immune': 'O'}, {'defence': 'O'}, {'against': 'O'}, {'viruses': 'I-Entity'}, {'and': 'O'}, {'intracellular': 'O'}, {'bacteria.': 'O'}]"
The aim of this work was to clarify the effect of leflunomide (LEF) on the eye dryness in patients with secondary Sjogrens syndrome associated with rheumatoid arthritis (RA-sSS) and in patients with rheumatoid arthritis (RA).,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'work': 'O'}, {'was': 'O'}, {'to': 'O'}, {'clarify': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'leflunomide': 'I-Entity'}, {'(LEF)': 'O'}, {'on': 'O'}, {'the': 'O'}, {'eye': 'B-Entity'}, {'dryness': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'secondary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA-sSS)': 'O'}, {'and': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}]"
"Herein, we review those diseases for which dermatologists may be asked to perform a biopsy on normal skin where analysis by optical microscopy, immunofluorescence or electronic microscopy may result in diagnosis of an ""internal"" disease.","[{'Herein,': 'O'}, {'we': 'O'}, {'review': 'O'}, {'those': 'O'}, {'diseases': 'O'}, {'for': 'O'}, {'which': 'O'}, {'dermatologists': 'O'}, {'may': 'O'}, {'be': 'O'}, {'asked': 'O'}, {'to': 'O'}, {'perform': 'O'}, {'a': 'O'}, {'biopsy': 'O'}, {'on': 'O'}, {'normal': 'O'}, {'skin': 'O'}, {'where': 'O'}, {'analysis': 'O'}, {'by': 'O'}, {'optical': 'O'}, {'microscopy,': 'O'}, {'immunofluorescence': 'O'}, {'or': 'O'}, {'electronic': 'O'}, {'microscopy': 'O'}, {'may': 'O'}, {'result': 'O'}, {'in': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'an': 'O'}, {'""internal""': 'O'}, {'disease.': 'O'}]"
"Parotid R2* value contributed to the diagnosis of Sjogren syndrome combined with MR nodular grade.The Affiliated Hospital of Nanjing University Medical School, Nanjing; ‚Äö√Ñ√∂‚àö√ë¬¨‚àûPhilips Healthcare, Shanghai; and ¬¨¬®‚àö√ºPhilips Healthcare, Hong Kong, P.R.","[{'Parotid': 'O'}, {'R2*': 'O'}, {'value': 'O'}, {'contributed': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'combined': 'O'}, {'with': 'O'}, {'MR': 'O'}, {'nodular': 'O'}, {'grade.The': 'O'}, {'Affiliated': 'O'}, {'Hospital': 'O'}, {'of': 'O'}, {'Nanjing': 'O'}, {'University': 'O'}, {'Medical': 'O'}, {'School,': 'O'}, {'Nanjing;': 'O'}, {'‚Äö√Ñ√∂‚àö√ë¬¨‚àûPhilips': 'O'}, {'Healthcare,': 'O'}, {'Shanghai;': 'O'}, {'and': 'O'}]"
Type 1 hyperlipoproteinemia (T1HLP) in childhood is most often due to genetic deficiency of lipoprotein lipase (LPL) or other related proteins.,"[{'Type': 'B-Entity'}, {'1': 'I-Entity'}, {'hyperlipoproteinemia': 'I-Entity'}, {'(T1HLP)': 'O'}, {'in': 'O'}, {'childhood': 'O'}, {'is': 'O'}, {'most': 'O'}, {'often': 'O'}, {'due': 'O'}, {'to': 'O'}, {'genetic': 'O'}, {'deficiency': 'O'}, {'of': 'O'}, {'lipoprotein': 'O'}, {'lipase': 'O'}, {'(LPL)': 'O'}, {'or': 'O'}, {'other': 'O'}, {'related': 'O'}, {'proteins.': 'O'}]"
Elevated FURIN levels associate with high levels of the Th1 type cytokine IFN-‚âà√≠‚Äö√¢‚Ä¢ and long duration of dry eye symptoms.,"[{'Elevated': 'O'}, {'FURIN': 'O'}, {'levels': 'O'}, {'associate': 'O'}, {'with': 'O'}, {'high': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'the': 'O'}, {'Th1': 'O'}, {'type': 'O'}, {'cytokine': 'O'}, {'IFN-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'and': 'O'}, {'long': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms.': 'I-Entity'}]"
"Taken together, the results indicate that Sema5A contributes to the pathogenesis of RA through antigen-independent T cell and NK cell activation.","[{'Taken': 'O'}, {'together,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'Sema5A': 'O'}, {'contributes': 'O'}, {'to': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'RA': 'I-Entity'}, {'through': 'O'}, {'antigen-independent': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'and': 'O'}, {'NK': 'O'}, {'cell': 'O'}, {'activation.': 'O'}]"
The samples were examined by Raman microscope.Support vector machine(SVM) was employed to analyze the data and establish the classification model.,"[{'The': 'O'}, {'samples': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'Raman': 'O'}, {'microscope.Support': 'O'}, {'vector': 'O'}, {'machine(SVM)': 'O'}, {'was': 'O'}, {'employed': 'O'}, {'to': 'O'}, {'analyze': 'O'}, {'the': 'O'}, {'data': 'O'}, {'and': 'O'}, {'establish': 'O'}, {'the': 'O'}, {'classification': 'O'}, {'model.': 'O'}]"
"Although it is well accepted to use corticosteroids for the treatment of systemic manifestations, there is scarce information available regarding the use of targeted therapy for refractory cases.","[{'Although': 'O'}, {'it': 'O'}, {'is': 'O'}, {'well': 'O'}, {'accepted': 'O'}, {'to': 'O'}, {'use': 'O'}, {'corticosteroids': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'manifestations,': 'O'}, {'there': 'O'}, {'is': 'O'}, {'scarce': 'O'}, {'information': 'O'}, {'available': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'targeted': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'refractory': 'O'}, {'cases.': 'O'}]"
"Since the introduction of the Schirmer's test in 1903, other tests have been developed to evaluate dry eye, such as biomicroscopy, the tear film breakup time (BUT), vital dyes (lissamine green and rose bengal), fluorescein, leaf fern test, corneal sensitivity test, conjunctiva impression cytology, optical coherence tomography (OCT), and tear osmolarity measurement.","[{'Since': 'O'}, {'the': 'O'}, {'introduction': 'O'}, {'of': 'O'}, {'the': 'O'}, {""Schirmer's"": 'O'}, {'test': 'O'}, {'in': 'O'}, {'1903,': 'O'}, {'other': 'O'}, {'tests': 'O'}, {'have': 'O'}, {'been': 'O'}, {'developed': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'biomicroscopy,': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'film': 'O'}, {'breakup': 'O'}, {'time': 'O'}, {'(BUT),': 'O'}, {'vital': 'O'}, {'dyes': 'O'}, {'(lissamine': 'O'}, {'green': 'I-Entity'}, {'and': 'O'}, {'rose': 'B-Entity'}, {'bengal),': 'I-Entity'}, {'fluorescein,': 'I-Entity'}, {'leaf': 'O'}, {'fern': 'I-Entity'}]"
"In this report, we present the results of a severe case of Sjogrens syndrome-related keratopathy after fluocinolone acetonide 190-‚âà√≠¬¨‚à´g intravitreal implant (Iluvien¬¨¬®‚àö√ú; Alimera Sciences Inc.) therapy.","[{'In': 'O'}, {'this': 'O'}, {'report,': 'O'}, {'we': 'O'}, {'present': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'case': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome-related': 'I-Entity'}, {'keratopathy': 'I-Entity'}, {'after': 'O'}, {'fluocinolone': 'B-Entity'}, {'acetonide': 'I-Entity'}, {'190-‚âà√≠¬¨‚à´g': 'O'}, {'intravitreal': 'O'}, {'implant': 'O'}, {'(Iluvien¬¨¬®‚àö√ú;': 'O'}]"
"After that, an international project supported by EULAR, emerged to develop consensus disease activity indexes: the EULAR Sjogrens Syndrome Patients Reported Index (ESSPRI), and the EULAR Sjogrens Syndrome Disease Activity Index (ESSDAI), a systemic activity index to assess systemic manifestations.","[{'After': 'O'}, {'that,': 'O'}, {'an': 'O'}, {'international': 'O'}, {'project': 'O'}, {'supported': 'O'}, {'by': 'O'}, {'EULAR,': 'O'}, {'emerged': 'O'}, {'to': 'O'}, {'develop': 'O'}, {'consensus': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'indexes:': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Patients': 'O'}, {'Reported': 'O'}, {'Index': 'O'}, {'(ESSPRI),': 'O'}, {'and': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI),': 'O'}]"
"It most commonly occurs in healthy individuals, in whom there is no associated illness or any other cause of Raynaud's phenomenon (primary or idiopathic Raynaud's phenomenon).","[{'It': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'individuals,': 'O'}, {'in': 'O'}, {'whom': 'O'}, {'there': 'O'}, {'is': 'O'}, {'no': 'O'}, {'associated': 'O'}, {'illness': 'I-Entity'}, {'or': 'O'}, {'any': 'O'}, {'other': 'O'}, {'cause': 'O'}, {'of': 'O'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon': 'I-Entity'}, {'(primary': 'O'}, {'or': 'O'}, {'idiopathic': 'B-Entity'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon).': 'I-Entity'}]"
"The majority of cases diagnosed with autoimmune pancreatitis in Japan are IgG4-related sclerosing pancreatitis, and it should be recognized that this is distinct from the Western type.","[{'The': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'cases': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'pancreatitis': 'I-Entity'}, {'in': 'O'}, {'Japan': 'O'}, {'are': 'O'}, {'IgG4-related': 'O'}, {'sclerosing': 'B-Entity'}, {'pancreatitis,': 'I-Entity'}, {'and': 'O'}, {'it': 'O'}, {'should': 'O'}, {'be': 'O'}, {'recognized': 'O'}, {'that': 'O'}, {'this': 'O'}, {'is': 'O'}, {'distinct': 'O'}, {'from': 'O'}, {'the': 'O'}, {'Western': 'O'}, {'type.': 'O'}]"
"Etiology of Sjogrens syndrome (SS) is still unknown, but there is strong evidence that certain pathogens of bacterial or viral origin can incite autoimmune response.","[{'Etiology': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'still': 'O'}, {'unknown,': 'O'}, {'but': 'O'}, {'there': 'O'}, {'is': 'O'}, {'strong': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'certain': 'O'}, {'pathogens': 'O'}, {'of': 'O'}, {'bacterial': 'O'}, {'or': 'O'}, {'viral': 'O'}, {'origin': 'O'}, {'can': 'O'}, {'incite': 'O'}, {'autoimmune': 'O'}, {'response.': 'O'}]"
"Thermodynamic punctum plug insertion only in inferior canaliculus is a simple, effective, and comfortable option for treatment of severe aqueous tear deficiency that cannot be controlled using preservative-free tears.saitegrilmez@yahoo.comMay 21.","[{'Thermodynamic': 'O'}, {'punctum': 'O'}, {'plug': 'O'}, {'insertion': 'O'}, {'only': 'O'}, {'in': 'O'}, {'inferior': 'O'}, {'canaliculus': 'O'}, {'is': 'O'}, {'a': 'O'}, {'simple,': 'O'}, {'effective,': 'O'}, {'and': 'O'}, {'comfortable': 'O'}, {'option': 'O'}, {'for': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'severe': 'O'}, {'aqueous': 'B-Entity'}, {'tear': 'I-Entity'}, {'deficiency': 'I-Entity'}, {'that': 'O'}, {'cannot': 'O'}, {'be': 'O'}, {'controlled': 'O'}, {'using': 'O'}, {'preservative-free': 'O'}, {'tears.saitegrilmez@yahoo.comMay': 'O'}, {'21.': 'O'}]"
"The Copas and Corbett (2002) correction, for bias resulting from using the same data to derive the combination rule and estimate the ROC, was also evaluated and an improved version was incorporated.","[{'The': 'O'}, {'Copas': 'O'}, {'and': 'O'}, {'Corbett': 'O'}, {'(2002)': 'O'}, {'correction,': 'O'}, {'for': 'O'}, {'bias': 'O'}, {'resulting': 'O'}, {'from': 'O'}, {'using': 'O'}, {'the': 'O'}, {'same': 'O'}, {'data': 'O'}, {'to': 'O'}, {'derive': 'O'}, {'the': 'O'}, {'combination': 'O'}, {'rule': 'O'}, {'and': 'O'}, {'estimate': 'O'}, {'the': 'O'}, {'ROC,': 'O'}, {'was': 'O'}, {'also': 'O'}, {'evaluated': 'O'}, {'and': 'O'}, {'an': 'O'}, {'improved': 'O'}, {'version': 'O'}, {'was': 'O'}, {'incorporated.': 'O'}]"
"Other types of ILD, such as organising pneumonia, usual interstitial pneumonia and lymphocytic interstitial pneumonitis, are rare.","[{'Other': 'O'}, {'types': 'O'}, {'of': 'O'}, {'ILD,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'organising': 'B-Entity'}, {'pneumonia,': 'I-Entity'}, {'usual': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonitis,': 'I-Entity'}, {'are': 'O'}, {'rare.': 'O'}]"
"Pharmacologic modulation of the LT‚âà√≠‚Äö√¢¬ßR signaling pathway was achieved by treating mice with LT‚âà√≠‚Äö√¢¬ßR-Ig, a therapeutic intervention currently being tested in pSS patients (Baminercept trial NCT01552681).","[{'Pharmacologic': 'O'}, {'modulation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'LT‚âà√≠‚Äö√¢¬ßR': 'O'}, {'signaling': 'O'}, {'pathway': 'O'}, {'was': 'O'}, {'achieved': 'O'}, {'by': 'O'}, {'treating': 'O'}, {'mice': 'O'}, {'with': 'O'}, {'LT‚âà√≠‚Äö√¢¬ßR-Ig,': 'O'}, {'a': 'O'}, {'therapeutic': 'O'}, {'intervention': 'O'}, {'currently': 'O'}, {'being': 'O'}, {'tested': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}]"
"To validate the findings in a large cohort, we retrospectively searched for ICD-9/10 codes for sialadenitis, xerostomia, and autoimmune disease associated with Sjogrens syndrome (AID-SS) in our existing database (n = 1507).","[{'To': 'O'}, {'validate': 'O'}, {'the': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'a': 'O'}, {'large': 'O'}, {'cohort,': 'O'}, {'we': 'O'}, {'retrospectively': 'O'}, {'searched': 'O'}, {'for': 'O'}, {'ICD-9/10': 'O'}, {'codes': 'O'}, {'for': 'O'}, {'sialadenitis,': 'I-Entity'}, {'xerostomia,': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(AID-SS)': 'O'}, {'in': 'O'}, {'our': 'O'}, {'existing': 'O'}, {'database': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'1507).': 'O'}]"
"As a definite correlation between the ANA patterns and the group of antibodies was detected by dot immunoblot, one could predict presence of certain specific auto antibodies for a particular ANA pattern identified.","[{'As': 'O'}, {'a': 'O'}, {'definite': 'O'}, {'correlation': 'O'}, {'between': 'O'}, {'the': 'O'}, {'ANA': 'O'}, {'patterns': 'O'}, {'and': 'O'}, {'the': 'O'}, {'group': 'O'}, {'of': 'O'}, {'antibodies': 'O'}, {'was': 'O'}, {'detected': 'O'}, {'by': 'O'}, {'dot': 'O'}, {'immunoblot,': 'O'}, {'one': 'O'}, {'could': 'O'}, {'predict': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'certain': 'O'}, {'specific': 'O'}, {'auto': 'O'}, {'antibodies': 'O'}, {'for': 'O'}, {'a': 'O'}, {'particular': 'O'}, {'ANA': 'O'}, {'pattern': 'O'}, {'identified.': 'O'}]"
To assess the role of MRI in the elucidation of the cause of metatarsalgia in patients with different autoimmune disorders presenting primarily with this symptom and to present the accompanying clinical and radiological findings of intermetatarsal bursitis.,"[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'MRI': 'O'}, {'in': 'O'}, {'the': 'O'}, {'elucidation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'metatarsalgia': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'different': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'presenting': 'O'}, {'primarily': 'O'}, {'with': 'O'}, {'this': 'O'}, {'symptom': 'O'}, {'and': 'O'}, {'to': 'O'}, {'present': 'O'}, {'the': 'O'}, {'accompanying': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'radiological': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'intermetatarsal': 'B-Entity'}, {'bursitis.': 'I-Entity'}]"
Primary Sjogrens syndrome (pSS) is a chronic autoimmune disease mainly affecting exocrine glands.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'mainly': 'O'}, {'affecting': 'O'}, {'exocrine': 'B-Entity'}, {'glands.': 'I-Entity'}]"
"These findings suggest that respiratory lesions are not rare in patients with IgG4-related MD, and that they present with various manifestations.","[{'These': 'O'}, {'findings': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'respiratory': 'B-Entity'}, {'lesions': 'I-Entity'}, {'are': 'O'}, {'not': 'O'}, {'rare': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IgG4-related': 'O'}, {'MD,': 'I-Entity'}, {'and': 'O'}, {'that': 'O'}, {'they': 'O'}, {'present': 'O'}, {'with': 'O'}, {'various': 'O'}, {'manifestations.': 'O'}]"
"An immune response (IgG) against Epstein-Barr virus (EBV) early antigen (EA) was positively associated with SS (OR 4; 95% CI: 1.82-8.83, p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.001) while a protective effect of IgG anti-cytomegalovirus (CMV) was observed (OR 0.3; 95%CI: 0.16-0.74, p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.009).","[{'An': 'O'}, {'immune': 'O'}, {'response': 'O'}, {'(IgG)': 'O'}, {'against': 'O'}, {'Epstein-Barr': 'B-Entity'}, {'virus': 'I-Entity'}, {'(EBV)': 'O'}, {'early': 'O'}, {'antigen': 'O'}, {'(EA)': 'O'}, {'was': 'O'}, {'positively': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'(OR': 'O'}, {'4;': 'O'}, {'95%': 'O'}, {'CI:': 'O'}, {'1.82-8.83,': 'O'}, {'p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.001)': 'O'}]"
"She was admitted to our hospital for further evaluation of hypergammaglobulinema, acute renal failure, and severe thrombocytopenia.","[{'She': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'to': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'for': 'O'}, {'further': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'hypergammaglobulinema,': 'I-Entity'}, {'acute': 'B-Entity'}, {'renal': 'I-Entity'}, {'failure,': 'I-Entity'}, {'and': 'O'}, {'severe': 'O'}, {'thrombocytopenia.': 'I-Entity'}]"
Nonspecific interstitial pneumonia is the most common histological finding in patients with CTD.,"[{'Nonspecific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'histological': 'O'}, {'finding': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'CTD.': 'I-Entity'}]"
"After systemic diseases involving autonomic failure were excluded, cardiac sympathetic neuroimaging was performed by 123I-metaliodobenzylguanidine (MIBG) scanning.","[{'After': 'O'}, {'systemic': 'O'}, {'diseases': 'O'}, {'involving': 'O'}, {'autonomic': 'B-Entity'}, {'failure': 'I-Entity'}, {'were': 'O'}, {'excluded,': 'O'}, {'cardiac': 'O'}, {'sympathetic': 'O'}, {'neuroimaging': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'by': 'O'}, {'123I-metaliodobenzylguanidine': 'B-Entity'}, {'(MIBG)': 'O'}, {'scanning.': 'O'}]"
"We discuss a challenging case of a 58-year-old Vietnamese-American woman who presented to her new primary care provider with an 8-year history of slowly progressive dysphagia, hoarseness, muscle weakness with associated frequent falls, and weight loss.","[{'We': 'O'}, {'discuss': 'O'}, {'a': 'O'}, {'challenging': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'58-year-old': 'O'}, {'Vietnamese-American': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'to': 'O'}, {'her': 'O'}, {'new': 'O'}, {'primary': 'O'}, {'care': 'O'}, {'provider': 'O'}, {'with': 'O'}, {'an': 'O'}, {'8-year': 'O'}, {'history': 'O'}, {'of': 'O'}, {'slowly': 'O'}, {'progressive': 'O'}, {'dysphagia,': 'I-Entity'}, {'hoarseness,': 'I-Entity'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'with': 'O'}, {'associated': 'O'}, {'frequent': 'O'}, {'falls,': 'I-Entity'}, {'and': 'O'}, {'weight': 'B-Entity'}, {'loss.': 'I-Entity'}]"
"Mice were sacrificed after eight weeks, and their arterial blood and tissues of submaxillary gland were collected.","[{'Mice': 'O'}, {'were': 'O'}, {'sacrificed': 'O'}, {'after': 'O'}, {'eight': 'O'}, {'weeks,': 'O'}, {'and': 'O'}, {'their': 'O'}, {'arterial': 'O'}, {'blood': 'O'}, {'and': 'O'}, {'tissues': 'O'}, {'of': 'O'}, {'submaxillary': 'O'}, {'gland': 'O'}, {'were': 'O'}, {'collected.': 'O'}]"
Systemic scores had a large sensitivity to change in patients whose disease activity improves.,"[{'Systemic': 'O'}, {'scores': 'O'}, {'had': 'O'}, {'a': 'O'}, {'large': 'O'}, {'sensitivity': 'O'}, {'to': 'O'}, {'change': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'whose': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'improves.': 'O'}]"
"Based on this observation, the pathogenesis of distal tubular acidosis during auto-immune diseases (Sjogrens syndrome, monoclonal hypergammaglobulinemia, hypothyroidism) was discussed as well as its consequences and management.thyro‚Äö√†√∂‚àö√≤dite auto-immune.manifestation of primary Sjogrens syndrome.","[{'Based': 'O'}, {'on': 'O'}, {'this': 'O'}, {'observation,': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'distal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'during': 'O'}, {'auto-immune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(Sjogrens': 'O'}, {'syndrome,': 'I-Entity'}, {'monoclonal': 'B-Entity'}, {'hypergammaglobulinemia,': 'I-Entity'}, {'hypothyroidism)': 'I-Entity'}, {'was': 'O'}, {'discussed': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'its': 'O'}, {'consequences': 'O'}, {'and': 'O'}, {'management.thyro‚Äö√†√∂‚àö√≤dite': 'O'}]"
"On multivariate analysis, age <60 years and low to intermediate international prognostic index were associated with improved OS and PFS; Sjogren disease was associated with improved OS.","[{'On': 'O'}, {'multivariate': 'O'}, {'analysis,': 'O'}, {'age': 'O'}, {'<60': 'O'}, {'years': 'O'}, {'and': 'O'}, {'low': 'O'}, {'to': 'O'}, {'intermediate': 'O'}, {'international': 'O'}, {'prognostic': 'O'}, {'index': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'improved': 'O'}, {'OS': 'O'}, {'and': 'O'}, {'PFS;': 'O'}, {'Sjogren': 'B-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'improved': 'O'}, {'OS.': 'O'}]"
"To identify the principal determinants of health-related quality of life (HRQOL) impairment in patients with active primary Sjogrens syndrome (SS) participating in a large therapeutic trial, Tolerance and Efficacy of Rituximab in Primary Sjogrens Syndrome (TEARS).","[{'To': 'O'}, {'identify': 'O'}, {'the': 'O'}, {'principal': 'O'}, {'determinants': 'O'}, {'of': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(HRQOL)': 'O'}, {'impairment': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'active': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'participating': 'O'}, {'in': 'O'}, {'a': 'O'}, {'large': 'O'}, {'therapeutic': 'O'}, {'trial,': 'O'}, {'Tolerance': 'O'}, {'and': 'O'}, {'Efficacy': 'O'}, {'of': 'O'}, {'Rituximab': 'I-Entity'}, {'in': 'O'}, {'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}]"
"The aim of our study was to investigate extraarticular manifestations (EAMs) in Turkish patients with rheumatoid arthritis (RA) and also assess the impact of EAMs on various health-related quality of life (HRQoL) domains, including physical, social, emotional, mental functioning, and bodily pain.","[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'our': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'extraarticular': 'O'}, {'manifestations': 'O'}, {'(EAMs)': 'O'}, {'in': 'O'}, {'Turkish': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'and': 'O'}, {'also': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'EAMs': 'O'}, {'on': 'O'}, {'various': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(HRQoL)': 'O'}, {'domains,': 'O'}, {'including': 'O'}, {'physical,': 'O'}, {'social,': 'O'}]"
"Peribronchovascular (19 of 21, 90%) and subpleural (19 of 21, 90%) cysts were typically present.","[{'Peribronchovascular': 'O'}, {'(19': 'O'}, {'of': 'O'}, {'21,': 'O'}, {'90%)': 'O'}, {'and': 'O'}, {'subpleural': 'O'}, {'(19': 'O'}, {'of': 'O'}, {'21,': 'O'}, {'90%)': 'O'}, {'cysts': 'I-Entity'}, {'were': 'O'}, {'typically': 'O'}, {'present.': 'O'}]"
"However, there have been no reported cases of patients with SLE/SjS who do not exhibit any neurological symptoms and AQP4-Ab-positivity, and it is likely that these 2 autoimmune diseases incidentally overlap.","[{'However,': 'O'}, {'there': 'O'}, {'have': 'O'}, {'been': 'O'}, {'no': 'O'}, {'reported': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SLE/SjS': 'I-Entity'}, {'who': 'O'}, {'do': 'O'}, {'not': 'O'}, {'exhibit': 'O'}, {'any': 'O'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'AQP4-Ab-positivity,': 'O'}, {'and': 'O'}, {'it': 'O'}, {'is': 'O'}, {'likely': 'O'}, {'that': 'O'}, {'these': 'O'}, {'2': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'incidentally': 'O'}, {'overlap.': 'O'}]"
The aim was to report a case of marked hypertriglyceridemia and recurrent acute pancreatitis due to the presence of LPL autoantibody in a young girl who was subsequently diagnosed with Sjogrens syndrome.,"[{'The': 'O'}, {'aim': 'O'}, {'was': 'O'}, {'to': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'marked': 'O'}, {'hypertriglyceridemia': 'I-Entity'}, {'and': 'O'}, {'recurrent': 'O'}, {'acute': 'O'}, {'pancreatitis': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'LPL': 'O'}, {'autoantibody': 'O'}, {'in': 'O'}, {'a': 'O'}, {'young': 'O'}, {'girl': 'O'}, {'who': 'O'}, {'was': 'O'}, {'subsequently': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"They all underwent screening tests for systemic vasculitis including rheumatoid factor, antinuclear antibody, antineutrophil cytoplasmic antibodies, anticardiolipin antibody, lupus anticoagulant, anti-DNA antibody, and anti-Ro/SSA and La/SSB antibodies.","[{'They': 'O'}, {'all': 'O'}, {'underwent': 'O'}, {'screening': 'O'}, {'tests': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'vasculitis': 'I-Entity'}, {'including': 'O'}, {'rheumatoid': 'O'}, {'factor,': 'O'}, {'antinuclear': 'O'}, {'antibody,': 'O'}, {'antineutrophil': 'O'}, {'cytoplasmic': 'O'}, {'antibodies,': 'O'}, {'anticardiolipin': 'O'}, {'antibody,': 'O'}, {'lupus': 'B-Entity'}, {'anticoagulant,': 'O'}, {'anti-DNA': 'O'}, {'antibody,': 'O'}, {'and': 'O'}]"
Such salivary biomarker signatures harbor great potential for improving timeliness of SS diagnosis and enabling suitable patient followup.Tubular Acidosis Associated with Sjogrens Syndrome.,"[{'Such': 'O'}, {'salivary': 'O'}, {'biomarker': 'O'}, {'signatures': 'O'}, {'harbor': 'O'}, {'great': 'O'}, {'potential': 'O'}, {'for': 'O'}, {'improving': 'O'}, {'timeliness': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'diagnosis': 'O'}, {'and': 'O'}, {'enabling': 'O'}, {'suitable': 'O'}, {'patient': 'O'}, {'followup.Tubular': 'O'}, {'Acidosis': 'I-Entity'}, {'Associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome.': 'I-Entity'}]"
Otolaryngologists who treat pediatric parotitis should have a high index of suspicion for Sjogrens syndrome.,"[{'Otolaryngologists': 'O'}, {'who': 'O'}, {'treat': 'O'}, {'pediatric': 'O'}, {'parotitis': 'I-Entity'}, {'should': 'O'}, {'have': 'O'}, {'a': 'O'}, {'high': 'O'}, {'index': 'O'}, {'of': 'O'}, {'suspicion': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"In addition to the regulation of human miRNA, many virus-derived miRNA were unexpectedly upregulated in the patients with pSS, suggesting that viral infection of PBMC plays a role in this disease.College Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.L.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'the': 'O'}, {'regulation': 'O'}, {'of': 'O'}, {'human': 'O'}, {'miRNA,': 'O'}, {'many': 'O'}, {'virus-derived': 'O'}, {'miRNA': 'O'}, {'were': 'O'}, {'unexpectedly': 'O'}, {'upregulated': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'suggesting': 'O'}, {'that': 'O'}, {'viral': 'B-Entity'}, {'infection': 'I-Entity'}, {'of': 'O'}, {'PBMC': 'O'}, {'plays': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'this': 'O'}, {'disease.College': 'O'}, {'Hospital;': 'O'}, {'Chinese': 'O'}, {'Academy': 'O'}, {'of': 'O'}, {'Medical': 'O'}, {'Sciences': 'O'}, {'and': 'O'}, {'Peking': 'O'}, {'Union': 'O'}, {'Medical': 'O'}, {'College;': 'O'}, {'State': 'O'}, {'Key': 'O'}, {'Laboratory': 'O'}]"
We demonstrate that FcRL4(+) cells are present in salivary gland tissue of pSS patients where they are closely associated with ductal epithelial cells forming lymphoepithelial lesions.,"[{'We': 'O'}, {'demonstrate': 'O'}, {'that': 'O'}, {'FcRL4(+)': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'present': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'tissue': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'where': 'O'}, {'they': 'O'}, {'are': 'O'}, {'closely': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'ductal': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'forming': 'O'}, {'lymphoepithelial': 'B-Entity'}, {'lesions.': 'O'}]"
"Furthermore, this review will highlight the difficulties and complexities that are inherent in the diagnosis of Sjogrens syndrome and the important role that dental practitioners can play in the management of its oral manifestations.","[{'Furthermore,': 'O'}, {'this': 'O'}, {'review': 'O'}, {'will': 'O'}, {'highlight': 'O'}, {'the': 'O'}, {'difficulties': 'O'}, {'and': 'O'}, {'complexities': 'O'}, {'that': 'O'}, {'are': 'O'}, {'inherent': 'O'}, {'in': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'important': 'O'}, {'role': 'O'}, {'that': 'O'}, {'dental': 'O'}, {'practitioners': 'O'}, {'can': 'O'}, {'play': 'O'}, {'in': 'O'}, {'the': 'O'}, {'management': 'O'}, {'of': 'O'}, {'its': 'O'}, {'oral': 'O'}, {'manifestations.': 'O'}]"
"However, clinical examination and thorough diagnostic investigations have to be carried out in order to identify cases that are secondary to infections or systemic diseases since these forms may be cured with appropriate etiologic treatment.","[{'However,': 'O'}, {'clinical': 'O'}, {'examination': 'O'}, {'and': 'O'}, {'thorough': 'O'}, {'diagnostic': 'O'}, {'investigations': 'O'}, {'have': 'O'}, {'to': 'O'}, {'be': 'O'}, {'carried': 'O'}, {'out': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'cases': 'O'}, {'that': 'O'}, {'are': 'O'}, {'secondary': 'O'}, {'to': 'O'}, {'infections': 'I-Entity'}, {'or': 'O'}, {'systemic': 'O'}, {'diseases': 'I-Entity'}, {'since': 'O'}, {'these': 'O'}, {'forms': 'O'}, {'may': 'O'}, {'be': 'O'}, {'cured': 'O'}, {'with': 'O'}, {'appropriate': 'O'}, {'etiologic': 'O'}, {'treatment.': 'O'}]"
"Maintenance of acinar cells is impaired in Sjogrens syndrome (SS), which is also characterized by low levels of serum and salivary androgens.","[{'Maintenance': 'O'}, {'of': 'O'}, {'acinar': 'O'}, {'cells': 'O'}, {'is': 'O'}, {'impaired': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'which': 'O'}, {'is': 'O'}, {'also': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'low': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'androgens.': 'O'}]"
His medical background was unremarkable except for cigarette smoking and hyperlipidemia.,"[{'His': 'O'}, {'medical': 'O'}, {'background': 'O'}, {'was': 'O'}, {'unremarkable': 'O'}, {'except': 'O'}, {'for': 'O'}, {'cigarette': 'O'}, {'smoking': 'I-Entity'}, {'and': 'O'}, {'hyperlipidemia.': 'I-Entity'}]"
"On the other hand, CD was diagnosed in 28% of the patients who presented worse renal function (eGFR 68.6 ¬¨¬®¬¨¬± 27.7 mL/min/1.73 m(2)).","[{'On': 'O'}, {'the': 'O'}, {'other': 'O'}, {'hand,': 'O'}, {'CD': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'in': 'O'}, {'28%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'worse': 'O'}, {'renal': 'O'}, {'function': 'O'}, {'(eGFR': 'O'}, {'68.6': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'27.7': 'O'}, {'mL/min/1.73': 'O'}, {'m(2)).': 'O'}]"
"Our molecular and cellular studies indicated that the target of autoimmunity in SS, the activated glandular epithelial cells, play significant role in the initiation and perpetuation of the autoimmune process.","[{'Our': 'O'}, {'molecular': 'O'}, {'and': 'O'}, {'cellular': 'O'}, {'studies': 'O'}, {'indicated': 'O'}, {'that': 'O'}, {'the': 'O'}, {'target': 'O'}, {'of': 'O'}, {'autoimmunity': 'I-Entity'}, {'in': 'O'}, {'SS,': 'I-Entity'}, {'the': 'O'}, {'activated': 'O'}, {'glandular': 'O'}, {'epithelial': 'O'}, {'cells,': 'O'}, {'play': 'O'}, {'significant': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'initiation': 'O'}, {'and': 'O'}, {'perpetuation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'autoimmune': 'I-Entity'}, {'process.': 'O'}]"
"The results suggest M3R internalization as a potential mechanism to explain the exocrinopathy seen in pSS patients.Research Institute, Seoul 110-749, Republic of Korea.Epub 2011 Nov 21.","[{'The': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'M3R': 'O'}, {'internalization': 'O'}, {'as': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'mechanism': 'O'}, {'to': 'O'}, {'explain': 'O'}, {'the': 'O'}, {'exocrinopathy': 'I-Entity'}, {'seen': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.Research': 'O'}, {'Institute,': 'O'}, {'Seoul': 'O'}, {'110-749,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'Korea.Epub': 'O'}, {'2011': 'O'}, {'Nov': 'O'}, {'21.': 'O'}]"
